

## **Clinical Pharmacokinetic of Cefixime: A Systematic Review**

Maria Ajmal<sup>1</sup>, Ammara Zamir<sup>1</sup>, Anees ur Rehman<sup>1</sup>, Imran Imran<sup>2</sup>, Hamid Saeed<sup>3</sup>, Abdul Majeed<sup>4</sup>, Majid Aziz<sup>1</sup>, Faleh Alqahtani<sup>5</sup>, & Muhammad Fawad Rasool<sup>1\*</sup>

<sup>1</sup> Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin Zakariya University, 60800, Multan, Pakistan

<sup>2</sup> Department of Pharmacology, Faculty of Pharmacy, Bahauddin Zakariya University, 60800, Multan, Pakistan

<sup>3</sup> University College of Pharmacy, Allama Iqbal Campus, University of the Punjab, 54000, Lahore, Pakistan

<sup>4</sup> Department of Pharmaceutics, Faculty of Pharmacy, Bahauddin Zakariya University, 60800, Multan, Pakistan

<sup>5</sup> Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia

\*Corresponding author: fawadrasool@bzu.edu.pk

Telephone:+92 3008639046

**Supplementary Table 1:** Introduction of Cefixime

Name of Drug:	Cefixime (Leggett et al. 1990).
Solubility in water:	55.11 mg/L (Abdullah et al. 2022).
Lipophilicity (Log P) value:	-0.4 (Abdullah et al. 2022).
Chemical formula:	$C_{16}H_{15}N_5O_7S_2$ (Naqvi et al. 2011).
Molecular weight:	453.4 g/mol (Naqvi et al. 2011).
Physical appearance:	White to slightly yellowish crystal or crystalline powder (Genvresse and Carbon 1993).
Available Dosage Forms and route:	Oral dosage forms: <ul style="list-style-type: none"><li>• Tablet, Chewable tablet (100 mg and 200 mg),</li><li>• Powder for suspension (100 mg per 5 ml),</li><li>• Capsule (400 mg) (Jabbar et al. 2021).</li></ul>
Pregnancy category:	(B) (Özyüncü et al. 2010)

--	--

**Supplementary Table 2:** Screening of articles based on title, abstract, involvement of animals, and accessibility

Sr#	Title	Exclusion
1	Long SS, editor. Principles and Practice of Pediatric Infectious Disease (Third Edition). Edinburgh: W.B. Saunders; 2008. p. 1507-1618.	Title
2	Waldman SA, Terzic A, Egan LJ, et al., editors. Pharmacology and Therapeutics. Philadelphia: W.B. Saunders; 2009. p. 1333-1378.	Title
3	Cohen J, Opal SM, Powderly WG, editors. Infectious Diseases (Third Edition). London: Mosby; 2010. p. I-1-I-72.	Title
4	Finch RG, Greenwood D, Norrby SR, et al., editors. Antibiotic and Chemotherapy (Ninth Edition). London: W.B. Saunders; 2011. p. 861-900.	Title
5	Kester M, Karpa KD, Vrana KE, editors. Elsevier's Integrated Review Pharmacology (Second Edition) (Second Edition). Philadelphia: W.B. Saunders; 2012. p. 235-245.	Title
6	Wolverton SE, editor. Comprehensive Dermatologic Drug Therapy (Third Edition). London: W.B. Saunders; 2013. p. 793-826.	Title
7	2 - Spezielle Arzneimitteltherapie in der Schwangerschaft. In: Schaefer C, Spielmann H, Vetter K, et al., editors. Arzneimittel in Schwangerschaft und Stillzeit (Achte Ausgabe). Munich: Urban & Fischer; 2012. p. 33-574.	Title

8	Alcaide B, Aragoncillo C, Almendros P. 2.02 - Cephalosporins. In: Katritzky AR, Ramsden CA, Scriven EFV, et al., editors. <i>Comprehensive Heterocyclic Chemistry III</i> . Oxford: Elsevier; 2008. p. 111-171.	Title
9	Garbis H, van Tonningen MR, Reuvers M. 2.6 - Anti-infective agents. In: Schaefer C, Peters P, Miller RK, editors. <i>Drugs During Pregnancy and Lactation (Second Edition)</i> . Oxford: Academic Press; 2007. p. 123-177.	Title
10	García-Estrada C, Martín JF. 3.24 - Penicillins and Cephalosporins. In: Moo-Young M, editor. <i>Comprehensive Biotechnology (Second Edition)</i> . Burlington: Academic Press; 2011. p. 255-268.	Title
11	García-Estrada C, Martín JF. 3.24 - Penicillins and Cephalosporins☆. In: Moo-Young M, editor. <i>Comprehensive Biotechnology (Third Edition)</i> . Oxford: Pergamon; 2019. p. 283-296.	Title
12	Nord CE. 4 - Effect of Antimicrobials on Human Flora. In: Finegold SM, George WL, editors. <i>Anaerobic Infections in Humans</i> : Academic Press; 1989. p. 55-80.	Title
13	Anaya J, Sánchez RM. 4 - Four-membered ring systems. In: Gribble GW, Joule JA, editors. <i>Progress in Heterocyclic Chemistry</i> . Vol. 33: Elsevier; 2021. p. 53-91.	Title
14	Kester M, Karpa KD, Vrana KE. 4 - Treatment of Infectious Diseases. In: Kester M, Karpa KD, Vrana KE, editors. <i>Elsevier's Integrated Review Pharmacology (Second Edition) (Second Edition)</i> . Philadelphia: W.B. Saunders; 2012. p. 41-78.	Title
15	Greenwood D, Irving WL. 5 - Antimicrobial agents. In: Greenwood D, Barer M, Slack R, et al., editors. <i>Medical Microbiology (Eighteenth Edition)</i> . Edinburgh: Churchill Livingstone; 2012. p. 54-68.	Title
16	Adam D, Hostalek U, Tröster K. 5-day therapy of bacterial pharyngitis and tonsillitis with cefixime. Comparison with 10 day treatment with penicillin V. Cefixime Study Group [Clinical Trial; Comparative Study; English Abstract; Journal Article; Multicenter Study; Randomized Controlled Trial]. <i>Klinische Padiatrie</i> . 1996;208(5):310-313.	Abstract

17	Artursson P, Neuhoff S, Matsson P, et al. 5.11 - Passive Permeability and Active Transport Models for the Prediction of Oral Absorption. In: Taylor JB, Triggle DJ, editors. Comprehensive Medicinal Chemistry II. Oxford: Elsevier; 2007. p. 259-278.	Title
18	Pucci MJ, Callebaut C, Cathcart A, et al. 5.17 - Recent Epidemiological Changes in Infectious Diseases. In: Chackalamannil S, Rotella D, Ward SE, editors. Comprehensive Medicinal Chemistry III. Oxford: Elsevier; 2017. p. 511-552.	Title
19	Khan NU, Miao T, Ju X, et al. 6 - Carrier-mediated transportation through BBB. In: Gao H, Gao X, editors. Brain Targeted Drug Delivery System: Academic Press; 2019. p. 129-158.	Title
20	Sparreboom A, Evans WE, Baker SD. 6 - Chemotherapy in the Pediatric Patient. In: Orkin SH, Fisher DE, Look AT, et al., editors. Oncology of Infancy and Childhood. Philadelphia: W.B. Saunders; 2009. p. 173-207.	Title
21	Bradley JS. 7 - Antimicrobial Chemoprophylaxis. In: Long SS, Prober CG, Fischer M, editors. Principles and Practice of Pediatric Infectious Diseases (Fifth Edition): Elsevier; 2018. p. 71-79.e2.	Title
22	Lai Y. 7 - Organic anion, organic cation and zwitterion transporters of the SLC22 and SLC47 superfamily (OATs, OCTs, OCTNs and MATEs). In: Lai Y, editor. Transporters in Drug Discovery and Development: Woodhead Publishing; 2013. p. 455-631.	Title
23	Iyer RN. 7.02 - Beta lactam. In: Kenakin T, editor. Comprehensive Pharmacology. Oxford: Elsevier; 2022. p. 3-63.	Title
24	Bal AM. 7.09 - Macrolide Antibiotics. In: Kenakin T, editor. Comprehensive Pharmacology. Oxford: Elsevier; 2022. p. 170-184.	Title
25	Gerrett D. 8 - Pharmacology. In: Turner WA, Merriman LM, editors. Clinical Skills in Treating the Foot (Second Edition). Oxford: Churchill Livingstone; 2005. p. 161-191.	Title

26	Kim S, Michaels BD, Kim GK, et al. 8 - Systemic Antibacterial Agents. In: Wolverson SE, editor. Comprehensive Dermatologic Drug Therapy (Third Edition). London: W.B. Saunders; 2013. p. 61-97.e11.	Title
27	Snodgrass A, Motaparthy K. 9 - Systemic Antibacterial Agents. In: Wolverson SE, editor. Comprehensive Dermatologic Drug Therapy (Fourth Edition): Elsevier; 2021. p. 69-98.e13.	Title
28	Rehman S, Nabi B, Ahmad S, et al. 10 - Polysaccharide-based amorphous solid dispersions (ASDs) for improving solubility and bioavailability of drugs. In: Maiti S, Jana S, editors. Polysaccharide Carriers for Drug Delivery: Woodhead Publishing; 2019. p. 271-317.	Title
29	Lawrence RM. 12 - Transmission of Infectious Diseases Through Breast Milk and Breastfeeding. In: Lawrence RA, Lawrence RM, editors. Breastfeeding (Ninth Edition). Philadelphia: Elsevier; 2022. p. 393-456.	Title
30	Best BM. 13 - Clinical Pharmacology of Anti-Infectives During Pregnancy. In: Mattison DR, editor. Clinical Pharmacology During Pregnancy: Academic Press; 2013. p. 173-199.	Title
31	13th European Congress of Clinical Microbiology and Infectious Diseases. Clinical Microbiology and Infection. 2003 2003/01/01/;9:1-422.	Title
32	Craig WA, Andes DR. 21 - Cephalosporins. In: Bennett JE, Dolin R, Blaser MJ, editors. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases (Eighth Edition). Philadelphia: W.B. Saunders; 2015. p. 278-292.e4.	Title
33	Mackell SM, Anderson S. 22 - The Pregnant and Breastfeeding Traveler. In: Keystone JS, Freedman DO, Kozarsky PE, et al., editors. Travel Medicine (Third Edition). London: Elsevier; 2013. p. 219-230.	Title
34	Midtvedt T. 25 - Penicillins, cephalosporins, other beta-lactam antibiotics, and tetracyclines. In: Aronson JK, editor. Side Effects of Drugs Annual. Vol. 30: Elsevier; 2008. p. 280-296.	Title

35	Scotta MC, Marostica PJC, Stein RT. 25 - Pneumonia in Children. In: Wilmott RW, Deterding R, Li A, et al., editors. Kendig's Disorders of the Respiratory Tract in Children (Ninth Edition). Philadelphia: Elsevier; 2019. p. 427-438.e4.	Title
36	Feasey NA, Gordon MA. 25 - Salmonella Infections. In: Farrar J, Hotez PJ, Junghanss T, et al., editors. Manson's Tropical Infectious Diseases (Twenty-third Edition). London: W.B. Saunders; 2014. p. 337-348.e2.	Title
37	Chan KH, Abzug MJ, Liu AH. 26 - Sinusitis. In: Leung DYM, Szeffler SJ, Bonilla FA, et al., editors. Pediatric Allergy: Principles and Practice (Third Edition). London: Elsevier; 2016. p. 228-237.e3.	Title
38	Imhof A, Laffer R. 26 Miscellaneous antibacterial drugs. In: Aronson JK, editor. Side Effects of Drugs Annual. Vol. 29: Elsevier; 2007. p. 253-279.	Title
39	Koh AY, Pizzo PA. 27 - Infectious Diseases in Pediatric Cancer. In: Orkin SH, Fisher DE, Look AT, et al., editors. Oncology of Infancy and Childhood. Philadelphia: W.B. Saunders; 2009. p. 1099-1120.	Title
40	Pelton SI. 29 - Otitis Media. In: Long SS, Prober CG, Fischer M, editors. Principles and Practice of Pediatric Infectious Diseases (Fifth Edition): Elsevier; 2018. p. 216-223.e3.	Title
41	Kumar P. 33 - Pharmacology of Specific Drug Groups: Antibiotic Therapy**The author wishes to recognize Dr. Thomas J. Pallasch for his past contributions to this chapter. In: Dowd FJ, Johnson BS, Mariotti AJ, editors. Pharmacology and Therapeutics for Dentistry (Seventh Edition): Mosby; 2017. p. 457-487.	Title
42	Barber GR, Safdar A. 35 - Unique Antibacterial Agents. In: Bennett JE, Dolin R, Blaser MJ, editors. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases (Eighth Edition). Philadelphia: W.B. Saunders; 2015. p. 440-446.e2.	Title
43	Waller DG, Sampson AP. 51 - Chemotherapy of infections. In: Waller DG, Sampson AP, editors. Medical Pharmacology and Therapeutics (Fifth Edition): Elsevier; 2018. p. 581-629.	Title

44	Pai MP, Bertino JS. 54 - Tables of Anti-infective Agent Pharmacology. In: Bennett JE, Dolin R, Blaser MJ, editors. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases (Eighth Edition). Philadelphia: W.B. Saunders; 2015. p. 631-707.	Title
45	Harris JB, Brooks WA. 69 - Typhoid and Paratyphoid (Enteric) Fever. In: Magill AJ, Hill DR, Solomon T, et al., editors. Hunter's Tropical Medicine and Emerging Infectious Disease (Ninth Edition). London: W.B. Saunders; 2013. p. 568-576.	Title
46	Harris JB, Brooks WA. 74 - Typhoid and Paratyphoid (Enteric) Fever. In: Ryan ET, Hill DR, Solomon T, et al., editors. Hunter's Tropical Medicine and Emerging Infectious Diseases (Tenth Edition). London: Elsevier; 2020. p. 608-616.	Title
47	Ardura MI, Koh AY. 97 - Fever and Granulocytopenia. In: Long SS, Prober CG, Fischer M, editors. Principles and Practice of Pediatric Infectious Diseases (Fifth Edition): Elsevier; 2018. p. 578-586.e4.	Title
48	Koh AY, Pizzo PA. 99 - Fever and Granulocytopenia. In: Long SS, editor. Principles and Practice of Pediatric Infectious Diseases (Fourth Edition). London: Elsevier; 2012. p. 567-573.e4.	Title
49	Harris JB, Ryan ET. 102 - Enteric Fever and Other Causes of Fever and Abdominal Symptoms. In: Bennett JE, Dolin R, Blaser MJ, editors. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases (Eighth Edition). Philadelphia: W.B. Saunders; 2015. p. 1270-1282.e3.	Title
50	Marrazzo JM, Apicella MA. 214 - Neisseria gonorrhoeae (Gonorrhea). In: Bennett JE, Dolin R, Blaser MJ, editors. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases (Eighth Edition). Philadelphia: W.B. Saunders; 2015. p. 2446-2462.e3.	Title
51	Neely MN, Reed MD. 291 - Pharmacokinetic-Pharmacodynamic Basis of Optimal Antibiotic Therapy. In: Long SS, Prober CG, Fischer M, editors. Principles and Practice of Pediatric Infectious Diseases (Fifth Edition): Elsevier; 2018. p. 1478-1498.e6.	Title



52	Neely MN, Reed MD. 291 - Pharmacokinetic–Pharmacodynamic Basis of Optimal Antibiotic Therapy. In: Long SS, editor. Principles and Practice of Pediatric Infectious Diseases (Fourth Edition). London: Elsevier; 2012. p. 1433-1452.e10.	Title
53	Bradley JS, Sauberan JB. 292 - Antimicrobial Agents. In: Long SS, editor. Principles and Practice of Pediatric Infectious Diseases (Fourth Edition). London: Elsevier; 2012. p. 1453-1484.e5.	Title
54	Sauberan JB, Bradley JS. 292 - Antimicrobial Agents. In: Long SS, Prober CG, Fischer M, editors. Principles and Practice of Pediatric Infectious Diseases (Fifth Edition): Elsevier; 2018. p. 1499-1531.e3.	Title
55	Drusano GL, Craig WA. 295 - Antibacterial Chemotherapy. In: Goldman L, Schafer AI, editors. Goldman's Cecil Medicine (Twenty Fourth Edition). Philadelphia: W.B. Saunders; 2012. p. 1803-1815.	Title
56	Castagnola E, Mikulska M, Viscoli C. 310 - Prophylaxis and Empirical Therapy of Infection in Cancer Patients. In: Bennett JE, Dolin R, Blaser MJ, editors. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases (Eighth Edition). Philadelphia: W.B. Saunders; 2015. p. 3395-3413.e2.	Title
57	Weiner CP, Buhimschi C. A. In: Weiner CP, Buhimschi C, editors. Drugs for Pregnant and Lactating Women (Second Edition). Philadelphia: W.B. Saunders; 2009. p. 1-79.	Title
58	Weiner CP, Mason C. A. In: Weiner CP, Mason C, editors. Drugs for Pregnant and Lactating Women (Third Edition). Philadelphia: Elsevier; 2019. p. 1-58.	Title
59	Park G-B, Roh H-G, Lee K-P. Absorption Mechanism of Cefixime through the Nasal Cavity and Jejunum in Rats. YAKHAK HOEJI. 1994;38(2):114-122.	Animal
60	TOKUMA Y, SEKIGUCHI M, FUJIWARA T, et al. Absorption, distribution, excretion and metabolism of cefixime in rats. Drug Metabolism and Pharmacokinetics. 1987;2(6):637-648.	Animal
61	Abstracts. Journal of Allergy and Clinical Immunology. 1993 1993/01/01/;91(1, Part 2):141-379.	Title
62	Abstracts. Clinical Microbiology and Infection. 2004 2004/01/01/;10:1-86.	Title

63	Abstracts. <i>Clinical Microbiology and Infection</i> . 2005 2005/01/01/;11:1-98.	Title
64	Abstracts. <i>Annals of Allergy, Asthma &amp; Immunology</i> . 2015 2015/11/01/;115(5, Supplement):A1-A142.	Title
65	Abstracts accepted for publication only. <i>Clinical Microbiology and Infection</i> . 2007 2007/01/01/;13:S609-S676.	Title
66	Abstracts accepted for publication only. <i>Clinical Microbiology and Infection</i> . 2008 2008/05/01/;14:S667-S759.	Title
67	Abstracts accepted for publication only. <i>Clinical Microbiology and Infection</i> . 2011 2011/05/01/;17:S669-S834.	Title
68	Abstracts cont. <i>Clinical Microbiology and Infection</i> . 2004 2004/01/01/;10:486-543.	Title
69	Abstracts cont. <i>Clinical Microbiology and Infection</i> . 2005 2005/01/01/;11:238-390.	Title
70	Abstracts for Supplement. <i>International Journal of Infectious Diseases</i> . 2010 2010/03/01/;14:e191-e335.	Title
71	Dagan R. Achieving bacterial eradication using pharmacokinetic/pharmacodynamic principles. <i>International journal of infectious diseases</i> . 2003;7:S21-S26.	Title
72	Koeth L, Good C, Jacobs M, et al., editors. Activity of amoxicillin/clavulanic acid and 16 comparator agents against respiratory isolates, collected worldwide in 2000. Presented at the 101st General Meeting of the American Society for Microbiology; 2001.	Title
73	Fera MT, Carbone M, Focà A. Activity of cefixime against <i>Helicobacter pylori</i> . <i>International Journal of Antimicrobial Agents</i> . 1993;3(2):105-108.	Abstract
74	Kohl PK, Tu Y, Hostalek U, et al. Activity of cefixime against <i>Neisseria gonorrhoeae</i> . <i>Journal of the European Academy of Dermatology and Venereology</i> . 1995;4(2):155-159.	Abstract

75	Jones RN, Critchley IA, Whittington WLH, et al. Activity of faropenem tested against <i>Neisseria gonorrhoeae</i> isolates including fluoroquinolone-resistant strains. <i>Diagnostic Microbiology and Infectious Disease</i> . 2005 2005/12/01/;53(4):311-317.	Title
76	Rossi R, Castellani P, Younes G, et al. Activity of FCE 22891 compared with cefuroxime axetil and cefixime in pulmonary and subcutaneous infections in mice. <i>J Antimicrob Chemother</i> . 1989 Mar;23 Suppl C:149-55.	Animal
77	Pottumarthy S, Fritsche TR, Jones RN. Activity of gemifloxacin tested against <i>Neisseria gonorrhoeae</i> isolates including antimicrobial-resistant phenotypes. <i>Diagnostic Microbiology and Infectious Disease</i> . 2006 2006/02/01/;54(2):127-134.	Title
78	Cynamon MH, Sklaney M, Yeo AET. The activity of grepafloxacin in two murine models of <i>Mycobacterium avium</i> infection. <i>Journal of Infection and Chemotherapy</i> . 2004 2004/01/01/;10(3):185-188.	Title
79	Peric M, Browne FA, Jacobs MR, et al. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents. <i>Clinical therapeutics</i> . 2003;25(1):169-177.	Title
80	Doern GV. Activity of oral $\beta$ -lactam antimicrobial agents versus respiratory tract isolates of <i>Streptococcus pneumoniae</i> , <i>Haemophilus influenzae</i> , and <i>Moraxella catarrhalis</i> in the era of antibiotic resistance. <i>Otolaryngology - Head and Neck Surgery</i> . 2002 2002/12/01/;127(6, Supplement):S17-S23.	Title
81	PICHICHERO ME. Activity of the newer oral extended-spectrum antimicrobials against resistant respiratory pathogens. <i>Pediatric Asthma, Allergy &amp; Immunology</i> . 1995;9(3):143-155.	Title
82	Brook I. Acute Sinusitis in Children. <i>Pediatric Clinics of North America</i> . 2013 2013/04/01/;60(2):409-424.	Title

83	Liu X, Chen Y, Yang H, et al. Acute toxicity is a dose-limiting factor for intravenous polymyxin B: A safety and pharmacokinetic study in healthy Chinese subjects. <i>Journal of Infection</i> . 2021 2021/02/01/;82(2):207-215.	Title
84	Amfilcon A. Acyl glucuronides.	Title
85	Qin Z. Advances in biopharmaceutical analysis in the People's Republic of China: 1991–1993. <i>Journal of Pharmaceutical and Biomedical Analysis</i> . 1995 1995/01/01/;13(1):1-7.	Title
86	Wong SHY. Advances in liquid chromatography and related methodologies for therapeutic drug monitoring. <i>Journal of Pharmaceutical and Biomedical Analysis</i> . 1989 1989/01/01/;7(9):1011-1032.	Title
87	Siddiqui MA, More-O'Ferrall D, Hammod RS, et al. Agranulocytosis associated with yohimbine use. <i>Archives of Internal Medicine</i> . 1996;156(11):1235-1238.	Title
88	Alert. <i>International Journal of Antimicrobial Agents</i> . 1992 1992/01/01/;1(4):193-199.	Title
89	Jacobs MR, Felmingham D, Appelbaum PC, et al. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. <i>J Antimicrob Chemother</i> . 2003 Aug;52(2):229-46.	Title
90	Zafar S, Ali A, Ashraf M, et al. Alteration in disposition kinetics of warfarin mediated by caffeine in healthy male albino rabbits. <i>JAPS: Journal of Animal &amp; Plant Sciences</i> . 2019;29(2).	Animal
91	Labro M, el Benna J, Jemni A. Alteration of bacteria induced by subinhibitory concentrations of cefixime: consequences on bactericidal activity of human polynuclear neutrophils. <i>Pathologie-biologie</i> . 1992;40(5):427-432.	Abstract
92	Yasui H, Yamaoka K, Nakagawa T. Alternative continuous infusion method for analysis of enterohepatic circulation and biliary excretion of cefixime in the rat. <i>J Pharm Sci</i> . 1994 Jun;83(6):819-23.	Animal

93	The American Academy of Allergy and Immunology. Journal of Allergy and Clinical Immunology. 1994 1994/01/01/;93(1, Part 2):A4-304.	Title
94	Mahadevan U, Kane S. American Gastroenterological Association Institute Technical Review on the Use of Gastrointestinal Medications in Pregnancy. Gastroenterology. 2006 2006/07/01/;131(1):283-311.	Title
95	Okabe T, Yamazaki Y, Shiotani M, et al. An amino acid substitution in PBP-3 in Haemophilus influenzae associate with the invasion to bronchial epithelial cells. Microbiological Research. 2010 2010/01/29/;165(1):11-20.	Title
96	García-Cobos S, Campos J, Lázaro E, et al. Ampicillin-resistant non- $\beta$ -lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime. Antimicrobial agents and chemotherapy. 2007;51(7):2564-2573.	Abstract
97	Isla A, Canut A, Rodríguez-Gascón A, et al. Análisis farmacocinético/farmacodinámico (PK/PD) de la antibioterapia en odontoestomatología. Enfermedades Infecciosas y Microbiología Clínica. 2005 2005/03/01/;23(3):116-121.	Title
98	Natalia R. Analisis Minimalisasi Biaya Konversi Antibiotik Seftriakson menjadi Sefiksim Peroral pada Pasien di Bangsal Penyakit dalam RSUD Prof. Dr. Margono Soekarjo: Universitas Jenderal Soedirman; 2018.	Title
99	El-Shaboury SR, Saleh GA, Mohamed FA, et al. Analysis of cephalosporin antibiotics. Journal of Pharmaceutical and Biomedical Analysis. 2007 2007/09/21/;45(1):1-19.	Abstract
100	Churihar R, Tanwani H, Gupta K. Analysis of cephalosporins available in India: A pharmaco-economic perspective. Asian Journal of Medical Sciences. 2022;13(5):119-124.	Abstract

101	Naik PP, Mehta CD, Srivastava SK. Analysis of commonly used pediatric systemic antibacterial liquid formulations for rational drug therapy. National Journal of Physiology, Pharmacy and Pharmacology. 2017;7(4):348.	Title
102	Kitagishi K, Shintani H. Analysis of compounds containing carboxyl groups in biological fluids by capillary electrophoresis. Journal of Chromatography B: Biomedical Sciences and Applications. 1998 1998/10/09;717(1):327-339.	Title
103	Yamaoka K, Kanba M, Toyoda Y, et al. Analysis of enterohepatic circulation of cefixime in rat by fast inverse Laplace transform (FILT). Journal of pharmacokinetics and biopharmaceutics. 1990;18(6):545-559.	Animal
104	Vishwanath M, Arpitha D, Murgesh J. Analysis of pattern of antimicrobial usage in children of age 1 to 12 years with respiratory tract infections admitted in pediatric intensive care unit in a tertiary care hospital. National Journal of Physiology, Pharmacy and Pharmacology. 2022;12(6):856-856.	Title
105	Protic D, Pejovic A, Djukanovic N, et al. Analysis of the third-and fourth-generation cephalosporin use for the treatment of infections caused by Gram-negative bacteria in hospital settings. International journal of clinical practice. 2016;70(12):1033-1040.	Abstract
106	Nagaraju K, Chowdary Y. Analytical Method Development <i>and</i> Validation for The Simultaneous Estimation of Azithromycin and Cefixime by Rp-Hplc Method in Bulk and Pharmaceutical Formulations. 2018.	Abstract
107	Kathiravan S, Anbarasi B, Mathankumar S. Analytical method development and validation of cefixime and dicloxacillin tablet by RP-HPLC. Asian Journal of Research in Chemistry. 2010;3(4):865-868.	Abstract
108	Ibrahim F, Wahba M, Magdy G. Analytical method development and validation of spectrofluorimetric and spectrophotometric determination of some antimicrobial drugs in their pharmaceuticals. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. 2018;188:525-536.	Title

109	Okeke CC, Srinivasan VS. and Harry G. Britain'. Analytical Profiles of Drug Substances and Excipients. 1998:39.	Title
110	Musther H, Olivares-Morales A, Hatley OJD, et al. Animal versus human oral drug bioavailability: Do they correlate? European Journal of Pharmaceutical Sciences. 2014 2014/06/16/;57:280-291.	Title
111	Jacobs MR. Anti-infective pharmacodynamics – maximizing efficacy, minimizing toxicity. Drug Discovery Today: Therapeutic Strategies. 2004 2004/12/01/;1(4):505-512.	Title
112	Bauernfeind A, Jungwirth R, Schweighart S, et al. [Antibacterial activity and beta-lactamase stability of eleven oral cephalosporins]. Infection. 1990;18 Suppl 3:S155-67.	Not accessible
113	Wiedemann B, Jansen A. Antibacterial activity of cefpodoxime proxetil in a pharmacokinetic in-vitro model. Journal of Antimicrobial Chemotherapy. 1990;26(1):71-79.	Title
114	Nakamura T, Takahashi H. Antibacterial activity of oral cepheems against various clinically isolated strains and evaluation of efficacy based on the pharmacokinetics/pharmacodynamics theory. The Japanese journal of antibiotics. 2004;57(6):465-474.	Title
115	Kern TJ. Antibacterial agents for ocular therapeutics. Veterinary Clinics of North America: Small Animal Practice. 2004 2004/05/01/;34(3):655-668.	Animal
116	Bowlware KL, Stull T. Antibacterial agents in pediatrics. Infectious Disease Clinics of North America. 2004 2004/09/01/;18(3):513-531.	Title
117	Chavez-Bueno S, Stull TL. Antibacterial Agents in Pediatrics. Infectious Disease Clinics of North America. 2009 2009/12/01/;23(4):865-880.	Title
118	LiPuma JJ, Stull TL. Antibacterial agents in pediatrics. Infectious Disease Clinics of North America. 1995;9(3):561-574.	Title

119	San Joaquin VH, Stull TL. Antibacterial agents in Pediatrics. Infectious Disease Clinics of North America. 2000;14(2):341-355.	Title
120	Papich MG. Antibacterial drug therapy: focus on new drugs. Veterinary Clinics: Small Animal Practice. 1998;28(2):215-231.	Animal
121	Soussy CJ, Meyran M, Duval J. [Antibacterial effect of cefixime]. Presse Med. 1989 Oct 11;18(32):1546-50.	Not accessible
122	Arayne MS, Sultana N, Khanum F, et al. Antibacterial studies of cefixime copper, zinc and cadmium complexes. Pak J Pharm Sci. 2002;15:1-8.	Abstract
123	Kazantsev V, Guchev I. Antibacterial treatment of moderate chronic obstructive pulmonary disease exacerbation. PULMONOLOGIYA. 2014 (4):105-111.	Title
124	Jain A, Parihar DK. Antibacterial, biofilm dispersal and antibiofilm potential of alkaloids and flavonoids of Curcuma. Biocatalysis and Agricultural Biotechnology. 2018 2018/10/01/;16:677-682.	Title
125	Troeltzsch M, Pache C, Probst FA, et al. Antibiotic Concentrations in Saliva: A Systematic Review of the Literature, With Clinical Implications for the Treatment of Sialadenitis. Journal of Oral and Maxillofacial Surgery. 2014 2014/01/01/;72(1):67-75.	Title
126	Van Bambeke F, Michot J-M, Tulkens PM. Antibiotic efflux pumps in eukaryotic cells: occurrence and impact on antibiotic cellular pharmacokinetics, pharmacodynamics and toxicodynamics. Journal of Antimicrobial Chemotherapy. 2003;51(5):1067-1077.	Title
127	Crowe HM, Quintiliani R. Antibiotic formulary selection. Medical Clinics of North America. 1995 1995/01/01/;79(3):463-476.	Title
128	Lutsar I, McCracken Jr GH, Friedland IR. Antibiotic pharmacodynamics in cerebrospinal fluid. Clinical Infectious Diseases. 1998:1117-1127.	Title



129	Majhi B, Panda A, Barma SK. Antibiotic prescribing pattern in paediatrics outpatient in a tertiary care hospital. <i>J Evid Based Med.</i> 2017;4:3048-3051.	Title
130	Esposito S, Biasucci G, Pasini A, et al. Antibiotic Resistance in Paediatric Febrile Urinary Tract Infections. <i>Journal of Global Antimicrobial Resistance.</i> 2022 2022/06/01/;29:499-506.	Title
131	Chartrand SA. Antibiotic resistance in pediatric respiratory tract pathogens. <i>Seminars in Pediatric Infectious Diseases.</i> 1998 1998/10/01/;9(4):292-300.	Title
132	Nuermberger EL, Bishai WR. Antibiotic resistance in <i>Streptococcus pneumoniae</i> : what does the future hold? <i>Clinical infectious diseases.</i> 2004;38(Supplement_4):S363-S371.	Title
133	Sah SK, Regmi S, Upreti AR, et al. Antibiotic resistance patterns and evaluation of treatment in out-patients with urinary tract infections in Nepal. <i>International journal of pharmaceutical sciences and research.</i> 2016;7(11):4626.	Title
134	Roe VA. Antibiotic Resistance: A Guide for Effective Prescribing in Women's Health. <i>Journal of Midwifery &amp; Women's Health.</i> 2008 2008/05/01/;53(3):216-226.	Title
135	Brown PD. Antibiotic selection for urinary tract infection: new microbiologic considerations. <i>Current infectious disease reports.</i> 1999;1(4):384-388.	Title
136	Ellison MJ, Crabtree DW. Antibiotic Therapy for Common Infections. <i>Primary Care: Clinics in Office Practice.</i> 1990 1990/09/01/;17(3):521-541.	Title
137	Iravani A, Bischoff W. Antibiotic therapy for urinary tract infections. <i>The American Journal of Medicine.</i> 1992 1992/06/22/;92(6, Supplement 1):S95-S100.	Title
138	Antibiotic treatment of children with secretory otitis media. A randomized, double-blind, placebo-controlled study: Thomsen, J., Sederberg-Olsen, J., Balle, V., Vejlsgaard, R., Stangerup S.-E. and Bondesson, G., <i>Arch.</i>	Title

	Otolaryngol. Head Neck Surg. (1989) 115/4 (447–451). International Journal of Pediatric Otorhinolaryngology. 1989 1989/09/01/;18(1):87-95.	
139	Cunha BA. The antibiotic treatment of community-acquired, atypical, and nosocomial pneumonias. Medical Clinics of North America. 1995 1995/01/01/;79(3):581-597.	Title
140	Panday DR, Amar A, Subedi A, et al. Antibiotic Usage and its Culture Sensitivity Pattern in Urinary Tract Infections at Tertiary Hospital in Eastern Nepal. Kathmandu Univ Med J (KUMJ). 2017 Oct.- Dec.;15(60):332-335.	Title
141	Ambrose PG, Owens RC, Quintiliani R, et al. ANTIBIOTIC USE IN THE CRITICAL CARE UNIT. Critical Care Clinics. 1998 1998/04/01/;14(2):283-308.	Title
142	Pollack ES, Pollack CV. Antibiotic use in the emergency department: I. The penicillins and cephalosporins. The Journal of Emergency Medicine. 1996 1996/03/01/;14(2):213-222.	Abstract
143	Aloy B, Launay-Vacher V, Bleibtreu A, et al. Antibiotics and chronic kidney disease: Dose adjustment update for infectious disease clinical practice. Medecine et Maladies Infectieuses. 2020;50(4):323-331.	Title
144	Gura KM. Antibiotics and Drugs: Drug–Nutrient Interactions. In: Caballero B, Finglas PM, Toldrá F, editors. Encyclopedia of Food and Health. Oxford: Academic Press; 2016. p. 174-191.	Title
145	Comunián-Carrasco G, Peña-Martí GE, Martí-Carvajal AJ. Antibiotics for treating gonorrhoea in pregnancy. Cochrane Database of Systematic Reviews. 2018 (2).	Title
146	Darmstadt GL. ANTIBIOTICS IN THE MANAGEMENT OF PEDIATRIC SKIN DISEASE. Dermatologic Clinics. 1998 1998/07/01/;16(3):509-525.	Title
147	Mirzaei R, Mesdaghinia A, Hoseini SS, et al. Antibiotics in urban wastewater and rivers of Tehran, Iran: consumption, mass load, occurrence, and ecological risk. Chemosphere. 2019;221:55-66.	Title

148	Uddin MB, Rabby SF. Antibiotics Prescribing in Labor and Delivery Patients in a Tertiary Care Hospital: Bangladesh Perspective. International Journal of Pharma Sciences and Research. 2015;6:1412-1417.	Title
149	Guerrero Sánchez F, Brun Romero F, Girón González JA. Antiinfecciosos de empleo en infecciones del sistema nervioso central. Medicine - Programa de Formación Médica Continuada Acreditado. 2003 2003/01/01/;8(97):5254-5259.	Title
150	Ishii Y, Suzuki Y, Ishihara R, et al. [Antimicrobial activities of cefetamet against clinical isolates from urinary tract infection]. Jpn J Antibiot. 1996 Dec;49(12):1073-84.	Title
151	Jones RN, Barry AL. Antimicrobial activity and disk diffusion susceptibility testing of U-76,253 A (R-3746), the active metabolite of the new cephalosporin ester, U-76,252 (CS-807). Antimicrobial Agents and Chemotherapy. 1988;32(4):443-449.	Title
152	Johnson DM, Biedenbach DJ, Beach ML, et al. Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species. Diagnostic microbiology and infectious disease. 2000;37(2):99-105.	Title
153	Jones RN. Antimicrobial activity and spectrum of ceftibuten (7432-S, SCH 39720) a review of United States and canadian results. Diagnostic microbiology and infectious disease. 1991;14(1):37-43.	Title
154	Deguchi K, Yokota N, Koguchi M, et al. Antimicrobial activity of cefetamet against fresh clinical isolates of Branhamella catarrhalis. The Japanese Journal of Antibiotics. 1992;45(4):359-363.	Title
155	Marchese A, Debbia EA, Bryskier A, et al. Antimicrobial activity of faropenem, a new oral penem, against lower respiratory tract pathogens. Clinical Microbiology and Infection. 1999 1999/05/01/;5(5):282-287.	Title
156	Jones RN, Sader HS, Fritsche TR. Antimicrobial activity of LBM415 (NVP PDF-713) tested against pathogenic Neisseria spp. (Neisseria gonorrhoeae and Neisseria meningitidis). Diagnostic Microbiology and Infectious Disease. 2005 2005/02/01/;51(2):139-141.	Title

157	Neuman M. The antimicrobial activity of nonantibiotics and their interactions with antibiotics: Synergy and antagonism. Antimicrobial Newsletter. 1990 1990/06/01/;7(6):41-46.	Title
158	Jones RN, Fuchs PC, Barry AL, et al. Antimicrobial activity of Ro 19-5247 (T-2525), a new oral cephalosporin, tested against 7,745 recent clinical isolates. Diagnostic microbiology and infectious disease. 1987;6(3):193-198.	Title
159	Jones RN. Antimicrobial activity, spectrum and pharmacokinetics of old and new orally administered cepheems. Antimicrobial Newsletter. 1988;5(1):1-7.	Title
160	Jones RN, Barry AL. Antimicrobial activity, spectrum, and recommendations for disk diffusion susceptibility testing of ceftibuten (7432-S; SCH 39720), a new orally administered cephalosporin. Antimicrobial agents and chemotherapy. 1988;32(10):1576-1582.	Title
161	Embil JM, Nicolle LE. Antimicrobial Agents. Physical Medicine and Rehabilitation Clinics of North America. 1999 1999/05/01/;10(2):403-436.	Title
162	Epstein ME, Amodio-Groton M, Sadick NS. Antimicrobial agents for the dermatologist. I. $\beta$ -Lactam antibiotics and related compounds. Journal of the American Academy of Dermatology. 1997 1997/08/01/;37(2, Part 1):149-165.	Title
163	Neu HC. Antimicrobial agents: The old and the new. American Journal of Infection Control. 1989;17(5):276-285.	Title
164	Pai MP, Bearden DT. Antimicrobial dosing considerations in obese adult patients: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2007;27(8):1081-1091.	Title
165	Jean S-S, Hsueh P-R. Antimicrobial Drug Resistance in Taiwan. Journal of the Formosan Medical Association. 2011 2011/01/01/;110(1):4-13.	Title

166	Jang H-S, Park M-G, Kook J-K, et al. Antimicrobial effect of cefixime on 6 species of periodopathogens. The Journal of the Korean Academy of Periodontology. 2005;35(2):401-411.	Abstract
167	Jacobs MR, Dagan R. Antimicrobial resistance among pediatric respiratory tract infections: clinical challenges. Seminars in Pediatric Infectious Diseases. 2004 2004/01/01/;15(1):5-20.	Title
168	Shi J, Yan Y, Links MG, et al. Antimicrobial resistance genetic factor identification from whole-genome sequence data using deep feature selection. BMC Bioinformatics. 2019 Dec 24;20(Suppl 15):535.	Title
169	Craig WA. Antimicrobial resistance issues of the future. Diagnostic microbiology and infectious disease. 1996;25(4):213-217.	Title
170	Pulingam T, Parumasivam T, Gazzali AM, et al. Antimicrobial resistance: Prevalence, economic burden, mechanisms of resistance and strategies to overcome. European Journal of Pharmaceutical Sciences. 2022 2022/03/01/;170:106103.	Title
171	Owens RC, Ambrose PG. Antimicrobial stewardship and the role of pharmacokinetics–pharmacodynamics in the modern antibiotic era. Diagnostic Microbiology and Infectious Disease. 2007 2007/03/01/;57(3, Supplement):S77-S83.	Title
172	Lagacé-Wiens P, Adam H, Laing N, et al. Antimicrobial susceptibility of clinical isolates of Neisseria gonorrhoeae to alternative antimicrobials with therapeutic potential. Journal of Antimicrobial Chemotherapy. 2017;72(8):2273-2277.	Title
173	Quilter LA, Cyr SBS, Hong J, et al. Antimicrobial susceptibility of urogenital and extragenital Neisseria gonorrhoeae isolates among men who have sex with men: Strengthening the US Response to Resistant Gonorrhea and Enhanced Gonococcal Isolate Surveillance Project, 2018 to 2019. Sexually Transmitted Diseases. 2021;48(12S):S111-S117.	Title

174	Humphries RM, Schuetz AN. Antimicrobial Susceptibility Testing of Bacteria That Cause Gastroenteritis. Clinics in Laboratory Medicine. 2015 2015/06/01/;35(2):313-331.	Title
175	Jorgensen JH. Antimicrobial susceptibility testing of Haemophilus influenzae: An update. Antimicrobial Newsletter. 1989 1989/08/01/;6(8):65-68.	Title
176	McCue JD. Antimicrobial Therapy. Clinics in Geriatric Medicine. 1992 1992/11/01/;8(4):925-946.	Title
177	Spach DH. Antimicrobial Therapy.	Title
178	Henry NK, Hoecker JL, Rhodes KH. Antimicrobial Therapy for Infants and Children: Guidelines for the Inpatient and Outpatient Practice of Pediatric Infectious Diseases. Mayo Clinic Proceedings. 2000 2000/01/01/;75(1):86-97.	Title
179	Houang ET. Antimicrobial therapy in gynaecology. Current Obstetrics & Gynaecology. 1994 1994/06/01/;4(2):107-112.	Title
180	Liu P, Derendorf H. Antimicrobial tissue concentrations. Infectious Disease Clinics of North America. 2003 2003/09/01/;17(3):599-613.	Title
181	Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Disease-a-Month. 2001 2001/11/01/;47(11):537-585.	Title
182	Anon JB, Jacobs MR, Poole MD, et al. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg. 2004 Jan;130(1 Suppl):1-45.	Title
183	Antimicrobial treatment guidelines for acute bacterial rhinosinusitis: Sinus and Allergy Health Partnership *. Otolaryngology - Head and Neck Surgery. 2000 2000/07/01/;123(1, Part 2):S4-S31.	Title
184	Giebink GS, Canafax DM, Kempthorne J. Antimicrobial treatment of acute otitis media. The Journal of pediatrics. 1991;119(3):495-500.	Title

185	Giebink GS, Canafax DM. Antimicrobial treatment of otitis media. <i>Semin Respir Infect.</i> 1991 Jun;6(2):85-93.	Title
186	Cohen R, Raymond J, Launay E, et al. Antimicrobial treatment of urinary tract infections in children. <i>Archives de Pédiatrie.</i> 2017;24(12):S22-S25.	Title
187	Sinyakova L, Kosova I. Antimikrobnaya terapiya neoslozhnennykh infektsiy mochevykh putey. <i>Consilium Medicum.</i> 2014;16(7):29-33.	Title
188	Ward K, Azzarano L, Evans C, et al. Apparent absolute oral bioavailability in excess of 100% for a vitronectin receptor antagonist (SB-265123) in rat. I. Investigation of potential experimental and mechanistic explanations. <i>Xenobiotica.</i> 2004;34(4):353-366.	Animal
189	Prankerd RJ. Appendix B. Profiles of Drug Substances, Excipients and Related Methodology. Vol. 33: Academic Press; 2007. p. 425-626.	Title
190	Appendix D - Drugs in breast milk and the effect on the infant. In: Lawrence RA, Lawrence RM, editors. <i>Breastfeeding (Sixth Edition).</i> Philadelphia: Mosby; 2005. p. 832-994.	Title
191	Deshpande MM, Kasture VS, Gosavi SA. Application of HPLC and HPTLC for the simultaneous determination of cefixime trihydrate and ambroxol hydrochloride in pharmaceutical dosage form. <i>Eurasian J Anal Chem.</i> 2010;5(3):227-238.	Abstract
192	Lu W-Y, Li H-J, Li Q-Y, et al. Application of marine natural products in drug research. <i>Bioorganic &amp; Medicinal Chemistry.</i> 2021 2021/04/01;35:116058.	Title
193	Andes D, Anon J, Jacobs MR, et al. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections. <i>Clinics in Laboratory Medicine.</i> 2004 2004/06/01;24(2):477-502.	Title

194	Ravichandiran V, Sumithra M. Application of quality by design (CCD Technique) for simultaneous estimation of cefixime and ofloxacin by HPTLC method. <i>Int J Pharm Pharm Sci.</i> 2016;8(7):200-28.	Abstract
195	Gan L-SL, Thakker DR. Applications of the Caco-2 model in the design and development of orally active drugs: elucidation of biochemical and physical barriers posed by the intestinal epithelium. <i>Advanced Drug Delivery Reviews.</i> 1997 1997/01/15/;23(1):77-98.	Title
196	Rodríguez-Gascón A, Aguirre-Quiñonero A, Canut-Blasco A. Are oral cefuroxime axetil, cefixime and cefditoren pivoxil adequate to treat uncomplicated acute pyelonephritis after switching from intravenous therapy? A pharmacokinetic/pharmacodynamic perspective. <i>Enfermedades Infecciosas y Microbiología Clínica.</i> 2020;38(7):306-311.	Abstract
197	Mori N, Kodama T, Sakai A, et al. AS-924, a novel, orally active, bifunctional prodrug of ceftizoxime: physicochemical properties, oral absorption in animals, and antibacterial activity. <i>International Journal of Antimicrobial Agents.</i> 2001 2001/11/01/;18(5):451-461.	Animal
198	Bolognesi M, Spallarossa A. [Assessing the chemical cross-reaction from cefixime and some nonsteroidal anti-inflammatory agents in a soluble formulation]. <i>Boll Chim Farm.</i> 2001 Nov-Dec;140(6):445-7.	Not Accessible
199	Low DE. Assessment of the use of cefixime for switch therapy. <i>Infection.</i> 1995;23 Suppl 2:S91-4.	Abstract
200	Phongphaew W, Kongtia M, Kim K, et al. Association of bacterial isolates and antimicrobial susceptibility between prostatic fluid and urine samples in canine prostatitis with concurrent cystitis. <i>Theriogenology.</i> 2021 2021/10/01/;173:202-210.	Title
201	Author index. <i>Journal of Chromatography B: Biomedical Sciences and Applications.</i> 1987 1987/01/01/;422:361-364.	Title
202	Author index. <i>International Journal of Antimicrobial Agents.</i> 1994 1994/01/01/;3(4):281-283.	Title
203	Author Index. <i>Journal of Chromatography B.</i> 2005 2005/05/25/;819(2):347-350.	Title



204	Author index and Subject index Volumes 1–149. <i>International Journal of Pharmaceutics</i> . 1997 1997/01/01/;150:1-271.	Title
205	Author index volumes 351–400. <i>Journal of Chromatography A</i> . 1987 1987/01/01/;401:1-136.	Title
206	Author index volumes 401–450. <i>Journal of Chromatography A</i> . 1988 1988/01/01/;451:1-154.	Title
207	Author index volumes 551–600. <i>Journal of Chromatography A</i> . 1993 1993/04/02/;601(1):1-128.	Title
208	Authors. In: Enna SJ, Bylund DB, editors. <i>xPharm: The Comprehensive Pharmacology Reference</i> . New York: Elsevier; 2011. p. 1-107.	Title
209	Auto-Immunity, Allergy and Inflammation. <i>Journal of Investigative Dermatology</i> . 2014 2014/01/01/;134:S1-S17.	Title
210	Giri A, Karkey A, Dongol S, et al. Azithromycin and cefixime combination versus azithromycin alone for the out-patient treatment of clinically suspected or confirmed uncomplicated typhoid fever in South Asia: a randomised controlled trial protocol. <i>Wellcome Open Research</i> . 2021;6.	Abstract
211	Pacifico L, Chiesa C. Azithromycin in children: A critical review of the evidence. <i>Current Therapeutic Research</i> . 2002 2002/01/01/;63(1):54-76.	Title
212	Hoepelman IM, Schneider MME. Azithromycin: the first of the tissue-selective azalides. <i>International Journal of Antimicrobial Agents</i> . 1995 1995/05/01/;5(3):145-167.	Title
213	Bryskier A. <i>Bacillus anthracis</i> and antibacterial agents. <i>Clinical Microbiology and Infection</i> . 2002 2002/08/01/;8(8):467-478.	Title
214	Harris J-AS. Bacterial pneumonia in the 1990s. <i>Seminars in Pediatric Infectious Diseases</i> . 1995 1995/07/01/;6(3):142-148.	Title

215	Cappelletty DM, Rybak MJ. Bactericidal activities of cefprozil, penicillin, cefaclor, cefixime, and loracarbef against penicillin-susceptible and-resistant <i>Streptococcus pneumoniae</i> in an in vitro pharmacodynamic infection model. <i>Antimicrobial Agents and Chemotherapy</i> . 1996;40(5):1148-1152.	Abstract
216	Rolin O, Roche G, Bouanchaud D. Bactericidal activity of cefotaxime and cefixime in a kinetic model in vitro. <i>Presse Medicale[PRESSE MED]</i> . 1989;18(32).	Abstract
217	Takahata M, Sugiura Y, Shinmura Y, et al. Bactericidal activity of garenoxacin against in vitro biofilm formed by nontypeable <i>Haemophilus influenzae</i> . <i>Journal of Infection and Chemotherapy</i> . 2013 2013/01/01;19(3):441-446.	Title
218	Bedenic B, Vranes J, Suto S, et al. Bactericidal activity of oral $\beta$ -lactam antibiotics in plasma and urine versus isogenic <i>Escherichia coli</i> strains producing broad- and extended-spectrum $\beta$ -lactamases. <i>International Journal of Antimicrobial Agents</i> . 2005 2005/06/01;25(6):479-487.	Title
219	Gómez-Lus R. [Bacteriological aspects of acute otitis media [corrected]. <i>An Esp Pediatr</i> . 1991 Dec;35 Suppl 46:99-100.	Not Accessible
220	Toyonaga Y, Hatakeyama K, Yamori K, et al. Bacteriological, pharmacokinetic and clinical studies of 5% and 10% granules of cefdinir in the pediatric field. <i>The Japanese Journal of Antibiotics</i> . 1992;45(1):48-73.	Title
221	Toyonaga Y, Ishihara T, Sano T, et al. Bacteriological, pharmacokinetic and clinical studies of cefditoren pivoxil in the pediatric field. <i>The Japanese Journal of Antibiotics</i> . 1993;46(7):604-628.	Title
222	Shahbazi E, Morshedzadeh F, Zaeifi D. Bacteriostatic potency of Fe <sub>2</sub> O <sub>3</sub> against <i>Enterococcus faecalis</i> in synergy with antibiotics by DDST method. <i>Avicenna Journal of Medical Biotechnology</i> . 2019;11(2):176.	Title
223	Bignell C. BASHH guideline for gonorrhoea. <i>The Medical Society for the Study of Venereal Disease</i> ; 2004. p. 330-331.	Title

224	Motohiro T, Handa S, Yamada S, et al. Basic and clinical studies on cefditoren pivoxil in pediatric field. The Japanese Journal of Antibiotics. 1994;47(4):409-427.	Title
225	Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of $\beta$ -lactams, glycopeptides, and linezolid. Infectious Disease Clinics of North America. 2003 2003/09/01/;17(3):479-501.	Title
226	Zaman M, Hanif M, Hassan SSU, et al. Beta-Cyclodextrin and Maltodextrin Based Solid Dispersion of Meloxicam to Enhance the Solubility of Meloxicam; Formulation and In-vitro Evaluation. Journal of the Chemical Society of Pakistan. 2019;41(1):133-133.	Title
227	Danziger LH, Horn KS. Beta-lactam antibiotics. Drug Interactions in Infectious Diseases: Antimicrobial Drug Interactions: Springer; 2018. p. 1-56.	Title
228	Martin SI, Kaye KM. Beta-lactam antibiotics: Newer formulations and newer agents. Infectious Disease Clinics of North America. 2004 2004/09/01/;18(3):603-619.	Title
229	Novelli A, Mazzei T, Fallani S, et al. Betalactam therapy and intestinal flora [Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial]. Journal of chemotherapy (Florence, Italy). 1995;7 Suppl 1:25-31.	Title
230	Hinderling PH. Biased estimates of nonrenal clearance. Journal of pharmaceutical sciences. 2001;90(7):960-966.	Title
231	Wang X, Liu Y, Liu J, et al. A bifunctional electrochemical sensor for simultaneous determination of electroactive and non-electroactive analytes: A universal yet very effective platform serving therapeutic drug monitoring. Biosensors and Bioelectronics. 2022 2022/07/15/;208:114233.	Title
232	Shariatnia Z. Big family of nano- and microscale drug delivery systems ranging from inorganic materials to polymeric and stimuli-responsive carriers as well as drug-conjugates. Journal of Drug Delivery Science and Technology. 2021 2021/12/01/;66:102790.	Title

233	Akhtar M, Jamshaid M, Zaman M, et al. Bilayer tablets: A developing novel drug delivery system. Journal of Drug Delivery Science and Technology. 2020 2020/12/01/;60:102079.	Title
234	Westphal JF, Brogard JM, Jehl F, et al. [Biliary excretion and hepatic disposal of cefixime: experimental and clinical study]. Pathol Biol (Paris). 1992 May;40(5):538-44.	Not Accessible
235	Bhinge SD, Malipatil SM, Sonawane LV. Bioanalytical method development and validation for simultaneous estimation of cefixime and dicloxacillin by RP-HPLC in human plasma. Acta Chimica Slovenica. 2014;61(3):580-586.	Abstract
236	Pomeranz A, El-Khayam A, Korzets Z, et al. A bioassay evaluation of the urinary antibacterial efficacy of low dose prophylactic antibiotics in children with vesicoureteral reflux. The Journal of urology. 2000;164(3 Part 2):1070-1073.	Title
237	Pomeranz A, El-Khayam A, Korzets Z, et al. A bioassay evaluation of the urinary antibacterial efficacy of low dose prophylactic antibiotics in children with vesicoureteral reflux. J Urol. 2000 Sep;164(3 Pt 2):1070-3.	Title
238	Chaudhari R, Singh K, Kodgire P. Biochemical and Molecular Mechanisms of Antibiotic Resistance in Salmonella spp. Research in Microbiology. 2022 2022/08/06/:103985.	Title
239	Ammoo AM, Al-Tamimi DJ, Al-Mahroos MI, et al. Bioequivalence and Pharmacokinetic Comparison of Two Levofloxacin Oral Formulations in Arabic Healthy Men.	Title
240	Jeong E-J, Kang W-K, Kwon K-I. Bioequivalence of Cepirin Capsule to Suprax Capsule (Cefixime 100 mg). Journal of Pharmaceutical Investigation. 1999;29(2):145-149.	Abstract
241	Tctr. Bioequivalence Study of 100 mg Cefixime Capsules in Healthy Thai Volunteers. <a href="https://trialssearchwhoint/Trial2.aspx?TrialID=TCTR20170814002">https://trialssearchwhoint/Trial2.aspx?TrialID=TCTR20170814002</a> . 2017.	Extensive reading
242	Nct. Bioequivalence Study of Cefixime Trihydrate Dry Syrup in Indonesia Healthy Volunteers. <a href="https://clinicaltrials.gov/show/NCT04982861">https://clinicaltrials.gov/show/NCT04982861</a> . 2021.	Abstract

243	Zhang Y, He J-R, Wen A-D. Bioequivalency and pharmacokinetics of oral dispersion tablets of cefixime in healthy volunteers. CHINESE JOURNAL OF HOSPITAL PHARMACY. 2003;23(7):388-389.	Abstract
244	Kang WK, Woo JS, Kwon KI. Bioequivalency on the Comparative Bioavailability of Two Capsule Formulations of Cefixime in Human Volunteers. Korean Journal of Clinical Pharmacy. 1998;8(1):19-22.	Abstract
245	Ory J, Bricheux G, Robin F, et al. Biofilms in hospital effluents as a potential crossroads for carbapenemase-encoding strains. Science of The Total Environment. 2019 2019/03/20/;657:7-15.	Title
246	Regiel-Futyra A, Dąbrowski JM, Mazuryk O, et al. Bioinorganic antimicrobial strategies in the resistance era. Coordination Chemistry Reviews. 2017 2017/11/15/;351:76-117.	Title
247	Babadi D, Dadashzadeh S, Osouli M, et al. Biopharmaceutical and pharmacokinetic aspects of nanocarrier-mediated oral delivery of poorly soluble drugs. Journal of Drug Delivery Science and Technology. 2021 2021/04/01/;62:102324.	Title
248	Leitner F, Pursiano T, Buck R, et al. BMY 28100, a new oral cephalosporin. Antimicrobial agents and chemotherapy. 1987;31(2):238-243.	Abstract
249	Jones RN, Barry AL. BMY-28100, a new oral cephalosporin: antimicrobial activity against nearly 7,000 recent clinical isolates, comparative potency with other oral agents, and activity against beta-lactamase producing isolates. Diagnostic microbiology and infectious disease. 1988;9(1):11-26.	Abstract
250	van Saene HKF, Percival A. Bowel microorganisms—a target for selective antimicrobial control. Journal of Hospital Infection. 1991 1991/09/01/;19:19-41.	Title
251	Mmeje OO, Qin JZ, Wetmore MK, et al. Breakdown in the expedited partner therapy treatment cascade: from reproductive healthcare provider to the pharmacist [Journal: Article]. American Journal of Obstetrics and Gynecology. 2020;223(3):417.e1-417.e8.	Title

252	Sharma P, Vyas M, Sharma N, et al. Brief overview of pharmacological therapy for urinary tract infections. 2018.	Title
253	Eltantawy MNM. Bromometric analysis of Lamotrigine, Minoxidil and Cefixime. Asian Pharma Press. 2012;2:22-28.	Abstract
254	Shorr RI, Hoth AB, Rawls N, editors. Drugs for the Geriatric Patient. Philadelphia: W.B. Saunders; 2007. p. 173-320.	Title
255	Studdert VP, Gay CC, Hinchcliff KW, editors. Saunders Comprehensive Veterinary Dictionary (Fifth Edition). St. Louis (MO): W.B. Saunders; 2021. p. 168-295.	Title
256	Weiner CP, Buhimschi C. C. In: Weiner CP, Buhimschi C, editors. Drugs for Pregnant and Lactating Women (Second Edition). Philadelphia: W.B. Saunders; 2009. p. 120-251.	Title
257	SPRY DO, SNYDER NJ, KASHER JS. C (3)-cyclopropyl cepheems and carbacepheems. The Journal of Antibiotics. 1989;42(11):1653-1660.	Title
258	Boone CM, Waterval JCM, Lingeman H, et al. Capillary electrophoresis as a versatile tool for the bioanalysis of drugs—a review. Journal of Pharmaceutical and Biomedical Analysis. 1999 1999/09/02/;20(6):831-863.	Title
259	Levêque D, Gallion-Renault C, Monteil H, et al. Capillary electrophoresis for pharmacokinetic studies. Journal of Chromatography B: Biomedical Sciences and Applications. 1997;697(1-2):67-75.	Title
260	Sánchez-Hernández L, Marina ML. Capillary Electrophoresis—Antibiotics. Reference Module in Chemistry, Molecular Sciences and Chemical Engineering: Elsevier; 2016.	Title
261	Barre J. Caractéristiques pharmacocinétiques du céfixime. La Presse médicale (1983). 1989;18(32):1578-1582.	Title
262	Cooper RD. The carbacepheems: a new beta-lactam antibiotic class. The American journal of medicine. 1992;92(6):S2-S6.	Title

263	Tamai I, Tsuji A, Kin Y. Carrier-mediated transport of cefixime, a new cephalosporin antibiotic, via an organic anion transport system in the rat renal brush-border membrane. <i>J Pharmacol Exp Ther.</i> 1988 Jul;246(1):338-44.	Animal
264	Łowicki D, Przybylski P. Cascade synthetic strategies opening access to medicinal-relevant aliphatic 3- and 4-membered N-heterocyclic scaffolds. <i>European Journal of Medicinal Chemistry.</i> 2022 2022/08/05/;238:114438.	Title
265	Namoju R, Ismail M, Golla VK, et al. A case of acute generalized exanthematous pustulosis by cefixime with oral mucosal involvement. <i>Current Drug Safety.</i> 2020;15(3):236-239.	Abstract
266	Masetti M, Magalotti D, Martino E, et al. A Case of Acute Liver Failure during Ritonavir-Boosted Paritaprevir, Ombitasvir and Dasabuvir Therapy in a Patient with HCV Genotype 1b Cirrhosis. <i>Journal of Gastrointestinal &amp; Liver Diseases.</i> 2016;25(4).	Title
267	Dass P, Gulabani MM, Raikar S. A case of cefixime, ofloxacin combination tablet induced erythematous macules. <i>Indian Journal of Pharmacy Practice.</i> 2014;7(4).	Abstract
268	Naumann BD, Silverman KC, Dixit R, et al. Case studies of categorical data-derived adjustment factors. <i>Human and Ecological Risk Assessment: An International Journal.</i> 2001;7(1):61-105.	Title
269	Arsalan A, Ahmad I, Ali SA. Cefaclor: clinical, biochemical, analytical and stability aspects. <i>Advances in medicine and biology.</i> 2017;123:1-52.	Title
270	Appelbaum P. Cefdinir. <i>Clinical drug investigation.</i> 1995;9(3):54-64.	Title
271	Gerlach EH, Jones RN, Allen SD, et al. Cefdinir (FK482), an orally administered cephalosporin in vitro activity comparison against recent clinical isolates from five medical centers and determination of MIC quality control guidelines. <i>Diagnostic microbiology and infectious disease.</i> 1992;15(6):537-543.	Title

272	Guay DRP. Cefdinir: An advanced-generation, broad-spectrum oral cephalosporin. <i>Clinical Therapeutics</i> . 2002 2002/04/01/;24(4):473-489.	Title
273	Jones RN, Pfaller MA, Jacobs MR, et al. Cefditoren in vitro activity and spectrum: a review of international studies using reference methods. <i>Diagn Microbiol Infect Dis</i> . 2001 Sep-Oct;41(1-2):1-14.	Title
274	Capparelli FJ, Diaz MF, Hlavnik A, et al. Cefepime- and cefixime-induced encephalopathy in a patient with normal renal function. <i>Neurology</i> . 2005 Dec 13;65(11):1840.	Abstract
275	Bryson HM, Brogden RN. Cefetamet pivoxil. <i>Drugs</i> . 1993;45(4):589-621.	Title
276	Blouin RA, Stoeckel K. Cefetamet pivoxil clinical pharmacokinetics. <i>Clinical pharmacokinetics</i> . 1993;25(3):172-188.	Title
277	Kissling M. Cefetamet pivoxil: a review of clinical experience. <i>Médecine et Maladies Infectieuses</i> . 1992 1992/06/01/;22:565-575.	Title
278	Cullmann W, Edwards DJ, Kissling M, et al. Cefetamet pivoxil: a review of its microbiology, toxicology, pharmacokinetics and clinical efficacy. <i>International journal of antimicrobial agents</i> . 1992;1(4):175-191.	Title
279	Bryson HM, Brogden RN. Cefetamet pivoxil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. <i>Drugs</i> . 1993 Apr;45(4):589-621.	Title
280	Olszewski J. Cefiksym w leczeniu zapalenia zatok przynosowych i ucha środkowego—przegląd badań. <i>Świat Medycyny i Farmacji</i> . 2019 (10).	Title
281	Rafal'skiĭ VV, Divgan EV, Derevitskiĭ AV. [Cefixim: clinical pharmacology and role in therapy of urogenital infections]. <i>Urologiia</i> . 2011 Mar-Apr(2):63-6.	Not Accessible
282	Brogden RN, Campoli-Richards DM. Cefixime. <i>Drugs</i> . 1989;38(4):524-550.	Title
283	Castle SS. Cefixime. In: Enna SJ, Bylund DB, editors. <i>xPharm: The Comprehensive Pharmacology Reference</i> . New York: Elsevier; 2007. p. 1-5.	Title



284	Genvresse I, Carbon C. Cefixime. International Journal of Antimicrobial Agents. 1993;3(1):1-16.	Title
285	Guay D. Cefixime. Kucers' The Use of Antibiotics: CRC Press; 2017. p. 539-547.	Title
286	Langer N. Cefixime. Compendium. 2002.	Title
287	Leggett NJ, Caravaggio C, Rybak MJ. Cefixime. DICP. 1990;24(5):489-495.	Title
288	Long SS. Cefixime. Pediatric Annals. 1993;22(3):177-186.	Title
289	Markham A, Brogden RN. Cefixime. Drugs. 1995;49(6):1007-1022.	Title
290	Mogal P, Derle D. Cefixime. General, Class. 2017;4:2.	Title
291	Okeke CC, Srinivasan VS, Brittain HG. Cefixime. In: Brittain HG, editor. Analytical Profiles of Drug Substances and Excipients. Vol. 25: Academic Press; 1998. p. 39-83.	Title
292	Papich MG. Cefixime. In: Papich MG, editor. Papich Handbook of Veterinary Drugs (Fifth Edition). St. Louis (MO): W.B. Saunders; 2021. p. 143-145.	Title
293	加地正伸, 斎藤篤, 嶋田甚五郎, et al. Cefixime (CFIX) にかんする臨床的研究. CHEMOTHERAPY. 1985;33(Supplement6):284-292.	Title
294	加藤政仁, 加藤錠一, 鈴木幹三, et al. Cefixime (CFIX) に関する基礎的・臨床的検討. Chemotherapy. 1985;33(Supplement6):367-376.	Title
295	島田馨, 稲松孝思, 浦山京子, et al. Cefixime (CFIX) の老年者における薬動力学的・臨床的研究. Chemotherapy. 1985;33(Supplement6):298-303.	Title
296	清水武昭, 関根理, 吉田奎介. Cefixime (CFIX) の胆汁内移行に関する検討および胆道感染症の治療経験. Chemotherapy. 1985;33(Supplement6):491-498.	Title

297	Crews K, Stewart C, Panetta J, et al. Cefixime (CFX) enables higher plasma exposures of SN-38 to be achieved in pediatric patients receiving oral irinotecan (IRN). <i>Clinical Pharmacology &amp; Therapeutics</i> . 2004;75(2):P77-P77.	Abstract
298	ROCHE G. Cefixime (Oroken). <i>Concours médical (Paris)</i> . 1989;111(39):3477-3482.	Title
299	Furman WL, Crews KR, Billups C, et al. Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors. <i>Journal of clinical oncology</i> . 2006;24(4):563-570.	Abstract
300	Yesmin F, Islam S. Cefixime and Metals Complex Interaction: A systemic review on Drug-metals interaction J. <i>Pharmaceutics and Pharmacology Research</i> . 2020;3(1).	Title
301	Kumar S, Nirmal K, Nirmal AK, et al. Cefixime and Ofloxacin fixed dose combination induced petechial rash: a case report. <i>International Journal of Basic &amp; Clinical Pharmacology</i> . 2017;6(1):211.	Abstract
302	Morita M, Nakagawa H, Suzuki K. [Cefixime concentration in human prostatic tissue following 3-days of administration]. <i>Hinyokika Kyo</i> . 1991 Nov;37(11):1581-4.	Not Accessible
303	Karimian N, Gholivand M, Malekzadeh G. Cefixime detection by a novel electrochemical sensor based on glassy carbon electrode modified with surface imprinted polymer/multiwall carbon nanotubes. <i>Journal of Electroanalytical Chemistry</i> . 2016;771:64-72.	Abstract
304	CRISTOFARO G, GALIANO R, CAPILLO S, et al. Cefixime for the prophylaxis of urinary tract infections in children with malformative uropathies: an open study.	Abstract
305	Fiscella RG, Chow JM. Cefixime for treatment of maxillary sinusitis. <i>American Journal of Rhinology</i> . 1991;5(5):193-197.	Abstract
306	Egorova O, Kozlov S. CEFIXIME IN MANAGEMENT OF ENT INFECTIONS IN CHILDREN. <i>Current Pediatrics</i> . 2015;7(3):52-57.	Abstract

307	Quintiliani R. Cefixime in the treatment of patients with lower respiratory tract infections: results of US clinical trials. <i>Clinical therapeutics</i> . 1996;18(3):373-390.	Abstract
308	Fanos V, Cataldi L. Cefixime in urinary tract infections with special reference to pediatrics: overview. <i>Journal of chemotherapy</i> . 2001;13(2):112-117.	Abstract
309	Naber K. Cefixime in urinary tract infections.(Specific studies and literature review). <i>Infection</i> . 1990;18:S132-9.	Title
310	LP H, Racht E. Cefixime may be given with an aluminium-magnesium antacid. <i>InPharma</i> . 1989.	Abstract
311	Capelli O, Bonucchi M, Ragno T, et al. Cefixime once-a-day in the treatment of lower respiratory tract infections in adults. <i>Journal of chemotherapy (Florence, Italy)</i> . 1989;1(4 Suppl):775-778.	Abstract
312	Leroy A, Oser B, Grise P, et al. Cefixime penetration in human renal parenchyma. <i>Antimicrobial agents and chemotherapy</i> . 1995;39(6):1240-1242.	Abstract
313	Backhaus A, Tinzl J. Cefixime therapy in patients with proven gonorrhoea. <i>Infection</i> . 1990;18:S145-6.	Abstract
314	Natarajan R, Rajendran NN. Cefixime trihydrate loaded chitosan-alginate transdermal patches. <i>World Journal of Pharmaceutical Sciences</i> . 2014;997-1008.	Abstract
315	Samarinas M, Skriapas K, Mitsogiannis I, et al. Cefixime versus prulifloxacin as a prophylactic treatment for prostate biopsy: a randomized study. <i>Central European Journal of Urology</i> . 2020;73(4):544.	Extensive reading
316	Cox CE. Cefixime versus trimethoprim/sulfamethoxazole in treatment of patients with acute, uncomplicated lower urinary tract infections. <i>Urology</i> . 1989;34(5):322-326.	Abstract
317	Principi N, Marchisio P. Cefixime vs amoxicillin in the treatment of acute otitis media in infants and children. <i>Drugs</i> . 1991;42(4):25-29.	Abstract

318	김형기, 권준택, 손동렬, et al. Cefixime 경구제제의 생물학적 동등성 연구. 순천향의대논문집. 2004;10(1):77-80.	Title
319	구강은, 여러, 종류의, et al. Cefixime 의 치주병원성 세균 6 종에 대한 항균 효과. 대한치주과학회지: Vol. 2005;35(2).	Title
320	徳間洋二, 関口正己, 藤原友一, et al. Cefixime のラットにおける吸収, 分布, 排せつ, 代謝. 薬物動態. 1987;2(6):637-648.	Title
321	Iakovlev V. Cefixime--a new cephalosporin antibiotic for oral administration. Antibiotiki i khimioterapiia= Antibiotics and chemotherapy [sic]. 1994;39(1):51-62.	Abstract
322	Cefixime--a new oral cephalosporin. Med Lett Drugs Ther. 1989 Aug 11;31(798):73-5.	Abstract
323	Kumar V, Kalaiselvan V, Kumar AP, et al. Cefixime-associated acute generalized exanthematous pustulosis: Rare cases in India. Indian Journal of Pharmacology. 2018;50(4):204.	Abstract
324	Taheri-Ledari R, Fazeli A, Kashtiaray A, et al. Cefixime-Containing Silica Nanoseeds Coated by a Hybrid PVA-Gold Network with a Cys-Arg Dipeptide Conjugation: Enhanced Antimicrobial and Drug Release Properties. Langmuir. 2022 Jan 11;38(1):132-146.	Abstract
325	Taheri-Ledari R, Fazeli A, Kashtiaray A, et al. Cefixime-Containing Silica Nanoseeds Coated by a Hybrid PVA-Gold Network with a Cys-Arg Dipeptide Conjugation: Enhanced Antimicrobial and Drug Release Properties. Langmuir. 2021;38(1):132-146.	Abstract
326	Mirshahi R, Sardarinia M, Nilforushan N. Cefixime-induced angle closure and transient myopic shift in a healthy individual; A case report. American Journal of Ophthalmology Case Reports. 2020;20:100903.	Abstract
327	Al Haboob AAN. Cefixime-induced hepatotoxicity and acute renal failure: a case report. European Journal of Medical Case Reports. 2018;2(2):55-58.	Abstract

328	Anzellotti F, Ricciardi L, Monaco D, et al. Cefixime-induced nonconvulsive status epilepticus. Neurological Sciences. 2012;33(2):325-329.	Abstract
329	Bayram E, Bayram MT, Hiz S, et al. Cefixime-induced oculogyric crisis. Pediatric emergency care. 2012;28(1):55-56.	Abstract
330	Quintiliani R. Cefixime: a pharmacoeconomic perspective. Current therapeutic research. 1996;57(12):892-912.	Abstract
331	Ashraf MM, Javed I, Aslam B, et al. CEFIXIME: DISPOSITION KINETICS AND BIOAVAILABILITY COMPARISON OF TWO FORMULATIONS OF CEFIXIME IN HEALTHY ADULT MALE SUBJECTS. The Professional Medical Journal. 2015;22(07):959-965.	Not Accessible
332	Naber K, Kees F, Linden K. Cefixime: in vitro activity, pharmacokinetics. clinical efficacy and safety in the treatment of complicated UTIs. Adv Exp Clin Res. 1988;1:61-70.	Abstract
333	Brogden RN, Campoli-Richards DM. Cefixime. A review of its antibacterial activity. Pharmacokinetic properties and therapeutic potential. Drugs. 1989 Oct;38(4):524-50.	Title
334	Markham A, Brogden RN. Cefixime. A review of its therapeutic efficacy in lower respiratory tract infections. Drugs. 1995 Jun;49(6):1007-22.	Title
335	Di Nola F, Arione R, Bramato C. [Cefixime. Microbiologic, kinetic and clinical profile]. Minerva Med. 1991 Oct;82(10):633-56.	Not Accessible
336	Imada A, Hirai S. Cefotiam hexetil. International Journal of Antimicrobial Agents. 1995 1995/04/01/;5(2):85-99.	Title
337	Del Beccaro MA. Cefpodoxime proxetil. Pediatric Annals. 1993;22(3):187-196.	Title
338	Frampton JE, Brogden RN, Langtry HD, et al. Cefpodoxime proxetil. Drugs. 1992;44(5):889-917.	Title
339	Fulton B, Perry CM. Cefpodoxime proxetil. Paediatric drugs. 2001;3(2):137-158.	Title

340	Papich MG. Cefpodoxime Proxetil. In: Papich MG, editor. Papich Handbook of Veterinary Drugs (Fifth Edition). St. Louis (MO): W.B. Saunders; 2021. p. 152-154.	Title
341	Crauste-Manciet S, Huneau JF, Decroix MO, et al. Cefpodoxime proxetil esterase activity in rabbit small intestine: A role in the partial cefpodoxime absorption. International Journal of Pharmaceutics. 1997 1997/04/28/;149(2):241-249.	Animal
342	Todd WM. Cefpodoxime proxetil: a comprehensive review. International Journal of Antimicrobial Agents. 1994 1994/03/01/;4(1):37-62.	Title
343	Fulton B, Perry CM. Cefpodoxime proxetil: a review of its use in the management of bacterial infections in paediatric patients. Paediatr Drugs. 2001;3(2):137-58.	Title
344	Frampton JE, Brogden RN, Langtry HD, et al. Cefpodoxime proxetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs. 1992 Nov;44(5):889-917.	Title
345	Aggarwal A, Rath S. Cefpodoxime—utility in respiratory tract infections and typhoid fever. The Indian Journal of Pediatrics. 2004;71(5):413-415.	Title
346	Chugh K, Agrawal S. Cefpodoxime: pharmacokinetics and therapeutic uses. The Indian Journal of Pediatrics. 2003;70(3):227-231.	Title
347	Wiseman LR, Benfield P. Cefprozil. Drugs. 1993;45(2):295-317.	Title
348	Bhargava S, Lodha R, Kabra S. Cefprozil: A review. The Indian Journal of Pediatrics. 2003;70(5):395-400.	Title
349	Wiseman LR, Benfield P. Cefprozil. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic potential. Drugs. 1993 Feb;45(2):295-317.	Title
350	Jones R, Barry A. Ceftibuten (7432-S, SCH 39720): comparative antimicrobial activity against 4735 clinical isolates, beta-lactamase stability and broth microdilution quality control guidelines. European Journal of Clinical Microbiology and Infectious Diseases. 1988;7(6):802-807.	Title

351	Bauernfeind A. Ceftibuten and bactericidal kinetics comparative in vitro activity against enterobacteriaceae producing extended spectrum $\beta$ -lactamases. Diagnostic microbiology and infectious disease. 1991;14(1):89-92.	Title
352	Kearns GL, Young RA. Ceftibuten pharmacokinetics and pharmacodynamics. Clinical pharmacokinetics. 1994;26(3):169-189.	Title
353	Lo JY, Ho K, Leung AO, et al. Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection. Antimicrobial agents and chemotherapy. 2008;52(10):3564-3567.	Title
354	Herrera-Hidalgo L, Gil-Navarro M, Penchala SD, et al. Ceftriaxone pharmacokinetics by a sensitive and simple LC-MS/MS method: development and application. Journal of Pharmaceutical and Biomedical Analysis. 2020;189:113484.	Title
355	Unemo á, Golparian D, Hestner A. Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010. Eurosurveillance. 2011;16(6):19792.	Title
356	Anacona JR, Santaella J, Al-shemary RKR, et al. Ceftriaxone-based Schiff base transition metal(II) complexes. Synthesis, characterization, bacterial toxicity, and DFT calculations. Enhanced antibacterial activity of a novel Zn(II) complex against S. aureus and E. coli. Journal of Inorganic Biochemistry. 2021 2021/10/01;223:111519.	Title
357	Dellamonica P. Cefuroxime axetil. International Journal of Antimicrobial Agents. 1994 1994/03/01;4(1):23-36.	Title
358	Christian SS, Christian JS. The cephalosporin antibiotics. Primary Care Update for OB/GYNS. 1997 1997/09/01;4(5):168-174.	Abstract

359	Ribeiro AR, Sures B, Schmidt TC. Cephalosporin antibiotics in the aquatic environment: A critical review of occurrence, fate, ecotoxicity and removal technologies. Environmental Pollution. 2018 2018/10/01/;241:1153-1166.	Title
360	Alqahtani YS, Alyami BA, Alqarni AO, et al. Cephalosporin as Potent Urease and Tyrosinase Inhibitor: Exploration through Enzyme Inhibition, Kinetic Mechanism, and Molecular Docking Studies. BioMed Research International. 2022;2022.	Abstract
361	Chisholm SA, Mouton JW, Lewis DA, et al. Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink? Journal of antimicrobial chemotherapy. 2010;65(10):2141-2148.	Abstract
362	Shoaib MH, Naqvi SBS, Sheikh D, et al. Cephalosporin resistance and $\beta$ -lactamase production in clinical isolates of Staphylococcus aureus in Karachi. Pakistan Journal of Pharmaceutical Sciences. 2001;14(2):23-32.	Abstract
363	Parish LC, Witkowski JA. Cephalosporin therapy in dermatologic practice. Clinics in Dermatology. 1991 1991/10/01/;9(4):459-469.	Abstract
364	DePestel DD, Benninger MS, Danziger L, et al. Cephalosporin use in treatment of patients with penicillin allergies. Journal of the American Pharmacists Association. 2008 2008/07/01/;48(4):530-540.	Abstract
365	Kirkcaldy RD, Bolan GA, Wasserheit JN. Cephalosporin-resistant gonorrhea in North America. JAMA. 2013;309(2):185-187.	Abstract
366	Bryan JP. Cephalosporins and carbapenems. Current Opinion in Infectious Diseases. 1991;4(6):727-741.	Abstract
367	Del Rosso JQ. Cephalosporins in dermatology. Clinics in Dermatology. 2003 2003/01/01/;21(1):24-32.	Abstract
368	Del Rosso JQ. Cephalosporins in dermatology. Disease-a-Month. 2004 2004/06/01/;50(6):315-331.	Abstract
369	Frigo N, Guchev I, Sidorenko S, et al. Cephalosporins of the third generation for the treatment of gonorrhea. Vestnik dermatologii i venerologii. 2011;87(3):34-44.	Abstract



370	Harrison CJ, Bratcher D. Cephalosporins: a review. <i>Pediatrics in review</i> . 2008;29(8):264-273.	Title
371	Shahbaz K. Cephalosporins: pharmacology and chemistry. <i>Pharmaceutical and Biological Evaluations</i> . 2017.	Title
372	NH H, II I, OCH I. CH <sub>2</sub> -S N.	Title
373	Hamacher J, Luepke J, Reidenberg BE, et al. Changes in fecal flora and comparative multiple-dose pharmacokinetics of ceftibuten, cefpodoxime proxetil and amoxicillin/clavulanate. <i>Clinical microbiology and infection</i> . 1999;5(6):339-354.	Title
374	Chapitre 15 - Infectiologie. In: Jonville-Béra A-P, Vial T, editors. <i>Médicaments et Grossesse : Prescrire et évaluer le Risque</i> . Paris: Elsevier Masson; 2012. p. 117-156.	Title
375	Bourrillon A. Chapitre 18 - Pathologies infectieuses. In: Bourrillon A, editor. <i>Pédiatrie (Sixième Édition)</i> . Paris: Elsevier Masson; 2011. p. 427-539.	Title
376	Tungland B. Chapter 1 - Gut Microbiota, Early Colonization and Factors in its Development that Influence Health. In: Tungland B, editor. <i>Human Microbiota in Health and Disease</i> : Academic Press; 2018. p. 1-35.	Title
377	Davis JL. Chapter 2 - Pharmacologic Principles. In: Reed SM, Bayly WM, Sellon DC, editors. <i>Equine Internal Medicine (Fourth Edition)</i> : W.B. Saunders; 2018. p. 79-137.	Title
378	Dasgupta A. Chapter 3 - Advances in antibiotic measurement. In: Makowski GS, editor. <i>Advances in Clinical Chemistry</i> . Vol. 56: Elsevier; 2012. p. 75-104.	Title
379	Rehman K, Pervaiz W, Victor F, et al. Chapter 3 - Antibiotics' presence in hospitals and associated wastes. In: Hashmi MZ, editor. <i>Antibiotics and Antimicrobial Resistance Genes in the Environment</i> . Vol. 1: Elsevier; 2020. p. 28-38.	Title
380	Choudhary D, Goykar H, Kalyane D, et al. Chapter 3 - Dose, dosage regimen, and dose adjustment in organ failure. In: Tekade RK, editor. <i>Biopharmaceutics and Pharmacokinetics Considerations</i> . Vol. 1: Academic Press; 2021. p. 29-82.	Title

381	Simonazzi A, Cid AG, Villegas M, et al. Chapter 3 - Nanotechnology applications in drug controlled release. In: Grumezescu AM, editor. Drug Targeting and Stimuli Sensitive Drug Delivery Systems: William Andrew Publishing; 2018. p. 81-116.	Title
382	Mir MA, Nabi B, Ahlawat S, et al. Chapter 4 - Combating human bacterial infections: need for new antibacterial drugs and therapeutics. In: Mir MA, editor. Human Pathogenic Microbes: Academic Press; 2022. p. 71-102.	Title
383	Landowski CP, Suzuki Y, Hediger MA. CHAPTER 4 - The Mammalian Transporter Families. In: Alpern RJ, Hebert SC, editors. Seldin and Giebisch's The Kidney (Fourth Edition). San Diego: Academic Press; 2008. p. 91-146.	Title
384	Norrby SR. CHAPTER 5 - Antimicrobial agents and the kidneys. In: Finch RG, Greenwood D, Norrby SR, et al., editors. Antibiotic and Chemotherapy (Ninth Edition). London: W.B. Saunders; 2010. p. 60-67.	Title
385	Nasrollahzadeh M, Bidgoli NSS, Soleimani F, et al. Chapter 5 - Biomedical applications of biopolymer-based (nano)materials. In: Nasrollahzadeh M, editor. Biopolymer-Based Metal Nanoparticle Chemistry for Sustainable Applications: Elsevier; 2021. p. 189-332.	Title
386	Gumustas M, Sengel-Turk CT, Gumustas A, et al. Chapter 5 - Effect of Polymer-Based Nanoparticles on the Assay of Antimicrobial Drug Delivery Systems. In: Grumezescu AM, editor. Multifunctional Systems for Combined Delivery, Biosensing and Diagnostics: Elsevier; 2017. p. 67-108.	Title
387	Bartlett JD. Chapter 5 - Pharmacotherapeutic agents: basic principles and clinical applications. In: Stapleton F, editor. The Anterior Eye and Therapeutics. London: Butterworth-Heinemann; 2003. p. 166-207.	Title
388	Yaneva Z, Georgieva N. Chapter 5 - Physicochemical and morphological characterization of pharmaceutical nanocarriers and mathematical modeling of drug encapsulation/release mass transfer processes. In:	Title

	Grumezescu AM, editor. Nanoscale Fabrication, Optimization, Scale-Up and Biological Aspects of Pharmaceutical Nanotechnology: William Andrew Publishing; 2018. p. 173-218.	
389	Rai M, Kon K, Gade A, et al. Chapter 6 - Antibiotic Resistance: Can Nanoparticles Tackle the Problem? In: Kon K, Rai M, editors. Antibiotic Resistance: Academic Press; 2016. p. 121-143.	Title
390	Padmanaban G, Nagaraj VA. Chapter 6 - Curcumin From Turmeric as an Adjunct Drug? In: Atta ur R, editor. Studies in Natural Products Chemistry. Vol. 57: Elsevier; 2018. p. 179-202.	Title
391	Nicolle LE. Chapter 6 - Use of Quinolones in Urinary Tract Infection and Prostatitis. In: Andriole VT, editor. The Quinolones (Third Edition). San Diego: Academic Press; 2000. p. 203-225.	Title
392	Wanger A, Chavez V, Huang RSP, et al. Chapter 7 - Antibiotics, Antimicrobial Resistance, Antibiotic Susceptibility Testing, and Therapeutic Drug Monitoring for Selected Drugs. In: Wanger A, Chavez V, Huang RSP, et al., editors. Microbiology and Molecular Diagnosis in Pathology: Elsevier; 2017. p. 119-153.	Title
393	Alvarez-Elcoro S, Yao JDC. Chapter 7 - Antimicrobial Macrolides in Clinical Practice*. In: Ōmura S, editor. Macrolide Antibiotics (Second Edition). San Diego: Academic Press; 2003. p. 363-402.	Title
394	Garnero C, Zoppi A, Aloisio C, et al. Chapter 7 - Technological delivery systems to improve biopharmaceutical properties. In: Grumezescu AM, editor. Nanoscale Fabrication, Optimization, Scale-Up and Biological Aspects of Pharmaceutical Nanotechnology: William Andrew Publishing; 2018. p. 253-299.	Title
395	Gupta N, Rai DB, Jangid AK, et al. Chapter 7 - Use of nanotechnology in antimicrobial therapy. In: Gurtler V, Ball AS, Soni S, editors. Methods in Microbiology. Vol. 46: Academic Press; 2019. p. 143-172.	Title
396	DiCarlo RP, Martin DH. Chapter 7 - Use of the Quinolones in Sexually Transmitted Diseases. In: Andriole VT, editor. The Quinolones (Third Edition). San Diego: Academic Press; 2000. p. 227-254.	Title
397	Brunner M, Müller M. Chapter 7.1 Microdialysis in clinical drug delivery studies. In: Westerink BHC, Cremers TIFH, editors. Handbook of Behavioral Neuroscience. Vol. 16: Elsevier; 2006. p. 625-644.	Title

398	Maddison JE, Watson ADJ, Elliott J. Chapter 8 - Antibacterial drugs. In: Maddison JE, Page SW, Church DB, editors. Small Animal Clinical Pharmacology (Second Edition). Edinburgh: W.B. Saunders; 2008. p. 148-185.	Title
399	Sykes JE, Papich MG. Chapter 8 - Antibacterial Drugs. In: Sykes JE, editor. Canine and Feline Infectious Diseases. Saint Louis: W.B. Saunders; 2014. p. 66-86.	Title
400	Chauhan S, Jain K, Naqvi S. Chapter 8 - Dendrimers and its theranostic applications in infectious diseases. In: Jain K, Ahmad J, editors. Nanotheranostics for Treatment and Diagnosis of Infectious Diseases: Academic Press; 2022. p. 199-228.	Title
401	Memon N, Laghari SH, Qureshi T, et al. Chapter 9 - Quantum Dots Coated with Molecularly Imprinted Polymer as Probes for Environmentally and Medicinally Important Analytes. In: Denizli A, editor. Molecular Imprinting for Nanosensors and Other Sensing Applications: Elsevier; 2021. p. 223-253.	Title
402	Campbell KB. Chapter 10 - Antimicrobial agents and torsades de pointes. In: Tisdale JE, editor. Torsades de Pointes: Academic Press; 2022. p. 231-266.	Title
403	Misra SK, Pathak K. Chapter 10 - Drug nanocrystals as drug delivery systems. In: Mallakpour S, Hussain CM, editors. Industrial Applications of Nanocrystals: Elsevier; 2022. p. 153-178.	Title
404	McLawhon RW. Chapter 10 - Guidelines for the Monitoring of Vancomycin, Aminoglycosides and Certain Antibiotics. In: Dasgupta A, editor. Therapeutic Drug Monitoring. Boston: Academic Press; 2012. p. 197-218.	Title
405	Kaur A, Dang S. Chapter 10 - Synergistic combination of phytotherapeutics for infectious diseases. In: Baboota S, Ali J, editors. Nanocarriers for the Delivery of Combination Drugs: Elsevier; 2021. p. 337-392.	Title

406	Hamer DH, Gorbach SL. Chapter 10 - Use of the Quinolones for Treatment and Prophylaxis of Bacterial Gastrointestinal Infections. In: Andriole VT, editor. The Quinolones (Third Edition). San Diego: Academic Press; 2000. p. 303-323.	Title
407	Yolton DP, Haesaert SP. Chapter 11 - Anti-Infective Drugs. In: Bartlett JD, Jaanus SD, Fiscella RG, et al., editors. Clinical Ocular Pharmacology (Fifth Edition). Saint Louis: Butterworth-Heinemann; 2008. p. 175-220.	Title
408	Heck JV. Chapter 11. Antibacterial Agents. In: Allen RC, editor. Annual Reports in Medicinal Chemistry. Vol. 24: Academic Press; 1989. p. 101-110.	Title
409	Momper JD, Best BM. Chapter 12 - Clinical pharmacology of anti-infectives during pregnancy. In: Mattison D, Halbert L-A, editors. Clinical Pharmacology During Pregnancy (Second Edition). Boston: Academic Press; 2022. p. 177-202.	Title
410	Neofytos D, El-Beyrouty C, DeSimone JA. CHAPTER 12 - PHARMACOBIOLOGY OF INFECTIONS. In: Waldman SA, Terzic A, Egan LJ, et al., editors. Pharmacology and Therapeutics. Philadelphia: W.B. Saunders; 2009. p. 173-191.	Title
411	Gallagher JJ, Williams-Bouyer N, Villarreal C, et al. Chapter 12 - Treatment of infection in burns. In: Herndon DN, editor. Total Burn Care (Third Edition). Edinburgh: W.B. Saunders; 2007. p. 136-176.	Title
412	Farrington M. Chapter 13 - Antibacterial drugs. In: Bennett PN, Brown MJ, Sharma P, editors. Clinical Pharmacology (Eleventh Edition). Oxford: Churchill Livingstone; 2012. p. 173-190.	Title
413	Isoherranen N, Burbacher TM. CHAPTER 13 - The Use of Nonhuman Primates in Evaluating the Safety of Therapeutic Medications Used During Pregnancy. In: Burbacher TM, Sackett GP, Grant KS, editors. Primate Models of Children's Health and Developmental Disabilities. New York: Academic Press; 2008. p. 325-375.	Title

414	Telekes A, HegedŰS M, Kiss I. Chapter 13 - Therapeutic drug monitoring and measurement of drug concentrations using mass spectrometry. In: V��key K, Telekes A, Vertes A, editors. Medical Applications of Mass Spectrometry. Amsterdam: Elsevier; 2008. p. 263-289.	Title
415	Greenwood D. CHAPTER 13 - $\beta$ -Lactam antibiotics: cephalosporins. In: Finch RG, Greenwood D, Norrby SR, et al., editors. Antibiotic and Chemotherapy (Ninth Edition). London: W.B. Saunders; 2010. p. 170-199.	Title
416	Brighty KE, McGuirk PR. Chapter 13. Antibacterial Agents. In: Bristol JA, editor. Annual Reports in Medicinal Chemistry. Vol. 26: Academic Press; 1991. p. 123-132.	Title
417	Walsh TF. Chapter 13. Beta-Lactam Antibiotics. In: Allen RC, editor. Annual Reports in Medicinal Chemistry. Vol. 23: Academic Press; 1988. p. 121-131.	Title
418	Thielman NM, Guerrant RL, Weller PF, et al. Chapter 14 - Chemotherapy of Bacterial, Fungal, and Viral Diseases. In: Guerrant RL, Walker DH, Weller PF, editors. Tropical Infectious Diseases (Second Edition). Philadelphia: Churchill Livingstone; 2006. p. 169-194.	Title
419	Savoia MC. Chapter 16 - Bacterial, Fungal, and Parasitic Disease. In: Burrow GN, Duffy TP, Copel JA, editors. Medical Complications During Pregnancy (Sixth Edition). Philadelphia: W.B. Saunders; 2004. p. 305-345.	Title
420	Krishnamurthy A, Palombo E. Chapter 17 - Current therapeutics and prophylactic approaches to treat pneumonia. In: Kon K, Rai M, editors. The Microbiology of Respiratory System Infections. Vol. 1: Academic Press; 2016. p. 263-279.	Title
421	Naveed M, Chaudhry Z, Bukhari SA, et al. Chapter 19 - Antibiotics resistance mechanism. In: Hashmi MZ, editor. Antibiotics and Antimicrobial Resistance Genes in the Environment. Vol. 1: Elsevier; 2020. p. 292-312.	Title

422	Gökaltun A, Çetin K, Alharthi S, et al. Chapter 19 - Chromatographic nano-column technology and its application in beverage analysis. In: Amrane A, Rajendran S, Nguyen TA, et al., editors. Nanotechnology in the Beverage Industry: Elsevier; 2020. p. 549-584.	Title
423	dos Santos CA, Rai M, de Oliveira JM, et al. Chapter 19 - Curcumin and related antioxidants: applications to tissue pathology. In: Preedy VR, editor. Pathology: Academic Press; 2020. p. 197-204.	Title
424	Klein JO, Bluestone CD. CHAPTER 19 - OTITIS MEDIA. In: Feigin RD, Cherry JD, Demmler-Harrison GJ, et al., editors. Feigin and Cherry's Textbook of Pediatric Infectious Diseases (Sixth Edition). Philadelphia: W.B. Saunders; 2009. p. 216-237.	Title
425	DiVall MV, Ziegler KA. Chapter 19 - Pharmacologic Agents. In: Paz JC, West MP, editors. Acute Care Handbook for Physical Therapists (Fourth Edition). St. Louis: W.B. Saunders; 2014. p. 409-450.	Title
426	Maheshwari R, Kuche K, Mane A, et al. Chapter 20 - Manipulation of Physiological Processes for Pharmaceutical Product Development. In: Tekade RK, editor. Dosage Form Design Considerations: Academic Press; 2018. p. 701-729.	Title
427	Tambe V, Pande S, Gadeval A, et al. Chapter 20 - Microdialysis: an emerging technique for pharmacokinetic–pharmacodynamic profiling. In: Tekade RK, editor. Biopharmaceutics and Pharmacokinetics Considerations. Vol. 1: Academic Press; 2021. p. 601-616.	Title
428	Mackell SM, Anderson SA. Chapter 20 - The Pregnant and Breast-feeding Traveler. In: Keystone JS, Kozarsky PE, Freedman DO, et al., editors. Travel Medicine (Second Edition). Edinburgh: Mosby; 2008. p. 211-222.	Title
429	Macek K, Macek J. Chapter 20 Drugs. In: Heftmann E, editor. Journal of Chromatography Library. Vol. 51: Elsevier; 1992. p. B393-B445.	Title

430	Subramani PA, Panati K, Lebaka VR, et al. Chapter 21 - Nanostructures for Curcumin Delivery: Possibilities and Challenges. In: Grumezescu AM, editor. Nano- and Microscale Drug Delivery Systems: Elsevier; 2017. p. 393-418.	Title
431	Pacios-Michelena S, García-García JD, Ramos-González R, et al. Chapter 25 - Nanocarrier-based formulations: Concepts and applications. In: Abd-Elsalam KA, Murugan K, editors. Bio-Based Nanoemulsions for Agri-Food Applications: Elsevier; 2022. p. 413-439.	Title
432	Midtvedt T. Chapter 25 - Penicillins, cephalosporins, other beta-lactam antibiotics, and tetracyclines. In: Aronson JK, editor. Side Effects of Drugs Annual. Vol. 31: Elsevier; 2009. p. 413-425.	Title
433	Toussaint KA, Gallagher JC. Chapter 25 - Penicillins, cephalosporins, other beta-lactam antibiotics, and tetracyclines. In: Aronson JK, editor. Side Effects of Drugs Annual. Vol. 35: Elsevier; 2014. p. 447-461.	Title
434	Vardanyan R, Hruby V. Chapter 30 - Antibiotics. In: Vardanyan R, Hruby V, editors. Synthesis of Best-Seller Drugs. Boston: Academic Press; 2016. p. 573-643.	Title
435	Pelton SI. CHAPTER 31 - Otitis Media. In: Long SS, editor. Principles and Practice of Pediatric Infectious Disease (Third Edition). Edinburgh: W.B. Saunders; 2008. p. 221-230.	Title
436	Strupczewski JD, Ellis DB. Chapter 34. To Market, To Market – 1992. In: Bristol JA, editor. Annual Reports in Medicinal Chemistry. Vol. 28: Academic Press; 1993. p. 325-341.	Title
437	Crawford SE, Daum RS. Chapter 35 - Bacterial Pneumonia, Lung Abscess, and Empyema. In: Taussig LM, Landau LI, editors. Pediatric Respiratory Medicine (Second Edition). Philadelphia: Mosby; 2008. p. 501-553.	Title
438	Mitchell MA. Chapter 36 - Therapeutics. In: Mader DR, editor. Reptile Medicine and Surgery (Second Edition). Saint Louis: W.B. Saunders; 2006. p. 631-664.	Title



439	Sáez-Llorens X, McCracken GH. Chapter 37 - Clinical Pharmacology of Antibacterial Agents. In: Remington JS, Klein JO, Wilson CB, et al., editors. Infectious Diseases of the Fetus and Newborn Infant (Sixth Edition). Philadelphia: W.B. Saunders; 2006. p. 1223-1267.	Title
440	Barry B, Muffat-Joly M. Chapter 43 - Gerbil Model of Acute Otitis Media. In: Zak O, Sande MA, editors. Handbook of Animal Models of Infection. London: Academic Press; 1999. p. 375-384.	Title
441	Sharma S, Anthonisen N. Chapter 54 - Antibiotics. In: Barnes PJ, Drazen JM, Rennard S, et al., editors. Asthma and COPD. London: Academic Press; 2002. p. 573-585.	Title
442	Hay P, Pittrof R. CHAPTER 55 - Infections in pregnancy. In: Finch RG, Greenwood D, Norrby SR, et al., editors. Antibiotic and Chemotherapy (Ninth Edition). London: W.B. Saunders; 2010. p. 702-717.	Title
443	Kakar S, Mindel A. CHAPTER 56 - Sexually transmitted diseases. In: Finch RG, Greenwood D, Norrby SR, et al., editors. Antibiotic and Chemotherapy (Ninth Edition). London: W.B. Saunders; 2010. p. 718-742.	Title
444	Igietseme JU, Omosun Y, Black CM. Chapter 78 - Bacterial Sexually Transmitted Infections (STIs): A Clinical Overview**Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. In: Tang Y-W, Sussman M, Liu D, et al., editors. Molecular Medical Microbiology (Second Edition). Boston: Academic Press; 2015. p. 1403-1420.	Title
445	Estripeaut D, Sáez-Llorens X. CHAPTER 78 - PERINATAL BACTERIAL DISEASES. In: Feigin RD, Cherry JD, Demmler-Harrison GJ, et al., editors. Feigin and Cherry's Textbook of Pediatric Infectious Diseases (Sixth Edition). Philadelphia: W.B. Saunders; 2009. p. 979-1020.	Title
446	Matsson P, Giacomini KM, Craig Brater D. Chapter 95 - Renal Disposition of Drugs and Translation to Dosing Strategies. In: Alpern RJ, Moe OW, Caplan M, editors. Seldin and Giebisch's The Kidney (Fifth Edition): Academic Press; 2013. p. 3185-3214.	Title

447	Dagan R, Greenberg D, Jacobs MR, et al. CHAPTER 96 - PNEUMOCOCCAL INFECTIONS. In: Feigin RD, Cherry JD, Demmler-Harrison GJ, et al., editors. Feigin and Cherry's Textbook of Pediatric Infectious Diseases (Sixth Edition). Philadelphia: W.B. Saunders; 2009. p. 1288-1342.	Title
448	Koh AY, Pizzo PA. CHAPTER 99 - Fever and Granulocytopenia. In: Long SS, editor. Principles and Practice of Pediatric Infectious Disease (Third Edition). Edinburgh: W.B. Saunders; 2008. p. 563-570.	Title
449	Finch RG. Chapter 129 - Principles of anti-infective therapy. In: Cohen J, Opal SM, Powderly WG, editors. Infectious Diseases (Third Edition). London: Mosby; 2010. p. 1275-1287.	Title
450	Noel GJ, Kendler JS, Hartman BJ, et al. Chapter 134 - $\beta$ -Lactam antibiotics. In: Cohen J, Opal SM, Powderly WG, editors. Infectious Diseases (Third Edition). London: Mosby; 2010. p. 1340-1354.	Title
451	Shaw SP. Chapter 195 - Penicillins and Cephalosporins. In: Silverstein DC, Hopper K, editors. Small Animal Critical Care Medicine. Saint Louis: W.B. Saunders; 2009. p. 828-829.	Title
452	Michelow IC, McCracken GH. CHAPTER 248 - ANTIBACTERIAL THERAPEUTIC AGENTS. In: Feigin RD, Cherry JD, Demmler-Harrison GJ, et al., editors. Feigin and Cherry's Textbook of Pediatric Infectious Diseases (Sixth Edition). Philadelphia: W.B. Saunders; 2009. p. 3178-3227.	Title
453	Raszka WV. Chapter 284 - Antimicrobials. In: Osborn LM, DeWitt TG, First LR, et al., editors. Pediatrics. Philadelphia: Mosby; 2005. p. 1808-1828.	Title
454	Christenson JC, Korgenski EK. CHAPTER 286 - Laboratory Diagnosis of Infection Due to Bacteria, Fungi, Parasites, and Rickettsiae. In: Long SS, editor. Principles and Practice of Pediatric Infectious Disease (Third Edition). Edinburgh: W.B. Saunders; 2008. p. 1341-1352.	Title
455	Neely MN, Reed MD. CHAPTER 291 - Pharmacokinetic–Pharmacodynamic Basis of Optimal Antibiotic Therapy. In: Long SS, editor. Principles and Practice of Pediatric Infectious Disease (Third Edition). Edinburgh: W.B. Saunders; 2008. p. 1404-1420.	Title

456	Bradley JS, Sauberan J. CHAPTER 292 - Antimicrobial Agents. In: Long SS, editor. Principles and Practice of Pediatric Infectious Disease (Third Edition). Edinburgh: W.B. Saunders; 2008. p. 1420-1452.	Title
457	Darwish IA, Darwish HW, Bakheit AH, et al. Chapter Five - Irbesartan (a comprehensive profile). In: Al-Majed AA, editor. Profiles of Drug Substances, Excipients and Related Methodology. Vol. 46: Academic Press; 2021. p. 185-272.	Title
458	Mostafa GAE, Al-Otaibi YH, Al-Badr AA. Chapter One - Cefpodoxime proxetil. Profiles of Drug Substances, Excipients and Related Methodology. Vol. 44: Academic Press; 2019. p. 1-165.	Title
459	Al Omari MMH, Jaafari DS, Al-Sou'od KA, et al. Chapter Seven - Moxifloxacin Hydrochloride. In: Brittain HG, editor. Profiles of Drug Substances, Excipients and Related Methodology. Vol. 39: Academic Press; 2014. p. 299-431.	Title
460	Kuriyama T, Karasawa T, Williams DW. Chapter Thirteen - Antimicrobial Chemotherapy: Significance to Healthcare. In: Percival SL, Williams DW, Randle J, et al., editors. Biofilms in Infection Prevention and Control. Boston: Academic Press; 2014. p. 209-244.	Title
461	Al-Badr AA, Alasseiri FA. Chapter Two - Cefdinir. In: Brittain HG, editor. Profiles of Drug Substances, Excipients and Related Methodology. Vol. 39: Academic Press; 2014. p. 41-112.	Title
462	Poschet JF, HammondPeter D, Fairclough SM. Characterisation of penicillin-G uptake in rabbit small-intestinal brush-border membrane vesicles. Biochimica et Biophysica Acta (BBA) - Biomembranes. 1996 1996/01/31;1278(2):233-240.	Animal
463	Benkhelifa S, Decroix M-O, Arnaud P, et al. Characteristics of Cephalexin transport across isolated rabbit ileum. International journal of pharmaceutics. 1997;159(1):115-125.	Animal
464	Mura P, Valleri M, Baldanzi S, et al. Characterization and evaluation of the performance of different calcium and magnesium salts as excipients for direct compression. Int J Pharm. 2019 Aug 15;567:118454.	Title

465	Maestrelli F, Jug M, Cirri M, et al. Characterization and microbiological evaluation of chitosan-alginate microspheres for cefixime vaginal administration. <i>Carbohydrate polymers</i> . 2018;192:176-183.	Abstract
466	Nagai J, Taogoshi T, Tokunaga A, et al. Characterization of Prostaglandin E1 Transport in Rat Renal Brush-border Membrane. <i>Drug Metabolism and Pharmacokinetics</i> . 2006 2006/01/01/;21(3):186-193.	Animal
467	Epling D. Characterization of the Intestinal Permeability and Oral Absorption of Valacyclovir in Wildtype and huPepT1 Transgenic Mice 2019.	Animal
468	Friedman DI, Amidon GL. Characterization of the intestinal transport parameters for small peptide drugs. <i>Journal of Controlled Release</i> . 1990 1990/08/01/;13(2):141-146.	Title
469	Oh DM, Sinko PJ, Amidon GL. Characterization of the oral absorption of some beta-lactams: effect of the alpha-amino side chain group. <i>J Pharm Sci</i> . 1993 Sep;82(9):897-900.	Title
470	Goldstein FW. Choice of an oral beta-lactam antibiotic for infections due to penicillin-resistant <i>Streptococcus pneumoniae</i> . <i>Scand J Infect Dis</i> . 1997;29(3):255-7.	Title
471	Nicolau DP, Quintiliani R. Choosing between the New Cephalosporin Antibiotics. <i>Pharmacoeconomics</i> . 1994;5(2):34-39.	Abstract
472	Marzo A, Dal Bo L. Chromatography as an analytical tool for selected antibiotic classes: a reappraisal addressed to pharmacokinetic applications. <i>Journal of Chromatography A</i> . 1998;812(1-2):17-34.	Title
473	Berlioz F, Lepere-Prevot B, Julien S, et al. Chronic nifedipine dosing enhances cephalexin bioavailability and intestinal absorption in conscious rats. <i>Drug metabolism and disposition</i> . 2000;28(11):1267-1269.	Animal
474	LeBel M. Ciprofloxacin: chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions. <i>Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy</i> . 1988;8(1):3-30.	Title

475	Hardy DJ, Guay DR, Jones RN. Clarithromycin, a unique macrolide: a pharmacokinetic, microbiological, and clinical overview. <i>Diagnostic microbiology and infectious disease</i> . 1992;15(1):39-53.	Title
476	Birgy A, Madhi F, Jung C, et al. Clavulanate combinations with mecillinam, cefixime or cefpodoxime against ESBL-producing Enterobacterales frequently associated with bla OXA-1 in a paediatric population with febrile urinary tract infections. <i>Journal of Antimicrobial Chemotherapy</i> . 2021;76(11):2839-2846.	Abstract
477	Saudagar PS, Survase SA, Singhal RS. Clavulanic acid: A review. <i>Biotechnology Advances</i> . 2008 2008/07/01;26(4):335-351.	Title
478	Chambers ST, Murdoch DR, Pearce MJ. Clinical and economic considerations in the use of third-generation oral cephalosporins. <i>PharmacoEconomics</i> . 1995;7(5):416-427.	Abstract
479	Edlund C, Ternhag A, Skoog Ståhlgren G, et al. The clinical and microbiological efficacy of temocillin versus cefotaxime in adults with febrile urinary tract infection, and its effects on the intestinal microbiota: a randomised multicentre clinical trial in Sweden. <i>The Lancet Infectious Diseases</i> . 2022 2022/03/01;22(3):390-400.	Title
480	Canafax DM, Giebink GS. Clinical and pharmacokinetic basis for the antimicrobial treatment of acute otitis media. <i>Otolaryngologic Clinics of North America</i> . 1991;24(4):859-875.	Title
481	Saito A. Clinical Breakpoints for Antimicrobial Agents in Pulmonary Infections and Sepsis: Report of The Committee for Japanese Standards for Antimicrobial Susceptibility Testing for Bacteria. <i>Journal of Infection and Chemotherapy</i> . 1995 1995/01/01;1(1):83-88.	Title
482	Gehanno P, Boucot I, Berche P, et al. Clinical efficacy and tolerability of cefixime in the treatment of acute sinusitis. <i>Drugs</i> . 1991;42(4):19-24.	Abstract
483	Cohen R. Clinical efficacy of cefpodoxime in respiratory tract infection. <i>Journal of Antimicrobial Chemotherapy</i> . 2002;50(suppl_1):23-27.	Title

484	Meguro H, Arimasu O, Sohda H, et al. Clinical evaluation of cefixime in children. The Japanese Journal of Antibiotics. 1986;39(4):1007-1019.	Abstract
485	Aihara R, Kobashi H, Nishioka A, et al. Clinical experience with cefixime in the pediatric field. The Japanese Journal of Antibiotics. 1986;39(4):1138-1148.	Abstract
486	Furukawa S, Okada T. Clinical experience with cefixime in the pediatric infections. The Japanese Journal of Antibiotics. 1986;39(4):1128-1137.	Abstract
487	Cohen R. Clinical experience with cefpodoxime proxetil in acute otitis media. The Pediatric Infectious Disease Journal. 1995;14(4 Suppl):S12-8.	Title
488	Young LS. Clinical infections. Antimicrobial Newsletter. 1985 1985/08/01;2(8):57-59.	Title
489	Kadhiravan T, Wig N, Kapil A, et al. Clinical outcomes in typhoid fever: adverse impact of infection with nalidixic acid-resistant Salmonella typhi. BMC Infect Dis. 2005 May 18;5:37.	Title
490	Garau J. Clinical perspectives on the management of community-acquired pneumonia. Diagnostic Microbiology and Infectious Disease. 1996 1996/08/01;25(4):205-211.	Title
491	Shiu J, Ting G, Kiang TK. Clinical pharmacokinetics and pharmacodynamics of delafloxacin. European Journal of Drug Metabolism and Pharmacokinetics. 2019;44(3):305-317.	Title
492	Reed MD. Clinical pharmacokinetics of amoxicillin and clavulanate. The Pediatric infectious disease journal. 1996;15(10):949-954.	Title
493	Meyers BR, Wilkinson P. Clinical pharmacokinetics of antibacterial drugs in the elderly. Clinical pharmacokinetics. 1989;17(6):385-395.	Title
494	Westphal J-F, Brogard J-M. Clinical pharmacokinetics of newer antibacterial agents in liver disease. Clinical pharmacokinetics. 1993;24(1):46-58.	Title

495	Klepser ME, Marangos MN, Patel KB, et al. Clinical pharmacokinetics of newer cephalosporins. <i>Clinical pharmacokinetics</i> . 1995;28(5):361-384.	Abstract
496	Stoeckel K, Hayton WL, Edwards DJ. Clinical pharmacokinetics of oral cephalosporins. <i>Oral Cephalosporins</i> . 1995;47:34-71.	Abstract
497	Lavy E, Ziv G, Aroch I, et al. Clinical pharmacologic aspects of cefixime in dogs. <i>Am J Vet Res</i> . 1995 May;56(5):633-8.	Animal
498	Ziv G, Lavy E, Glickman A, et al. Clinical pharmacology of cefixime in unweaned calves. <i>Journal of Veterinary Pharmacology and Therapeutics</i> . 1995;18(2):94-100.	Animal
499	Nakazawa S, Sato H, Narita A, et al. Clinical studies of cefixime granules in pediatrics. <i>The Japanese Journal of Antibiotics</i> . 1986;39(4):1020-1034.	Abstract
500	Nishimura T, Takashima T, Tabuki K, et al. Clinical studies of cefixime in pediatric field. <i>The Japanese Journal of Antibiotics</i> . 1986;39(4):1115-1127.	Abstract
501	Hosoda T, Masuda M, Miyao M, et al. Clinical studies on cefixime in pediatrics. <i>The Japanese Journal of Antibiotics</i> . 1986;39(4):1149-1156.	Abstract
502	ChiCtr. Clinical study for pharmacokinetics and coefficient of variation of cefixime granules [Trial registry record; Clinical trial protocol]. <a href="http://www.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000032945">http://www.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000032945</a> . 2020.	Abstract
503	Haruta T, Kuroki S, Kobayashi Y. Clinical study on cefixime granules in the field of pediatrics. <i>The Japanese Journal of Antibiotics</i> . 1986;39(4):1106-1114.	Abstract
504	Chiu C, Lin T, Ou J. A clinical trial comparing oral azithromycin, cefixime and no antibiotics in the treatment of acute uncomplicated <i>Salmonella enteritis</i> in children. <i>Journal of paediatrics and child health</i> . 1999;35(4):372-374.	Abstract

505	Mehta SN, Stafylis C, Tellalian DM, et al. Clinical trial protocol to evaluate the efficacy of cefixime in the treatment of early syphilis. <i>Trials</i> . 2020;21(1):1-9.	Abstract
506	Ogawa R, Echizen H. Clinically significant drug interactions with antacids. <i>Drugs</i> . 2011;71(14):1839-1864.	Title
507	Dhahir S, Mohammed N, editors. Cloud point extraction of Cefixime drug by direct (UV-Vis) spectrophotometer and indirect (Flame Atomic Absorption) technique. <i>Journal of Physics: Conference Series</i> ; 2019: IOP Publishing.	Abstract
508	Jacobs MR. Combating resistance: application of the emerging science of pharmacokinetics and pharmacodynamics. <i>International journal of antimicrobial agents</i> . 2007;30:122-126.	Title
509	Yu M, Gu X, Qu Y, et al. Combination Therapy with TCM Preparation Kumu Injection and Azithromycin against Bacterial Infection and Inflammation: In Vitro and In Vivo. <i>Evidence-Based Complementary and Alternative Medicine</i> . 2022;2022.	Title
510	Jones RN, Johnson DM. Combinations of orally administered beta-lactams to maximize spectrum and activity against drug-resistant respiratory tract pathogens: I. Synergy studies of amoxicillin and cefixime with <i>Streptococcus pneumoniae</i> . <i>Diagn Microbiol Infect Dis</i> . 1998 Jun;31(2):373-6.	Title
511	Madhi F, Biscardi S, Bingen E, et al. Combined Relay Therapy With Oral Cefixime and Clavulanate for Febrile Urinary Tract Infection Caused by Extended-Spectrum $\beta$ -lactamase-producing <i>Escherichia coli</i> . <i>The Pediatric infectious disease journal</i> . 2013;32(1):96-97.	Abstract
512	Zhu L, Wang H. Commentary on "Beta-Lactam Antibiotics as A Possible Novel Therapy for Managing Epilepsy and Autism, A Case Report and Review of Literature". <i>Iranian Journal of Child Neurology</i> . 2018;12(3):139-140.	Title



513	Hernández Marco R, Guillén Olmos E, Bretón-Martínez JR, et al. Community-acquired febrile urinary tract infection caused by extended-spectrum beta-lactamase-producing bacteria in hospitalised infants. <i>Enfermedades infecciosas y microbiología clinica</i> (English ed). 2017 2017/05/01/;35(5):287-292.	Title
514	Granton JT, Grossman RF. COMMUNITY-ACQUIRED PNEUMONIA IN THE ELDERLY PATIENT: Clinical Features, Epidemiology, and Treatment. <i>Clinics in Chest Medicine</i> . 1993 1993/09/01/;14(3):537-553.	Title
515	Nies B. Comparative activity of cefixime and cefaclor in an in vitro model simulating human pharmacokinetics. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> . 1989;8(6):558-561.	Abstract
516	Goldstein F, Kitzis MD, Gutmann L, et al. Comparative activity of oral cephalosporins against $\beta$ -lactamase producing pathogens. <i>Médecine et Maladies Infectieuses</i> . 1992 1992/06/01/;22:535-543.	Abstract
517	Goonetilleke A, Dev D, Aziz I, et al. A comparative analysis of pharmacokinetics of ceftriaxone in serum and pleural fluid in humans: a study of once daily administration by intramuscular and intravenous routes. <i>Journal of Antimicrobial Chemotherapy</i> . 1996;38(6):969-976.	Title
518	Verbist L, Jacobs J, Hens K. Comparative antimicrobial activity of ceftibuten against multiply-resistant microorganisms from Belgium. <i>Diagnostic microbiology and infectious disease</i> . 1991;14(1):53-61.	Title
519	Bauernfeind A. Comparative antimicrobial spectrum and activity of ceftibuten against clinical isolates from West Germany. <i>Diagnostic microbiology and infectious disease</i> . 1991;14(1):63-74.	Title
520	Ige OM, Okesola AO. COMPARATIVE EFFICACY AND SAFETY OF CEFIXIME AND CIPROFLOXACIN IN THE MANAGEMENT OF ADULTS WITH COMMUNITY-ACQUIRED PNEUMONIA IN IBADAN, NIGERIA. <i>Ann Ib Postgrad Med</i> . 2015 Dec;13(2):72-8.	Abstract
521	Sengupta J, Mondai A, Jain P, et al. Comparative evaluation of cefpodoxime versus cefixime in children with lower respiratory tract infections. <i>The Indian Journal of Pediatrics</i> . 2004;71(6):517-521.	Abstract

522	Cazzola M, Vinciguerra A, Beghi G, et al. Comparative evaluation of the clinical and microbiological efficacy of co-amoxiclav vs cefixime or ciprofloxacin in bacterial exacerbation of chronic bronchitis. Journal of chemotherapy. 1995;7(5):432-441.	Abstract
523	Koeth LM, Jacobs MR, Good CE, et al. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000. International journal of infectious diseases. 2004;8(6):362-373.	Title
524	Hamilton-Miller J, Brumfitt W. Comparative in vitro activity of cefixime, cefaclor and loracarbef against urinary pathogens. Drugs under experimental and clinical research. 1991;17(10-11):517-519.	Abstract
525	Mortensen JE, Egleton JH. Comparative in vitro activity of fuopenem against aerobic bacteria isolated from pediatric patients. Diagnostic Microbiology and Infectious Disease. 1995 1995/07/01;22(3):301-306.	Title
526	Arshad HM, Mohiuddin OA, Azmi MB. Comparative in vitro antibacterial analysis of different brands of cefixime against clinical isolates of Staphylococcus aureus and Escherichia coli. Journal of Applied Pharmaceutical Science. 2012 (Issue):109-113.	Abstract
527	Danafar H. Comparative in vitro assessment of tolterodine tartrate tablets by high performance liquid chromatographic (HPLC). Pharmaceutical and Biomedical Research. 2016;2(2):47-57.	Title
528	Hassouna ME, Mohamed MA. Comparative in-vitro dissolution studies for determination of cefixime in an innovator product of suprax powder for oral suspension dosage form using RP-HPLC method. Glob J Oto. 2018;14(3):555886.	Abstract
529	Wise R. Comparative microbiological activity and pharmacokinetics of cefprozil. European Journal of Clinical Microbiology and Infectious Diseases. 1994;13(10):839-845.	Title
530	SITAR D, HOBAN D, AOKI F, editors. COMPARATIVE PHARMACOKINETIC DISPOSITION OF CEFIXIME AND CEFUROXIME IN HEALTHY-YOUNG VOLUNTEERS AT STEADY-STATE.	Abstract

	CLINICAL PHARMACOLOGY & THERAPEUTICS; 1993: MOSBY-YEAR BOOK INC 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318.	
531	Deppermann KM, Garbe C, Hasse K, et al. Comparative pharmacokinetics of cefotiam hexetil (CEHX), cefuroxime axetil (CEFUR), Cefixime (CEFIX), Cephalexine (CEPHA), and the influence of a standard breakfast, ranitidine, and Maalox 70 on enteral absorption of cefotiam hexetil. <i>Klinische Wochenschrift</i> . 1990;68(Suppl 19):48-49.	Abstract
532	Naz U, Ashraf MM, Javed I, et al. Comparative pharmacokinetics of cefspan and ceforal-3 in adult human healthy female subjects. <i>Lat Am J Pharm</i> . 2017;36(4):776-782.	Title
533	Deppermann G, Hasse K, Borner K, et al., editors. Comparative pharmacokinetics of ceftotiam hexetil, cefuroxim, cefixime, cephalixin and the effect of H2 blockers, standard breakfast and antacid on the bioavailability of ceftotiam hexetil, abstr. 1223. Program and abstract of the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, DC; 1989.	Abstract
534	Nix D, Symonds W, Wilton J, et al., editors. COMPARATIVE PHARMACOKINETICS OF ORAL CEFTIBUTEN, CEFIXIME, CEFACLOR, AND CEFUROXIME AXETIL IN NORMAL ADULTS. CLINICAL PHARMACOLOGY & THERAPEUTICS; 1994: MOSBY-YEAR BOOK INC 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318.	Abstract
535	Lode H, Fassbender M, Schaberg T, et al. Comparative pharmacokinetics of the new oral cephalosporins. <i>Drugs</i> . 1994;47(3):10-20.	Abstract
536	Notario G, Siepman N, Devcich K, et al. Comparative safety and efficacy of clarithromycin and three oral cephalosporins in the treatment of outpatients with bacterial bronchitis. <i>Current Therapeutic Research</i> . 1993 1993/12/01/;54(6):628-640.	Abstract

537	McCarty JM, Siepman N, Craft JC. Comparative safety and efficacy of clarithromycin versus amoxicillin/clavulanate in the treatment of acute otitis media in pediatric patients. <i>Current Therapeutic Research</i> . 1994 1994/09/01/;55(9):1016-1026.	Title
538	Mishra C, Jha AK, Ahmad MP, et al. A comparative study between cefixime and ofloxacin in the treatment of uncomplicated typhoid fever attending a tertiary care teaching hospital. <i>Journal of National Medical College</i> . 2017;2(1):3-7.	Abstract
539	Cao XT, Kneen R, Nguyen TA, et al. A comparative study of ofloxacin and cefixime for treatment of typhoid fever in children. The Dong Nai Pediatric Center Typhoid Study Group. <i>Pediatr Infect Dis J</i> . 1999 Mar;18(3):245-8.	Abstract
540	Pipitpanpipit T, Sntanirand P, Kongchareonsombat K. A Comparative Study of Oral Medication to Prevent Transient Bacteriemia and Adverse Events From Transrectal Prostatic Biopsy: Ciprofloxacin Versus Cefixime. <i>J Med Assoc Thailand</i> . 2017;100:528.	Title
541	Reinert R, Lütticken R, Lemperle M, et al. A comparative study of the in-vitro activity of levofloxacin against <i>Streptococcus pneumoniae</i> . <i>Journal of Antimicrobial Chemotherapy</i> . 1999;43(suppl_3):5-8.	Title
542	Jieying H, Min H, Xianglan Z. comparative study on pharmacokinetics in volunteers of domestic and imported cefixime in 3 dosage forms. <i>Chin New Drugs J</i> . 1996;6:48-53.	Abstract
543	Arguedas A, Loaiza C, Herrera M, et al. Comparative trial of 3-day azithromycin versus 10-day amoxicillin/clavulanate potassium in the treatment of children with acute otitis media with effusion. <i>International Journal of Antimicrobial Agents</i> . 1996 1996/04/01/;6(4):233-238.	Title
544	Kiani R, Johnson D, Nelson B. Comparative, multicenter studies of cefixime and amoxicillin in the treatment of respiratory tract infections. <i>The American journal of medicine</i> . 1988;85(3):6-13.	Abstract

545	Singh K, Mohan M, Nautiyal S. Comparing Cefixime, Cefpodoxime and Ofloxacin as Anti-Microbial Agents and their Effects on Gut Microbiota. <i>Int J Sci Res Sci Technol.</i> 2020;7:131-152.	Abstract
546	Levenstein J, * Summerfield, PJF, Fourie, S., Brink, G.,* Michaelides, B.,* Murray, E.*, Naidoo N. Comparison of cefixime and co-trimoxazole in acute uncomplicated urinary tract infection-a double-blind general practice study. <i>South African medical journal.</i> 1986;70(4):455-460.	Abstract
547	Asmar BI, Dajani AS, Del Beccaro MA, et al. Comparison of cefpodoxime proxetil and cefixime in the treatment of acute otitis media in infants and children. <i>Pediatrics.</i> 1994;94(6):847-852.	Abstract
548	Stutman HR, Arguedas AG. Comparison of cefprozil with other antibiotic regimens in the treatment of children with acute otitis media. <i>Clinical infectious diseases.</i> 1992;14(Supplement_2):S204-S208.	Title
549	Schatz BS, Karavokiros KT, Taeubel MA, et al. Comparison of cefprozil, cefpodoxime proxetil, loracarbef, cefixime, and ceftibuten. <i>Annals of Pharmacotherapy.</i> 1996;30(3):258-268.	Abstract
550	Orozco H, Sifuentes-Osornio J, Chan C, et al. Comparison of ceftibuten vs. amoxicillin/clavulanic acid as antibiotic prophylaxis in cholecystectomy and/or biliary tract surgery. <i>Journal of Gastrointestinal Surgery.</i> 2000 2000/11/01;4(6):606-610.	Title
551	Eldin AB, Ismaeil O, Hassan W, et al. Comparison of FT-NIR and HPLC for green approach to assay cefixime in its pharmaceutical capsules. <i>Eurasian Journal of Analytical Chemistry.</i> 2016;11(2):79-88.	Abstract
552	Boisson M, Jacobs M, Grégoire N, et al. Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients. <i>Antimicrobial agents and chemotherapy.</i> 2014;58(12):7331-7339.	Title
553	Salvarezza C, Mingrone H, Fachinelli H, et al. Comparison of roxithromycin with cefixime in the treatment of adults with community-acquired pneumonia. <i>The Journal of antimicrobial chemotherapy.</i> 1998;41(suppl_2):75-80.	Abstract

554	Handsfield HH, McCormack WM, Hook EW, 3rd, et al. A comparison of single-dose cefixime with ceftriaxone as treatment for uncomplicated gonorrhea. The Gonorrhea Treatment Study Group. N Engl J Med. 1991 Nov 7;325(19):1337-41.	Abstract
555	Hook 3rd E, McCormack WM, Martin D, et al. Comparison of single-dose oral grepafloxacin with cefixime for treatment of uncomplicated gonorrhea in men. The STD Study Group. Antimicrobial agents and chemotherapy. 1997;41(8):1843-1845.	Abstract
556	Eddy EP, Wood C, Miller J, et al. A comparison of the affinities of dipeptides and antibiotics for the di-/tripeptide transporter in Caco-2 cells. International Journal of Pharmaceutics. 1995 1995/02/28;115(1):79-86.	Title
557	Cuzzolin L, Benoni G, Deganello A, et al. Comparison of the effects of cefuroxime axetil and cefaclor on the fecal flora in pediatric patients. Current Therapeutic Research. 1992 1992/10/01;52(4):562-570.	Title
558	Zhang F, Xue J, Shao J, et al. Compilation of 222 drugs' plasma protein binding data and guidance for study designs. Drug Discovery Today. 2012 2012/05/01;17(9):475-485.	Title
559	Esposito S, Canevini MP, Principi N. Complications associated with antibiotic administration: neurological adverse events and interference with antiepileptic drugs. International Journal of Antimicrobial Agents. 2017 2017/07/01;50(1):1-8.	Title
560	Compound index volumes 551–600. Journal of Chromatography A. 1993 1993/04/02;601(1):233-409.	Title
561	Kiang TK, Häfeli UO, Ensom MH. A comprehensive review on the pharmacokinetics of antibiotics in interstitial fluid spaces in humans: implications on dosing and clinical pharmacokinetic monitoring. Clinical pharmacokinetics. 2014;53(8):695-730.	Title
562	Khandelwal A, Bahadduri PM, Chang C, et al. Computational models to assign biopharmaceutics drug disposition classification from molecular structure. Pharmaceutical research. 2007;24(12):2249-2262.	Title

563	Moorthi K, Fleckenstein G, Nies B. Concentration of cefixime in bile, gallbladder wall and serum after preoperative administration in patients undergoing cholecystectomy. <i>Methods Find Exp Clin Pharmacol.</i> 1990 May;12(4):287-90.	Abstract
564	Martin C, Cottin A, François-Godfroy N, et al. Concentrations de ceftriaxone (1 000 mg IV) dans les tissus abdominaux après emploi en antibioprofylaxie au cours de la chirurgie pancréatique. <i>Médecine et Maladies Infectieuses.</i> 1997 1997/06/01/;27:674-677.	Title
565	Pramanik S, Sali V. Connecting the dots in drug delivery: A tour d'horizon of chitosan-based nanocarriers system. <i>International Journal of Biological Macromolecules.</i> 2021 2021/02/01/;169:103-121.	Title
566	Monsees EA, Burns AN, Lee BR, et al. Considerations for implementation: Pediatric outpatient antimicrobial stewardship program. <i>American Journal of Infection Control.</i> 2021 2021/12/01/;49(12):1543-1546.	Title
567	Yuk-Choi JH, Nightingale CH, Williams TW. Considerations in dosage selection for third generation cephalosporins. <i>Clinical pharmacokinetics.</i> 1992;22(2):132-143.	Abstract
568	Contents. <i>International Journal of Antimicrobial Agents.</i> 1994 1994/01/01/;3(4):285-287.	Title
569	Contents of volume 46 and author index. <i>Biochemical Pharmacology.</i> 1993 1993/01/01/;46:v-xxxvi.	Title
570	Bergan T, Michalsen H, Malmborg AS, et al. Contents, Vol. 39, 1993. <i>Chemotherapy.</i> 1993;39(6):I-VI.	Title
571	Liu Y, Wu K, Wang J, et al. Continuous production of antioxidant liposome for synergistic cancer treatment using high-gravity rotating packed bed. <i>Chemical Engineering Journal.</i> 2018 2018/02/15/;334:1766-1774.	Title
572	Westphal F. Contributions de la pharmacocinetique clinique a l'exploration des mecanismes cellulaires regulant l'absorption intestinale des batelactamines: applications a l'amoxicilline et au cefixime: Strasbourg 1; 1993.	Title

573	Van Hout MC. The controversies, challenges and complexities of Lyme disease: implications for medical education, clinical practice and research. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> . 2018;21(1):429-436.	Title
574	Attimarad MV, Alnajjar AO. A conventional HPLC-MS method for the simultaneous determination of ofloxacin and cefixime in plasma: Development and validation. <i>Journal of Basic and Clinical Pharmacy</i> . 2013;4(2):36.	Abstract
575	Frimodt-Møller N. Correlation between pharmacokinetic/pharmacodynamic parameters and efficacy for antibiotics in the treatment of urinary tract infection. <i>International journal of antimicrobial agents</i> . 2002;19(6):546-553.	Title
576	Jewesson P. Cost-effectiveness and value of an IV switch. <i>Pharmacoeconomics</i> . 1994;5(2):20-26.	Title
577	Ranjan Sahoo C, Sahoo J, Mahapatra M, et al. Coumarin derivatives as promising antibacterial agent(s). <i>Arabian Journal of Chemistry</i> . 2021 2021/02/01;14(2):102922.	Title
578	Zhang L, Xu Z. Coumarin-containing hybrids and their anticancer activities. <i>European Journal of Medicinal Chemistry</i> . 2019 2019/11/01;181:111587.	Title
579	Jones RN. Critical assessment of the newer non-quinolone oral antimicrobial agents. <i>Antimicrobial Newsletter</i> . 1989;6(7):53-60.	Title
580	Cluzel R. [Critical concentrations of cefixime and disc potency]. <i>Presse Med</i> . 1989 Oct 11;18(32):1567-8.	Not Accessible
581	Zagursky RJ, Pichichero ME. Cross-reactivity in $\beta$ -Lactam Allergy. <i>The Journal of Allergy and Clinical Immunology: In Practice</i> . 2018 2018/01/01;6(1):72-81.e1.	Title



582	Shrestha S, Manandhar SR, Malla OK. Culture Positive Cases of Ophthalmia Neonatorum in a Tertiary Care Centre of Nepal: A Descriptive Cross-sectional Study. JNMA J Nepal Med Assoc. 2021 Apr 30;59(236):369-373.	Title
583	Cumulative Index. Clinics in Laboratory Medicine. 2004 2004/12/01/;24(4):1037-1064.	Title
584	Cumulative Index. Pediatric Clinics of North America. 2005 2005/12/01/;52(6):1805-1872.	Title
585	Cumulative Index 1990. Primary Care: Clinics in Office Practice. 1990 1990/12/01/;17(4):905-928.	Title
586	CUMULATIVE INDEX 1995. Infectious Disease Clinics of North America. 1995 1995/12/01/;9(4):1075-1092.	Title
587	Cumulative NCE Introduction Index, 1983–2017. In: Goodnow RA, editor. Annual Reports in Medicinal Chemistry. Vol. 50: Academic Press; 2017. p. 621-647.	Title
588	Aturki Z, Rocco A, Rocchi S, et al. Current applications of miniaturized chromatographic and electrophoretic techniques in drug analysis. Journal of Pharmaceutical and Biomedical Analysis. 2014 2014/12/01/;101:194-220.	Title
589	Current Literature. The Journal of Urology. 1987 1987/06/01/;137(6):1330-1335.	Title
590	Herrera-Ruiz D, Knipp GT. Current Perspectives on Established and Putative Mammalian Oligopeptide Transporters. Journal of Pharmaceutical Sciences. 2003 2003/04/01/;92(4):691-714.	Title
591	Gao F, Xiao J, Huang G. Current scenario of tetrazole hybrids for antibacterial activity. European Journal of Medicinal Chemistry. 2019 2019/12/15/;184:111744.	Title
592	Saaby L, Nielsen CU, Steffansen B, et al. Current status of rational design of prodrugs targeting the intestinal di/tri-peptide transporter hPEPT1 (SLC15A1). Journal of Drug Delivery Science and Technology. 2013 2013/01/01/;23(4):307-314.	Title

593	Jayanthi C, Bedwal A, Rajarathna K. Cutaneous adverse drug reactions from a teaching hospital in Bengaluru: An observational study to determine the spectrum and outcome. National Journal of Physiology, Pharmacy and Pharmacology. 2017;7(5):476.	Title
594	Weiner CP, Buhimschi C. D. In: Weiner CP, Buhimschi C, editors. Drugs for Pregnant and Lactating Women (Second Edition). Philadelphia: W.B. Saunders; 2009. p. 252-338.	Title
595	Weiner CP, Mason C. D. In: Weiner CP, Mason C, editors. Drugs for Pregnant and Lactating Women (Third Edition). Philadelphia: Elsevier; 2019. p. 187-252.	Title
596	Smith PL, Wall DA, Gochoco CH, et al. (D) Routes of delivery: Case studies: (5) Oral absorption of peptides and proteins. Advanced Drug Delivery Reviews. 1992 1992/03/01/;8(2):253-290.	Title
597	Cafini F, Aguilar L, Sevillano D, et al. Decrease in bacterial load versus resistance selection of pneumococcal subpopulations by beta-lactam physiological concentrations over time: an in vitro pharmacodynamic simulation. Microb Drug Resist. 2008 Mar;14(1):13-21.	Title
598	Namiki Y, Tanabe T, Kobayashi T, et al. Degradation kinetics and mechanisms of a new cephalosporin, cefixime, in aqueous solution. Journal of pharmaceutical sciences. 1987;76(3):208-214.	Abstract
599	Naveed S. Degradation study of different brands of cefixime by UV spectroscopy. international Research Journal of Pharmaceutical Sciences. 2014;5(1).	Abstract
600	KHAN A. DEPARTMENT OF PHARMACY UNIVERSITY OF PESHAWAR.	Title
601	Gunti SK, Sunil R. Design and characterization of sustained release mini-tablets of Cefixime trihydrate. International Journal of Pharmacy and Biology Sciences. 2014;1(4):79-88.	Abstract
602	Lal G, Bajpai M. Design and Delivery Characteristics of Extended Release Dosage Form Using a Unique Combination of HPMC K100, Guar Gum and Chitosan as Release Retardant. Current Trends in Biotechnology and Pharmacy. 2021;15(4):416-425.	Title

603	Saifullah S, Kanwal T, Ullah S, et al. Design and development of lipid modified chitosan containing muco-adhesive self-emulsifying drug delivery systems for cefixime oral delivery. Chemistry and Physics of Lipids. 2021;235:105052.	Abstract
604	Babu JR. Design and in vitro Evaluation of Gastroretentive Drug Delivery System of Cefixime Trihydrate. Asian Journal of Pharmaceutics (AJP). 2016;10(04).	Abstract
605	Thummel KE, Shen DD, Isoherranen N, et al. Design and optimization of dosage regimens: pharmacokinetic data. Goodman & Gilman's the pharmacological basis of therapeutics, 11th ed McGraw-Hill, New York, NY. 2006:1787-1888.	Title
606	Naik SD, Hosamani KM. Design and Synthesis of Novel C4-Linked Substituted 2H-Chromen-2-one-hypoxanthine Hybrids as Potential Antimicrobial Agents: An Approach to Molecular Docking Studies. Journal of Heterocyclic Chemistry. 2019 2019/02/01/;56(2):579-588.	Title
607	Baskar B. Design Development and Evaluation of Cefixime Solid Lipid Nanoparticles for Enhancement of Oral Bioavailability: KMCH College Of Pharmacy, Coimbatore; 2020.	Abstract
608	Mohapatra S, Barik B, Kar R, et al. Design, Development and Optimization of Gastro Retentive Floating Tablets of Cefixime Trihydrate. Asian Journal of Chemistry. 2013;25(13).	Abstract
609	Rahayu A, Sari DP, Ebtavanny TG. Design, Optimization and Characterization of Cefixime Microspheres. Int J Pharma Res Heal Sci. 2019;7(5):3051-5.	Abstract
610	Tahir S, Mahmood T, Dastgir F, et al. Design, synthesis and anti-bacterial studies of piperazine derivatives against drug resistant bacteria. European Journal of Medicinal Chemistry. 2019 2019/03/15/;166:224-231.	Title
611	Hay P, Ugwumadu A. Detecting and treating common sexually transmitted diseases. Best Practice & Research Clinical Obstetrics & Gynaecology. 2009 2009/10/01/;23(5):647-660.	Title

612	Shi A, Feng Y, LI K, et al. Determination of Bioequivalence of Cefixime by Three-way Crossover Design. China Pharmacy. 1991.	Abstract
613	Jiang B, Ruan Z, Lou H, et al. Determination of cefaclor in human plasma by reversed-phase high-performance liquid chromatography with UV detection and its application to the bioequivalence studies. Analytical letters. 2009;42(14):2170-2179.	Title
614	Breilh D, Lavallee C, Fratta A, et al. Determination of cefepime and ceftiofime in human serum by high-performance liquid chromatography using an ultrafiltration for antibiotics serum extraction. Journal of Chromatography B: Biomedical Sciences and Applications. 1999 1999/10/29/;734(1):121-127.	Title
615	Pisarev V, Zaitseva K, Smirnova L, et al. Determination of cefixime blood plasma levels by HPLC. Antibiotiki i Khimioterapiia= Antibiotics and Chemoterapy [sic]. 2009;54(7-8):37-40.	Abstract
616	Pisarev VV, Zaitseva KV, Smirnova LB, et al. [Determination of cefixime blood plasma levels by HPLC]. Antibiot Khimioter. 2009;54(7-8):37-40.	Abstract
617	Talebpour Z, Pourabdollahi H, Rafati H, et al. Determination of cefixime by a validated stability-indicating HPLC method and identification of its related substances by LC-MS/MS studies. Scientia pharmaceutica. 2013;81(2):493-504.	Abstract
618	Liu G, Sha R, Gao S, et al. Determination of cefixime in human plasma and urine using high performance liquid chromatography column switching technique. Yao xue xue bao= Acta pharmaceutica Sinica. 1993;28(3):216-221.	Abstract
619	Zhang H, Zhang J, Shao Z. Determination of Cefixime in Human Plasma with HPLC. China Pharmacy. 2001.	Abstract
620	Elias B, Alfeen A. Determination of cefuroxime axetil and cefixime trihydrate in pharmaceutical dosage forms by RP-HPLC Method. Pharm Anal Chem. 2016;2:114.	Abstract

621	Djabarouti S, Boselli E, Allaouchiche B, et al. Determination of levofloxacin in plasma, bronchoalveolar lavage and bone tissues by high-performance liquid chromatography with ultraviolet detection using a fully automated extraction method. <i>Journal of Chromatography B</i> . 2004 2004/01/05/;799(1):165-172.	Title
622	Toutain J, Boselli E, Djabarouti S, et al. Determination of linezolid in plasma and bronchoalveolar lavage by high-performance liquid chromatography with ultraviolet detection using a fully automated extraction method. <i>Journal of Chromatography B</i> . 2004 2004/12/25/;813(1):145-150.	Title
623	Cheng C-L, Chou C-H. Determination of metformin in human plasma by high-performance liquid chromatography with spectrophotometric detection. <i>Journal of Chromatography B: Biomedical Sciences and Applications</i> . 2001 2001/10/05/;762(1):51-58.	Title
624	Lemoine T, Breilh D, Ducint D, et al. Determination of moxifloxacin (BAY 12-8039) in plasma and lung tissue by high-performance liquid chromatography with ultraviolet detection using a fully automated extraction method with a new polymeric cartridge. <i>Journal of Chromatography B: Biomedical Sciences and Applications</i> . 2000 2000/06/09/;742(2):247-254.	Title
625	Garraffo R, Drugeon H, Dellamonica P, et al. Determination of optimal dosage regimen for amikacin in healthy volunteers by study of pharmacokinetics and bactericidal activity. <i>Antimicrobial Agents and Chemotherapy</i> . 1990;34(4):614-621.	Title
626	Molina F, Jehl F, Gallion C, et al. Determination of the third generation oral cephalosporin cefpodoxime in biological fluids by high-speed high-performance liquid chromatography. <i>Journal of Chromatography B: Biomedical Sciences and Applications</i> . 1991 1991/01/18/;563(1):205-210.	Title
627	Pehourcq F, Jarry C. Determination of third-generation cephalosporins by high-performance liquid chromatography in connection with pharmacokinetic studies. <i>Journal of Chromatography A</i> . 1998;812(1-2):159-178.	Abstract

628	Kamran M, Khan MA, Shafique M, et al. Development and Characterization of Binary Solid Lipid Nano Suspension of Atorvastatin: In-Vitro Drug Release and In-Vivo Pharmacokinetic Studies. <i>Nanoscience and Nanotechnology Letters</i> . 2019;11(11):1522-1530.	Title
629	Khan QU, Siddique MI, Rasool F, et al. Development and characterization of orodispersible film containing cefixime trihydrate. <i>Drug Dev Ind Pharm</i> . 2020 Dec;46(12):2070-2080.	Abstract
630	Gade PP, Iqbal MM, Rao KS. Development and In-Vitro Evaluation of Gastro-Retentive Floating Drug Delivery System of Cefixime Trihydrate. <i>Magnesium</i> . 2009;55(55):55.	Abstract
631	Adam EH, Saeed AE, Barakat IE. Development and validation of a high performance liquid chromatography method for determination of cefixime trihydrate and its degraded products formed under stress condition of UV light. <i>International Journal of Pharmaceutical Sciences and Research</i> . 2012;3(2):469.	Abstract
632	Kundu S, Majumder T, Barat PK, et al. Development and validation of a HPLC-UV method for simultaneous determination of cefixime and ofloxacin in tablet formulation. <i>International Journal of Pharmaceutical Sciences and Research</i> . 2015;6(2):884.	Abstract
633	Mathew C, Swathi B, Ajitha M, et al. Development and validation of a new and economical stability indicating RP-HPLC method for cefixime trihydrate. <i>Brazilian Journal of Pharmaceutical Sciences</i> . 2016;52:87-94.	Abstract
634	Gouda AA, Hashem H, Jira T. Development and validation of a rapid stability indicating HPLC-method using monolithic stationary phase and two spectrophotometric methods for determination of antihistaminic acrivastine in capsules. <i>Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy</i> . 2014 2014/09/15/;130:480-487.	Title

635	Bhinge SD, Malipatil SM. Development and validation of a stability-indicating method for the simultaneous estimation of cefixime and dicloxacillin using the RP-HPLC method. Journal of Taibah University for Science. 2016;10(5):734-744.	Abstract
636	Islambulchilar Z, Ghanbarzadeh S, Emami S, et al. Development and validation of an HPLC method for the analysis of sirolimus in drug products. Advanced pharmaceutical bulletin. 2012;2(2):135.	Title
637	He G, Mai L, Wang X. Development and validation of an HPLC-MS/MS method for rapid simultaneous determination of cefprozil diastereomers in human plasma. International Journal of Analytical Chemistry. 2018;2018.	Title
638	Shah V, Raj H. Development and validation of derivative spectroscopic method for simultaneous estimation of cefixime trihydrate and azithromycin dihydrate in combined dosage form. International Journal of Pharmaceutical Sciences And Research. 2012;3(6):1753.	Abstract
639	Naveen C. Development and Validation of HPTLC Method for Cefixime, Cefpodoxime, Cefepime in Bulk and Pharmaceutical Dosage form and Analytical and Bioanalytical Method for Brivudine: Sri Ramakrishna Institute of Paramedical Sciences, Coimbatore; 2017.	Abstract
640	Al-Laham MK. Development and Validation of Spectrophotometric Method for Determination of Cefixime and Glimepiride by Ternary complex Formation: Batch2; 2013.	Abstract
641	Wale R, Pandharkar T, Kalyankar TM, et al. Development and Validation of Spectrophotometric Methods for Simultaneous Estimation of Cefixime Trihydrate and Linezolid in Tablet Dosage Form.	Abstract
642	Nayon MAU, Nesa J-U, Uddin MN, et al. Development and validation of UV Spectrometric Method for the Determination of Cefixime trihydrate in Bulk and Pharmaceutical Formulation. Asian Journal of Biomedical and Pharmaceutical Sciences. 2013;3(22):15.	Abstract

643	Aher SS, Saudagar R. Development and validation of UV Spectrophotometric Method for determination of Cefixime Trihydrate and Ornidazole in tablet dosage form. Research Journal of Pharmacy and Technology. 2014;7(9):4.	Abstract
644	Jayasundara P. Development of a within-host mathematical model of urethral gonorrhoea infection and application to treatment: UNSW Sydney; 2022.	Title
645	Darabi R, Shabani-Nooshabadi M. Development of an amplified nanostructured electrochemical sensor for the detection of cefixime in pharmaceuticals and biological samples. Journal of Pharmaceutical and Biomedical Analysis. 2022;212:114657.	Abstract
646	Patel D, Akhtar J, Master S, et al. DEVELOPMENT OF ANALYTICAL METHOD FOR SIMULTANEOUS ESTIMATION OF CEFIXIME AND LINEZOLID DEVELOPMENT OF ANALYTICAL METHOD FOR SIMULTANEOUS ESTIMATION OF CEFIXIME AND LINEZOLID IN TABLET DOSAGE FORM IN TABLET DOSAGE FORM.	Abstract
647	Akhtar J, Baghel M, Patel D. Development of Analytical Method for Simultaneous Estimation of Cefixime and Linezolid in Tablet Dosage Form. Research Journal of Pharmacy and Technology. 2013;6(5):592-594.	Abstract
648	Arshad HM, Gauhar S, Bano R, et al. Development of HPLC-UV method for analysis of cefixime in raw materials and in capsule. Jordan journal of pharmaceutical sciences. 2009;2(1):53-65.	Abstract
649	Jones RN, Gerlach EH, Koontz FP, et al. Development of Neisseria gonorrhoeae in vitro susceptibility test methods for cefixime including quality control guidelines. Diagnostic microbiology and infectious disease. 1991;14(5):383-388.	Abstract
650	Hook III EW, Newman L, Drusano G, et al. Development of new antimicrobials for urogenital gonorrhea therapy: clinical trial design considerations. Clinical Infectious Diseases. 2020;70(7):1495-1500.	Title



651	Erdoğan N. Development of oral tablet formulation containing erlotinib: Randomly methylated- $\beta$ -cyclodextrin inclusion complex using direct compression method. Turkish Journal of Pharmaceutical Sciences. 2021;18(5):589.	Title
652	Zhang D, Armour E, Sherma J. Development of quantitative HPTLC–densitometry methods following a model approach for transfer of TLC screening methods for pharmaceutical products of cefixime, cefuroxime axetil, cephalexin· H <sub>2</sub> O, ciprofloxacin HCl, levofloxacin, and metronidazole. Acta Chromatographica. 2017;29(4):484-486.	Abstract
653	Prabakaran C. Development of Solid Oral Flexible Tablet OFT Formulation Platform for Pediatric and Geriatric Drug Delivery.	Title
654	DGHM 2016 Abstractband. International Journal of Medical Microbiology. 2016 2016/12/01/;306(8, Supplement 1):1-149.	Title
655	Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and Management of Rhinitis: Complete Guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. Annals of Allergy, Asthma & Immunology. 1998 1998/11/01/;81(5):478-518.	Title
656	Incaudo GA. THE DIAGNOSIS AND TREATMENT OF RHINOSINUSITIS DURING PREGNANCY AND LACTATION. Radiologic Clinics of North America. 2000 2000/11/01/;20(4):807-830.	Title
657	Fendrick AM, Saint S, Brook I, et al. Diagnosis and treatment of upper respiratory tract infections in the primary care setting. Clinical Therapeutics. 2001 2001/10/01/;23(10):1683-1706.	Title
658	Yang X, Zhang Y, Lin H, et al. Diagnostic Value of the Triple Combination of Serum Heparin-Binding Protein, Procalcitonin, and C-Reactive Protein in Children with Acute Bacterial Upper Respiratory Tract Infection. J Healthc Eng. 2022;2022:1877960.	Title

659	Winchester JF. Dialysis and hemoperfusion in poisoning. <i>Advances in Renal Replacement Therapy</i> . 2002 2002/01/01/;9(1):26-30.	Title
660	Ludwig E, Miglioli P, Ragazzi E, et al. Diarrhea in intensive care: diagnosis and treatment G. Bleichner, O. Thomas and JP Sollet Controversies on pharmacokinetics of fluoroquinolones in elderly patients. <i>International Journal of Antimicrobial Agents</i> . 1994;3:285-287.	Title
661	KANT R, BODLA R, BHUTANI R, et al. Difference Spectrophotometric Method For Simultaneous Estimation of Moxifloxacin And Cefixime Trihydrate in Bulk and Combined Dosage Form. <i>International Journal of pharmacy and pharmaceutical sciences</i> , 7 (9). 2015:316-321.	Abstract
662	Phanucharas JP, Gorby GL. Differential intracellular efficacies of ciprofloxacin and cefixime against <i>Neisseria gonorrhoeae</i> in human fallopian tube organ culture. <i>Antimicrobial agents and chemotherapy</i> . 1997;41(7):1547-1551.	Abstract
663	Quinet B, Bégué P. Diffusion des antibiotiques dans l'oreille. Limites de l'apport de cette information. <i>Médecine et Maladies Infectieuses</i> . 1992 1992/02/01/;22:95-102.	Title
664	Stewart BH, Chan OH, Jezyk N, et al. Discrimination between drug candidates using models for evaluation of intestinal absorption. <i>Advanced Drug Delivery Reviews</i> . 1997 1997/01/15/;23(1):27-45.	Title
665	Herrman J. Discussion session 1. <i>Veterinary Microbiology</i> . 1993 1993/06/01/;35(3):227-231.	Title
666	Halperin-Walega E, Batra VK, Tonelli AP, et al. Disposition of cefixime in the pregnant and lactating rat. Transfer to the fetus and nursing pup. <i>Drug Metab Dispos</i> . 1988 Jan-Feb;16(1):130-4.	Animal
667	St Peter J, Borin M, Hughes G, et al. Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function. <i>Antimicrobial agents and chemotherapy</i> . 1992;36(1):126-131.	Title
668	Ilgaz F, Timur SS, Eylem CC, et al. Do Thickening Agents Used in Dysphagia Diet Affect Drug Bioavailability? <i>European Journal of Pharmaceutical Sciences</i> . 2022 2022/07/01/;174:106197.	Title

669	Tomić Z, Tomas A, Vukmirović S, et al. Do we bury antibacterials when launching? Cefaclor example. Journal of pharmaceutical sciences. 2016;105(3):1295-1300.	Title
670	Banerjee A, Pal S, Goswami P, et al. Docking analysis of circulating CTX-M variants in multi-drug resistant, beta-lactamase and biofilm-producing E. coli isolated from pet animals and backyard livestock. Microbial Pathogenesis. 2022 2022/09/01/;170:105700.	Animal
671	Kenyon CR, De Baetselier I, Crucitti T. Does gonorrhoea screening intensity play a role in the early selection of antimicrobial resistance in men who have sex with men (MSM)? A comparative study of Belgium and the United Kingdom. F1000Research. 2018;7.	Title
672	Bialer M, Batra VK, Morrison JA, et al. Dose-dependent pharmacokinetics of a new oral cephalosporin, cefixime, in the dog. Pharmaceutical research. 1987;4(1):33-37.	Animal
673	Higashimori M, Yamaoka K, Nakagawa T. Dose-Dependency in Local Disposition of 5-Fluorouracil under Non-Steady-State Condition in Rat Liver. Journal of Pharmaceutical Sciences. 2000 2000/01/01/;89(1):100-107.	Animal
674	Lin JH. Dose-dependent pharmacokinetics: experimental observations and theoretical considerations. Biopharmaceutics & drug disposition. 1994;15(1):1-31.	Title
675	Raz R, Rottensterich E, Leshem Y, et al. Double-blind study comparing 3-day regimens of cefixime and ofloxacin in treatment of uncomplicated urinary tract infections in women. Antimicrobial agents and chemotherapy. 1994;38(5):1176-1177.	Abstract
676	Iravani A, Richard GA, Johnson D, et al. A double-blind, multicenter, comparative study of the safety and efficacy of cefixime versus amoxicillin in the treatment of acute urinary tract infections in adult patients. The American journal of medicine. 1988;85(3):17-23.	Abstract

677	Imran M, Shah MR, Ullah F, et al. Double-tailed acyl glycoside niosomal nanocarrier for enhanced oral bioavailability of Cefixime. <i>Artificial cells, nanomedicine, and biotechnology</i> . 2017;45(7):1440-1451.	Abstract
678	Cantt N. Dr. Yasar Shah: Department of Pharmacy, University of Peshawar, Pakistan; 1999.	Title
679	Blowey BL, Leeder JS, Blowey DL. Drug Administration and Pharmacogenomics in Children Receiving Acute or Chronic Renal Replacement Therapy. <i>Pediatric Dialysis</i> : Springer; 2021. p. 683-707.	Title
680	Lassiter J, Bennett WM, Olyaei AJ. Drug Dosing in Elderly Patients with Chronic Kidney Disease. <i>Clinics in Geriatric Medicine</i> . 2013 2013/08/01/;29(3):657-705.	Title
681	Petitjean O, Nicolas P, Tod M. Drug interaction and pharmacological considerations during anti-infective therapy in cancer patients. <i>Infectious Complications of Cancer</i> . 1995:255-280.	Title
682	Klotz U, Kroemer HK. The drug interaction potential of ranitidine: An update. <i>Pharmacology &amp; Therapeutics</i> . 1991 1991/01/01/;50(2):233-244.	Title
683	Kapp PA, Klop A, Jenkins L. Drug interactions in primary health care in the George subdistrict, South Africa: a cross-sectional study. <i>South African Family Practice</i> . 2013;55(1):78-84.	Title
684	Wallace RJ, Brown BA, Griffith DE. Drug intolerance to high-dose clarithromycin among elderly patients. <i>Diagnostic Microbiology and Infectious Disease</i> . 1993 1993/03/01/;16(3):215-221.	Title
685	Sharma C, Endow A, Dey R, et al. Drug prescribing pattern for wheezers below one year of age: A cross-sectional study at tertiary care hospital from Northeast India. <i>National Journal of Physiology, Pharmacy and Pharmacology</i> . 2020;10(5):413-413.	Title
686	Hashempour-Baltork F, Hosseini H, Shojaee-Aliabadi S, et al. Drug resistance and the prevention strategies in food borne bacteria: An update review. <i>Advanced pharmaceutical bulletin</i> . 2019;9(3):335.	Title
687	Davis GA, Chandler MHH. DRUG THERAPY AND DRUG INTERACTIONS. <i>Oral and Maxillofacial Surgery Clinics of North America</i> . 1996 1996/05/01/;8(2):245-263.	Title

688	Thacker KB, Chaudhari V, Patel S, et al. A drug utilization study in pregnancy at a tertiary care teaching hospital. <i>National Journal of Physiology, Pharmacy and Pharmacology</i> . 2021;11(3):308-308.	Title
689	Harris KA, Garey KW, Rodvold KA. Drug-Food interactions. <i>Drug interactions in infectious diseases</i> : Springer; 2005. p. 383-430.	Title
690	Sprandel-Harris K, Yoo L, Rodvold KA. Drug-Food Interactions. <i>Drug Interactions in Infectious Diseases</i> : Springer; 2011. p. 73-130.	Title
691	Oravcova J, Bořhs B, Lindner W. Drug-protein binding studies new trends in analytical and experimental methodology. <i>Journal of Chromatography B: Biomedical Sciences and Applications</i> . 1996 1996/02/23/;677(1):1-28.	Title
692	Franz CC. Drug-related problems and dosage adjustment in patients with liver disease: <i>University_of_Basel</i> ; 2012.	Title
693	Jacobs MR. Drug-resistant <i>Streptococcus pneumoniae</i> : rational antibiotic choices. <i>The American Journal of Medicine</i> . 1999 1999/05/03/;106(5, Supplement 1):19-25.	Title
694	Conner KG. Drug–Nutrient Interactions. In: Caballero B, editor. <i>Encyclopedia of Human Nutrition</i> (Third Edition). Waltham: Academic Press; 2013. p. 90-98.	Title
695	Garey KW, Rodvold KA. Drug—Food Interactions. <i>Drug Interactions in Infectious Diseases</i> : Springer; 2001. p. 249-285.	Title
696	Howard CR, Lawrence RA. Drugs and Breastfeeding. <i>Clinics in Perinatology</i> . 1999 1999/06/01/;26(2):447-478.	Title
697	Moran JS, Levine WC. Drugs of choice for the treatment of uncomplicated gonococcal infections. <i>Clinical Infectious Diseases</i> . 1995;20(Supplement_1):S47-S65.	Title

698	Gece G. Drugs: A review of promising novel corrosion inhibitors. <i>Corrosion Science</i> . 2011;53(12):3873-3898.	Title
699	Bachmann LH, Desmond RA, Stephens J, et al. Duration of persistence of gonococcal DNA detected by ligase chain reaction in men and women following recommended therapy for uncomplicated gonorrhoea. <i>J Clin Microbiol</i> . 2002 Oct;40(10):3596-601.	Title
700	Ramirez JA, Srinath L, Ahkee S, et al. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia [Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't]. <i>Archives of internal medicine</i> . 1995;155(12):1273-1276.	Abstract
701	ECC-4 Abstracts. <i>International Journal of Antimicrobial Agents</i> . 2002 2002/05/01;19:S1-S105.	Title
702	Ahmad A, Dutta J. Ecotoxicological studies of cephalosporin antibiotics on <i>Daphnia magna</i> . <i>Toxicol Int</i> . 2018;25:21-30.	Abstract
703	Callaghan R, Desmond PV, Masheord ML. The effect of a nutritional model of chronic liver injury on the hepatic glucuronidation of morphine in rats. <i>Journal of pharmacy and pharmacology</i> . 1993;45(11):998-999.	Animal
704	Shyu W, Wilber R, Pittman K, et al. Effect of antacid on the bioavailability of cefprozil. <i>Antimicrobial agents and chemotherapy</i> . 1992;36(5):962-965.	Title
705	Sullivan Å, Edlund C, Nord CE. Effect of antimicrobial agents on the ecological balance of human microflora. <i>The Lancet Infectious Diseases</i> . 2001 2001/09/01;1(2):101-114.	Title
706	Nord CE. The effect of antimicrobial agents on the ecology of the human intestinal microflora. <i>Veterinary Microbiology</i> . 1993 1993/06/01;35(3):193-197.	Title
707	Wiedermann BL, Schwartz RH. Effect of blood contamination on the interpretation of antibiotic concentrations in middle ear fluid. <i>Pediatr Infect Dis J</i> . 1992 Mar;11(3):244-5.	Title

708	Tomiyama M. The effect of cefaclor and cefixime on nasopharyngeal pathogens in children [Clinical Trial; Controlled Clinical Trial; English Abstract; Journal Article]. Nihon Jibiinkoka Gakkai kaiho. 1995;98(4):659-668.	Abstract
709	Niwa T, Shiraga T, Hashimoto T, et al. Effect of cefixime and cefdinir, oral cephalosporins, on cytochrome P450 activities in human hepatic microsomes. Biological and Pharmaceutical Bulletin. 2004;27(1):97-99.	Abstract
710	Kumar V, Lal J, Singh MM, et al. Effect of concurrently coadministered drugs on the pharmacokinetic/pharmacodynamic profile of centchroman, a nonsteroidal oral contraceptive, in rats. Contraception. 2006;74(2):165-173.	Animal
711	Dalhoff K, Kanfer I. Effect of Food on Bioavailability and the Assessment of Bioequivalence. Generic Drug Product Development: CRC Press; 2007. p. 228-253.	Title
712	Mohammed MF. Effect of green tea on the effectiveness of Cefixime on Escherichia coli and Pseudomonas aeruginosa bacteria. Tikret Journal of Pharmaceutical Sciences. 2011;7(1).	Abstract
713	Singlas E, Lebrec D, Gaudin C, et al. Effect of hepatic failure upon the pharmacokinetics of cefixime. Presse Medicale (Paris, France: 1983). 1989;18(32):1587-1588.	Abstract
714	Bollam V, Doodle J, Anisetti R. Effect of lansoprazole on pharmacokinetics of nebivolol in hypertensive patients. Annals of Biological Research. 2013;4(10):6-10.	Title
715	Morimoto K, Kishimura K, Nagami T, et al. Effect of Milk on the Pharmacokinetics of Oseltamivir in Healthy Volunteers. Journal of Pharmaceutical Sciences. 2011 2011/09/01/;100(9):3854-3861.	Title
716	Koitabashi Y, Kumai T, Matsumoto N, et al. The effect of orange juice on the pharmacokinetics of the 3-hydroxy-3-methylglutaryl COA (HMG-COA) reductase inhibitor pravastatin. Clinical Pharmacology & Therapeutics. 2004;75(2):P77-P77.	Title

717	Kurkov SV, Madden DE, Carr D, et al. The effect of parenterally administered cyclodextrins on the pharmacokinetics of coadministered drugs. <i>Journal of pharmaceutical sciences</i> . 2012;101(12):4402-4408.	Title
718	Yano Y, Yamaoka K, Yasui H, et al. Effect of perfusion rate on the local disposition of cefixime in liver perfusion system based on two-compartment dispersion model. <i>Drug Metab Dispos</i> . 1991 Nov-Dec;19(6):1022-7.	Abstract
719	Liaqat A, Khan A-u, Asad M, et al. Effect of Quinolones Versus Cefixime on International Normalized Ratio Levels After Valve Replacement Surgery with Warfarin Therapy. <i>Medicina</i> . 2019;55(10):644.	Abstract
720	Borin MT, Driver MR, Forbes KK. Effect of timing of food on absorption of cefpodoxime proxetil. <i>The Journal of Clinical Pharmacology</i> . 1995;35(5):505-509.	Title
721	Samanthula KS, Bairi AG, Satla SR, et al. Effect of various Polymers on Drug Release from Mucoadhesive Tablets of Cefixime Trihydrate. 2021.	Abstract
722	Edlund C, Nord CE. Effect on the human normal microflora of oral antibiotics for treatment of urinary tract infections. <i>Journal of antimicrobial chemotherapy</i> . 2000;46(suppl_1):41-48.	Title
723	Al-Huseini LMA, Swadi AA, Swadi SM. Effective cefixime treatment in pregnant women with urinary tract infection. <i>J Chem Pharm Res</i> . 2016;8(2):73-8.	Abstract
724	Al-Tamimi M, Abu-Raideh J, Albalawi H, et al. Effective oral combination treatment for extended-spectrum beta-lactamase-producing <i>Escherichia coli</i> . <i>Microbial Drug Resistance</i> . 2019;25(8):1132-1141.	Title
725	Korting H, Kollmann M. Effective single dose treatment of uncomplicated gonorrhoea. <i>International journal of STD &amp; AIDS</i> . 1994;5(4):239-243.	Title
726	Hamid OA, Dokhan MAAA, El Gamea A, et al. Effectiveness and safety of cefpodoxime in upper respiratory tract infections in adult Egyptian population a report from the Egyptian STAR registry. <i>Egyptian Journal of Ear, Nose, Throat and Allied Sciences</i> . 2017 2017/07/01/;18(2):131-135.	Title



727	Carstens C, Hostalek U. [Effectiveness and tolerance of cefixime in bacterial urinary tract infections in patients with myelomeningocele]. <i>Klin Padiatr.</i> 1994 Jan-Feb;206(1):22-5.	Not Accessible
728	Weissbach L, Segal A, Tröster K. Effectiveness and tolerance of cefixime in the treatment of acute pyelonephritis. <i>Infection.</i> 1990;18:S140-4.	Abstract
729	VOGEL F. EFFECTIVENESS OF ORAL CEPHALOSPORINS. <i>INNERE MEDIZIN.</i> 1991;18(6):150-156.	Abstract
730	McBroom M, Barbaro D. The effectiveness of oral suppression in high risk prosthetic joint infections after total knee arthroplasty. <i>International Journal of Infectious Diseases.</i> 2010;14:e197-e198.	Title
731	The effects of adenotonsillectomy on growth in young children: Williams E.F. III; Woo P.; Miller R.; Kellman R.M. <i>OTOLARYNGOL. HEAD NECK SURG.</i> (1991) 104/4 (509–516). <i>International Journal of Pediatric Otorhinolaryngology.</i> 1992 1992/01/01;23(1):101.	Title
732	Maraki S, Barbounakis E, Chatzinikolaou I, et al. Effects of cefepime, cefixime and ceftibuten on murine gut colonization by <i>Candida albicans</i> . <i>Chemotherapy.</i> 1998;44(6):405-408.	Abstract
733	AHmadi Z, Ramezani M, Sohrabi D. Effects of Cefixime on the Testis Structure and Pituitary-Gonadal Hormones in Adult Balb/C Mice. <i>J Adv Med Biomed Res.</i> 2011;19(74):54-62.	Animal
734	Li Y, Revalde J, Paxton JW. The effects of dietary and herbal phytochemicals on drug transporters. <i>Advanced Drug Delivery Reviews.</i> 2017 2017/07/01;116:45-62.	Title
735	Singh BN. Effects of food on clinical pharmacokinetics. <i>Clinical pharmacokinetics.</i> 1999;37(3):213-255.	Title
736	Yang N, Zhan Y, Wan J, et al. Effects of Lacidophilin Tablets, Yogurt, and Bifid Triple Viable Capsules on the Gut Microbiota of Mice with Antibiotic-Associated Diarrhea. <i>Canadian Journal of Infectious Diseases and Medical Microbiology.</i> 2022;2022.	Animal

737	Deslandes A, Camus F, Lacroix C, et al. Effects of nifedipine and diltiazem on pharmacokinetics of cefpodoxime following its oral administration. <i>Antimicrobial agents and chemotherapy</i> . 1996;40(12):2879-2881.	Title
738	Kennedy JM, Van Riji AM. Effects of surgery on the pharmacokinetic parameters of drugs. <i>Clinical pharmacokinetics</i> . 1998;35(4):293-312.	Title
739	van Riet-Nales DA, Schobben AFAM, Egberts TCG, et al. Effects of the pharmaceutical technologic aspects of oral pediatric drugs on patient-related outcomes: A systematic literature review. <i>Clinical Therapeutics</i> . 2010 2010/05/01/;32(5):924-938.	Title
740	Iwasaki K, Matsuda H, Nagase K, et al. Effects of twenty-three drugs on the metabolism of FK506 by human liver microsomes. <i>Res Commun Chem Pathol Pharmacol</i> . 1993 Nov;82(2):209-16.	Title
741	Jacobs MR, Bajaksouzian S, Windau A, et al. Effects of various test media on the activities of 21 antimicrobial agents against <i>Haemophilus influenzae</i> . <i>J Clin Microbiol</i> . 2002 Sep;40(9):3269-76.	Title
742	Helwig H, Luchtrath M, Hostalek U. Efficacy and safety of cefixime once daily compared to twice daily in otitis media, URTI and LRTI in children [Journal: Conference Paper]. <i>Journal of drug development, supplement</i> . 1993;6(1):27-29.	Abstract
743	Adam D, Hostalek U. Efficacy and safety of cefixime once daily vs. penicillin V three times daily in bacterial pharyngitis and tonsillitis in children [Journal: Conference Paper]. <i>Journal of drug development, supplement</i> . 1993;6(1):31-33.	Abstract
744	Neu HC, Chick TW. Efficacy and safety of clarithromycin compared to cefixime as outpatient treatment of lower respiratory tract infections. <i>Chest</i> . 1993;104(5):1393-1399.	Abstract
745	Mohammed T, Tawab H, El-Moktader A. Efficacy and safety of oral cefixime for the short-term treatment of typhoid fever in a group of egyptian children. <i>Der Pharmacia Lettre</i> . 2018;10:11-23.	Abstract

746	Unal S. Efficacy and tolerability of switch therapy with oral cefixime in lower respiratory tract infections. 2000.	Abstract
747	Cars O. Efficacy of beta-lactam antibiotics: integration of pharmacokinetics and pharmacodynamics. Diagnostic microbiology and infectious disease. 1997;27(1-2):29-33.	Title
748	Ryzhko IV, Shcherbaniuk AI, Moldavan IA, et al. [Efficacy of cefixime and cefepime vs. other cephalosporins in experimental plague of albino mice due to variants FI+ and FI- of the plague microbe]. Antibiot Khimioter. 2007;52(9-10):24-7.	Animal
749	Mora R, Salami A, Mora F, et al. Efficacy of cefpodoxime in the prophylaxis of recurrent pharyngotonsillitis. International Journal of Pediatric Otorhinolaryngology. 2003 2003/12/01/;67:S225-S228.	Title
750	Haynes AM, Giacani L, Mayans MV, et al. Efficacy of linezolid on Treponema pallidum, the syphilis agent: A preclinical study. EBioMedicine. 2021 2021/03/01/;65:103281.	Title
751	Samarinas M, Skriapas K, Karatzas A, et al. Efficacy of prophylactic administration of prurifloxacin vs. cefixime in patients undergoing ultrasound guided prostate biopsy: a prospective randomized study [Journal: Conference Abstract]. European urology, supplements. 2019;18(1):e118-.	Extensive reading
752	Abrishamkar M, Ehsani Tilami S, Hosseini Kaldozakh S. Electrocatalytic oxidation of cefixime at the surface of modified carbon paste electrode with synthesized nano zeolite. Advanced Journal of Chemistry-Section A. 2020;3(5):767-776.	Abstract
753	Electronic Posters. Urology. 2012 2012/09/01/;80(3, Supplement):S189-S345.	Title
754	Esposito S, Principi N. Emerging resistance to antibiotics against respiratory bacteria: impact on therapy of community-acquired pneumonia in children. Drug Resistance Updates. 2002 2002/04/01/;5(2):73-87.	Title
755	Naghibi S, Sahebi H. Employment of modified Fe(3) O(4) nanoparticles using thermo-sensitive polymer for extraction and pre-concentration of cefexime in biological samples. Biomed Chromatogr. 2018 Feb;32(2).	Abstract

756	Valamla B, Thakor P, Phuse R, et al. Engineering drug delivery systems to overcome the vaginal mucosal barrier: Current understanding and research agenda of mucoadhesive formulations of vaginal delivery. <i>Journal of Drug Delivery Science and Technology</i> . 2022 2022/04/01/;70:103162.	Title
757	Mohamed D, Kamal M. Enhanced HPLC-MS/MS method for the quantitative determination of the co-administered drugs ceftriaxone sodium and lidocaine hydrochloride in human plasma following an intramuscular injection and application to a pharmacokinetic study. <i>Biomed Chromatogr</i> . 2018 Oct;32(10):e4322.	Title
758	Nozawa T, Toyobuku H, Kobayashi D, et al. Enhanced intestinal absorption of drugs by activation of peptide transporter PEPT1 using proton-releasing polymer. <i>Journal of pharmaceutical sciences</i> . 2003;92(11):2208-2216.	Title
759	Yamamoto A, Morishita Y, Sugishita S, et al. Enhanced Permeability of Phenylalanyl-glycine (Phe-Gly) Across the Intestinal Membranes by Chemical Modification with Various Fatty Acids. <i>Drug Metabolism and Pharmacokinetics</i> . 2003 2003/01/01/;18(1):23-32.	Title
760	Funaki T. Enterohepatic circulation model for population pharmacokinetic analysis. <i>Journal of pharmacy and pharmacology</i> . 1999;51(10):1143-1148.	Title
761	ENTIS 33rd conference abstracts 2022 September 8th-10th Bergamo, Italy. <i>Neurotoxicology and Teratology</i> . 2022 2022/07/01/;92:107108.	Title
762	Xu D, Hu J, Pan X, et al. Enzyme-Powered Liquid Metal Nanobots Endowed with Multiple Biomedical Functions. <i>ACS Nano</i> . 2021 Jun 28.	Title
763	Ball P. Epidemiology and Treatment of Chronic Bronchitis and Its Exacerbations. <i>Chest</i> . 1995 1995/08/01/;108(2, Supplement):43S-52S.	Title

764	Bagnasco F, Piaggio G, Mesini A, et al. Epidemiology of Antibiotic Resistant Pathogens in Pediatric Urinary Tract Infections as a Tool to Develop a Prediction Model for Early Detection of Drug-Specific Resistance. <i>Antibiotics (Basel)</i> . 2022 May 26;11(6).	Title
765	Hardy D, Barry A, Fuchs P, et al. Error rates in cefoperazone and cefoperazone-sulbactam disk tests with enterobacteriaceae and <i>Pseudomonas aeruginosa</i> . <i>European Journal of Clinical Microbiology and Infectious Diseases</i> . 1992;11(10):926-930.	Title
766	Nanda R, Gaikwad J, Prakash A, et al. Estimation of Cefixime and Erdosteine in its Pharmaceutical Dosage Form by Spectrophotometric Method. <i>Asian Journal of Research in Chemistry</i> . 2009;2(4):404-406.	Abstract
767	Kumar A, Kishore L, Nair A, et al. Estimation of cefixime and ofloxacin in its pharmaceutical dosage form by spectrophotometric methods. <i>Journal of Pharmacy Research</i> . 2011;4(6):1864-1866.	Abstract
768	El Hachlafi N, Chebat A, Fikri-Benbrahim K. Ethnopharmacology, Phytochemistry, and Pharmacological Properties of <i>Thymus satureioides</i> Coss. <i>Evidence-Based Complementary and Alternative Medicine</i> . 2021;2021.	Title
769	Goldstein F, Bryskier A, Appelbaum PC, et al. The etiology of respiratory tract infections and the antibacterial activity of fluoroquinolones and other oral antibacterial agents against respiratory pathogens. <i>Clinical Microbiology and Infection</i> . 1998 1998/04/01;4:2S8-2S18.	Title
770	Petitjean O, Brion N, Tod M, et al. Etude de l'interaction pharmacocinétique entre le céfixime et deux antiacides: résultats préliminaires. <i>La Presse médicale</i> (1983). 1989;18(32):1596-1598.	Title
771	Amikacin O, Amikacin B, Cefdinir O, et al. Evaluating safety reporting in paediatric antibiotic trials 2000-2016: a systematic review and meta-analysis. <i>Adler</i> . 2000;2.	Title

772	François P, Bensman A, Bégué P, et al. Evaluation de l'efficacité et du coût de deux stratégies thérapeutiques dans les pyélonéphrites de l'enfant : céfixime per os versus ceftriaxone parentérale en relais d'une bithérapie intraveineuse. <i>Médecine et Maladies Infectieuses</i> . 1997 1997/06/01/;27:667-673.	Title
773	Hinderling PH. Evaluation of a novel method to estimate absolute bioavailability of drugs from oral data. <i>Biopharmaceutics &amp; drug disposition</i> . 2003;24(1):1-16.	Title
774	Ramdhani D, Kusuma SAF. EVALUATION OF CEFIXIME ANTIBIOTIC RESISTANCE: RELATION OF ANTIBIOTIC QUALITY PARAMETERS TO CASES OF RESISTANCE OCCURRING IN ARIS DISEASE IN TASIKMALAYA CITY HEALTH CENTER. 2017.	Abstract
775	Westphal JF, Brogard JM, Jehl F, et al. Evaluation of cefixime biliary disposition in the isolated perfused rabbit liver model and in humans. <i>Drugs Exp Clin Res</i> . 1992;18(8):329-36.	Animal
776	Gajul S, Mohite S, Kakade S, et al. Evaluation of Cefixime-Clavulanate Combination by Comparative Disk Diffusion Method in Klebsiella pneumoniae Clinical Isolates-An In-Vitro Study. <i>JOURNAL OF KRISHNA INSTITUTE OF MEDICAL SCIENCES UNIVERSITY</i> . 2015;4(2):38-45.	Abstract
777	Murtaza G, Ahmad M, Khan SA, et al. Evaluation of cefixime-loaded chitosan microspheres: Analysis of dissolution data using DDSolver. <i>Dissolution Technologies</i> . 2012;19(2):13-19.	Abstract
778	Maheshwari ML, Ubed-ur-Rahman Mughal GK, Shaikh B, et al. Evaluation of Different Brands of Cefixime Available in Pakistan by Newly Developed Spectrophotometric Method. <i>Evaluation</i> . 2021;33(29A).	Abstract
779	Ogden A, Kuhn M, Dority M, et al. Evaluation of pharmacokinetic/pharmacodynamic relationships of PD-0162819, a biotin carboxylase inhibitor representing a new class of antibacterial compounds, using in vitro infection models. <i>Antimicrobial agents and chemotherapy</i> . 2012;56(1):124-129.	Title

780	Joshi AS, Shah RK, Suthar MH, et al. Evaluation of rationality of antimicrobial and antidiarrheal fixed dose combination available in Indian market. National Journal of Physiology, Pharmacy and Pharmacology. 2021;11(2):222-226.	Title
781	Davies HD, Low DE, Schwartz B, et al. Evaluation of short-course therapy with cefixime or rifampin for eradication of pharyngeally carried group A streptococci. The Ontario GAS Study Group. Clin Infect Dis. 1995 Nov;21(5):1294-9.	Abstract
782	Quaye N, Cole MJ, Ison CA. Evaluation of the activity of ertapenem against gonococcal isolates exhibiting a range of susceptibilities to cefixime. Journal of Antimicrobial Chemotherapy. 2014;69(6):1568-1571.	Abstract
783	Low DE, Scriver SR. Evaluation of the in vitro activity of cefixime for its use in switch therapy. Current therapeutic research. 1994;55:35-41.	Abstract
784	Cormican MG, Jones RN. Evaluation of the in-vitro activity of furopenem (SY5555 or SUN5555) against respiratory tract pathogens and $\beta$ -lactamase producing bacteria. Journal of Antimicrobial Chemotherapy. 1995;35(4):535-539.	Title
785	Tsuji A, Hirooka H, Tamai I, et al. Evidence for a carrier-mediated transport system in the small intestine available for FK089, a new cephalosporin antibiotic without an amino group. The Journal of antibiotics. 1986;39(11):1592-1597.	Title
786	Thelen H, Dilworth TJ, Mercier R-C. Examining the Combination of Cefixime and Amoxicillin/Clavulanate against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli Isolates. Chemotherapy. 2022.	Abstract
787	Executive summary. Otolaryngology - Head and Neck Surgery. 2004 2004/01/01/;130(1, Supplement):1-45.	Title
788	de Cueto M, Aliaga L, Alós J-I, et al. Executive summary of the diagnosis and treatment of urinary tract infection: Guidelines of the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC). Enfermedades infecciosas y microbiologia clinica (English ed). 2017 2017/05/01/;35(5):314-320.	Title

789	Nct. Expedited Partner Therapy and the HIV Prevention Cascade. <a href="https://clinicaltrials.gov/show/NCT04553211">https://clinicaltrials.gov/show/NCT04553211</a> . 2020.	Title
790	Nct. Expedited Partner Therapy for MSM in Peru. <a href="https://clinicaltrials.gov/show/NCT01720654">https://clinicaltrials.gov/show/NCT01720654</a> . 2012.	Title
791	Basavaraj H, Mruthyunjayaswamy B. An Experimental Design Approach for Validation and Optimisation of Spectrophotometric Determination of Cefixime in Pharmaceutical Dosage Form. Indian Journal of Pharmaceutical Sciences. 2022;84(1):115-120.	Abstract
792	Magit AE, Dolitsky JN, Doyle WJ, et al. An experimental study of cefixime in the treatment of Streptococcus pneumoniae otitis media. International journal of pediatric otorhinolaryngology. 1994;29(1):1-9.	Abstract
793	Eriksen NL, Blanco JD. EXTENDED-SPECTRUM (SECOND-AND THIRD-GENERATION) CEPHALOSPORINS. Obstetrics and Gynecology Clinics of North America. 1992 1992/09/01;19(3):461-474.	Abstract
794	Sagar P, Srivastava M, Prakash R, et al. The fabrication of an MoS <sub>2</sub> QD–AuNP modified screen-printed electrode for the improved electrochemical detection of cefixime. Analytical Methods. 2020;12(23):3014-3024.	Abstract
795	Balya H, Radhakrishnan A, Jabaris SL, et al. Fabrication of novel bio-compatible cefixime nanoparticles using chitosan and Azadirachta indica fruit mucilage as natural polymers. Journal of Drug Delivery Science and Technology. 2021;66:102750.	Abstract
796	Hussain I, AL-Othman Z, Saleem K, et al. Fast Analysis of Third-Generation Cephalosporins in Human Plasma by SPE and HPLC Methods. 2011.	Abstract
797	Kawamoto H, Tabei Y, Kimura T, et al. Feasibility and pharmacokinetic study of potential ABCG2 inhibitor, gefitinib (GB), in combination with irinotecan (IRN) for adolescents and young adults (AYA). Journal of Clinical Oncology. 2011;29(15_suppl):9564-9564.	Title



798	Harrison RF, Ouyang H. Fever and the Rational Use of Antimicrobials in the Emergency Department. <i>Emergency Medicine Clinics of North America</i> . 2013 2013/11/01/;31(4):945-968.	Title
799	BA E, ÖZDEMİR S, ÇAĞLAYAN MG, et al. First derivative spectrophotometric determination of cefixime and cefdinir in pharmaceutical preparations. <i>Turk J Pharm Sci</i> . 2013;10(3):321-328.	Abstract
800	Liang J, Yang R, Li X, et al. First four failures of cefthiamidine to treat urogenital gonorrhoea in Guangzhou, China, 2014–15. <i>Sexual Health</i> . 2017;14(3):289-292.	Title
801	Adam D, Hostalek U, Troster K. Five day treatment of bacterial pharyngitis and tonsillitis with cefixime. comparison with a 10 day treatment with penicillin V. <i>Klinische padiatrie</i> . 1996;208(5):310-313.	Abstract
802	Temocin F, Tülek NE, Hekimoğlu Ş, et al. Five-years tigecycline experience an analysis of real-life data. 2018.	Title
803	Wenzel U, Kuntz S, Daniel H. Flavonoids with epidermal growth factor-receptor tyrosine kinase inhibitory activity stimulate PEPT1-mediated cefixime uptake into human intestinal epithelial cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> . 2001;299(1):351-357.	Abstract
804	Jayabalan N, Code Q. Fluindione and cefixime induced cutaneous bleeding manifestations–A case report and review of literature. <i>IJPR</i> . 2018;8(03).	Title
805	Akhgari F, Samadi N, Farhadi K. Fluorescent carbon dot as nanosensor for sensitive and selective detection of cefixime based on inner filter effect. <i>Journal of fluorescence</i> . 2017;27(3):921-927.	Abstract
806	Prince RA. Fluoroquinolone-drug interactions: An overview. <i>Antimicrobial Newsletter</i> . 1989 1989/12/01/;6(12):93-98.	Title
807	Effa EE, Lassi ZS, Critchley JA, et al. Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever). <i>Cochrane Database of Systematic Reviews</i> . 2011 (10).	Title
808	Fluoroquinolones I. <i>Clinical Microbiology and Infection</i> . 1999 1999/03/01/;5:138-148.	Title

809	Hooton TM, Garrison J. Fluoroquinolones in the treatment of acute uncomplicated urinary tract infections in adult women. Expert opinion on pharmacotherapy. 2001;2(8):1227-1237.	Title
810	Jain S, Ancheriya R, Srivastva S, et al. Formulation and Characterization of Cefixime Phytosomes for Oral Drug Delivery. Asian Journal of Pharmaceutical Research and Development. 2019;7(5):65-73.	Abstract
811	Singh A, Jha K, Singh PS, et al. Formulation and evaluation of cefixime floating beads. International Journal of Research in Pharmacy and Chemistry. 2011;1(4):922-924.	Abstract
812	AMIR YKA, ALSOUZ MA, SALIM A. FORMULATION AND EVALUATION OF CONTROLLED RELEASE CEFIXIME-CMC BIOPOLYMER USING ION CROSS LINKING TECHNIQUE.	Abstract
813	Arora K, Grover I, Chandna A, et al. Formulation and Evaluation of Fast Dissolving Tablets of Cefixime Trihydrate. Magnesium. 2015;6(6):6.	Abstract
814	Akelesh T, Johnson S, Chander JU, et al. Formulation and evaluation of floating tablets of cefixime trihydrate using chitosan. Research Journal of Pharmacy and Technology. 2015;8(11):1502.	Abstract
815	Subhojit S. Formulation And Evaluation Of Floating Tablets Of Cefixime Trihydrate Using Chitosan: RVS College of Pharmaceutical Sciences, Coimbatore, Tamilnadu, India; 2012.	Abstract
816	Ganesan V, Allimalarkodi S. Formulation and in vitro evaluation cefixime lipospheres. World J Pharma Res. 2015;4(10):1266-80.	Abstract
817	Paul Y, Kumar M, Singh B. Formulation and in Vitro evaluation of Gastroretentive drug delivery system of Cefixime Trihydrate. International Journal of Drug Development and Research. 2011;3(4):0-0.	Abstract
818	Vasam M, Ponugoti RSR. Formulation and pharmacokinetic (in-vitro and in-vivo) evaluation of cefixime microspheres. World Journal of Pharmacy and Pharmaceutical Sciences. 2017;6(7):1476-1488.	Abstract

819	Kamran M, Khan MA, Shafique M, et al. Formulation Design, Characterization and In-Vivo Assessment of Cefixime Loaded Binary Solid Lipid Nanoparticles to Enhance Oral Bioavailability. Journal of Biomedical Nanotechnology. 2022;18(4):1215-1226.	Abstract
820	Karthikeyan A. FORMULATION DEVELOPMENT AND EVALUATION OF CEFIXIME DISPERSIBLE TABLETS. Evaluation.6(3.0):0.1500.	Abstract
821	Natarajan R, Rajendran N, Priya MR. Formulation development and invitro evaluation of cefixime trihydrate Loaded chitosan–alginate transdermal patches. Int J RRPAS. 2011;4:240-254.	Abstract
822	Madhu S. Formulation Development and Invitro Evaluation of Sustained Release Oral Dosage Forms Containing Cefixime: JKK Nattraja College of Pharmacy, Kumarapalayam; 2016.	Abstract
823	Razdan K, Sahajpal NS, Singh K, et al. Formulation of sustained-release microspheres of cefixime with enhanced oral bioavailability and antibacterial potential. Therapeutic Delivery. 2019;10(12):769-782.	Abstract
824	Devi YM, Basha VS, Sailaja G. Formulation, Characterization and Comparison of Cefixime, Cefaclor and Cefdinir Microspheres.	Abstract
825	SHETTY A, SELVAM P, SHETTY S, et al. Formulation, optimization and evaluation of mucoadhesive microspheres of captopril. Journal of Research in Pharmacy. 2019;23(5).	Title
826	Kwan ACF, Beahm NP. Fosfomycin for bacterial prostatitis: a review. International Journal of Antimicrobial Agents. 2020 2020/10/01/;56(4):106106.	Title
827	Livermore DM. Fourteen years in resistance. International Journal of Antimicrobial Agents. 2012 2012/04/01/;39(4):283-294.	Title
828	Pedretti A, De Luca L, Marconi C, et al. Fragmental modeling of hPepT2 and analysis of its binding features by docking studies and pharmacophore mapping. Bioorganic & Medicinal Chemistry. 2011 2011/08/01/;19(15):4544-4551.	Title

829	Free oral communications. Journal of the European Academy of Dermatology and Venereology. 1995 1995/10/01/;5:S71-S122.	Title
830	Al-Hakkani MF, Gouda GA, Hassan SH, et al. Fully investigation of RP-HPLC analytical method validation parameters for determination of Cefixime traces in the different pharmaceutical dosage forms and urine analysis. Acta Pharmaceutica Scientia. 2021;59(1).	Abstract
831	Tamai I, Tomizawa N, Kadowiki A, et al. Functional expression of intestinal dipeptide/ $\beta$ -lactam antibiotic transporter in <i>Xenopus laevis</i> oocytes. Biochemical Pharmacology. 1994 1994/08/30/;48(5):881-888.	Title
832	Tamai I, Tomizawa N, Takeuchi T, et al. Functional expression of transporter for beta-lactam antibiotics and dipeptides in <i>Xenopus laevis</i> oocytes injected with messenger RNA from human, rat and rabbit small intestines. J Pharmacol Exp Ther. 1995 Apr;273(1):26-31.	Animal
833	Sunakawa K, Saito N, Ishizuka Y, et al. Fundamental and clinical studies of cefixime granules in pediatrics. The Japanese Journal of Antibiotics. 1986;39(4):1035-1054.	Abstract
834	Nakayama N, Yanagishima M, Tsuji Y. Fundamental and clinical studies of cefixime in children. The Japanese Journal of Antibiotics. 1986;39(4):1202-1213.	Abstract
835	Toyonaga Y, Sugita M, Nakamura H, et al. Fundamental and clinical studies on cefixime (5% granules) in the pediatric field. The Japanese Journal of Antibiotics. 1986;39(4):1055-1075.	Abstract
836	Miyazaki M, Kida K, Matsuda H, et al. Fundamental and clinical studies on cefixime in pediatric field. The Japanese Journal of Antibiotics. 1986;39(4):1166-1175.	Abstract
837	Iwai N, Shibata M, Mizoguchi F, et al. Fundamental and clinical studies on cefixime in pediatrics. The Japanese Journal of Antibiotics. 1986;39(4):1087-1105.	Abstract
838	Kurashige T, Morita H, Araki K, et al. Fundamental and clinical studies on cefixime in pediatrics. The Japanese Journal of Antibiotics. 1986;39(4):1157-1165.	Abstract

839	Nakashima S, Hayakawa F, Nakashima T, et al. Fundamental and clinical studies on cefixime in the pediatric field. The Japanese journal of antibiotics. 1986;39(4):1076-1086.	Abstract
840	THEK CP. Future meeting dates and sites of the American Society for Clinical Pharmacology and Therapeutics. Clin Pharmacokinet. 1988;15:326-54.	Title
841	Mahadevan U. Gastrointestinal medications in pregnancy. Best Practice & Research Clinical Gastroenterology. 2007 2007/10/01/;21(5):849-877.	Title
842	Gillespie WR. Generalized pharmacokinetic modeling for drugs with nonlinear binding: I. Theoretical framework. Journal of pharmacokinetics and biopharmaceutics. 1993;21(1):99-124.	Title
843	Barbee LA, Soge OO, Morgan J, et al. Gentamicin alone is inadequate to eradicate Neisseria gonorrhoeae from the pharynx. Clinical infectious diseases. 2020;71(8):1877-1882.	Title
844	Enikeev D, Spivak L. Gestational pyelonephritis: modern diagnostic and treatment. Consilium Medicum. 2016;18(7):49-54.	Title
845	Imran M, Shah MR, Ullah F, et al. Glycoside-based niosomal nanocarrier for enhanced in-vivo performance of Cefixime. International Journal of Pharmaceutics. 2016 2016/05/30/;505(1):122-132.	Abstract
846	Afkhami A, Soltani-Felehgari F, Madrakian T. Gold nanoparticles modified carbon paste electrode as an efficient electrochemical sensor for rapid and sensitive determination of cefixime in urine and pharmaceutical samples. Electrochimica acta. 2013;103:125-133.	Abstract
847	Irimie M. Gonoreea–o boală netratabilă în viitor? 2017.	Title
848	Singh AE, Gratrix J, Martin I, et al. Gonorrhoea treatment failures with oral and injectable expanded spectrum cephalosporin monotherapy vs dual therapy at 4 Canadian sexually transmitted infection clinics, 2010–2013. Sexually transmitted diseases. 2015;42(6):331-336.	Title

849	Skerlev M, Čulav-Košćak I. Gonorrhea: New challenges. Clinics in Dermatology. 2014 2014/03/01/;32(2):275-281.	Title
850	Graphical Abstract TOC. Journal of Drug Delivery Science and Technology. 2021 2021/12/01/;66:103011.	Title
851	Wagstaff AJ, Balfour JA. Grepafloxacin. Drugs. 1997;53(5):817-824.	Title
852	Mroczkowski T, Hook Iii E, Jones R, et al. Grepafloxacin versus cefixime as single-dose therapy for uncomplicated gonorrhea in women. Infectious diseases in obstetrics and gynecology. 1997;5(6):370-375.	Abstract
853	Vogel F. A guide to the treatment of lower respiratory tract infections. Drugs. 1995;50(1):62-72.	Title
854	Pong AL, Bradley JS. Guidelines for the Selection of Antibacterial Therapy in Children. Pediatric Clinics of North America. 2005 2005/06/01/;52(3):869-894.	Title
855	Williams PC, Berkley JA. Guidelines for the treatment of dysentery (shigellosis): a systematic review of the evidence. Paediatrics and international child health. 2018;38(sup1):S50-S65.	Title
856	Sugawara M, Iseki K, Miyazaki K. H <sup>+</sup> coupled transport of orally active cephalosporins lacking an alpha-amino group across brush-border membrane vesicles from rat small intestine. J Pharm Pharmacol. 1991 Jun;43(6):433-5.	Animal
857	Inui K, Okano T, Maegawa H, et al. H <sup>+</sup> coupled transport of p.o. cephalosporins via dipeptide carriers in rabbit intestinal brush-border membranes: difference of transport characteristics between cefixime and cephradine. J Pharmacol Exp Ther. 1988 Oct;247(1):235-41.	Animal
858	Jones RN, Erwin ME. Haemophilus test medium interpretive criteria for disk diffusion susceptibility tests with cefdinir, cefetamet, cefmetazole, cefpodoxime, cefdaloxime (RU29246, HR-916 metabolite), and trospectomycin. Diagnostic Microbiology and Infectious Disease. 1992 1992/11/01/;15(8):693-701.	Title

859	Loo V, Sherman P, Matlow A. Helicobacter pylori infection in a pediatric population: in vitro susceptibilities to omeprazole and eight antimicrobial agents. Antimicrobial agents and chemotherapy. 1992;36(5):1133-1135.	Title
860	Kimoto E, Bi Y-A, Kosa RE, et al. Hepatobiliary Clearance Prediction: Species Scaling From Monkey, Dog, and Rat, and In Vitro–In Vivo Extrapolation of Sandwich-Cultured Human Hepatocytes Using 17 Drugs. Journal of Pharmaceutical Sciences. 2017 2017/09/01/;106(9):2795-2804.	Animal
861	Tarirai C, Viljoen AM, Hamman JH. Herb–drug pharmacokinetic interactions reviewed. Expert opinion on drug metabolism & toxicology. 2010;6(12):1515-1538.	Title
862	Colalto C. Herbal interactions on absorption of drugs: Mechanisms of action and clinical risk assessment. Pharmacological Research. 2010 2010/09/01/;62(3):207-227.	Title
863	Jacobsson S, Mason C, Khan N, et al. High in vitro activity of DIS-73285, a novel antimicrobial with a new mechanism of action, against MDR and XDR Neisseria gonorrhoeae. Journal of Antimicrobial Chemotherapy. 2020;75(11):3244-3247.	Title
864	Jacobsson S, Golparian D, Alm RA, et al. High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug-resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea. Antimicrobial agents and chemotherapy. 2014;58(9):5585-5588.	Title
865	Unemo M, Ringlander J, Wiggins C, et al. High in vitro susceptibility to the novel spiropyrimidinetrione ETX0914 (AZD0914) among 873 contemporary clinical Neisseria gonorrhoeae isolates from 21 European countries from 2012 to 2014. Antimicrobial agents and chemotherapy. 2015;59(9):5220-5225.	Title
866	Yoo B-I, Yeom ZH, Kang MH, et al. High performance liquid chromatographic analysis and pharmacokinetic characteristics of ID-7181, a novel quaternary ammoniopropenyl cephalosporin, following intravenous and intramuscular injections to rats. Arzneimittelforschung. 2005;55(09):549-556.	Animal

867	Danafar H. High performance liquid chromatographic method for determination of ezetimibe in pharmaceutical formulation tablets. <i>Pharmaceutical and Biomedical Research</i> . 2016;2(3):38-46.	Title
868	Unemo M, Ahlstrand J, Sánchez-Busó L, et al. High susceptibility to zoliflodacin and conserved target (GyrB) for zoliflodacin among 1209 consecutive clinical <i>Neisseria gonorrhoeae</i> isolates from 25 European countries, 2018. <i>Journal of Antimicrobial Chemotherapy</i> . 2021;76(5):1221-1228.	Title
869	Kushner BH, Kramer K, Modak S, et al. High-dose cyclophosphamide–irinotecan–vincristine for primary refractory neuroblastoma. <i>European Journal of Cancer</i> . 2011 2011/01/01/;47(1):84-89.	Title
870	Allen SJ, Wareham K, Wang D, et al. A high-dose preparation of lactobacilli and bifidobacteria in the prevention of antibiotic-associated and <i>clostridium difficile</i> diarrhoea in older people admitted to hospital: a multicentre, randomised, double-blind, placebo-controlled, parallel arm trial (PLACIDE) [Journal: Article]. <i>Health technology assessment</i> . 2013;17(57):1-139.	Title
871	Unemo M, Golparian D, Nicholas R, et al. High-level cefixime-and ceftriaxone-resistant <i>Neisseria gonorrhoeae</i> in France: novel penA mosaic allele in a successful international clone causes treatment failure. <i>Antimicrobial agents and chemotherapy</i> . 2012;56(3):1273-1280.	Abstract
872	Elkhaïli H, Linger L, Monteil H, et al. High-performance liquid chromatographic assay for cefepime in serum. <i>Journal of Chromatography B: Biomedical Sciences and Applications</i> . 1997 1997/03/07/;690(1):181-188.	Title
873	Elkhaïli H, Niedergang S, Pompei D, et al. High-performance liquid chromatographic assay for meropenem in serum. <i>Journal of Chromatography B: Biomedical Sciences and Applications</i> . 1996 1996/11/08/;686(1):19-26.	Title



874	Amini H, Ahmadiani A. High-performance liquid chromatographic determination of rivastigmine in human plasma for application in pharmacokinetic studies. Iranian Journal of Pharmaceutical Research: IJPR. 2010;9(2):115.	Title
875	Zendelovska D, Stafilov T, Miloševski P. High-performance liquid chromatographic method for simultaneous determination of cefixime and cefotaxime in plasma samples. Bulletin of the Chemists and Technologists of Macedonia, 22, 39–45 (2003). 2003.	Abstract
876	Jehl F, Gallion C, Monteil H. High-performance liquid chromatography of antibiotics. Journal of Chromatography B: Biomedical Sciences and Applications. 1990 1990/10/12/;531:509-548.	Title
877	Sader HS, Jones RN. Historical overview of the cephalosporin spectrum: Four generations of structural evolution. Antimicrobial Newsletter. 1992 1992/12/01/;8(12):75-82.	Abstract
878	Kumazawa J, Yagisawa M. The history of antibiotics: The Japanese story. Journal of Infection and Chemotherapy. 2002 2002/01/01/;8(2):125-133.	Title
879	Complete Natal D. home> pill identifier and drug identification.	Title
880	Jacobs MR. How can we predict bacterial eradication? Int J Infect Dis. 2003 Mar;7 Suppl 1:S13-20.	Title
881	Carbon C. How to evaluate the ecologic impact of antibiotics in phase III trials. Clinical Microbiology and Infection. 2001 2001/01/01/;7:42-45.	Title
882	Kahsay G, Song H, Van Schepdael A, et al. Hydrophilic interaction chromatography (HILIC) in the analysis of antibiotics. Journal of Pharmaceutical and Biomedical Analysis. 2014 2014/01/18/;87:142-154.	Title
883	ICW – 2021 Virtual Workshop of the International Complement Society (ICS) – Abstracts; December 07 – 10, 2021. Molecular Immunology. 2022 2022/01/01/;141:116-235.	Title

884	Jain N, Sk MF, Mishra A, et al. Identification of novel efflux pump inhibitors for <i>Neisseria gonorrhoeae</i> via multiple ligand-based pharmacophores, e-pharmacophore, molecular docking, density functional theory, and molecular dynamics approaches. <i>Computational Biology and Chemistry</i> . 2022 2022/06/01/;98:107682.	Title
885	Pradnyadhita II. IDENTIFIKASI DAN UJI SENSITIVITAS BAKTERI <i>Neisseria gonorrhoeae</i> TERHADAP ANTIBIOTIK SEFIKSIM PADA PEKERJA SEKS KOMERSIAL DI PUSKESMAS II DENPASAR SELATAN: JURUSAN ANALIS KESEHATAN; 2018.	Title
886	Patel U, Joshi AS, Ganjiwale J, et al. Impact of antimicrobial stewardship program on prescribing pattern of cephalosporins in the department of surgery. <i>National Journal of Physiology, Pharmacy and Pharmacology</i> . 2020;10(2):109-115.	Abstract
887	Khan A. Impact Of Omeprazole, Rosuvastatin And Clopidogrel On The Pharmacokinetics Of Cefixime In Healthy Adult Human Subjects: UNIVERSITY OF PESHAWAR; 2012.	Title
888	Faure S, Perrin-Guyomard A, Delmas JM, et al. Impact of therapeutic treatment with beta-lactam on transfer of the bla(CTX-M-9) resistance gene from <i>Salmonella enterica</i> serovar Virchow to <i>Escherichia coli</i> in gnotobiotic rats. <i>Appl Environ Microbiol</i> . 2009 Sep;75(17):5523-8.	Title
889	Tsuji A. Impact of transporter-mediated drug absorption, distribution, elimination and drug interactions in antimicrobial chemotherapy. <i>Journal of Infection and Chemotherapy</i> . 2006 2006/01/01/;12(5):241-250.	Title
890	Ramirez-Malule H, Junne S, López C, et al. An improved HPLC-DAD method for clavulanic acid quantification in fermentation broths of <i>Streptomyces clavuligerus</i> . <i>Journal of Pharmaceutical and Biomedical Analysis</i> . 2016 2016/02/20/;120:241-247.	Title
891	Yu S, Zhang Y, Wang XZ. Improved understanding of cefixime trihydrate reactive crystallization and process scale-up with the aid of PAT. <i>Organic Process Research &amp; Development</i> . 2019;23(2):177-188.	Abstract

892	Velický M, Tam KY, Dryfe RAW. In situ artificial membrane permeation assay under hydrodynamic control: Correlation between drug in vitro permeability and fraction absorbed in humans. <i>European Journal of Pharmaceutical Sciences</i> . 2011 2011/10/09/;44(3):299-309.	Title
893	Mustafa G. IN TREATMENT oF ENTERic FeveR IN. <i>Mental</i> .2:1.	Title
894	Thakur N, Thakral S, Goswami M, et al. In vitro Absorption Study of Carbamazepine Solid Dispersion Using Everted Gut Sac Method. <i>Indonesian Journal of Pharmacy</i> . 2013;24(2):93-99.	Title
895	Garcia-Rodriguez J, García Sánchez J, García García M, et al. In vitro activities of new oral beta-lactams and macrolides against <i>Campylobacter pylori</i> . <i>Antimicrobial agents and chemotherapy</i> . 1989;33(9):1650-1651.	Title
896	Jacobsson S, Golparian D, Phan LT, et al. In vitro activities of the novel bicyclics modithromycin (EDP-420, EP-013420, S-013420) and EDP-322 against MDR clinical <i>Neisseria gonorrhoeae</i> isolates and international reference strains. <i>Journal of Antimicrobial Chemotherapy</i> . 2015;70(1):173-177.	Title
897	Grimm H. In vitro activity and cross resistance studies with cefpodoxime. <i>Zentralblatt für Bakteriologie</i> . 1991;276(1):54-62.	Title
898	Stefani S, Pellegrino M, Privitera A, et al. In vitro activity of a new broad-spectrum, beta-lactamase-stable oral cephalosporin, cefixime, in comparison with other drugs, against <i>Haemophilus influenzae</i> , <i>Haemophilus parainfluenzae</i> , <i>Moraxella catarrhalis</i> and <i>Streptococcus pneumoniae</i> . <i>Chemotherapy</i> . 1992;38(1):36-45.	Abstract
899	Chin N, Neu HC. In vitro activity of an oral iminomethoxy aminothiazolyl cephalosporin, R-3746. <i>Antimicrobial agents and chemotherapy</i> . 1988;32(5):671-677.	Title
900	Rizwan M, Bakht J, Bacha N, et al. In vitro activity of antimicrobial agents against <i>Streptococcus pyogenes</i> isolated from different regions of Khyber Pakhtun Khwa Pakistan. <i>Pakistan journal of pharmaceutical sciences</i> . 2016;29(1).	Title

901	Sultan T, Baltch AL, Smith RP, et al. In vitro activity of cefdinir (FK482) and ten other antibiotics against gram-positive and gram-negative bacteria isolated from adult and pediatric patients. <i>Chemotherapy</i> . 1994;40(2):80-91.	Title
902	Mulligan ME, Kwok Y. In vitro activity of cefixime and six other agents against nosocomial pathogens of the Enterobacteriaceae family. <i>Infection Control &amp; Hospital Epidemiology</i> . 1987;8(6):241-244.	Abstract
903	Sader HS, Jones RN, Washington JA, et al. In vitro activity of cefpodoxime compared with other oral cephalosporins tested against 5556 recent clinical isolates from five medical centers. <i>Diagnostic microbiology and infectious disease</i> . 1993;17(2):143-150.	Abstract
904	Sen B, Bhattacharya M, Niyogi SK. In vitro activity of cefpodoxime, a third generation cephalosporin against <i>Salmonella enterica</i> serotype Typhi. <i>Antimicrobial Agents and Chemotherapy</i> . 2007.	Title
905	Sen B, Bhattacharya M, Niyogi SK. In vitro activity of cefpodoxime, an expanded-spectrum cephalosporin, against <i>Salmonella enterica</i> serotype typhi. <i>Antimicrobial agents and chemotherapy</i> . 2008;52(2):802-803.	Title
906	Bowie W, Shaw C, Chan D, et al. In vitro activity of difloxacin hydrochloride (A-56619), A-56620, and cefixime (CL 284,635; FK 027) against selected genital pathogens. <i>Antimicrobial agents and chemotherapy</i> . 1986;30(4):590-593.	Abstract
907	Hunfeld K-P, Rödel R, Wichelhaus TA. In vitro activity of eight oral cephalosporins against <i>Borrelia burgdorferi</i> . <i>International Journal of Antimicrobial Agents</i> . 2003 2003/04/01/;21(4):313-318.	Abstract
908	García-Rodríguez J, Martín IT, Baquero F, et al. In vitro activity of fosfomicin trometamol against pathogens from urinary tract infections: a Spanish multicenter study. <i>Journal of chemotherapy</i> . 1997;9(6):394-402.	Title
909	Doern G. In vitro activity of loracarbef and effects of susceptibility test methods. <i>Am J Med</i> . 1992 Jun 22;92(6a):7s-15s.	Title

910	Pistiki A, Tsaganos T, Galani I, et al. In vitro activity of oral cephalosporins (cefprozil and cefixime) against ciprofloxacin-resistant Enterobacteriaceae from community-acquired urinary-tract infections. Infectious diseases and therapy. 2015;4(4):425-432.	Abstract
911	Jones RN, Erwin ME, Barrett MS, et al. In vitro activity of RU29246 the metabolite of a new HR916 cephalosporin ester. Diagnostic Microbiology and Infectious Disease. 1991 1991/11/01/;14(6):473-483.	Title
912	Golparian D, Fernandes P, Ohnishi M, et al. In vitro activity of the new fluoroketolide solithromycin (CEM-101) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains, including those with high-level antimicrobial resistance: potential treatment option for gonorrhea? Antimicrobial agents and chemotherapy. 2012;56(5):2739-2742.	Title
913	Jacobsson S, Mason C, Khan N, et al. In vitro activity of the novel oral antimicrobial SMT-571, with a new mechanism of action, against MDR and XDR Neisseria gonorrhoeae: future treatment option for gonorrhoea? Journal of Antimicrobial Chemotherapy. 2019;74(6):1591-1594.	Title
914	Jacobsson S, Paukner S, Golparian D, et al. In vitro activity of the novel pleuromutilin lefamulin (BC-3781) and effect of efflux pump inactivation on multidrug-resistant and extensively drug-resistant Neisseria gonorrhoeae. Antimicrobial agents and chemotherapy. 2017;61(11):e01497-17.	Title
915	Fietta A, Merlini C, Grassi G. In vitro activity of two new oral cephalosporins, cefixime and cefdinir (CI 983), on human peripheral mononuclear and polymorphonuclear leukocyte functions. Chemotherapy. 1994;40(5):317-323.	Abstract
916	Tamura A, Okamoto R, Yoshida T, et al. In vitro and in vivo antibacterial activities of ME1207, a new oral cephalosporin. Antimicrob Agents Chemother. 1988 Sep;32(9):1421-6.	Title

917	Mirghani M, Mohamed EA, Ahmed SI, et al. IN VITRO ANTI-BACTERIAL ACTIVITY OF ETHANOL EXTRACT OF ZINGIBER OFFICINALE (ZINGIBERACEAE) COMBINED WITH AMOXYCILLIN AND CEFIXIME. 2018.	Abstract
918	Komolpis P. In Vitro Anti-Staphylococcal Activity of Cefdinir.	Title
919	Cheng L-Y, Xia W, Zhang X, et al. In vitro binding comparison of cephalosporins to human serum albumin by spectroscopy and molecular docking approaches: A novel structural pursuing. Journal of Molecular Liquids. 2017 2017/12/01/;248:168-176.	Abstract
920	AM THABIT A, AL-GHANI AM. IN VITRO CEFIXIME DISSOLUTION IN PHARMACOPEIA-RECOMMENDED MEDIUM AND SIMULATED GASTROINTESTINAL FLUIDS: A COMPARATIVE STUDY. IN VITRO. 2019;12(12).	Abstract
921	Felmingham D, Robbins MJ, Ghosh G, et al. An in vitro characterization of cefditoren, a new oral cephalosporin. Drugs Exp Clin Res. 1994;20(4):127-47.	Title
922	Rolin O, Roche G, Bouanchaud D. In vitro comparative bactericidal effect of cefotaxime and cefixime in a kinetic model. Presse Medicale (Paris, France: 1983). 1989;18(32):1569-1571.	Abstract
923	Westermeyer RR, Roy AF, Mitchell MS, et al. In vitro comparison of Staphylococcus pseudintermedius susceptibility to common cephalosporins used in dogs. Vet Ther. 2010;11(3):1-9.	Animal
924	Bakthavatchalam Y, Kumar D, Tayubi I, et al. In vitro efficacy and in silico analysis of cefixime–ofloxacin combination for Salmonella Typhi from bloodstream infection. Journal of Applied Microbiology. 2017;123(3):615-624.	Abstract
925	Allen GP, Deao KM, Hill SA, et al. In vitro evaluation of antimicrobial resistance selection in Neisseria gonorrhoeae. International Journal of Antimicrobial Agents. 2021;58(4):106417.	Title

926	Fuchs PC, Jones RN, Barry AL, et al. In vitro evaluation of cefixime (FK027, FR17027, CL284635): Spectrum against recent clinical isolates, comparative antimicrobial activity, $\beta$ -lactamase stability, and preliminary susceptibility testing criteria. <i>Diagnostic microbiology and infectious disease</i> . 1986;5(2):151-162.	Abstract
927	Chiu C-H, Lin T-Y, Ou JT. In vitro evaluation of intracellular activity of antibiotics against non-typhoid Salmonella. <i>International Journal of Antimicrobial Agents</i> . 1999 1999/06/01/;12(1):47-52.	Title
928	Jones RN, Barry AL. In vitro evaluations of U-76,252 (CS-807): antimicrobial spectrum, beta-lactamase stability, and enzyme inhibition. <i>Diagnostic microbiology and infectious disease</i> . 1987;8(4):245-249.	Title
929	Patil SV, Hajare AL, Patankar M, et al. In vitro fractional inhibitory concentration (FIC) study of cefixime and azithromycin fixed dose combination (FDC) against respiratory clinical isolates. <i>Journal of Clinical and Diagnostic Research: JCDR</i> . 2015;9(2):DC13.	Abstract
930	Istifli ES, Topaktaş M. In vitro genotoxicity and cytotoxicity of a particular combination of pemetrexed and cefixime in human peripheral blood lymphocytes. <i>SpringerPlus</i> . 2015;4(1):1-9.	Abstract
931	De Vecchi E, Nicola L, Zucchetti E, et al. In vitro induction of resistance by tissue concentrations of azithromycin, clarithromycin, cefixime and amoxicillin/clavulanate in clinical isolates of <i>Streptococcus pyogenes</i> . <i>Journal of chemotherapy</i> . 2006;18(4):379-388.	Abstract
932	Bingen E, Bidet P, Birgy A, et al. In vitro interaction between cefixime and amoxicillin-clavulanate against extended-spectrum-beta-lactamase-producing <i>Escherichia coli</i> causing urinary tract infection. <i>Journal of clinical microbiology</i> . 2012;50(7):2540-2541.	Abstract
933	Gil-Alonso S, Jauregizar N, Ortega I, et al. In vitro pharmacodynamic modelling of anidulafungin against <i>Candida</i> spp. <i>International Journal of Antimicrobial Agents</i> . 2016 2016/03/01/;47(3):178-183.	Title

934	Bialer M, Wu WH, Faulkner RD, et al. In vitro protein binding interaction studies involving cefixime. <i>Biopharm Drug Dispos.</i> 1988 May-Jun;9(3):315-20.	Abstract
935	Negri MC, Morosini MI, Loza E, et al. In vitro selective antibiotic concentrations of beta-lactams for penicillin-resistant <i>Streptococcus pneumoniae</i> populations. <i>Antimicrobial Agents and Chemotherapy.</i> 1994;38(1):122-125.	Title
936	Spangler SK, Jacobs MR, Appelbaum PC. In vitro susceptibilities of 185 penicillin-susceptible and-resistant pneumococci to WY-49605 (SUN/SY 5555), a new oral penem, compared with those to penicillin G, amoxicillin, amoxicillin-clavulanate, cefixime, cefaclor, cefpodoxime, cefuroxime, and cefdinir. <i>Antimicrobial agents and chemotherapy.</i> 1994;38(12):2902-2904.	Title
937	Agger W, Callister S, Jobe D. In vitro susceptibilities of <i>Borrelia burgdorferi</i> to five oral cephalosporins and ceftriaxone. <i>Antimicrobial agents and chemotherapy.</i> 1992;36(8):1788-1790.	Abstract
938	Powell M, Williams J. In vitro susceptibility of <i>Haemophilus influenzae</i> to cefixime. <i>Antimicrobial agents and chemotherapy.</i> 1987;31(11):1841-1842.	Abstract
939	Cern A, Connolly KL, Jerse AE, et al. In vitro susceptibility of <i>Neisseria gonorrhoeae</i> strains to mupirocin, an antibiotic reformulated for parenteral administration in nanoliposomes. <i>Antimicrobial agents and chemotherapy.</i> 2018;62(4):e02377-17.	Title
940	Westblom T, Gudipati S, Midkiff B. In vitro susceptibility of <i>Helicobacter pylori</i> to the new oral cephalosporins cefpodoxime, ceftibuten and cefixime. <i>European Journal of Clinical Microbiology and Infectious Diseases.</i> 1990;9(9):691-693.	Abstract
941	Mine Y, Yokota Y, Wakai Y, et al. In vivo antibacterial activity of FK482, a new orally active cephalosporin. <i>J Antibiot (Tokyo).</i> 1988 Dec;41(12):1888-95.	Title



942	Sun N, Xie Y, Sheng C, et al. In vivo pharmacokinetics and in vitro antifungal activity of iodiconazole, a new triazole, determined by microdialysis sampling. International journal of antimicrobial agents. 2013;41(3):229-235.	Title
943	Cao C, Chin N, Neu H. In-vitro activity and $\beta$ -lactamase stability of LY163892. Journal of antimicrobial Chemotherapy. 1988;22(2):155-165.	Title
944	Arguedas AG, Arrieta AC, Stutman HR, et al. In-vitro activity of cefprozil (BMY 28100) and loracarbef (LY 163892) against pathogens obtained from middle ear fluid. Journal of antimicrobial chemotherapy. 1991;27(3):311-318.	Title
945	McLinn S, Williams D. Incidence of antibiotic-resistant Streptococcus pneumoniae and beta-lactamase-positive Haemophilus influenzae in clinical isolates from patients with otitis media. The Pediatric infectious disease journal. 1996;15(9):3-9.	Title
946	Pinatih KJP, Suastika K, Sukrama IDM, et al. Increase in bacteroides/firmicutes ratio after early-life repeated administration of Cefixime in Rat. Bali Med J. 2017;6.	Animal
947	Harcouët L, Lebrech D, Rozé C, et al. Increased intestinal absorption of cefixime by nifedipine in the rat intestinal perfusion model: evidence for a neural regulation. J Pharmacol Exp Ther. 1997 May;281(2):738-45.	Animal
948	Finegold SM, George WL, editors. Anaerobic Infections in Humans: Academic Press; 1989. p. 819-851.	Title
949	Index. Primary Care: Clinics in Office Practice. 1990 1990/09/01;17(3):703-712.	Title
950	Griffin JP, D'Arcy PF, editors. A Manual of Adverse Drug Interactions (Fifth Edition). Amsterdam: Elsevier Science B.V.; 1997. p. 611-649.	Title
951	Sussman M, editor. Molecular Medical Microbiology. London: Academic Press; 2002. p. i-lxx.	Title
952	Stapleton F, editor. The Anterior Eye and Therapeutics. London: Butterworth-Heinemann; 2003. p. 247-261.	Title

953	Pediatric Clinics of North America. 2005 2005/06/01/;52(3):949-961.	Title
954	Rosenstock L, Cullen MR, Brodtkin CA, et al., editors. Textbook of Clinical Occupational and Environmental Medicine (Second Edition). Edinburgh: W.B. Saunders; 2005. p. 1285-1338.	Title
955	Vékey K, Telekes A, Vertes A, editors. Medical Applications of Mass Spectrometry. Amsterdam: Elsevier; 2008. p. 561-581.	Title
956	Wexler P, editor. Encyclopedia of Toxicology (Third Edition). Oxford: Academic Press; 2014. p. 1067-1276.	Title
957	Bennett JE, Dolin R, Blaser MJ, editors. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases (Eighth Edition). Philadelphia: W.B. Saunders; 2015. p. I1-I120.	Title
958	Cohen J, Powderly WG, Opal SM, editors. Infectious Diseases (Fourth Edition): Elsevier; 2017. p. I1-I76.	Title
959	Waller DG, Sampson AP, editors. Medical Pharmacology and Therapeutics (Fifth Edition): Elsevier; 2018. p. 707-729.	Title
960	Schmidt TM, editor. Encyclopedia of Microbiology (Fourth Edition). Oxford: Academic Press; 2019. p. 617-689.	Title
961	Preedy VR, editor. Pathology: Academic Press; 2020. p. 403-415.	Title
962	Wolverton SE, editor. Comprehensive Dermatologic Drug Therapy (Fourth Edition): Elsevier; 2021. p. 787-825.	Title
963	Chassagne F, editor. Medicinal Plants as Anti-Infectives: Academic Press; 2022. p. 555-574.	Title
964	Nissenson AR, Fine RN, Mehrotra R, et al., editors. Handbook of Dialysis Therapy (Sixth Edition). New Delhi: Elsevier; 2023. p. 809-863.	Title
965	Aronson JK, editor. Side Effects of Drugs Annual. Vol. 23: Elsevier; 2000. p. 555-592.	Title
966	Cefprozil CS. Index to volume 8. Diagn Microbiol Infect Dis. 1991;14:361-364.	Title

967	Kinoshita Y, Ueno H, Kurata H, et al. Infection-Induced Elevated Plasma Perampanel in a Patient with Hemimegalencephaly. Case Reports in Pediatrics. 2022;2022.	Title
968	Infectious cost of leisure (Keynote lecture). Clinical Microbiology and Infection. 2001 2001/01/01/;7:1-357.	Title
969	Singlas E, Lebrec D, Gaudin C, et al. Influence de l'insuffisance hépatique sur la pharmacocinétique du céfixime. La Presse médicale (1983). 1989;18(32):1587-1588.	Title
970	SINGLAS E, LEBREC D, GAUDIN C, et al. INFLUENCE OF IMPAIRED LIVER-FUNCTION UPON PHARMACOKINETICS OF CEFIXIME. PRESSE MEDICALE. 1989;18(32):1587-1588.	Abstract
971	Fenoll A, Giménez M, Robledo O, et al. Influence of penicillin/amoxicillin non-susceptibility on the activity of third-generation cephalosporins against Streptococcus pneumoniae. European Journal of Clinical Microbiology & Infectious Diseases. 2008;27(1):75-80.	Abstract
972	Satoh T, Igarashi A, Tanno M, et al. Inhibitory effects of baicalein derived from Japanese traditional herbal medicine on SN-38 glucuronidation. Journal of Pharmacy & Pharmaceutical Sciences. 2018;21:195-206.	Title
973	Atta S, Khaliq S, Islam A, et al. Injectable biopolymer based hydrogels for drug delivery applications. Int J Biol Macromol. 2015 Sep;80:240-5.	Title
974	Salehi B, Sharifi-Rad J, Quispe C, et al. Insights into Eucalyptus genus chemical constituents, biological activities and health-promoting effects. Trends in Food Science & Technology. 2019 2019/09/01/;91:609-624.	Title
975	Luckner P, Brandsch M. Interaction of 31 beta-lactam antibiotics with the H <sup>+</sup> /peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24.	Title
976	Kramer W, Gutjahr U, Kowalewski S, et al. Interaction of the orally active dianionic cephalosporin cefixime with the uptake system for oligopeptides and $\alpha$ -amino- $\beta$ -lactam antibiotics in rabbit small intestine. Biochemical pharmacology. 1993;46(3):542-546.	Animal

977	Biswas S, Anisuzzaman SM, Rana MS. International Journal of Pharmaceutical and Phytopharmacological Research (eIJPPR).	Title
978	Nishio H. An international review of the safety profile of cefixime. Current therapeutic research. 1994;55:63-67.	Title
979	Scaglione F, Demartini G, Dugnani S, et al. Interpretation of middle ear fluid concentrations of antibiotics: comparison between ceftibuten, cefixime and azithromycin. British journal of clinical pharmacology. 1999;47(3):267.	Abstract
980	Bergogne-Bérézin E. Interpretation of pharmacologic data in respiratory tract infections. International Journal of Antimicrobial Agents. 1993 1993/01/01/;3:S3-S14.	Title
981	Jones RN, Erwin ME, Gooding BB. Interpretive criteria for disk diffusion tests using 5-microgram cefdinir disks with rapidly growing clinical isolates. Journal of clinical microbiology. 1992;30(4):1022-1023.	Title
982	Cazzola M, Matera MG. Interrelationship between pharmacokinetics and pharmacodynamics in choosing the appropriate antibiotic and the dosage regimen for treating acute exacerbations of chronic bronchitis. Respiratory Medicine. 1998 1998/07/01/;92(7):895-901.	Title
983	Liu P, Müller M, Grant M, et al. Interstitial tissue concentrations of cefpodoxime. Journal of Antimicrobial Chemotherapy. 2002;50(suppl_1):19-22.	Title
984	Hu YQ, Qian CQ, Zheng LY, et al. Intestinal absorption of cefixime in rats. Zhongguo Yao Li Xue Bao. 1999 Jan;20(1):55-8.	Animal
985	Katsura T, Inui K-i. Intestinal Absorption of Drugs Mediated by Drug Transporters: Mechanisms and Regulation. Drug Metabolism and Pharmacokinetics. 2003 2003/01/01/;18(1):1-15.	Title

986	Tsuji A, Tamai I, Nakanishi M, et al. Intestinal brush-border transport of the oral cephalosporin antibiotic, cefdinir, mediated by dipeptide and monocarboxylic acid transport systems in rabbits. <i>Journal of pharmacy and pharmacology</i> . 1993;45(11):996-998.	Animal
987	Estudante M, Morais JG, Soveral G, et al. Intestinal drug transporters: An overview. <i>Advanced Drug Delivery Reviews</i> . 2013 2013/10/15/;65(10):1340-1356.	Title
988	Anderle P, Huang Y, Sadée W. Intestinal membrane transport of drugs and nutrients: genomics of membrane transporters using expression microarrays. <i>European Journal of Pharmaceutical Sciences</i> . 2004 2004/01/01/;21(1):17-24.	Title
989	Walter E, Kissel T, Amidon GL. The intestinal peptide carrier: A potential transport system for small peptide derived drugs. <i>Advanced Drug Delivery Reviews</i> . 1996 1996/07/12/;20(1):33-58.	Title
990	Bretschneider B, Brandsch M, Neubert R. Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H <sup>+</sup> /peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. <i>Pharm Res</i> . 1999 Jan;16(1):55-61.	Title
991	Kavi J, Ashby J, Wise R, et al. Intraperitoneal penetration of cefpirome. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> . 1989;8(6):556-558.	Title
992	Chiu LM, Amsden GW. Intrapulmonary pharmacokinetics of antibacterial agents. <i>American Journal of Respiratory Medicine</i> . 2002;1(3):201-209.	Title
993	Fujiu M, Yokoo K, Sato J, et al. Introduction of a Thio Functional Group to Diazabicyclooctane: An Effective Modification to Potentiate the Activity of $\beta$ -Lactams against Gram-Negative Bacteria Producing Class A, C, and D Serine $\beta$ -Lactamases. <i>ACS Infect Dis</i> . 2020 Nov 13;6(11):3034-3047.	Title
994	Song J-H. Introduction: the goals of antimicrobial therapy. <i>International Journal of Infectious Diseases</i> . 2003;7:S1-S4.	Title

995	Ni Y, Chen J, Kokot S. Investigation of the pharmacokinetics and determination of certain cephalosporins in rabbit plasma by a kinetic spectrophotometric method with the aid of chemometrics. Science china chemistry. 2011;54(5):827-834.	Animal
996	Kato Y, Sugiura T, Nakadera Y, et al. Investigation of the role of oligopeptide transporter PEPT1 and sodium/glucose cotransporter SGLT1 in intestinal absorption of their substrates using small GTP-binding protein Rab8-null mice. Drug metabolism and disposition. 2009;37(3):602-607.	Animal
997	YAMAN YT, Bolat G, Yardimci C, et al. An ionic liquid/bismuth film-modified sensor for the electrochemical detection of cefixime. Turkish Journal of Chemistry. 2018;42(3):826-838.	Abstract
998	Bishai WR. Issues in the management of bacterial sinusitis. Otolaryngology - Head and Neck Surgery. 2002 2002/12/01/;127(6, Supplement):S3-S9.	Title
999	Al-Sadawi M, Rodriguez Ortega R, Sun N, et al. Jerky movement with ceftazidime: A case of ceftazidime-induced neurotoxicity with a review of the literature. Case Reports in Medicine. 2019;2019.	Title
1000	Tablet M, Patel B, Patel B. Journal Club for Pharmaceutical Sciences (JCPS).	Title
1001	O.A.Egorova. Justification of the choice of generation III cephalosporin in the therapy of acute bacterial rhinosinusitis. Academic journal.	Abstract
1002	Keyword Index. Journal of Chromatography B. 2005 2005/05/25/;819(2):351-358.	Title
1003	Bingen E, Bourgeois F, Chardon H, et al. Killing kinetics of five orally administered antibiotics at clinically achievable concentrations against moraxella catarrhalis. European Journal of Clinical Microbiology and Infectious Diseases. 1992;11(10):923-926.	Title

100 4	Westphal JF, Jehl F, Brogard JM. [Kinetics of cefixime biliary clearance in cholecystectomized patients]. Therapie. 1994 Jan-Feb;49(1):35-9.	Not Accessible
100 5	Kenyon C, De Baetselier I, Crucitti T. Kingdom [version 1; referees: awaiting peer review].	Title
100 6	Nakao Y, Andoh Y, Kitoh O, et al. Laboratory and clinical studies on cefdinir in pediatric field [Journal: Article]. Japanese journal of antibiotics. 1990;43(8):1476-1488.	Title
100 7	Grunder G, Zysset-Aschmann Y, Vollenweider F, et al. Lack of pharmacokinetic interaction between linezolid and antacid in healthy volunteers. Antimicrobial agents and chemotherapy. 2006;50(1):68-72.	Title
100 8	Kuang Y-Y, Zhang Z-B, Xie M-L, et al. Large-scale preparation of amorphous cefixime nanoparticles by antisolvent precipitation in a high-gravity rotating packed bed. Industrial & Engineering Chemistry Research. 2015;54(33):8157-8165.	Abstract
100 9	Danafar H, Hamidi M. LC-MS method for studying the pharmacokinetics and bioequivalence of clonidine hydrochloride in healthy male volunteers. Avicenna journal of medical biotechnology. 2016;8(2):91.	Title
101 0	Shipkova M, Svinarov D. LC-MS/MS as a tool for TDM services: Where are we? Clinical Biochemistry. 2016 2016/09/01;49(13):1009-1023.	Title
101 1	Novelli A. Le rino-sino-otiti Opinioni a confronto: Il parere del farmacologo.	Title
101 2	Navratil H. Le traitement des prostatites aiguës. Médecine et Maladies Infectieuses. 1991 1991/02/01;21(2, Part 2):138-141.	Title
101 3	PRICOP C, PUIA D, ANDONE D, et al. LEVOFLOXACIN VERSUS CEFIXIME AS AN EMPIRIC TREATMENT IN ACUTE BACTERIAL PROSTATITIS. FARMACIA. 2021;69(4):682-687.	Abstract

101 4	Gehring R, Riviere JE. Limitations of MIC as the sole criterion in antimicrobial drug dosage regimen design: The need for full characterization of antimicrobial pharmacodynamic profile especially for drug-resistant organisms. <i>Vet J.</i> 2013;198(1):15-18.	Title
101 5	Peris-Vicente J, Peris-García E, Albiol-Chiva J, et al. Liquid chromatography, a valuable tool in the determination of antibiotics in biological, food and environmental samples. <i>Microchemical Journal.</i> 2022 2022/06/01/;177:107309.	Title
101 6	Liquid column chromatography. <i>Journal of Chromatography A.</i> 1987 1987/01/01/;412:B505-B566.	Title
101 7	Liquid column chromatography. <i>Journal of Chromatography A.</i> 1988 1988/01/01/;460:B121-B262.	Title
101 8	Liquid column chromatography. <i>Journal of Chromatography A.</i> 1990 1990/01/01/;524(4):B481-B641.	Title
101 9	Liquid column chromatography. <i>Journal of Chromatography A.</i> 1991 1991/09/11/;561(1):B433-B563.	Title
102 0	Liquid column chromatography. <i>Journal of Chromatography A.</i> 1992 1992/06/12/;610(2):B185-B276.	Title
102 1	Yang N, Gong F, Zhou Y, et al. Liquid metals: Preparation, surface engineering, and biomedical applications. <i>Coordination Chemistry Reviews.</i> 2022 2022/11/15/;471:214731.	Title
102 2	McAteer JA, Hiltke MF, Silber BM, et al. Liquid-chromatographic determination of five orally active cephalosporins--cefixime, cefaclor, cefadroxil, cephalixin, and cephradine--in human serum. <i>Clinical Chemistry.</i> 1987;33(10):1788-1790.	Abstract



102 3	Ata S, Rasool A, Islam A, et al. Loading of Cefixime to pH sensitive chitosan based hydrogel and investigation of controlled release kinetics. International journal of biological macromolecules. 2020;155:1236-1244.	Abstract
102 4	Dalhoff A, Ambrose P, Mouton J. A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints. Infection. 2009;37(4):296-305.	Title
102 5	Rubinstein E, Carbon C, Rangaraj M, et al. Lower respiratory tract infections: etiology, current treatment, and experience with fluoroquinolones. Clinical Microbiology and Infection. 1998 1998/04/01/;4:2S42-2S50.	Title
102 6	Alvarez-Elcoro S, Enzler MJ. The Macrolides: Erythromycin, Clarithromycin, and Azithromycin. Mayo Clinic Proceedings. 1999 1999/06/01/;74(6):613-634.	Title
102 7	Nassr N, Lahu G, Hunnemeyer A, et al. Magnesium hydroxide/aluminium hydroxide-containing antacid does not affect the pharmacokinetics of the targeted phosphodiesterase 4 inhibitor roflumilast. Journal of clinical pharmacology. 2007;47(5):660-667.	Title
102 8	Rubio-Aliaga I, Daniel H. Mammalian peptide transporters as targets for drug delivery. Trends in Pharmacological Sciences. 2002 2002/09/01/;23(9):434-440.	Title
102 9	Principi N. Management issues in paediatric pharyngitis and otitis media. International Journal of Antimicrobial Agents. 1995 1995/12/01/;6(2):65-79.	Title
103 0	Hoehn B, Varon E, de Debroucker T, et al. Management of acute community-acquired bacterial meningitis (excluding newborns). Long version with arguments. Médecine et Maladies Infectieuses. 2019 2019/09/01/;49(6):405-441.	Title
103 1	Nueremberger EL, Bishai WR. Management of community-acquired pneumonia caused by drug-resistant Streptococcus pneumoniae. Management of multiple drug-resistant infections: Springer; 2004. p. 3-29.	Title

103 2	Baker KA, Fotos PG. THE MANAGEMENT OF ODONTOGENIC INFECTIONS: A Rationale for Appropriate Chemotherapy. Dental Clinics of North America. 1994 1994/10/01/;38(4):689-706.	Title
103 3	Akin I, KARADEMİR Ü, Belge A, et al. Marbofloxacin Overdose: the Culprit for Acute Blindness in a Dog. Kafkas Univ Vet Fak Derg. 2016;22:623-626.	Animal
103 4	Ropponen H-K, Richter R, Hirsch AKH, et al. Mastering the Gram-negative bacterial barrier – Chemical approaches to increase bacterial bioavailability of antibiotics. Advanced Drug Delivery Reviews. 2021 2021/05/01/;172:339-360.	Title
103 5	Özyüncü Ö, Beksac MS, Nemutlu E, et al. Maternal blood and amniotic fluid levels of moxifloxacin, levofloxacin and cefixime. Journal of Obstetrics and Gynaecology Research. 2010;36(3):484-487.	Abstract
103 6	Cline MK, Bailey-Dorton C, Cayelli M. MATERNAL INFECTIONS: Diagnosis and Management. Primary Care: Clinics in Office Practice. 2000 2000/03/01/;27(1):13-33.	Title
103 7	Nahata MC. Measurement of cefixime in serum and cerebrospinal fluid by high-performance liquid chromatography. Journal of liquid chromatography. 1991;14(20):3755-3759.	Abstract
103 8	Bhatnagar S, Chandra J. Mechanism of Action. Indian Pediatrics. 1999;36:901-904.	Title
103 9	Sakamoto H, Hirose T, Nakamoto S, et al. Mechanism of renal excretion of FK027 in dogs and rabbits. J Antibiot (Tokyo). 1985 Aug;38(8):1088-95.	Animal
104 0	Ikeda F, Tawara S, Matsumoto K, et al. Mechanism of Therapeutic Effectiveness of.	Title
104 1	Matsumoto Y, Ikemoto A, Wakai Y, et al. Mechanism of therapeutic effectiveness of cefixime against typhoid fever. Antimicrobial agents and chemotherapy. 2001;45(9):2450-2454.	Abstract

104 2	Venisse N, Grégoire N, Marliat M, et al. Mechanism-based pharmacokinetic-pharmacodynamic models of in vitro fungistatic and fungicidal effects against <i>Candida albicans</i> . <i>Antimicrobial agents and chemotherapy</i> . 2008;52(3):937-943.	Title
104 3	Czock D, Keller F. Mechanism-based pharmacokinetic–pharmacodynamic modeling of antimicrobial drug effects. <i>Journal of pharmacokinetics and pharmacodynamics</i> . 2007;34(6):727-751.	Title
104 4	González MJ, Aguilar MV, Martínez MC. Mechanisms of Absorption of As <sub>2</sub> O <sub>5</sub> from Rat Small Intestine: the Effect of Different Parameters. <i>Journal of Trace Elements in Medicine and Biology</i> . 1997 1997/01/01;11(4):239-247.	Animal
104 5	Jacobs MR, Anon J, Appelbaum PC. Mechanisms of resistance among respiratory tract pathogens. <i>Clinics in Laboratory Medicine</i> . 2004 2004/06/01;24(2):419-453.	Title
104 6	Stern A, Elmore J. Medication for Gravid and Nursing Dental Patients. <i>Dental Clinics of North America</i> . 2016 2016/04/01;60(2):523-531.	Title
104 7	Shikov AN, Pozharitskaya ON, Makarov VG, et al. Medicinal Plants of the Russian Pharmacopoeia; their history and applications. <i>Journal of Ethnopharmacology</i> . 2014 2014/07/03;154(3):481-536.	Title
104 8	Munjampalli SKJ, Davis DE. Medicinal-Induced Behavior Disorders. <i>Neurologic Clinics</i> . 2016 2016/02/01;34(1):133-169.	Title
104 9	Rafailidis PI, Pitsounis AI, Falagas ME. Meta-analyses on the Optimization of the Duration of Antimicrobial Treatment for Various Infections. <i>Infectious Disease Clinics of North America</i> . 2009 2009/06/01;23(2):269-276.	Title
105 0	Danish M, Raza M, Ilyas T, et al. Metal complexes and organotin (IV) compounds of cefixime and their biological study. <i>Med Chem</i> . 2015;5.	Abstract

105 1	Alekseev V. Metal complexes of penicillins and cephalosporins. Pharmaceutical chemistry journal. 2012;45(11):679-697.	Abstract
105 2	Olurische C, Salawu O, Zezi A, et al. Metformin-Cefixime Co-administration affects glucose regulation and reno-pancreatic histology in alloxan-induced hyperglycemic rats. J Pharma Sci Tech. 2013;3:43-50.	Animal
105 3	Azmi S, Iqbal B, Al Mamari J, et al. Method Development and validation for the determination of cefixime in pure and commercial dosage forms by spectrophotometry. Int J Chem Molec Nucl Mat Metallurg Eng. 2014;8(6):595-601.	Abstract
105 4	Danafar H. Method validation of clonidine hydrochloride in human plasma by LC-MS technique. Pharmaceutical and Biomedical Research. 2015;1(4):48-58.	Title
105 5	Barry AL, Fuchs PC. Methods for predicting susceptibility of Streptococcus pneumoniae to cefixime. Journal of clinical microbiology. 1995;33(4):1031-1033.	Abstract
105 6	Scangarella-Oman N, Hossain M, Dixon P, et al. Microbiological analysis from a phase ii study in adults evaluating single doses of gepotidacin (GSK2140944) in the treatment of uncomplicated urogenital gonorrhoea caused by neisseria gonorrhoeae [Conference Abstract]. Sexually transmitted infections Conference: 2017 STI and HIV world congress Brazil. 2017;93(Supplement 2):A84.	Title
105 7	Brook I. Microbiology and Principles of Antimicrobial Therapy for Head and Neck Infections. Infectious Disease Clinics of North America. 2007 2007/06/01/;21(2):355-391.	Title
105 8	Brunner M, Derendorf H, Müller M. Microdialysis for in vivo pharmacokinetic/pharmacodynamic characterization of anti-infective drugs. Current opinion in pharmacology. 2005;5(5):495-499.	Title
105 9	Yu W, Cheng Q, Feng J, et al. Microdialysis for pharmacokinetic-pharmacodynamic studies. Die Pharmazie-An International Journal of Pharmaceutical Sciences. 2007;62(12):883-891.	Title

106 0	Plock N, Kloft C. Microdialysis—theoretical background and recent implementation in applied life-sciences. European Journal of Pharmaceutical Sciences. 2005 2005/05/01/;25(1):1-24.	Title
106 1	Tambe V, Pande S, Gadeval A, et al. Microdialysis: an emerging technique for pharmacokinetic–pharmacodynamic profiling. Biopharmaceutics and Pharmacokinetics Considerations: Elsevier; 2021. p. 601-616.	Title
106 2	Harrison CJ, Chartrand SA, Rodriguez W, et al. Middle ear effusion concentrations of cefixime during acute otitis media with effusion and otitis media with effusion. Pediatr Infect Dis J. 1997 Aug;16(8):816-7.	Abstract
106 3	Sharma V, Sharma PC, Kumar V. A mini review on pyridoacridines: Prospective lead compounds in medicinal chemistry. Journal of Advanced Research. 2015 2015/01/01/;6(1):63-71.	Title
106 4	Eskandari H, Amirzehni M, Asadollahzadeh H, et al. MIP-capped terbium MOF-76 for the selective fluorometric detection of cefixime after its preconcentration with magnetic graphene oxide. Sensors and Actuators B: Chemical. 2018;275:145-154.	Abstract
106 5	Hassouna MEM, Mohamed MA. Modeling and optimization of a novel RP-UPLC and MCR spectrophotometric methods for simultaneous determination of five cephalosporins in spiked human plasma: Application to lean six sigma thinking hats and antimicrobial activity. Microchemical Journal. 2019 2019/11/01/;150:104161.	Abstract
106 6	Rakhmatulina M. MODERN PRINCIPLES OF TREATMENT OF GONOCOCCAL INFECTION.	Title
106 7	Tan Z, Orndorff PE, Shirwaiker RA. Modified Pharmacokinetic/Pharmacodynamic model for electrically activated silver-titanium implant system. Biomater Biomech Bioeng. 2015;2(3):127-141.	Title

106 8	Alonso R, Rodríguez-Achaerandio A, Aguirre-Quñonero A, et al. Molecular Epidemiology, Antimicrobial Surveillance, and PK/PD Analysis to Guide the Treatment of Neisseria gonorrhoeae Infections. Pharmaceutics. 2021;13(10):1699.	Title
106 9	Ahmadian E, Samiei M, Hasanzadeh A, et al. Monitoring of drug resistance towards reducing the toxicity of pharmaceutical compounds: Past, present and future. Journal of Pharmaceutical and Biomedical Analysis. 2020 2020/07/15/;186:113265.	Title
107 0	Müller M. Monitoring tissue drug levels by clinical microdialysis. Alternatives to Laboratory Animals. 2009;37(1_suppl):57-59.	Animal
107 1	Kafetzis D. Multi-investigator evaluation of the efficacy and safety of cefprozil, amoxicillin-clavulanate, cefixime and cefaclor in the treatment of acute otitis media. European Journal of Clinical Microbiology and Infectious Diseases. 1994;13(10):857-865.	Abstract
107 2	Peyramond D, Tigaud S, Bremard-Oury C, et al. Multicenter comparative trial of cefixime and phenoxymethylpenicillin for group A beta-hemolytic streptococcal tonsillitis. Current therapeutic research. 1994;55:14-21.	Abstract
107 3	Smith BL, Mogabgab WJ, Dalu ZA, et al. Multicenter Trial of Fleroxacin Versus Ceftriaxone in the Treatment of Uncomplicated Gonorrhea. The American Journal of Medicine. 1993 1993/03/22/;94(3, Supplement 1):81S-84S.	Title
107 4	Taylor R, Bignell C. Multidrug-resistant gonorrhoea: tackling a meaner bug in the UK. Journal of Family Planning and Reproductive Health Care. 2012;38(2):70-72.	Title
107 5	Lode H, Müller C, Borner K, et al. Multiple-dose pharmacokinetics of cefprozil and its impact on intestinal flora of volunteers. Antimicrobial agents and chemotherapy. 1992;36(1):144-149.	Title

107 6	Lin C, Radwanski E, Affrime M, et al. Multiple-dose pharmacokinetics of ceftibuten in healthy volunteers. Antimicrobial agents and chemotherapy. 1995;39(2):356-358.	Title
107 7	Ensafi AA, Allafchian AR. Multiwall carbon nanotubes decorated with NiFe <sub>2</sub> O <sub>4</sub> magnetic nanoparticles, a new catalyst for voltammetric determination of cefixime. Colloids and Surfaces B: Biointerfaces. 2013;102:687-693.	Abstract
107 8	Matin A, Sharma S, Mathur P, et al. Myelosuppression-sparing treatment of central nervous system nocardiosis in a multiple myeloma patient utilizing a tedizolid-based regimen: a case report. International Journal of Antimicrobial Agents. 2017 2017/04/01;49(4):488-492.	Title
107 9	Zadaliasghar S, Rahimpour E, Khoubnasabjafari M, et al. A nano-platform for phenobarbital determination based on its inhibitory effect on the aggregation of silver nanoparticles/melamine system. Journal of Molecular Liquids. 2020 2020/10/10;316:113891.	Title
108 0	Vassallo A, Silletti MF, Faraone I, et al. Nanoparticulate antibiotic systems as antibacterial agents and antibiotic delivery platforms to fight infections. Journal of Nanomaterials. 2020;2020.	Title
108 1	Zhang W, Taheri-Ledari R, Ganjali F, et al. Nanoscale bioconjugates: A review of the structural attributes of drug-loaded nanocarrier conjugates for selective cancer therapy. Heliyon. 2022 2022/06/01;8(6):e09577.	Title
108 2	Rajendran R, Menon KN, Nair SC. Nanotechnology Approaches for Enhanced CNS Drug Delivery in the Management of Schizophrenia. Advanced Pharmaceutical Bulletin. 2022;12(3):490.	Title
108 3	Bavya MC, George L, Srivastava R, et al. Natural and Synthetic Materials in Regenerative Medicine: Progress Over the Past Five Years☆: Hydrogels: An Insight. In: Olabi A-G, editor. Encyclopedia of Smart Materials. Oxford: Elsevier; 2019. p. 113-144.	Title
108 4	Wang Q, Kuang H, Su Y, et al. Naturally derived anti-inflammatory compounds from Chinese medicinal plants. Journal of Ethnopharmacology. 2013 2013/03/07;146(1):9-39.	Title

108 5	Shaker SH, Razooqi QA, Shaban RK. Negative effect of therapeutic, double and overdoses of cefixime on the liver and kidneys of male albino rats. <i>Ann Trop Med Public Health</i> . 2020;23.	Animal
108 6	Tesh LD, Shaeer KM, Cho JC, et al. Neisseria gonorrhoeae and fosfomycin: Past, present and future. <i>International Journal of Antimicrobial Agents</i> . 2015 2015/09/01/;46(3):290-296.	Title
108 7	Allen VG, Mitterni L, Seah C, et al. Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. <i>Jama</i> . 2013;309(2):163-170.	Abstract
108 8	Bradley JS. <i>Nelson's pocket book of pediatric antimicrobial therapy</i> . AWWE; 2006.	Title
108 9	Berlioz F, Julien S, Tsocas A, et al. Neural modulation of cephalexin intestinal absorption through the di- and tripeptide brush border transporter of rat jejunum in vivo. <i>J Pharmacol Exp Ther</i> . 1999 Mar;288(3):1037-44.	Animal
109 0	Birnbaumer D, Fernández-Frackelton M. THE NEW ANTIBIOTICS. <i>Emergency Medicine Clinics of North America</i> . 2000 2000/11/01/;18(4):671-708.	Title
109 1	Singh J, Arrieta AC. New cephalosporins. <i>Seminars in Pediatric Infectious Diseases</i> . 1999 1999/01/01/;10(1):14-22.	Abstract
109 2	Talan DA. New concepts in antimicrobial therapy for emergency department infections. <i>Annals of Emergency Medicine</i> . 1999 1999/10/01/;34(4, Part 1):503-516.	Title
109 3	Jones RN. New drugs. <i>Antimicrobial Newsletter</i> . 1985 1985/08/01/;2(8):59-61.	Title
109 4	Jones RN. New drugs. <i>Antimicrobial Newsletter</i> . 1986 1986/09/01/;3(9):68-70.	Title
109 5	Hussar DA. New Drugs of 2001. <i>Journal of the American Pharmaceutical Association</i> (1996). 2002 2002/03/01/;42(2):227-266.	Title



109 6	Jones RN. New drugs— new hopes for infection chemotherapy: Highlights of the twenty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), October 4–7, 1987, New York, New York. Antimicrobial Newsletter. 1987 1987/11/01/;4(11):98-100.	Title
109 7	Wang L-L, Battini N, Bheemanaboina RRY, et al. A new exploration towards aminothiazolquinolone oximes as potentially multi-targeting antibacterial agents: Design, synthesis and evaluation acting on microbes, DNA, HSA and topoisomerase IV. European Journal of Medicinal Chemistry. 2019 2019/10/01/;179:166-181.	Title
109 8	Yasui H, Yamaoka K, Nakagawa T. New hepatocellular diffusion model for analysis of hepatobiliary transport processes of drugs. Journal of pharmacokinetics and biopharmaceutics. 1995;23(2):183-203.	Title
109 9	Mazzei T, Novelli A, Esposito S, et al. New insight into the clinical pharmacokinetics of cefaclor: tissue penetration. Journal of chemotherapy. 2000;12(1):53-62.	Title
110 0	Yamashita S, Hattori E, Shimada A, et al. New Methods to Evaluate Intestinal Drug Absorption Mediated by Oligopeptide Transporter from In vitro Study using Caco-2 Cells. Drug Metabolism and Pharmacokinetics. 2002 2002/01/01/;17(5):408-415.	Title
110 1	Yamada H, Ueda S, Mutoh M, et al. New orally active cephalosporin esters. J Antibiot (Tokyo). 1990 May;43(5):578-83.	Abstract
110 2	Ramesh M, Durga MK, Sravani A, et al. A New Stability Indicating Validated RP-HPLC Method for the Simultaneous Estimation of Azithromycin and Cefixime in Bulk and Pharmaceutical Dosage Forms. Asian Journal of Research in Chemistry. 2012;5(8):1067-1073.	Abstract
110 3	Neu HC. New strategies for the 1990's: antibacterial therapy. International Journal of Antimicrobial Agents. 1991 1991/01/01/;1(1):47-50.	Title

110 4	Ennis DM, Cobbs CG. The newer cephalosporins: aztreonam and imipenem. Infectious Disease Clinics of North America. 1995;9(3):687-713.	Abstract
110 5	Zuckerman JM, Kaye KM. THE NEWER MACROLIDES: Azithromycin and Clarithromycin. Infectious Disease Clinics of North America. 1995 1995/09/01;9(3):731-745.	Title
110 6	Manwar JV, Panchale WA, Bakal RL, et al. Newer RP-HPLC method development and validation of cefixime and linezolid in bulk drugs and combined dosage form. International Journal of Pharmacy & Life Sciences. 2021;12(1).	Abstract
110 7	Dailly E, Verdier M-C, Deslandes G, et al. Niveau de preuve du suivi thérapeutique pharmacologique de la ceftriaxone. Therapies. 2012 2012/03/01;67(2):145-149.	Title
110 8	Wang Q, Wang Y, Xie Y, et al. Nonionic surfactant vesicles as a novel drug delivery system for increasing the oral bioavailability of Ginsenoside Rb1. Food Bioscience. 2021 2021/08/01;42:101064.	Title
110 9	Hu Y, Hu C, Pan G, et al. Novel chalcone-conjugated, multi-flexible end-group coumarin thiazole hybrids as potential antibacterial repressors against methicillin-resistant Staphylococcus aureus. European Journal of Medicinal Chemistry. 2021 2021/10/15;222:113628.	Title
111 0	Anirudhan TS, Parvathy J, Nair AS. A novel composite matrix based on polymeric micelle and hydrogel as a drug carrier for the controlled release of dual drugs. Carbohydr Polym. 2016 Jan 20;136:1118-27.	Title
111 1	Rezki N, Al-Sodies SA, Ahmed HEA, et al. A novel dicationic ionic liquids encompassing pyridinium hydrazone-phenoxy conjugates as antimicrobial agents targeting diverse high resistant microbial strains. Journal of Molecular Liquids. 2019 2019/06/15;284:431-444.	Title
111 2	Dave RA, Morris ME. Novel high/low solubility classification methods for new molecular entities. International Journal of Pharmaceutics. 2016 2016/09/10;511(1):111-126.	Title

111 3	Mayumi K, Tachibana M, Yoshida M, et al. The Novel In Vitro Method to Calculate Tissue-to-Plasma Partition Coefficient in Humans for Predicting Pharmacokinetic Profiles by Physiologically-Based Pharmacokinetic Model With High Predictability. <i>Journal of Pharmaceutical Sciences</i> . 2020 2020/07/01/;109(7):2345-2355.	Title
111 4	Li F-F, Zhang P-L, Tangadanchu VKR, et al. Novel metronidazole-derived three-component hybrids as promising broad-spectrum agents to combat oppressive bacterial resistance. <i>Bioorganic Chemistry</i> . 2022 2022/05/01/;122:105718.	Title
111 5	Holban AM, Grumezescu AM. Novel Molecular Approaches to Target Microbial Virulence. <i>Novel Molecular Approaches to Target Microbial Virulence: De Gruyter Open Poland</i> ; 2015.	Title
111 6	Darabi R, Shabani-Nooshabadi M. A Novel Nanostructured Electrochemical Sensor for Determination of Cefixime in the Presence of Mefenamic Acid and Acetaminophen in Pharmaceuticals and Biological Samples. Available at SSRN 3880207. 2021.	Abstract
111 7	Atif S, Baig JA, Afridi HI, et al. Novel nontoxic electrochemical method for the detection of cefadroxil in pharmaceutical formulations and biological samples. <i>Microchemical Journal</i> . 2020 2020/05/01/;154:104574.	Title
111 8	Cazzola M. Novel oral cephalosporins. <i>Expert Opinion on Investigational Drugs</i> . 2000;9(2):237-246.	Abstract
111 9	Ojani R, Raof JB, Zamani S. A novel sensor for cephalosporins based on electrocatalytic oxidation by poly(o-anisidine)/SDS/Ni modified carbon paste electrode. <i>Talanta</i> . 2010 Jun 15;81(4-5):1522-8.	Abstract
112 0	Hassouna ME, Abdelrahman MM, Mohamed MA. Novel spectrophotometric methods for simultaneous determination of Cefixime trihydrate and sodium benzoate in powder for oral suspension dosage form. <i>Glob J Oto</i> . 2017;12(4):555841.	Abstract

112 1	Lieberman D, Schlaeffer F. Once-a-day cefixime versus co-amoxiclav three times daily in the treatment of lower respiratory infections. <i>Journal of Antimicrobial Chemotherapy</i> . 1995;35(2):354-357.	Abstract
112 2	Farooq S, Mazhar A, Ihsan Ul H, et al. One-pot multicomponent synthesis of novel 3, 4-dihydro-3-methyl-2(1H)-quinazolinone derivatives and their biological evaluation as potential antioxidants, enzyme inhibitors, antimicrobials, cytotoxic and anti-inflammatory agents. <i>Arabian Journal of Chemistry</i> . 2020 2020/12/01/;13(12):9145-9165.	Title
112 3	Chen N, Aleksa K, Woodland C, et al. Ontogeny of drug elimination by the human kidney. <i>Pediatric nephrology</i> . 2006;21(2):160-168.	Title
112 4	Amin MR, Das SK, Kabir A, et al. Open Label Randomized Controlled Comparison of Three Alternative Regimes of Ciprofloxacin, Azithromycin and Cefixime for Treatment of Uncomplicated Typhoid Fever in Bangladesh. <i>Mymensingh Med J</i> . 2021 Jul;30(3):725-737.	Abstract
112 5	Pandit A, Arjyal A, Day JN, et al. An open randomized comparison of gatifloxacin versus cefixime for the treatment of uncomplicated enteric fever. <i>PLoS One</i> . 2007 Jun 27;2(6):e542.	Abstract
112 6	Ong JJ, Pollard TD, Goyanes A, et al. Optical biosensors - Illuminating the path to personalized drug dosing. <i>Biosensors and Bioelectronics</i> . 2021 2021/09/15/;188:113331.	Title
112 7	Neu H. Optimal characteristics of agents to treat uncomplicated urinary tract infections. <i>Infection</i> . 1992;20(4):S266-S271.	Title
112 8	Meltzer EO, Weinstein SF, Zitt MJ. Optimal management of community-acquired acute bacterial rhinosinusitis: the allergist's perspective. <i>Annals of Allergy, Asthma &amp; Immunology</i> . 2006 2006/03/01/;96(3):390-397.	Title
112 9	Jacobs MR. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. <i>Clinical Microbiology and Infection</i> . 2001 2001/11/01/;7(11):589-596.	Title

113 0	Seña AC, Bachmann L, Johnston C, et al. Optimising treatments for sexually transmitted infections: surveillance, pharmacokinetics and pharmacodynamics, therapeutic strategies, and molecular resistance prediction. <i>The Lancet Infectious Diseases</i> . 2020 2020/08/01/;20(8):e181-e191.	Title
113 1	Maheshwari ML, Memon AA, Memon S, et al. Optimization of HPLC method for determination of cefixime using 2-thiophenecarboxaldehyde as derivatizing reagent: A new approach. <i>Saudi Pharmaceutical Journal</i> . 2015;23(4):444-452.	Abstract
113 2	Kzar TT, Rasheed AS, Hassan MJM. OPTIMIZATION OF HYDROPHILIC INTERACTION CHROMATOGRAPHY METHOD FOR DETERMINATION OF CEFIXIME IN SOME PHARMACEUTICAL PREPARATIONS USING HPLC COUPLED WITH UV DETECTION.	Abstract
113 3	Nicolau DP. Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling. <i>Journal of infection and chemotherapy</i> . 2003;9(4):292-296.	Title
113 4	Hampson NB, Woolf RA, Springmeyer SC. Oral Antibiotics for Pneumonia. <i>Clinics in Chest Medicine</i> . 1991 1991/06/01/;12(2):395-407.	Title
113 5	Shenep J, Flynn P, Baker D, et al. Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer. <i>Clinical infectious diseases</i> . 2001;32(1):36-43.	Abstract
113 6	PORTILLA I, LUTZ B, MONTALVO M, et al. Oral cefixime versus intramuscular ceftriaxone in patients with uncomplicated gonococcal infections. <i>Sexually transmitted diseases</i> . 1992:94-98.	Abstract
113 7	Stewart AG, Harris PN, Henderson A, et al. Oral cephalosporin and $\beta$ -lactamase inhibitor combinations for ESBL-producing Enterobacteriaceae urinary tract infections. <i>Journal of Antimicrobial Chemotherapy</i> . 2020;75(9):2384-2393.	Abstract

113 8	Bryskier A, Lebel M. Oral cephalosporins. Antimicrobial Agents: Antibacterials and Antifungals. 2005:222-268.	Abstract
113 9	HARRIS A. Oral cephalosporins. Journal of Antimicrobial Chemotherapy. 1992;30(3):398-399.	Abstract
114 0	Rimmer DM. Oral cephalosporins for use in a parenteral-to-oral switch programme. Infection. 1995;23 Suppl 2:S87-90.	Abstract
114 1	Moellering RC. Oral cephalosporins in perspective. Clinical Drug Investigation. 1995;9(3):1-10.	Abstract
114 2	Bergogne-Bérézin E. Oral cephalosporins in the treatment of respiratory tract infections. Current therapeutic research. 1996;57(13):87-96.	Abstract
114 3	Garcia-Rodriguez J, Bellido JM. Oral cephalosporins in uncomplicated urinary tract infections. Clinical microbiology and infection. 2000;6:73-75.	Abstract
114 4	Morrow JD. The Oral Cephalosporins—A Review. The American Journal of the Medical Sciences. 1992 1992/01/01/;303(1):35-39.	Title
114 5	Bennet R, Eriksson M, Odenholt I. Oral cephalosporins: how should they be used?	Abstract
114 6	Levi ME, Eusterman VD. Oral Infections and Antibiotic Therapy. Otolaryngologic Clinics of North America. 2011 2011/02/01/;44(1):57-78.	Title
114 7	Ayazi K, Tofigh AM, Qaderi S, et al. Oral Metronidazole and Cefixime as Prophylaxis on Wound Complications of Uncomplicated Appendicitis Following Appendectomy: A Randomized Clinical Trial. 2021.	Abstract

114 8	Oral presentations. <i>Clinical Microbiology and Infection</i> . 2010 2010/04/01/;16:S1-S131.	Title
114 9	Oral Sessions. <i>International Journal of Antimicrobial Agents</i> . 2017 2017/11/01/;50:S29-S68.	Title
115 0	Molloy L, Barron S, Khan N, et al. Oral $\beta$ -Lactam Antibiotics for Pediatric Otitis Media, Rhinosinusitis, and Pneumonia. <i>Journal of Pediatric Health Care</i> . 2020 2020/05/01/;34(3):291-300.	Title
115 1	Fujita D, Saito Y, Nakanishi T, et al. Organic Anion Transporting Polypeptide (OATP)2B1 Contributes to Gastrointestinal Toxicity of Anticancer Drug SN-38, Active Metabolite of Irinotecan Hydrochloride. <i>Drug Metab Dispos</i> . 2016 Jan;44(1):1-7.	Title
115 2	Rafal'skiy V. Ostryy neoslozhnennyy tsistit: novye tendentsii v antimikrobnoy terapii. <i>Consilium Medicum</i> . 2012;14(7):28-33.	Title
115 3	Novick WJ. The other side of early antimicrobial development. <i>Antimicrobial Newsletter</i> . 1986 1986/09/01/;3(9):63-68.	Title
115 4	Pokharel S, Karki M, Acharya B, et al. Outbreak of acute undifferentiated febrile illness in Kathmandu, Nepal: clinical and epidemiological investigation. <i>BMC Infect Dis</i> . 2020 Jan 30;20(1):89.	Title
115 5	Williams LL, Wilimas JA, Harris SC, et al. Outpatient therapy with ceftriaxone and oral cefixime for selected febrile children with sickle cell disease. <i>Journal of Pediatric Hematology Oncology</i> . 1996;18:257-261.	Abstract
115 6	Hamilton-Miller J. Overview of cefixime use in community-acquired infections. <i>Clinical microbiology and infection</i> . 2000;6:79-81.	Abstract
115 7	Craig WA. Overview of newer antimicrobial formulations for overcoming pneumococcal resistance. <i>The American Journal of Medicine Supplements</i> . 2004 2004/08/02/;117(3, Supplement 1):16-22.	Title

115 8	Brown TJ, Yen-Moore A, Tying SK. An overview of sexually transmitted diseases. Part I. Journal of the American Academy of Dermatology. 1999 1999/10/01/;41(4):511-529.	Title
115 9	Adam D. Overview of the clinical features of cefixime. Chemotherapy. 1998;44(Suppl. 1):1-5.	Abstract
116 0	山作房之輔, 鈴木康稔, 宇野勝次. Oxime 型新経口 Cephem 剤の薬動力学的研究 CS-807, T-2588, Cefixime の同一被験者における比較. Chemotherapy. 1988;36(Supplement1):267-273.	Title
116 1	Verma SR, Doshi A. P-01 Release study of Levofloxacin Hemihydrate from Nanostructured Hetrolipid matrix for Ocular Delivery. International journal of Nanomedicine. 2011;6:683-692.	Title
116 2	Golparian D, Hadad R, Hellmark B, et al. P2. 087 In Vitro Antimicrobial Synergy Testing, Using Etest Methodology, of Neisseria Gonorrhoeae For Evaluation of Susceptibility When Using Dual Antimicrobial Therapy? Sexually Transmitted Infections. 2013;89(Suppl 1):A114-A115.	Title
116 3	Acevedo A, Ingold A, Parnizzari F, et al. P2. 088 N. Gonorrhoeae Antimicrobial Resistance in Uruguay: Period 2010–2011. Sexually Transmitted Infections. 2013;89(Suppl 1):A115-A115.	Title
116 4	Lefebvre B, Labbé A, Venne S, et al. P2. 089 Antimicrobial Susceptibility Profile of Neisseria Gonorrhoeae Isolates in the Province of Québec: 2012. Sexually Transmitted Infections. 2013;89(Suppl 1):A115-A115.	Title
116 5	Barbee L, Black D, Golden M. P2. 090 Multi-Dose Cefixime For Reduced Susceptibility Gonorrhea: A Pharmacokinetic Model. Sexually Transmitted Infections. 2013;89(Suppl 1):A115-A116.	Abstract
116 6	Tantalo L, Mayans MV, Cazorla MU, et al. P394 Evaluation of the in vitro efficacy of cefixime, dalbavancin, isoniazid, and pyrazinamide against Treponema pallidum. BMJ Publishing Group Ltd; 2021.	Abstract
116 7	Kersh E, Kang J, Dorji T, et al. P693 Neisseria gonorrhoeae in-vitro susceptibilities to ceftriaxone, cefixime and azithromycin in GISP isolates, 1987–2017. Sexually Transmitted Infections. 2019;95(Suppl 1):A303.	Abstract



116 8	P941 – P1197. <i>Clinical Microbiology and Infection</i> . 2006 2006/01/01/;12:S292-S383.	Title
116 9	Cafini F, Torrico M, Gonzalez N, et al. P2060 Effects of cefditoren, cefuroxime, cefaclor and cefixime on the competitive growth of <i>Streptococcus pneumoniae</i> , as a model approach to selection of populations. <i>International Journal of Antimicrobial Agents</i> . 2007 2007/03/01/;29:S594-S595.	Abstract
117 0	Treadway G, Pontani D. Paediatric safety of azithromycin: worldwide experience. <i>Journal of Antimicrobial Chemotherapy</i> . 1996;37(suppl_C):143-149.	Title
117 1	Rashed AN, Jackson C, Gastine S, et al. Page Paediatric pharmacokinetics of the antibiotics in the Access and Watch groups of the 2019 WHO Model List of Essential Medicines for Children: A systematic review.	Title
117 2	Baba S, Kinoshita H, Mori Y, et al. A parallel comparative double blind study of cefixime with cefaclor in the treatment of acute suppurative otitis media in children. <i>The Japanese Journal of Antibiotics</i> . 1987;40(1):1-24.	Abstract
117 3	Matsunaga T, Ogino H, Asai H, et al. A parallel comparative double blind study of cefixime with cefroxadine in the treatment of acute lacunar tonsillitis. <i>The Japanese journal of antibiotics</i> . 1987;40(1):25-54.	Abstract
117 4	Debbia E, Marchese A, Pesce A, et al. Parameters characterizing the in vitro activity of cefixime, a new oral broad spectrum cephalosporin, against respiratory and urinary pathogens. <i>Journal of chemotherapy</i> . 1992;4(3):131-144.	Abstract
117 5	Craig WA, Andes DR. Parenteral versus oral antibiotic therapy. <i>Medical Clinics of North America</i> . 1995 1995/01/01/;79(3):497-508.	Title
117 6	Amraei A, Niazi A. Partial least square and parallel factor analysis methods applied for spectrophotometric determination of cefixime in pharmaceutical formulations and biological fluids. <i>Iranian Journal of Pharmaceutical Research: IJPR</i> . 2018;17(4):1191.	Abstract

117 7	Eltantawy MNM. Partial Surface Selenization of Cobalt Sulfide Microspheres for Enhancing the Hydrogen Evolution Reaction. American Chemical Society. 2018.	Title
117 8	Pichichero ME. Pathogen shifts and changing cure rates for otitis media and tonsillopharyngitis. Clinical pediatrics. 2006;45(6):493-502.	Title
117 9	Cornaglia G, Ligozzi M, Bauernfeind A, et al. PBP binding and periplasmic concentration as determinants of the antibacterial activities of three new oral cephalosporins in Escherichia coli. New Microbiol. 1994 Jul;17(3):203-10.	Abstract
118 0	Strickley RG, Iwata Q, Wu S, et al. Pediatric Drugs-A Review of Commercially Available Oral Formulations. Journal of Pharmaceutical Sciences. 2008 2008/05/01;97(5):1731-1774.	Title
118 1	Rashed AN, Jackson C, Gastine S, et al. Pediatric pharmacokinetics of the antibiotics in the access and watch groups of the 2019 WHO model list of essential medicines for children: a systematic review. Expert review of clinical pharmacology. 2019;12(12):1099-1106.	Title
118 2	Somekh E, Heifetz L, Dan M, et al. Penetration and bactericidal activity of cefixime in synovial fluid. Antimicrobial agents and chemotherapy. 1996;40(5):1198-1200.	Abstract
118 3	Lee VHL, Yamamoto A. Penetration and enzymatic barriers to peptide and protein absorption. Advanced Drug Delivery Reviews. 1989 1989/10/01;4(2):171-207.	Title
118 4	Tod B, Chaine G, Oliary J, et al. Penetration of cefixime in the anterior chamber of the human eye. Journal Francais D'ophtalmologie. 1991;14(8-9):477-480.	Abstract
118 5	Bergeron MG, Turcotte A. Penetration of cefixime into fibrin clots and in vivo efficacy against Escherichia coli, Klebsiella pneumoniae, and Staphylococcus aureus. Antimicrobial agents and chemotherapy. 1986;30(6):913-916.	Abstract

118 6	MacGowan A, White L, Brown E, et al. Penetration of cefixime into the cerebrospinal fluid of patients with non-inflamed meninges. <i>Journal of Antimicrobial Chemotherapy</i> . 1993;32(5):783-784.	Abstract
118 7	Muller-Serieys C, Bancal C, Dombret M, et al. Penetration of cefpodoxime proxetil in lung parenchyma and epithelial lining fluid of noninfected patients. <i>Antimicrobial agents and chemotherapy</i> . 1992;36(10):2099-2103.	Title
118 8	Nau R, Sorgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. <i>Clinical microbiology reviews</i> . 2010;23(4):858-883.	Title
118 9	Hadinegoro SRS, Tumbelaka AR, Satari HI. Pengobatan cefixime pada demam tifoid anak. <i>Sari Pediatri</i> . 2016;2(4):182-7.	Title
119 0	Midtvedt T. Penicillins, cephalosporins, and tetracyclines. In: Aronson JK, Van Boxtel CJ, editors. <i>Side Effects of Drugs Annual</i> . Vol. 17: Elsevier; 1993. p. 296-302.	Abstract
119 1	Midtvedt T. Penicillins, cephalosporins, other $\beta$ -lactam antibiotics, and tetracyclines. In: Aronson JK, editor. <i>Side Effects of Drugs Annual</i> . Vol. 23: Elsevier; 2000. p. 250-260.	Abstract
119 2	Wang L, Wang C, Liu Q, et al. PEPT1- and OAT1/3-mediated drug–drug interactions between bestatin and cefixime in vivo and in vitro in rats, and in vitro in human. <i>European Journal of Pharmaceutical Sciences</i> . 2014 2014/10/15/;63:77-86.	Animal
119 3	Wenzel U, Kuntz S, Diestel S, et al. PEPT1-mediated cefixime uptake into human intestinal epithelial cells is increased by Ca <sup>2+</sup> channel blockers. <i>Antimicrobial agents and chemotherapy</i> . 2002;46(5):1375-1380.	Abstract
119 4	Ma K, Hu Y, Smith DE. Peptide Transporter 1 Is Responsible for Intestinal Uptake of the Dipeptide Glycylsarcosine: Studies in Everted Jejunal Rings from Wild-type and Pept1 Null Mice. <i>Journal of Pharmaceutical Sciences</i> . 2011 2011/02/01/;100(2):767-774.	Animal

119 5	Hidalgo IJ, Ryan FM, Marks GJ, et al. pH-dependent transepithelial transport of cephalexin in rabbit intestinal mucosa. <i>International Journal of Pharmaceutics</i> . 1993 1993/08/31/;98(1):83-92.	Animal
119 6	Jewesson PJ. Pharmaceutical, pharmacokinetic and other considerations for intravenous to oral stepdown therapy. <i>Canadian Journal of Infectious Diseases</i> . 1995;6(Suppl A):11A-16A.	Title
119 7	Bergogne-Bérézin E. Pharmacocinétique des antibiotiques dans les voies respiratoires inférieures. Limites de l'apport de cette information. <i>Médecine et Maladies Infectieuses</i> . 1992 1992/02/01/;22:103-113.	Title
119 8	Montay G, Le Liboux A, Thebault J, et al. Pharmacocinétique du céfixime chez le volontaire sain après administration orale unique à la dose de 200 mg. <i>La Presse médicale (1983)</i> . 1989;18(32):1583-1586.	Title
119 9	Guay DR. Pharmacodynamics and pharmacokinetics of cefdinir, an oral extended spectrum cephalosporin. <i>The Pediatric infectious disease journal</i> . 2000;19(12):S141-S146.	Title
120 0	Smith PF, Tsuji B, Booker BM, et al. Pharmacodynamics of cefprozil against <i>Haemophilus influenzae</i> in an in vitro pharmacodynamic model. <i>Diagnostic Microbiology and Infectious Disease</i> . 2006 2006/12/01/;56(4):379-386.	Title
120 1	Werth BJ, Shireman LM. Pharmacodynamics of ceftaroline plus ampicillin against <i>Enterococcus faecalis</i> in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations. <i>Antimicrobial Agents and Chemotherapy</i> . 2017;61(4):e02235-16.	Title
120 2	Owens Jr RC, Tessier P, Nightingale CH, et al. Pharmacodynamics of ceftriaxone and cefixime against community-acquired respiratory tract pathogens. <i>International journal of antimicrobial agents</i> . 2001;17(6):483-489.	Abstract
120 3	Eandi M, Giudice ML. Pharmacoeconomic evaluation of cefaclor in the pharyngo-tonsillitis and acute otitis in children. <i>Farmeconomia Health economics and therapeutic pathways</i> . 2006;7(1):5-20.	Title

120 4	Dellamonica P, Garraffo R, Etesse-Carsenti H, et al. Pharmacokinetic and bacteriological study of cefadroxil-salicylate and josamycin-salicylate drug regimens. International journal of clinical pharmacology research. 1993;13(1):11-20.	Title
120 5	Muhammad IN, Shoaib MH, Yousuf RI. Pharmacokinetic and bioequivalence studies of oral cefuroxime axetil 250 mg tablets in healthy human subjects. Journal of Bioequivalence & Bioavailability. 2014;6(5):149.	Title
120 6	Zakeri-Milani P, Valizadeh H, Islambulchilar Z, et al. Pharmacokinetic and bioequivalence study of two brands of valsartan tablets in healthy male volunteers. Arzneimittelforschung. 2010;60(02):76-80.	Title
120 7	Neu H. Pharmacokinetic and clinical studies of cefixime: a worldwide review. Journal of chemotherapy (Florence, Italy). 1989;1(4 Suppl):531-533.	Title
120 8	Shimada K. Pharmacokinetic and clinical study on cefixime (CFIX) in the elderly. Chemotherapy. 1985;33(Suppl 6):298-303.	Abstract
120 9	Mazzei T, Cassetta MI, Fallani S, et al. Pharmacokinetic and pharmacodynamic aspects of antimicrobial agents for the treatment of uncomplicated urinary tract infections. International journal of antimicrobial agents. 2006;28:35-41.	Title
121 0	Tauzin M, Ouldali N, Béchet S, et al. Pharmacokinetic and pharmacodynamic considerations of cephalosporin use in children. Expert Opinion on Drug Metabolism & Toxicology. 2019;15(11):869-880.	Abstract
121 1	Mukker JK, Singh RSP, Derendorf H. Pharmacokinetic and pharmacodynamic implications in inhalable antimicrobial therapy. Advanced drug delivery reviews. 2015;85:57-64.	Title
121 2	Al-Tamimi DJJ, Al-Mahroos MIA, Al-Tamimi MJJ, et al. Pharmacokinetic Comparison and Bioequivalence Evaluation between a Newly Formulated Generic and the Brand Cefuroxime Axetil Tablets in Healthy Male Adult Fasting Subjects. Research Journal of Pharmacy and Technology. 2022;15(5):2184-2192.	Title

121 3	Smith A, Henriksen B, Cohen A. Pharmacokinetic considerations in Roux-en-Y gastric bypass patients. American Journal of Health-System Pharmacy. 2011;68(23):2241-2247.	Title
121 4	Kong FYS, Horner P, Unemo M, et al. Pharmacokinetic considerations regarding the treatment of bacterial sexually transmitted infections with azithromycin: a review. Journal of Antimicrobial Chemotherapy. 2019;74(5):1157-1166.	Title
121 5	Connolly KL, Eakin AE, Gomez C, et al. Pharmacokinetic data are predictive of in vivo efficacy for cefixime and ceftriaxone against susceptible and resistant Neisseria gonorrhoeae strains in the gonorrhea mouse model. Antimicrobial agents and chemotherapy. 2019;63(3):e01644-18.	Animal
121 6	Jack DB. Pharmacokinetic data on cephalosporins and other anti-infective agents. Handbook of Clinical Pharmacokinetic Data: Springer; 1992. p. 89-94.	Title
121 7	Negro RD. Pharmacokinetic drug interactions with anti-ulcer drugs. Clinical pharmacokinetics. 1998;35(2):135-150.	Title
121 8	Yasar S. Pharmacokinetic Drug-drug Interaction Studies Of Rosuvastatin With Ompeprazole, Cefixime And Clopidogrel: University of Peshawar, Peshawar; 2013.	Abstract
121 9	Petitjean O, Brion N, Tod M, et al. Pharmacokinetic interaction of cefixime and 2 antacids. Preliminary results. Presse Medicale (Paris, France: 1983). 1989;18(32):1596-1598.	Not Accessible
122 0	Homed KA, Tam JY, Prober CG. Pharmacokinetic optimisation of the treatment of septic arthritis. Clinical pharmacokinetics. 1996;31(2):156-163.	Title
122 1	Barre J. Pharmacokinetic properties of cefixime. Presse Medicale (Paris, France: 1983). 1989;18(32):1578-1582.	Abstract
122 2	Kneer J. Pharmacokinetic properties of new oral cephalosporins. Médecine et maladies infectieuses. 1992;22:556-564.	Abstract

122 3	Zhou H. Pharmacokinetic strategies in deciphering atypical drug absorption profiles. The Journal of Clinical Pharmacology. 2003;43(3):211-227.	Title
122 4	Nakamura H, Iwai N. Pharmacokinetic studies an oral antibiotics in pediatrics. I. A pharmacokinetic study on cefixime in pediatrics. Japanese journal of antibiotics. 1991;44(9):964-978.	Abstract
122 5	Saito A. Pharmacokinetic studies on cefixime. Chemotherapy. 1985;33(6):190-203.	Abstract
122 6	Nakamura H, Iwai N. Pharmacokinetic studies on oral antibiotics in pediatrics. I. A pharmacokinetic study on cefixime in pediatrics. The Japanese Journal of Antibiotics. 1991;44(9):964-978.	Abstract
122 7	Kanamaru MO, Kitada A. Pharmacokinetic Study of an Oral. Antimicrob Agents Chemother. 1998;42(7):1718.	Title
122 8	Hishida A, Ohishi K, Nagashima S, et al. Pharmacokinetic study of an oral cephalosporin, cefdinir, in hemodialysis patients. Antimicrobial agents and chemotherapy. 1998;42(7):1718-1721.	Title
122 9	EIDalo A, Ali A, Shaddad S, et al. Pharmacokinetic study of cefixime in the sheep the and cattle. Journal of Animal and Veterinary Advances. 2004.	Animal
123 0	Zhao D, Liu X-F, Tian Y-G, et al. The pharmacokinetic study of Tanreqing and the interaction with cefixime in rat model of pneumonia by validated UPLC-MS/MS. Journal of Pharmaceutical and Biomedical Analysis. 2022;209:114484.	Animal
123 1	Yamasaku F, Suzuki Y, Uno K. Pharmacokinetic study on new oxime-type oral cepheids, comparison of CS-807, T-2588 and cefixime in the same subjects. Chemotherapy (Tokyo). 1988;36(Suppl 1):267-273.	Abstract
123 2	Neely MN, Reed MD. Pharmacokinetic-pharmacodynamic basis of optimal antibiotic therapy. Principles and Practice of Pediatric Infectious Diseases 3rd ed Churchill Livingstone Elsevier. 2008:1404-15.	Title

123 3	Liu P, Rand KH, Obermann B, et al. Pharmacokinetic-pharmacodynamic modelling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic models. International journal of antimicrobial agents. 2005;25(2):120-129.	Abstract
123 4	Picco E, Cerra M, Stiefel S, et al. Pharmacokinetic-Pharmacodynamic study of Cephalexin and Gentamicin antibacterial activity against sensible strains using a simple one-compartment in vitro model. Revue Méd Vét. 2011;162(1):45-49.	Title
123 5	Katsube T, Yano Y, Yamano Y, et al. Pharmacokinetic–pharmacodynamic modeling and simulation for bactericidal effect in an in vitro dynamic model. Journal of pharmaceutical sciences. 2008;97(9):4108-4117.	Title
123 6	Katsube T, Yamano Y, Yano Y. Pharmacokinetic–pharmacodynamic modeling and simulation for in vivo bactericidal effect in murine infection model. Journal of pharmaceutical sciences. 2008;97(4):1606-1614.	Title
123 7	Tajima T, Kondo Y, Negishi S, et al. Pharmacokinetic, bacteriological and clinical studies on S-1108 in children. The Japanese Journal of Antibiotics. 1993;46(11):953-958.	Title
123 8	Theuretzbacher U, Barbee L, Connolly K, et al. Pharmacokinetic/pharmacodynamic considerations for new and current therapeutic drugs for uncomplicated gonorrhoea—challenges and opportunities. Clinical Microbiology and Infection. 2020;26(12):1630-1635.	Title
123 9	Schuck EL, Derendorf H. Pharmacokinetic/pharmacodynamic evaluation of anti-infective agents. Expert review of anti-infective therapy. 2005;3(3):361-373.	Title
124 0	Isla A, Canut A, Gascón AR, et al. Pharmacokinetic/pharmacodynamic evaluation of antimicrobial treatments of orofacial odontogenic infections. Clinical pharmacokinetics. 2005;44(3):305-316.	Title
124 1	Li Y, Nguyen MH, Cheng S, et al. A pharmacokinetic/pharmacodynamic mathematical model accurately describes the activity of voriconazole against Candida spp. in vitro. International journal of antimicrobial agents. 2008;31(4):369-374.	Title



124 2	Wu B, Derendorf H. Pharmacokinetic/pharmacodynamic model-based combination therapy approach to target antibiotic resistant populations emerged from ciprofloxacin exposure. <i>Die Pharmazie-An International Journal of Pharmaceutical Sciences</i> . 2010;65(6):417-420.	Title
124 3	Tasso L, de Andrade C, Dalla Costa T. Pharmacokinetic/pharmacodynamic modelling of the bactericidal activity of free lung concentrations of levofloxacin and gatifloxacin against <i>Streptococcus pneumoniae</i> . <i>International journal of antimicrobial agents</i> . 2011;38(4):307-313.	Title
124 4	Elhewaty MH. Pharmacokinetics and Bioavailability of cefotaxime in broiler chickens. <i>Egyptian Veterinary Medical Society of Parasitology Journal (EVMSPJ)</i> . 2019;15(1):130-139.	Animal
124 5	Peris-Ribera J-E, Torres-Molina F, Garcia-Carbonell MC, et al. Pharmacokinetics and bioavailability of diclofenac in the rat. <i>Journal of pharmacokinetics and biopharmaceutics</i> . 1991;19(6):647-665.	Animal
124 6	Huang M, Zhao XL. Pharmacokinetics and bioavailability of oral cefixime in healthy adult volunteers [Journal: Article]. <i>Chinese pharmacological bulletin</i> . 1994;10(1):24-26.	Abstract
124 7	Park YS, Woo SK, Jung MH, et al. Pharmacokinetics and bioavailability of oral cephalosporins, KR-984055 and its prodrugs, KR-999001 and KR-999002, in the rat. <i>Archives of pharmacal research</i> . 2003;26(1):83-88.	Animal
124 8	Valizadeh H, Hamishehkar H, Ghanbarzadeh S, et al. Pharmacokinetics and bioequivalence evaluation of two brands of ciprofloxacin 500 mg tablets in Iranian healthy volunteers. <i>Arzneimittelforschung</i> . 2012;62(12):566-570.	Title
124 9	Lin J, Kan Z, Feng W. Pharmacokinetics and Bioequivalence of Cefixime Capsules in Human. <i>CHINESE JOURNAL OF PHARMACEUTICALS</i> . 2006;37(7):480.	Abstract
125 0	Mudassar Ashraf M. Pharmacokinetics and Bioequivalence of Cefixime in Healthy Male and Female Volunteers: University of Agriculture, Faisalabad, Pakistan; 2015.	Abstract

125 1	Yan Z, Jian-feng C, Ai-dong W. Pharmacokinetics and bioequivalence of cefixime suspension and granules. CHINESE JOURNAL OF ANTIBIOTICS. 2002;27(11):681-684.	Title
125 2	Lin P-P, Wang C-J, Liu Y-P, et al. Pharmacokinetics and Bioequivalence of Cefprozil for Suspension and Granule Formulation in Healthy Chinese Volunteers: Two Single-Dose Crossover Studies. Advances in Therapy. 2021;38(2):1130-1142.	Title
125 3	Danafar H, Hamidi M. Pharmacokinetics and bioequivalence study of amlodipine and atorvastatin in healthy male volunteers by LC-MS. Pharmaceutical Sciences. 2015;21(3):167-174.	Title
125 4	Wei M-j, Lv Y, Kang Z-s. Pharmacokinetics and bioequivalence study of cefixime tablet in healthy volunteers. CHINESE JOURNAL OF CLINICAL PHARMACOLOGY. 2004;20(1):41-44.	Abstract
125 5	Motohiro T, Handa S, Yamada S, et al. Pharmacokinetics and clinical effects of cefdinir 5% fine granules in pediatrics. The Japanese Journal of Antibiotics. 1990;43(10):1813-1835.	Title
125 6	Motohiro T, Handa S, Yamada S, et al. Pharmacokinetics and clinical effects of cefdinir 10% fine granules in pediatrics. The Japanese Journal of Antibiotics. 1992;45(1):74-86.	Title
125 7	Motohiro T, Tanaka K, Koga T, et al. Pharmacokinetics and clinical effects of cefixime in pediatrics. The Japanese Journal of Antibiotics. 1986;39(4):1177-1200.	Title
125 8	Lin C, Lim J, Radwanski E, et al. Pharmacokinetics and dose proportionality of ceftibuten in men. Antimicrobial agents and chemotherapy. 1995;39(2):359-361.	Title
125 9	O'Neill P, Nye K, Douce G, et al. Pharmacokinetics and inflammatory fluid penetration of cefpodoxime proxetil in volunteers. Antimicrobial agents and chemotherapy. 1990;34(2):232-234.	Title
126 0	KULEMANN V, JOUKHADAR C. The pharmacokinetics and pharmacodynamics. Anaesthesia, Pain, Intensive Care and Emergency Medicine-APICE. 2005;19:177.	Title

126 1	Levison ME, Levison JH. Pharmacokinetics and pharmacodynamics of antibacterial agents. Infectious Disease Clinics. 2009;23(4):791-815.	Title
126 2	Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. The Pediatric infectious disease journal. 1996;15(3):255-259.	Title
126 3	Kulemann V, Joukhadar C. The pharmacokinetics and pharmacodynamics of antimicrobial agents in intensive care unit patients as assessed by microdialysis. Anaesthesia, Pain, Intensive Care and Emergency Medicine—APICE: Springer; 2005. p. 177-183.	Title
126 4	Czock D, Markert C, Hartman B, et al. Pharmacokinetics and pharmacodynamics of antimicrobial drugs. Expert opinion on drug metabolism & toxicology. 2009;5(5):475-487.	Title
126 5	Liu P. Pharmacokinetics and pharmacodynamics of cefpodoxime and cefixime. University of Florida; 2002.	Abstract
126 6	Lutsar I, Friedland IR. Pharmacokinetics and pharmacodynamics of cephalosporins in cerebrospinal fluid. Clinical pharmacokinetics. 2000;39(5):335-343.	Abstract
126 7	Cazzola M, Matera M, Donner C. Pharmacokinetics and pharmacodynamics of newer oral cephalosporins. Clinical drug investigation. 1998;16(4):335-346.	Abstract
126 8	Novelli A, Fallani S, Cassetta M, et al. Pharmacokinetics and pharmacodynamics of oral cephalosporins as critical factors in choice of antibiotics. International journal of antimicrobial agents. 2000;16(4):501-505.	Abstract
126 9	Auckenthaler R. Pharmacokinetics and pharmacodynamics of oral $\beta$ -lactam antibiotics as a two-dimensional approach to their efficacy. Journal of Antimicrobial Chemotherapy. 2002;50(suppl_1):13-17.	Title
127 0	Gure-Klinke H, Hamacher J, Lode H. Pharmacokinetics and possible interactions of Cefixime with N-Acetylcysteine in healthy volunteers [Journal: Article]. Chemotherapie journal. 1996;5(1):12-16.	Abstract

127 1	Zhang YC, Li MM, Sui XH, et al. Pharmacokinetics and relative bioavailability of cefixime capsules in healthy volunteers [Journal: Article]. <i>Pharmaceutical care and research</i> . 2008;8(6):429-431.	Abstract
127 2	Martin C, Ragni J, Lokiec F, et al. Pharmacokinetics and tissue penetration of a single dose of ceftriaxone (1,000 milligrams intravenously) for antibiotic prophylaxis in thoracic surgery. <i>Antimicrobial agents and chemotherapy</i> . 1992;36(12):2804-2807.	Title
127 3	Wise R, Nye K, O'Neill P, et al. Pharmacokinetics and tissue penetration of ceftibuten. <i>Antimicrobial agents and chemotherapy</i> . 1990;34(6):1053-1055.	Title
127 4	Sullins AK, Abdel-Rahman SM. Pharmacokinetics of antibacterial agents in the CSF of children and adolescents. <i>Pediatric Drugs</i> . 2013;15(2):93-117.	Title
127 5	Cruciani M, Gatti G, Cazzadori A, et al. Pharmacokinetics of antimicrobial agents in the respiratory tract. <i>Zentralblatt für Bakteriologie</i> . 1996 1996/06/01/;284(1):1-31.	Title
127 6	Stevens RC, Rodman JH, editors. <i>Pharmacokinetics of antimicrobial therapy</i> . <i>Seminars in Pediatric Infectious Diseases</i> ; 1998: Elsevier.	Title
127 7	Nahata MC. Pharmacokinetics of azithromycin in pediatric patients: comparison with other agents used for treating otitis media and streptococcal pharyngitis. <i>The Pediatric infectious disease journal</i> . 1995;14(4):S39-44.	Title
127 8	Whited L, Grove M, Rose D, et al. Pharmacokinetics of cefepime in patients with cancer and febrile neutropenia in the setting of hematologic malignancies or hematopoietic cell transplantation. <i>Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy</i> . 2016;36(9):1003-1010.	Title
127 9	Zimmerli W, Sansano S, Wittke B. Pharmacokinetics of cefetamet in plasma and skin blister fluid. <i>Antimicrobial agents and chemotherapy</i> . 1996;40(1):102-104.	Title

128 0	Montay G, Le Liboux A, Thebault J, et al. Pharmacokinetics of cefixime in healthy volunteers after a single oral administration of 200 mg. Presse Medicale (Paris, France: 1983). 1989;18(32):1583-1586.	Not Accessible
128 1	Maeda H, Sako M, Fujii A, et al. Pharmacokinetics of cefixime in patients with impaired renal function. The Japanese Journal of Antibiotics. 1986;39(10):2716-2720.	Abstract
128 2	Nakano H, Seko S, Nihira H, et al. Pharmacokinetics of cefixime in patients with impaired renal function by repeated-dose study. Chemotherapy. 1988;36(5):428-436.	Abstract
128 3	König S, Marre R, Schulz E, et al. The pharmacokinetics of cefixime in patients with renal insufficiency undergoing hemofiltration. Journal of chemotherapy (Florence, Italy). 1989;1(4 Suppl):536-537.	Not Accessible
128 4	Zhang Y, Sun Z, Li Q. Pharmacokinetics of cefixime in patients with respiratory tract infections. CHINESE PHARMACEUTICAL JOURNAL-BEIJING-. 1995;30:612-614.	Abstract
128 5	KREFT B, BOEKSTEGERS S, SCHULZ E, et al. PHARMACOKINETICS OF CEFIXIME IN SEVERE RENAL-INSUFFICIENCY AND PATIENTS UNDERGOING HEMOFILTRATION. NIEREN-UND HOCHDRUCKKRANKHEITEN. 1990;19(8):344-348.	Abstract
128 6	Greene D, Anslow J, Bohaychuk W, et al., editors. Pharmacokinetics of cefixime in the fed and fasted state. Workshop, 15th International Congress of Chemotherapy, July, 1987. Advances in Experimental and Clinical Chemotherapy 1988; 1988.	Title
128 7	Grassi GG, Bandera M, Bianchi L, et al. Pharmacokinetics of cefixime in the respiratory tract. Journal of Chemotherapy. 1991;3:216-218.	Abstract
128 8	Kees F, Naber K. Pharmacokinetics of cefixime in volunteers and a literature comparison with the new ester prodrug cephalosporins. Infection. 1990;18:S150-4.	Title

128 9	Silber D, Bohaychuk W, Stout M. Pharmacokinetics of cefixime in young and elderly volunteers. Workshop. 15th International Congress of Chemotherapy, Jul 87. Advances in Experimental and Clinical Chemotherapy. 1988;1:18-20.	Title
129 0	Saathoff N, Lode H, Neider K, et al. Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist. Antimicrobial agents and chemotherapy. 1992;36(4):796-800.	Title
129 1	Shyu W, Pittman K, Wilber R, et al. Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment. The Journal of Clinical Pharmacology. 1991;31(4):362-371.	Title
129 2	Barr WH, Lin C-C, Radwanski E, et al. The pharmacokinetics of ceftibuten in humans. Diagnostic microbiology and infectious disease. 1991;14(1):93-100.	Title
129 3	Gergs U, Clauss T, Ihlefeld D, et al. Pharmacokinetics of ceftriaxone in plasma and bone of patients undergoing hip or knee surgery. Journal of Pharmacy and Pharmacology. 2014;66(11):1552-1558.	Title
129 4	Sakamoto H, Hirose T, Mine Y. Pharmacokinetics of FK027 in rats and dogs. J Antibiot (Tokyo). 1985 Apr;38(4):496-504.	Animal
129 5	Sakamoto H, Hirose T, Nakamoto S, et al. Pharmacokinetics of FK482, a new orally active cephalosporin, in animals. The Journal of antibiotics. 1988;41(12):1896-1905.	Animal
129 6	Ammoo AM, Al-Tamimi DJJ, Al-Mahroos MIA, et al. Pharmacokinetics of Fluconazole tablets administered to healthy subjects. Journal of Advanced Pharmacy Education & Research  Apr-Jun. 2021;11(2):93.	Title
129 7	Stoeckel K. Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in human subjects. Drug Investigation. 1991;3(5):291-298.	Title
129 8	Kneer J, Tam Y, Blouin R, et al. Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in patients with renal insufficiency. Antimicrobial agents and chemotherapy. 1989;33(11):1952-1957.	Title

129 9	Roller S, Lode H, Stelzer I, et al. Pharmacokinetics of loracarbef and interaction with acetylcysteine. European Journal of Clinical Microbiology and Infectious Diseases. 1992;11(9):851-855.	Title
130 0	Edwards DJ, Stoeckel K. The pharmacokinetics of new oral cephalosporins in children. Chemotherapy. 1992;38(Suppl. 2):2-9.	Abstract
130 1	Fassbender M, Lode H, Schaberg T, et al. Pharmacokinetics of new oral cephalosporins, including a new carbacephem. Clinical infectious diseases. 1993;16(5):646-653.	Abstract
130 2	Fillastre J-P, Singlas E. Pharmacokinetics of newer drugs in patients with renal impairment (Part I). Clinical pharmacokinetics. 1991;20(4):293-310.	Title
130 3	Stoeckel K, Tarn Y, Kneer J. Pharmacokinetics of oral cefetamet pivoxil (Ro 15-8075) and intravenous cefetamet (Ro 15-8074) in humans: a review. Current medical research and opinion. 1989;11(7):432-441.	Title
130 4	Mazzei T, Dentico P. The pharmacokinetics of oral cephalosporins. Clinical Microbiology and Infection. 2000 2000/01/01;6:53-54.	Abstract
130 5	Wise R. The pharmacokinetics of the oral cephalosporins--a review. J Antimicrob Chemother. 1990 Dec;26 Suppl E:13-20.	Title
130 6	Alshare M. PHARMACOKINETICS OF THIRD GENERATION CEPHALOSPORINS IN CHILDEN WITH TYPHOID FEVER: University of Karachi; 2001.	Abstract
130 7	Smith PW, Zuccotto F, Bates RH, et al. Pharmacokinetics of $\beta$ -lactam antibiotics: clues from the past to help discover long-acting oral drugs in the future. ACS infectious diseases. 2018;4(10):1439-1447.	Title
130 8	Papich MG, Davis JL, Floerchinger AM. Pharmacokinetics, protein binding, and tissue distribution of orally administered cefpodoxime proxetil and cephalexin in dogs. American journal of veterinary research. 2010;71(12):1484-1491.	Animal

1309	Lees A, Andrews J, Wise R. The pharmacokinetics, tissue penetration and in-vitro activity of loracarbef, a $\beta$ -lactam antibiotic of the carbacephem class. <i>Journal of Antimicrobial Chemotherapy</i> . 1993;32(6):853-859.	Title
1310	Roe VA, Gudi A. Pharmacologic management of sexually transmitted diseases. <i>Journal of Nurse-Midwifery</i> . 1997 1997/05/06/;42(3):275-289.	Title
1311	Barriere SL. Pharmacology and pharmacokinetics of cefprozil. <i>Clinical infectious diseases</i> . 1992;14(Supplement_2):S184-S188.	Title
1312	Thoene DE, Johnson CE. Pharmacotherapy of otitis media. <i>Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy</i> . 1991;11(3):212-221.	Title
1313	Kees F, Naber K. Pharmakokinetik von Cefixim bei Probanden und ein Literaturvergleich mit neuen Ester Prodrug Cephalosporinen. <i>Infection</i> . 1990;18(3):S150-S154.	Title
1314	Barry B, Muffat-Joly M, Géhanno P. Pharrnacokinetics of antibiotics in the middle ear. <i>Clinical Microbiology and Infection</i> . 1997 1997/01/01/;3:3S37-3S42.	Title
1315	Trippett TM, Herzog C, Whitlock JA, et al. Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators' consortium. <i>Journal of clinical oncology</i> . 2009;27(30):5102.	Title
1316	Nakashima M, Uematsu T, Takiguchi Y, et al. Phase I clinical studies of 7432-S, a new oral cephalosporin: safety and pharmacokinetics. <i>The Journal of Clinical Pharmacology</i> . 1988;28(3):246-252.	Title
1317	Brennan R, Furman W, Mao S, et al. Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors. <i>Cancer chemotherapy and pharmacology</i> . 2014;74(6):1191-1198.	Title



131 8	Perentesis J, Wagner L, Ames M, et al. Phase I study of oral irinotecan, temozolomide, and vincristine for children with refractory solid tumors: A Children's Oncology Group study. <i>Journal of Clinical Oncology</i> . 2007;25(18_suppl):9563-9563.	Title
131 9	Wagner L, Perentesis J, Reid J, et al. Phase I trial and pharmacokinetic study of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with refractory solid tumors: A Children's Oncology Group Phase I Consortium study. <i>Journal of Clinical Oncology</i> . 2009;27(15_suppl):10017-10017.	Title
132 0	Wagner LM, Villablanca JG, Stewart CF, et al. Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study. <i>Journal of clinical oncology</i> . 2009;27(8):1290.	Title
132 1	Wagner LM, Perentesis JP, Reid JM, et al. Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study. <i>Pediatric blood &amp; cancer</i> . 2010;54(4):538-545.	Title
132 2	Taylor MM, Kara EO, Araujo MAL, et al. Phase II trial evaluating the clinical efficacy of cefixime for treatment of active syphilis in non-pregnant women in Brazil (CeBra). <i>BMC Infectious Diseases</i> . 2020;20(1):1-15.	Abstract
132 3	Jeverica S, Golparian D, Matičič M, et al. Phenotypic and molecular characterization of <i>Neisseria gonorrhoeae</i> isolates from Slovenia, 2006-12: rise and fall of the multidrug-resistant NG-MAST genogroup 1407 clone? <i>J Antimicrob Chemother</i> . 2014 Jun;69(6):1517-25.	Title
132 4	Pourtaheri A, Nezamzadeh-Ejehieh A. Photocatalytic properties of incorporated NiO onto clinoptilolite nanoparticles in the photodegradation process of aqueous solution of cefixime pharmaceutical capsule. <i>Chemical Engineering Research and Design</i> . 2015;104:835-843.	Abstract

132 5	Jadhav P, Petkar B, Pore Y, et al. Physicochemical and molecular modeling studies of cefixime–l-arginine–cyclodextrin ternary inclusion compounds. Carbohydrate polymers. 2013;98(2):1317-1325.	Abstract
132 6	Raddam QN. Physiological Changes of Some Biochemical Parameters in Blood, Liver and Kidney Result by used Antibiotic Cefixime. Annals of the Romanian Society for Cell Biology. 2021;25(6):8257-8263.	Abstract
132 7	Stader F, Kinvig H, Penny MA, et al. Physiologically based pharmacokinetic modelling to identify pharmacokinetic parameters driving drug exposure changes in the elderly. Clinical pharmacokinetics. 2020;59(3):383-401.	Title
132 8	Kamiya Y, Otsuka S, Miura T, et al. Physiologically based pharmacokinetic models predicting renal and hepatic concentrations of industrial chemicals after virtual oral doses in rats. Chemical research in toxicology. 2020;33(7):1736-1751.	Animal
132 9	Turpault S, Kanamaluru V, Lockwood G, et al. PI-64: Lack of effect of rimonabant on the pharmacokinetic of nicotine. Clinical Pharmacology & Therapeutics. 2006;79(2):P24-P24.	Title
133 0	Miller J, Migoya E, Talaty J, et al. PI-65: The effect of MK-0431 on the pharmacokinetics of digoxin after concomitant administration for 10 days in healthy subjects. Clinical Pharmacology & Therapeutics. 2006;79(2):P24-P24.	Title
133 1	Nallani S, Coles L. PI-66: A repository of clinical pharmacokinetics data for drugs used in pregnancy and lactation developed at FDA. Clinical Pharmacology & Therapeutics. 2006;79(2):P24-P24.	Title
133 2	Cui Y, Zhou Y, Sun P, et al. PI-67: Population pharmacokinetics of cefixime in Chinese male healthy subjects. Clinical Pharmacology & Therapeutics. 2006;79(2):P24-P24.	Abstract
133 3	Jprn U. Pilot study of gefitinib and irinotecan in young patients With Relapsed or Refractory Cancer. <a href="https://trialssearchwho.int/Trial2.aspx?TrialID=JPRN-UMIN000001730">https://trialssearchwho.int/Trial2.aspx?TrialID=JPRN-UMIN000001730</a> . 2009.	Title

133 4	Winchester JF. Poisoning: Is the Role of the Nephrologist Diminishing? American Journal of Kidney Diseases. 1989 1989/03/01/;13(3):171-183.	Title
133 5	Toscanini MA, Limeres MJ, Garrido AV, et al. Polymeric micelles and nanomedicines: Shaping the future of next generation therapeutic strategies for infectious diseases. Journal of Drug Delivery Science and Technology. 2021 2021/12/01/;66:102927.	Title
133 6	Jeong S-H, Jang J-H, Cho H-Y, et al. Population pharmacokinetic analysis of cefaclor in healthy Korean subjects. Pharmaceutics. 2021;13(5):754.	Title
133 7	Amsden GW, Ballow CH, Schentag JJ. Population pharmacokinetic methods to optimise antibiotic effects. Drug Investigation. 1993;5(5):256-268.	Title
133 8	Poster presentations. International Journal of Antimicrobial Agents. 2017 2017/09/01/;50:S87-S169.	Title
133 9	POSTER PRESENTATIONS: FRIDAY, NOVEMBER 8. Chest. 1991 1991/08/01/;100(2, Supplement):137S-150S.	Title
134 0	Poster Sessions. International Journal of Antimicrobial Agents. 2017 2017/11/01/;50:S69-S277.	Title
134 1	Posters. Clinical Microbiology and Infection. 2010 2010/04/01/;16:S133-S634.	Title
134 2	Posters. Clinical Microbiology and Infection. 2011 2011/05/01/;17:S108-S668.	Title
134 3	Flanagan T. Potential for pharmaceutical excipients to impact absorption: A mechanistic review for BCS Class 1 and 3 drugs. European Journal of Pharmaceutics and Biopharmaceutics. 2019 2019/08/01/;141:130-138.	Title

134 4	Mutalib AAA, Jaafar NF. Potential of deep eutectic solvent in photocatalyst fabrication methods for water pollutant degradation: A review. <i>Journal of Environmental Chemical Engineering</i> . 2022 2022/06/01/;10(3):107422.	Title
134 5	Broyles AD, Banerji A, Barmettler S, et al. Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs. <i>The Journal of Allergy and Clinical Immunology: In Practice</i> . 2020 2020/10/01/;8(9, Supplement):S16-S116.	Title
134 6	Fick J, Lindberg RH, Tysklind M, et al. Predicted critical environmental concentrations for 500 pharmaceuticals. <i>Regulatory Toxicology and Pharmacology</i> . 2010 2010/12/01/;58(3):516-523.	Title
134 7	van Os W, Zeitlinger M. Predicting antimicrobial activity at the target site: pharmacokinetic/pharmacodynamic indices versus time–kill approaches. <i>Antibiotics</i> . 2021;10(12):1485.	Title
134 8	Nielsen EI, Cars O, Friberg LE. Predicting in vitro antibacterial efficacy across experimental designs with a semimechanistic pharmacokinetic-pharmacodynamic model. <i>Antimicrobial agents and chemotherapy</i> . 2011;55(4):1571-1579.	Title
134 9	Yang X, Gandhi YA, Duignan DB, et al. Prediction of biliary excretion in rats and humans using molecular weight and quantitative structure–pharmacokinetic relationships. <i>The AAPS journal</i> . 2009;11(3):511-525.	Animal
135 0	Wajima T, Fukumura K, Yano Y, et al. Prediction of human pharmacokinetics from animal data and molecular structural parameters using multivariate regression analysis: oral clearance. <i>Journal of pharmaceutical sciences</i> . 2003;92(12):2427-2440.	Animal
135 1	Paixão P, Gouveia LF, Morais JAG. Prediction of the human oral bioavailability by using in vitro and in silico drug related parameters in a physiologically based absorption model. <i>International Journal of Pharmaceutics</i> . 2012 2012/06/15/;429(1):84-98.	Title

135 2	Paixão P, Gouveia LF, Morais JAG. Prediction of the in vitro intrinsic clearance determined in suspensions of human hepatocytes by using artificial neural networks. <i>European Journal of Pharmaceutical Sciences</i> . 2010 2010/03/18/;39(5):310-321.	Title
135 3	MacLeod CL. The pregnant traveler. <i>Medical Clinics of North America</i> . 1992 1992/11/01/;76(6):1313-1326.	Title
135 4	Jones RN, Barry AL. Preliminary antimicrobial susceptibility interpretive criteria for cefetamet (Ro 15-8074) and ceftoram (Ro 19-5247) disk tests. <i>Journal of clinical microbiology</i> . 1987;25(9):1796-1799.	Title
135 5	Ali I, Rehman JU, Ullah S, et al. Preliminary investigation of novel tetra-tailed macrocycle amphiphile based nano-vesicles for amphotericin B improved oral pharmacokinetics. <i>Artificial Cells, Nanomedicine, and Biotechnology</i> . 2018;46(sup3):S1204-S1214.	Title
135 6	Shirvany A, Rezayan AH, Alvandi H, et al. Preparation and Evaluation of a Niosomal Drug Delivery System Containing Cefazolin and Study of Its Antibacterial Activity. <i>Iranian Journal of Medical Microbiology</i> . 2021;15(6):638-657.	Title
135 7	rights are reserved by MUDER A, HAYDER A. Preparation and Evaluation of Cefixime Dispersible Tablets Using Co-Processed Excipients.	Abstract
135 8	Talaat HM, Aydia MI, Ibrahim IT, et al. Preparation of <sup>186</sup> Re-Cefixime as a potential diagnostic and therapeutic agent for bacterial infection. <i>Egyptian Journal of Radiation Sciences and Applications</i> . 2019;32(1):95-103.	Abstract
135 9	Stauffer W, Christenson JC, Fischer PR. Preparing children for international travel. <i>Travel Medicine and Infectious Disease</i> . 2008 2008/05/01/;6(3):101-113.	Title
136 0	Barbee LA. Preparing for an era of untreatable gonorrhoea. <i>Current opinion in infectious diseases</i> . 2014;27(3):282.	Title

136 1	Chachaty E, Depitre C, Mario N, et al. Presence of Clostridium difficile and antibiotic and beta-lactamase activities in feces of volunteers treated with oral cefixime, oral cefpodoxime proxetil, or placebo. Antimicrobial agents and chemotherapy. 1992;36(9):2009-2013.	Abstract
136 2	Bottoni P, Caroli S. Presence of residues and metabolites of pharmaceuticals in environmental compartments, food commodities and workplaces: A review spanning the three-year period 2014–2016. Microchemical Journal. 2018 2018/01/01/;136:2-24.	Title
136 3	Wu B, Sy SK, Derendorf H. Principles of applied pharmacokinetic–pharmacodynamic modeling. Fundamentals of antimicrobial pharmacokinetics and pharmacodynamics: Springer; 2014. p. 63-79.	Title
136 4	Blowey D. Principles of drug administration in children receiving renal replacement therapy. Pediatric dialysis: Springer; 2004. p. 545-565.	Title
136 5	Sabella C, Goldfarb J. Principles of selection and use of antimicrobial agents. Seminars in Pediatric Infectious Diseases. 1999 1999/01/01/;10(1):3-13.	Title
136 6	Pichichero ME, Doern GV, Kuti JL, et al. Probability of achieving requisite pharmacodynamic exposure for oral beta-lactam regimens against Haemophilus influenzae in children. Paediatr Drugs. 2008;10(6):391-7.	Title
136 7	Jana S, Mandlekar S, Marathe P. Prodrug design to improve pharmacokinetic and drug delivery properties: challenges to the discovery scientists. Current medicinal chemistry. 2010;17(32):3874-3908.	Title
136 8	Powers JL. Properties of azithromycin that enhance the potential for compliance in children with upper respiratory tract infections. The Pediatric infectious disease journal. 1996;15(9):30-37.	Title
136 9	Team S. PROPOSAL FOR THE INCLUSION OF CEFIXIME IN THE WHO MODEL LIST OF ESSENTIAL MEDICINES. 2004.	Abstract

137 0	Pipitpanpipit T, Santanirand P, Kongchareonsombat W. Prospective Randomized Controlled Study of the Results of Me-dication with Oral Ciprofloxacin versus Oralcefixime to Prevent Transient Bacteraemia and Adverse Events from Trans-Rectal Prostatic Biopsy.	Title
137 1	Smith DE, Cl��men��on B, Hediger MA. Proton-coupled oligopeptide transporter family SLC15: Physiological, pharmacological and pathological implications. <i>Molecular Aspects of Medicine</i> . 2013 2013/04/01/;34(2):323-336.	Title
137 2	Grellet J, Couraud L, Saux M, et al. Pulmonary diffusion of cefixime in man. <i>Presse Medicale (Paris, France: 1983)</i> . 1989;18(32):1589-1592.	Not Accessible
137 3	Kiang TK, Ensom MH. A qualitative review on the pharmacokinetics of antibiotics in saliva: implications on clinical pharmacokinetic monitoring in humans. <i>Clinical pharmacokinetics</i> . 2016;55(3):313-358.	Title
137 4	Azmi SNH, Iqbal B, Al-Humaimi NSH, et al. Quantitative analysis of cefixime via complexation with palladium (II) in pharmaceutical formulations by spectrophotometry. <i>Journal of pharmaceutical analysis</i> . 2013;3(4):248-256.	Abstract
137 5	Shimizu R, Sukegawa T, Tsuda Y, et al. Quantitative prediction of oral absorption of PEPT1 substrates based on in vitro uptake into Caco-2 cells. <i>Int J Pharm</i> . 2008 Apr 16;354(1-2):104-10.	Title
137 6	Grover A, Grover M, Sharma K. Quantitative structure property relationship studies for predicting plasma protein binding properties of Cephalosporins.	Abstract
137 7	Karalis V, Tsantili-Kakoulidou A, Macheras P. Quantitative structure–pharmacokinetic relationships for disposition parameters of cephalosporins. <i>European journal of pharmaceutical sciences</i> . 2003;20(1):115-123.	Abstract
137 8	Zhivkova Z, Doytchinova I. Quantitative structure—plasma protein binding relationships of acidic drugs. <i>Journal of Pharmaceutical Sciences</i> . 2012 2012/12/01/;101(12):4627-4641.	Title

1379	Danafar H. A quick and easy high performance liquid chromatography method for evaluation of cefixime in human plasma. <i>Pharmaceutical and Biomedical Research</i> . 2015;1(4):29-39.	Abstract
1380	Capoor MR, Nair D. Quinolone and cephalosporin resistance in enteric fever. <i>Journal of global infectious diseases</i> . 2010;2(3):258.	Abstract
1381	Christian JS. The quinolone antibiotics. <i>Primary Care Update for OB/GYNS</i> . 1996 1996/05/01/;3(3):87-92.	Title
1382	Suh B, Lorber B. Quinolones. <i>Medical Clinics of North America</i> . 1995 1995/01/01/;79(4):869-894.	Title
1383	R1885 – R2270. <i>Clinical Microbiology and Infection</i> . 2006 2006/01/01/;12:S635-S767.	Title
1384	Nathwani D. Ramirez and colleagues <sup>1</sup> recently reported the reduction in hospital stay and efficacy of an early. <i>Pharmacoeconomics</i> . 1994;5(2):S27-S33.	Title
1385	Vergheze A, Roberson D, Kalbfleisch J, et al. Randomized comparative study of cefixime versus cephalexin in acute bacterial exacerbations of chronic bronchitis. <i>Antimicrobial Agents and Chemotherapy</i> . 1990;34(6):1041-1044.	Abstract
1386	Basualdo W, Arbo A. Randomized comparison of azithromycin versus cefixime for treatment of shigellosis in children [Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial]. <i>Pediatric infectious disease journal</i> . 2003;22(4):374-377.	Extensive reading
1387	Zhao C, Li J, Hao F. [A randomized controlled clinical study of cefetamet pivoxil versus cefixime in the treatment of 99 cases bacterial infections]. <i>Zhonghua Nei Ke Za Zhi</i> . 1997 Jul;36(7):465-8.	Not Accessible



138 8	Nguyen PTT, Pham HV, Van DH, et al. Randomized controlled trial of the relative efficacy of high-dose intravenous ceftriaxone and oral cefixime combined with doxycycline for the treatment of Chlamydia trachomatis and Neisseria gonorrhoeae co-infection. BMC Infect Dis. 2022 Jul 9;22(1):607.	Abstract
138 9	Salam M, Khan WA, Bennish ML. Randomized double-blind study of efficacy of cefixime in the treatment of Shigellosis. 1992.	Abstract
139 0	Ramus RM, Sheffield JS, Mayfield JA, et al. A randomized trial that compared oral cefixime and intramuscular ceftriaxone for the treatment of gonorrhea in pregnancy [Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial]. American journal of obstetrics and gynecology. 2001;185(3):629-632.	Abstract
139 1	Bucko AD, Hunt BJ, Kidd SL, et al. Randomized, double-blind, multicenter comparison of oral cefditoren 200 or 400 mg BID with either cefuroxime 250 mg BID or cefadroxil 500 mg BID for the treatment of uncomplicated skin and skin-structure infections. Clinical Therapeutics. 2002 2002/07/01/;24(7):1134-1147.	Title
139 2	Al-Shathar AI, Aziz SH. A randomized, single dose, two treatment, two period, crossover bioequivalence study of cefixime (as trihydrate) suspension in healthy participants comparing Acacime® suspension produced by ACAI/Iraq to Suprax® suspension produced by Hikma/Jordan. Al Mustansiriyah Journal of Pharmaceutical Sciences. 2017;17(1):7-7.	Abstract
139 3	Asadollahi-Baboli M, Mani-Varnosfaderani A. Rapid and simultaneous determination of tetracycline and cefixime antibiotics by mean of gold nanoparticles-screen printed gold electrode and chemometrics tools. Measurement. 2014;47:145-149.	Abstract
139 4	Hoppe JE. Rational prescribing of antibacterials in ambulatory children. Pharmacoeconomics. 1996;10(6):552-574.	Title

139 5	File TM, Hadley JA. Rational use of antibiotics to treat respiratory tract infections. American journal of managed care. 2002;8(8):713-729.	Title
139 6	Craig W. Re-evaluating current antibiotic therapy. Respiratory Medicine. 2001;95:S12-S19.	Title
139 7	[Re-evaluation of current antimicrobials. Series 21: cefixime. Discussion]. Jpn J Antibiot. 1994 Nov;47(11):1449-56.	Not Accessible
139 8	Westphal J, Deslandes A, Brogard J, et al. Reappraisal of amoxicillin absorption kinetics. Journal of antimicrobial chemotherapy. 1991;27(5):647-654.	Title
139 9	Jaswal S, Nehra B, Kumar S, et al. Recent advancements in the medicinal chemistry of bacterial type II topoisomerase inhibitors. Bioorganic Chemistry. 2020 2020/11/01/;104:104266.	Title
140 0	Malik P, Mukherjee TK. Recent advances in gold and silver nanoparticle based therapies for lung and breast cancers. International Journal of Pharmaceutics. 2018 2018/12/20/;553(1):483-509.	Title
140 1	Kaialy W, Al Shafiee M. Recent advances in the engineering of nanosized active pharmaceutical ingredients: Promises and challenges. Advances in Colloid and Interface Science. 2016 2016/02/01/;228:71-91.	Title
140 2	Shamekhi Amiri F. Recent advances in the treatment of renal diseases with nebivolol: A literature review. Néphrologie & Thérapeutique. 2016 2016/06/01/;12(3):140-148.	Title
140 3	Jin HE, Jin SE, Maeng HJ. Recent bioanalytical methods for quantification of third-generation cephalosporins using HPLC and LC-MS (/MS) and their applications in pharmacokinetic studies. Biomedical Chromatography. 2014;28(11):1565-1587.	Abstract
140 4	Do NHN, Truong QT, Le PK, et al. Recent developments in chitosan hydrogels carrying natural bioactive compounds. Carbohydrate Polymers. 2022 2022/10/15/;294:119726.	Title

140 5	DÜRckheimer W, Adam F, Fischer G, et al. Recent Developments in the Field of Cephem Antibiotics. In: Testa B, editor. Advances in Drug Research. Vol. 17: Academic Press; 1988. p. 61-234.	Title
140 6	Mogabgab WJ. Recent developments in the treatment of sexually transmitted diseases. The American Journal of Medicine. 1991 1991/12/30;91(6, Supplement 1):S140-S144.	Title
140 7	Recent research in infectious disease drug resistance. Drug Resistance Updates. 2008 2008/08/01;11(4):180-199.	Title
140 8	Grant GB, Campbell H, Dowell SF, et al. Recommendations for treatment of childhood non-severe pneumonia. The Lancet Infectious Diseases. 2009 2009/03/01;9(3):185-196.	Title
140 9	Jerath N, Shetty G. Redefining the management of pediatric tonsillopharyngitis with cefprozil. Indian J Pediatr. 2007 Dec;74(12):1105-8.	Title
141 0	Wagner LM, Crews KR, Stewart CF, et al. Reducing irinotecan-associated diarrhea in children. Pediatric blood & cancer. 2008;50(2):201-207.	Title
141 1	Tonelli AP, Bialer M, Yacobi A. Relationship between protein binding and renal clearance of a new oral cephalosporin in the dog. J Pharm Sci. 1985 Nov;74(11):1242-4.	Animal
141 2	Kees F, Naber KG, Sigl G, et al. Relative bioavailability of three cefixime formulations [Journal: Article]. Arzneimittel-forschung/drug research. 1990;40(3):293-297.	Not Accessible
141 3	Drusano G, Craig W. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. Journal of chemotherapy (Florence, Italy). 1997;9:38-44.	Title
141 4	Tanaka M, Tunoe H, Egashira T, et al. A remarkable reduction in the susceptibility of Neisseria gonorrhoeae isolates to cepheims and the selection of antibiotic regimens for the single-dose treatment of gonococcal infection in Japan. Journal of infection and chemotherapy. 2002;8(1):81-86.	Title

141 5	Anwar M, Bilal A, Muhammad M, et al. Renal clearance and urinary excretion of cefspan® in healthy male volunteers. Scholar's Adv Anim Vet Res. 2015;2:117-122.	Title
141 6	Hoffmann F, Boesch D, Dörks M, et al. Renal insufficiency and medication in nursing home residents: a cross-sectional study (IMREN). Deutsches Ärzteblatt International. 2016;113(6):92.	Title
141 7	Huo X, Liu K. Renal organic anion transporters in drug–drug interactions and diseases. European Journal of Pharmaceutical Sciences. 2018 2018/01/15/;112:8-19.	Title
141 8	Liu Y, Lu Y, Xu Z, et al. Repurposing of the gold drug auranofin and a review of its derivatives as antibacterial therapeutics. Drug Discovery Today. 2022 2022/07/01/;27(7):1961-1973.	Title
141 9	Gunther EC, Smith LM, Kostylev MA, et al. Rescue of Transgenic Alzheimer's Pathophysiology by Polymeric Cellular Prion Protein Antagonists. Cell Reports. 2019 2019/01/02/;26(1):145-158.e8.	Title
142 0	Sakane K, Kawabata K, Inamoto Y, et al. Research and development of new oral cepheims, cefixime and cefdinir. Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan. 1993;113(9):605-626.	Abstract
142 1	Škerk V, Majdak-Gluhinić V, Arsov D. Research on the efficacy, tolerability and cost effectiveness of cefixime in the» switch «therapy of urinary tract infections and urosepsis. Infektološki glasnik. 2006;26(2):81-84.	Abstract
142 2	Khalim W, Mwesigye J, Tungotyo M, et al. Resistance pattern of infected chronic wound isolates and factors associated with bacterial resistance to third generation cephalosporins at Mbarara Regional Referral Hospital, Uganda. Plos one. 2021;16(12):e0261264.	Abstract
142 3	Verhoef J, Gillissen A. Resistant Haemophilus influenzae in community-acquired respiratory tract infections: a role for cefixime. International journal of antimicrobial agents. 2003;21(6):501-509.	Abstract

142 4	Manwar J, Kumbhar DD, Bakal R, et al. Response surface based co-optimization of release kinetics and mucoadhesive strength for an oral mucoadhesive tablet of cefixime trihydrate. Bulletin of Faculty of Pharmacy, Cairo University. 2016;54(2):227-235.	Abstract
142 5	Feshchenko Y, Dzyublik A, Pertseva T, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2011-13 in Ukraine. J Antimicrob Chemother. 2016 May;71 Suppl 1(Suppl 1):i63-9.	Title
142 6	Torumkuney D, Smayevsky J, Relloso MS, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2015-17 in Latin America (Argentina, Chile and Costa Rica): data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. J Antimicrob Chemother. 2020 Apr 1;75(Suppl 1):i43-i59.	Title
142 7	Torumkuney D, Anwar S, Nizamuddin S, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2015–17 in Pakistan: Data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. Journal of Antimicrobial Chemotherapy. 2020;75(Supplement_1):i76-i87.	Title
142 8	Torumkuney D, Mokaddas E, Jiman-Fatani A, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2015–17 in the Middle East (Kuwait, Lebanon and Saudi Arabia): Data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. Journal of Antimicrobial Chemotherapy. 2020;75(Supplement_1):i60-i75.	Title
142 9	Torumkuney D, Tunger A, Sancak B, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2015–17 in Turkey: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. Journal of Antimicrobial Chemotherapy. 2020;75(Supplement_1):i88-i99.	Title
143 0	Torumkuney D, Hammami A, Mezghani Maalej S, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2015–18 in Tunisia, Kenya and Morocco: Data based on CLSI, EUCAST (dose-specific) and	Title

	pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. Journal of Antimicrobial Chemotherapy. 2020;75(Supplement_1):i2-i18.	
143 1	Torumkuney D, Van PH, Thinh LQ, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2016-18 in Vietnam, Cambodia, Singapore and the Philippines: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. J Antimicrob Chemother. 2020 Apr 1;75(Suppl 1):i19-i42.	Title
143 2	Torumkuney D, Bratus E, Yuvko O, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2016-17 in Ukraine: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. Journal of Antimicrobial Chemotherapy. 2020;75(Supplement_1):i100-i111.	Title
143 3	Torumkuney D, Van P, Thinh L, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2016-18 in Vietnam, Cambodia, Singapore and the Philippines: Data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. Journal of Antimicrobial Chemotherapy. 2020;75(Supplement_1):i19-i42.	Title
143 4	Gratrix J, Bergman J, Egan C, et al. Retrospective review of pharyngeal gonorrhoea treatment failures in Alberta, Canada. Sexually transmitted diseases. 2013;40(11):877-879.	Title
143 5	Guay DRP. Review of cefditoren, an advanced-generation, broad-spectrum oral cephalosporin. Clinical Therapeutics. 2001 2001/12/01;23(12):1924-1937.	Title
143 6	Rzeszutek M, Wierzbowski A, Hoban DJ, et al. A review of clinical failures associated with macrolide-resistant Streptococcus pneumoniae. International Journal of Antimicrobial Agents. 2004 2004/08/01;24(2):95-104.	Title
143 7	Barriere SL. Review of in vitro activity, pharmacokinetic characteristics, safety, and clinical efficacy of cefprozil, a new oral cephalosporin. Annals of Pharmacotherapy. 1993;27(9):1082-1089.	Title

143 8	Borin MT. A review of the pharmacokinetics of cefpodoxime proxetil. <i>Drugs</i> . 1991;42(3):13-21.	Title
143 9	Kalman D, Barriere SL. Review of the pharmacology, pharmacokinetics, and clinical use of cephalosporins. <i>Texas Heart Institute Journal</i> . 1990;17(3):203.	Title
144 0	Silva O, Caldeira G, Serrano R. A review of the role of medicinal plants on <i>Neisseria gonorrhoeae</i> infection. <i>European Journal of Integrative Medicine</i> . 2020 2020/10/01/;39:101211.	Title
144 1	Sader HS, Jacobs MR, Fritsche TR. Review of the spectrum and potency of orally administered cephalosporins and amoxicillin/clavulanate. <i>Diagnostic Microbiology and Infectious Disease</i> . 2007 2007/03/01/;57(3, Supplement):S5-S12.	Title
144 2	Gerometta E, Grondin I, Smadja J, et al. A review of traditional uses, phytochemistry and pharmacology of the genus <i>Indigofera</i> . <i>Journal of Ethnopharmacology</i> . 2020 2020/05/10/;253:112608.	Title
144 3	Kalyani K, Radha K, Kumar SS, et al. Review on Bioanalytical Methods for Determination of Cephalosporins by Using HPLC and LC-MS.	Title
144 4	Al Kamaly O. Review on Characterization, Properties, and Analytical Methods of Cefepime. <i>International Journal of Analytical Chemistry</i> . 2022;2022:6909528-6909528.	Title
144 5	Maideen NM, Raj Kapoor B, Muthusamy S, et al. A Review on Pharmacokinetic and Pharmacodynamic Drug Interactions of Adrenergic $\beta$ -blockers with Clinically Relevant Drugs-An Overview. <i>Current Drug Metabolism</i> . 2021;22(9):672-682.	Title
144 6	Li S, Cheng X, Wang C. A review on traditional uses, phytochemistry, pharmacology, pharmacokinetics and toxicology of the genus <i>Peganum</i> . <i>Journal of Ethnopharmacology</i> . 2017 2017/05/05/;203:127-162.	Title
144 7	Winstead W. Rhinosinusitis. <i>Primary Care: Clinics in Office Practice</i> . 2003 2003/03/01/;30(1):137-154.	Title

144 8	Redington J, Ebert SC, Craig WA. Role of antimicrobial pharmacokinetics and pharmacodynamics in surgical prophylaxis. Reviews of infectious diseases. 1991;13(Supplement_10):S790-S799.	Title
144 9	Westphal JF, Jehl F, Adloff M, et al. Role of intrahepatic protein binding in the hepatobiliary extraction profile of cefixime in humans. Clinical Pharmacology & Therapeutics. 1993;54(5):476-484.	Abstract
145 0	Rial R, Liu Z, Messina P, et al. Role of nanostructured materials in hard tissue engineering. Advances in Colloid and Interface Science. 2022 2022/06/01/;304:102682.	Title
145 1	Anzueto A, Bishai WR, Pottumarthy S. Role of oral extended-spectrum cepheims in the treatment of acute exacerbation of chronic bronchitis. Diagnostic Microbiology and Infectious Disease. 2007 2007/03/01/;57(3, Supplement):S31-S38.	Title
145 2	Sugiura T, Kato Y, Tsuji A. Role of SLC xenobiotic transporters and their regulatory mechanisms PDZ proteins in drug delivery and disposition. Journal of Controlled Release. 2006 2006/11/28/;116(2):238-246.	Title
145 3	Ellington MJ, Ekelund O, Aarestrup FM, et al. The role of whole genome sequencing in antimicrobial susceptibility testing of bacteria: report from the EUCAST Subcommittee. Clinical Microbiology and Infection. 2017 2017/01/01/;23(1):2-22.	Title
145 4	Al-Kuraishy HM, Al-Gareeb AI, Al-Buhadily AK. Rosuvastatin as forthcoming antibiotic or as adjuvant additive agent: In vitro novel antibacterial study. Journal of laboratory physicians. 2018;10(03):271-275.	Title
145 5	Vignesh S. RP-HPLC Method Development and Validation for related Substance of Cefixime Oral Suspension: JKK Nattraja College of Pharmacy, Komarapalayam; 2018.	Abstract
145 6	Klesel N, Adam F, Isert D, et al. RU 29 246, THE ACTIVE COMPOUND OF THE CEPHALOSPORIN PRODRUG-ESTER HR 916 III. PHARMACOKINETIC PROPERTIES AND ANTIBACTERIAL ACTIVITY IN VIVO. The Journal of Antibiotics. 1992;45(6):922-931.	Abstract



145 7	Bauernfeind A, Jungwirth R, Eberlein E, et al. RU 29 246, the active compound of the cephalosporin-prodrug-ester HR 916. I. Antibacterial activity in vitro. J Antibiot (Tokyo). 1992 Apr;45(4):505-20.	Abstract
145 8	Weiner CP, Buhimschi C. S. In: Weiner CP, Buhimschi C, editors. Drugs for Pregnant and Lactating Women (Second Edition). Philadelphia: W.B. Saunders; 2009. p. 1016-1064.	Title
145 9	Weiner CP, Mason C. S. In: Weiner CP, Mason C, editors. Drugs for Pregnant and Lactating Women (Third Edition). Philadelphia: Elsevier; 2019. p. 793-836.	Title
146 0	Kong F. S02. 1 Antimicrobial resistance and extragenital STIs–pharmacokinetic considerations. BMJ Publishing Group Ltd; 2021.	Title
146 1	S8 – S47 and O50 – O440. Clinical Microbiology and Infection. 2006 2006/01/01/;12:S1-S110.	Title
146 2	Lode H. Safety and Tolerability of Commonly Prescribed Oral Antibiotics for the Treatment of Respiratory Tract Infections. The American Journal of Medicine. 2010 2010/04/01/;123(4, Supplement):S26-S38.	Title
146 3	Ball P, Stahlmann R, Kubin R, et al. Safety profile of oral and intravenous moxifloxacin: Cumulative data from clinical trials and postmarketing studies. Clinical Therapeutics. 2004 2004/07/01/;26(7):940-950.	Title
146 4	Bertino J, Fish D. The safety profile of the fluoroquinolones. Clinical Therapeutics. 2000 2000/07/01/;22(7):798-817.	Title
146 5	Venetis G, Chatzika K, Pitsiou G, et al. Saliva and Blood Concentration of Cefuroxime in Patients Undergoing Maxillofacial Surgery. Journal of Oral and Maxillofacial Surgery. 2012 2012/06/01/;70(6):1398-1403.	Title
146 6	Tonelli AP, Bialer M, Look ZM, et al. Saturable processes affecting renal clearance of cefixime in dogs. Pharmaceutical research. 1986;3(3):150-155.	Animal

146 7	Tsuji A, Hirooka H, Terasaki T, et al. Saturable uptake of cefixime, a new oral cephalosporin without an $\alpha$ -amino group, by the rat intestine. <i>Journal of pharmacy and pharmacology</i> . 1987;39(4):272-277.	Animal
146 8	Sangwan S, Yadav N, Kumar R, et al. A score years' update in the synthesis and biological evaluation of medicinally important 2-pyridones. <i>European Journal of Medicinal Chemistry</i> . 2022 2022/03/15/;232:114199.	Title
146 9	Mohamed HM. Screen-printed disposable electrodes: Pharmaceutical applications and recent developments. <i>TrAC Trends in Analytical Chemistry</i> . 2016 2016/09/01/;82:1-11.	Title
147 0	Baig JA, Muhammad M, Akhtar K, et al. Selective electrochemical sensing of cefixime by silver nanoparticle amalgam paste microelectrode. <i>Journal of Materials Science: Materials in Electronics</i> . 2022:1-13.	Abstract
147 1	Chen Z-j, Zhang J, Yu J-c, et al. Selective method for the determination of cefdinir in human plasma using liquid chromatography electrospray ionization tandem mass spectrometry. <i>Journal of Chromatography B</i> . 2006 2006/04/13/;834(1):163-169.	Title
147 2	Pulcini C, Tebano G, Mutters NT, et al. Selective reporting of antibiotic susceptibility test results in European countries: an ESCMID cross-sectional survey. <i>International Journal of Antimicrobial Agents</i> . 2017 2017/02/01/;49(2):162-166.	Title
147 3	Nielsen EI, Viberg A, Löwdin E, et al. Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments. <i>Antimicrobial agents and chemotherapy</i> . 2007;51(1):128-136.	Title
147 4	Oteo J, Alós J-I, Gómez-Garcés J-L. Sensibilidad in vitro actual de los patógenos respiratorios bacterianos más frecuentes: implicaciones clínicas. <i>Medicina Clínica</i> . 2001 2001/01/01/;116(14):541-549.	Title
147 5	Thiruvengadam E, Ramadoss R, Amudha M. Sensitive spectroscopic method for content analysis of cefixime in solid dosage form using hydrotrophy phenomenon. <i>Chronicles of Young Scientists</i> . 2012;3(4):299-299.	Abstract

147 6	Janknegt R, Van der Meer J. Sequential therapy with intravenous and oral cephalosporins. Journal of Antimicrobial Chemotherapy. 1994;33(1):169-177.	Abstract
147 7	Casellas J, Tome G, Exeni R, et al. Serum and urinary cefpodoxime levels and time killing curves performed in the urine of children presenting urinary tract infections. Pathologie-biologie. 1993;41(4):385-391.	Title
147 8	Dan M, Poch F, Edelman A, et al. Serum bactericidal activity of newer oral cephalosporins in healthy volunteers. The Journal of antimicrobial chemotherapy. 1998;41(4):485-488.	Abstract
147 9	Barbee LA, Dombrowski JC, Hermann S, et al. "Sex in the time of covid": clinical guidelines for sexually transmitted disease management in an era of social distancing. Sexually transmitted diseases. 2020;47(7):427.	Title
148 0	Donovan B. Sexually transmissible infections other than HIV. The Lancet. 2004 2004/02/14/;363(9408):545-556.	Title
148 1	Pfennig CL. Sexually Transmitted Diseases in the Emergency Department. Emergency Medicine Clinics of North America. 2019 2019/05/01/;37(2):165-192.	Title
148 2	Steen R, Dallabetta G. Sexually Transmitted Infection Control with Sex Workers: Regular Screening and Presumptive Treatment Augment Efforts to Reduce Risk and Vulnerability. Reproductive Health Matters. 2003 2003/11/01/;11(22):74-90.	Title
148 3	Niforatos JD, Rothman RE. Sexually Transmitted Infections Treatment Guidelines, 2021. Annals of Emergency Medicine. 2022;80(1):68-70.	Title
148 4	Unemo M, Bradshaw CS, Hocking JS, et al. Sexually transmitted infections: challenges ahead. The Lancet Infectious Diseases. 2017 2017/08/01/;17(8):e235-e279.	Title

148 5	Chachaty E, Bourneix C, Renard S, et al. Shedding of Clostridium difficile, fecal beta-lactamase activity, and gastrointestinal symptoms in 51 volunteers treated with oral cefixime. Antimicrobial agents and chemotherapy. 1993;37(7):1432-1435.	Abstract
148 6	Sanchez M, Collvinent B, Miro O, et al. Short-term effectiveness of ceftriaxone single dose in the initial treatment of acute uncomplicated pyelonephritis in women. A randomised controlled trial. Emergency medicine journal. 2002;19(1):19-22.	Title
148 7	Day MJ, Jacobsson S, Spiteri G, et al. Significant increase in azithromycin “resistance” and susceptibility to ceftriaxone and cefixime in Neisseria gonorrhoeae isolates in 26 European countries, 2019. BMC Infectious Diseases. 2022;22(1):1-10.	Abstract
148 8	Hue TTT, Son DC, Anh NTL, et al. A Simple and Rapid Method to Measure Residue of Cefexime—a Cephalosporin Antibiotic in the Wastewater of Pharmaceutical Production Plant. 2014.	Abstract
148 9	Mahrouse MA, Elwy HM, Salem EM. Simultaneous determination of cefixime and erdosteine in combined dosage form using validated spectrophotometric methods. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. 2020;241:118647.	Abstract
149 0	Madgulkar AR, Sonawane PA, Dhoka MV, et al. Simultaneous Determination of Cefixime Trihydrate and Erdosteine in Human Plasma by HPTLC Method. Research Journal of Pharmacy and Technology. 2011;4(7):1078-1082.	Abstract
149 1	Attimarad M, Al-Dhubiab BE, Alhaider IA, et al. Simultaneous determination of moxifloxacin and cefixime by first and ratio first derivative ultraviolet spectrophotometry. Chemistry Central Journal. 2012;6(1):1-7.	Abstract
149 2	Attimarad M, Nair A. Simultaneous determination of ofloxacin and cefixime by first and ratio first derivative UV spectrophotometry. Chronicles of young scientists. 2011;2(3):144-144.	Abstract

149 3	Patwari A, Dabhi M, Rathod I, et al. Simultaneous determination of Ofloxacin and Cefixime in combined tablet dosage form by HPLC and absorbance correction method. Bulletin of Pharmaceutical Research. 2014;4(3):112-7.	Abstract
149 4	Alnajjar AO. Simultaneous determination of ofloxacin and cefixime in tablet formulation using capillary electrophoresis. Journal of Liquid Chromatography & Related Technologies. 2013;36(19):2687-2697.	Abstract
149 5	Gundala U, Bonagiri C, Nayakanti D. SIMULTANEOUS ESTIMATION OF AZITHROMYCIN AND CEFIXIME IN BULK AND PHARMACEUTICAL FORMULATION BY REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (RP-HPLC). 2014.	Abstract
149 6	Raval PL, Mehta FA, Ahir KB, et al. Simultaneous estimation of azithromycin dihydrate and cefixime trihydrate in pharmaceutical formulation by HPTLC method. Journal of Liquid Chromatography & Related Technologies. 2014;37(13):1805-1818.	Title
149 7	Nyola N, Jeyabalan S. Simultaneous estimation of Cefixime and Azithromycin in API's and pharmaceutical dosage form by RP-HPLC. Indo American Journal of Pharmaceutical Research. 2013;2(12):1472-81.	Abstract
149 8	Bhinge SD, Malipatil SM, Sonawane LV. Simultaneous estimation of cefixime and cloxacillin in human plasma by reversed phase-HPLC with UV detection. Thai Journal of Pharmaceutical Sciences. 2012;36(2).	Abstract
149 9	Bhinge SD, Malipatil SM, Sonawane LV, et al. Simultaneous Estimation of Cefixime and Dicloxacillin in Bulk and Tablet Formulation by RP-HPLC Method/Sefiksim ve Dikloksasilin'in Ham Madde ve Farmasötik Formülasyonlardan TF-HPLC Yöntemi ile Eşzamanlı Tayini. FABAD Journal of Pharmaceutical Sciences. 2012;37(2):63.	Abstract
150 0	Natesan S, Loganathan R, Krishnaswami V, et al. Simultaneous estimation of Cefixime and ofloxacin in tablet dosage form by RP-HPLC. 2011.	Abstract

150 1	Hussein LA, Hussien EM, Magdy N, et al. Simultaneous estimation of Ofloxacin and Cefixime in tablet form in presence of the inactive Ofloxacin USP Related compound A. Bulletin of Faculty of Pharmacy, Cairo University. 2017;55(1):171-176.	Abstract
150 2	Fekri M, Shahverdi V, Chegeni M, et al. Simultaneous photocatalytic degradation of cefixime and cefuroxime antibiotics using g-C3N4/NaBiO3 nanocomposite and optimization of effective parameters by response surface methodology. Reaction Kinetics, Mechanisms and Catalysis. 2022;135(2):1059-1075.	Abstract
150 3	Xue K, Li G, Sun X, et al. Simultaneous quantification of fosinopril and its active metabolite fosinoprilat in rat plasma by UFLC-MS/MS: Application of formic acid in the stabilization of an ester-containing drug. Journal of Chromatography B. 2015 2015/05/15/;990:141-149.	Title
150 4	Helmy SA. Simultaneous quantification of linezolid, tinidazole, norfloxacin, moxifloxacin, levofloxacin, and gatifloxacin in human plasma for therapeutic drug monitoring and pharmacokinetic studies in human volunteers. Therapeutic drug monitoring. 2013;35(6):770-777.	Title
150 5	Nanda R, Gaikwad J, Prakash A. Simultaneous Spectrophotometric Methods for estimation of Cefixime and Erdosteine in synthetic mixture. Research Journal of Pharmacy and Technology. 2009;2(3):582-584.	Abstract
150 6	Plourde PJ, Tyndall M, Agoki E, et al. Single-dose cefixime versus single-dose ceftriaxone in the treatment of antimicrobial-resistant Neisseria gonorrhoeae infection. Journal of Infectious Diseases. 1992;166(4):919-922.	Abstract
150 7	Megran D, Lefebvre K, Willetts V, et al. Single-dose oral cefixime versus amoxicillin plus probenecid for the treatment of uncomplicated gonorrhoea in men. Antimicrobial agents and chemotherapy. 1990;34(2):355-357.	Abstract
150 8	Kumamoto Y. Single-dose treatment of female acute uncomplicated cystitis. Infection. 1992;20 Suppl 3:S173-4.	Title

1509	Lameire N, Malerczyk V, Drees B, et al. Single-dose pharmacokinetics of cefpirome in patients with renal impairment. <i>Clinical Pharmacology &amp; Therapeutics</i> . 1992;52(1):24-30.	Title
1510	Kaliner MA, Osguthorpe JD, Fireman P, et al. Sinusitis: Bench to bedside: Current findings, future directions. <i>Journal of Allergy and Clinical Immunology</i> . 1997 1997/06/01/;99(6, Part 3):S829-S847.	Title
1511	Agrawal GP, Maheshwari RK, Mishra P. Solubility enhancement of cefixime trihydrate by solid dispersions using hydrotropic solubilization technique and their characterization. <i>Brazilian Journal of Pharmaceutical Sciences</i> . 2022;58.	Extensive reading
1512	Mogal P, Derle D. Soluplus as a potential enhancer of cefixime biopharmaceutical properties through solid dispersion prepared by different pharmaceutical interventions. <i>Integr J Glob Health</i> . 2017;1(2):11.	Abstract
1513	Mouton JW. Soup with or without meatballs: impact of nutritional factors on the MIC, kill-rates and growth-rates. <i>European Journal of Pharmaceutical Sciences</i> . 2018;125:23-27.	Title
1514	Holton E, Archer E, Fidal J, et al. Spatiotemporal urban water profiling for the assessment of environmental and public exposure to antimicrobials (antibiotics, antifungals, and antivirals) in the Eerste River Catchment, South Africa. <i>Environment International</i> . 2022 2022/06/01/;164:107227.	Title
1515	Bukhari N, Al-Warthan AA, Wabaidur SM, et al. Spectrofluorimetric determination of cefixime in pharmaceutical preparation and biological fluids using calcein as a fluorescence probe. <i>Sensor Letters</i> . 2010;8(2):280-284.	Abstract
1516	Manzoori JL, Amjadi M, Soltani N, et al. Spectrofluorimetric determination of cefixime using terbium-danofloxacin probe. <i>Iranian Journal of Basic Medical Sciences</i> . 2014;17(4):256.	Abstract
1517	Shah J, Jan MR, Shah S. Spectrofluorimetric method for determination and validation of cefixime in pharmaceutical preparations through derivatization with 2-cyanoacetamide. <i>Journal of fluorescence</i> . 2011;21(2):579-585.	Abstract

151 8	Dhahir S, Mohammed N. SPECTROPHOTOMETRIC AND ATOMIC ABSORPTION DETERMINATION OF CEFIXIME BY CLOUD POINT EXTRACTION IN PURE FORM. The Iraqi Journal of Agricultural Science. 2019;50(4):1390-1404.	Abstract
151 9	Keskar MR, Jugade RM. Spectrophotometric determination of cefixime trihydrate in pharmaceutical formulations based on ion-pair reaction with bromophenol blue. Analytical chemistry insights. 2015;10:ACI. S28463.	Abstract
152 0	Önal C, Dinçel D. Spectrophotometric determination of erdosteine at capsule dosage forms. Bezmialem Science. 2021.	Title
152 1	Suganthi M, Elango KP. Spectroscopic studies on in vitro binding of cefixime and tolcapone drugs with serum albumin. Physics and Chemistry of Liquids. 2018;56(3):299-310.	Abstract
152 2	Parks KS, Dixon PB, Richey CM, et al. Spontaneous clearance of Chlamydia trachomatis infection in untreated patients. Sex Transm Dis. 1997 Apr;24(4):229-35.	Title
152 3	Alaei S, Ghasemian E, Vatanara A. Spray drying of cefixime nanosuspension to form stabilized and fast dissolving powder. Powder Technology. 2016;288:241-248.	Abstract
152 4	Haghighi DM, Faghihi H, Darabi M, et al. Spray freeze drying to solidify Nanosuspension of Cefixime into inhalable microparticles. DARU Journal of Pharmaceutical Sciences. 2022;30(1):17-27.	Abstract
152 5	Kline JA, Runge JW. Streptococcal pharyngitis: A review of pathophysiology, diagnosis, and management. The Journal of Emergency Medicine. 1994 1994/09/01;12(5):665-680.	Title
152 6	Paradisi J, Corti G, Cinelli R. Streptococcus pneumoniae as an agent of nosocomial infection: treatment in the era of penicillin-resistant strains. Clinical Microbiology and Infection. 2001 2001/01/01;7:34-42.	Title
152 7	Jacobs MR. Streptococcus pneumoniae: Epidemiology and patterns of resistance. The American Journal of Medicine Supplements. 2004 2004/08/02;117(3, Supplement 1):3-15.	Title



152 8	Kaplan SL. Streptococcus pneumoniae: Impact of antibiotic resistance in pediatrics. Current Problems in Pediatrics. 1997 1997/05/01/;27(5):187-195.	Title
152 9	Preston SL, Drusano GL. STRUCTURE ACTIVITY RELATIONSHIPS. Community-Acquired Respiratory Infections: Antimicrobial Management. 2003;31:110.	Title
153 0	Bingen E, Lambert-Zechovsky N. [Structure-activity relationship of oral cephalosporins]. Presse Med. 1989 Nov 25;18(39):1923-7.	Not Accessible
153 1	Singh B, Bhat HR, Kumawat MK, et al. Structure-guided discovery of 1,3,5-triazine-pyrazole conjugates as antibacterial and antibiofilm agent against pathogens causing human diseases with favorable metabolic fate. Bioorganic & Medicinal Chemistry Letters. 2014 2014/08/01/;24(15):3321-3325.	Title
153 2	Yamanaka H, Chiba T, Kawabata K, et al. Studies on beta-lactam antibiotics. IX. Synthesis and biological activity of a new orally active cephalosporin, cefixime (FK027). J Antibiot (Tokyo). 1985 Dec;38(12):1738-51.	Abstract
153 3	Yokoo C, Goi M, Onodera A, et al. Studies on cephalosporin antibiotics. IV. Synthesis, antibacterial activity and oral absorption of new 3-(2-substituted-vinylthio)-7 beta-[(Z)-2-(2-aminothiazol-4-yl)-2-(carboxymethoxyimino)acetamido]cephalosporins. J Antibiot (Tokyo). 1991 Dec;44(12):1422-31.	Abstract
153 4	Inamoto Y, Chiba T, Sakane K, et al. [Studies on FK482. II. Synthesis and structure-activity relationships of 7 beta-[(Z)-2-(2-aminothiazol-4-yl)-2-substituted acetamido]-3-vinyl-3-cephem-4-carboxylic acid derivatives]. Yakugaku Zasshi. 1990 Apr;110(4):246-57.	Not Accessible
153 5	Divya R, Sivaneswari S, Preethi N, et al. Studies on Oral Sustain Delivery of Cefixime from Floating Matrix Tablets Formulation and In Vitro Evaluation. Research Journal of Pharmacy and Technology. 2014;7(7):798.	Abstract

153 6	Kalia P, Kumar NR, Harjai K. Studies on the therapeutic effect of propolis along with standard antibacterial drug in Salmonella enterica serovar Typhimurium infected BALB/c mice. BMC complementary and alternative medicine. 2016;16(1):1-15.	Animal
153 7	Yamanaka H, CHIBA T, KAWABATA K, et al. Studies on $\beta$ -lactam antibiotics IX. Synthesis and biological activity of a new orally active cephalosporin, cefixime (FK027). The Journal of antibiotics. 1985;38(12):1738-1751.	Abstract
153 8	Petitjean O, Brion N, Tod M, et al. Study of a possible pharmacokinetic interaction between cefixime and two antacids. Preliminary results. ETUDE DE L'INTERACTION PHARMACOCINETIQUE ENTRE LE CEFIXIME ET DEUX ANTIACIDES. RESULTATS PRELIMINAIRES. Presse medicale (Paris, France : 1983). 1989;18(32):1596-1598.	Not Accessible
153 9	Mishra B, Singh AK, Yadav SK. Study of comparative aspects of gastroretentive delivery of cefixime trihydrate from microspheres and microsphere based tablets. Journal of Pharmaceutical Investigation. 2015;45(6):541-554.	Abstract
154 0	Tanimura H, Uchiyama K, Onishi H, et al. Study of the absorption of cefcapene pivoxil in patients with infectious disease and soft stool or diarrhea. Journal of Infection and Chemotherapy. 2003 2003/01/01;9(1):75-82.	Title
154 1	Combinations FD. A Study On Analysis Of Fixed Drug Combinations Widely Prescribed in India.	Title
154 2	Baby B, DAS S, HAQUE I, et al. A Study on Prescribing Pattern of Antibiotics for Respiratory Tract Infection in Pediatric Outpatient in A Tertiary Care Hospital: A Prospective Observational Study. International Journal of Pharmaceutical Sciences Review and Research. 2019;59(1):30-33.	Title

154 3	Huo B, Zhao L, Qiu F. Study on the content determination of Cefixime and its pharmacokinetics in human plasma. WEST CHINA JOURNAL OF PHARMACEUTICAL SCIENCES. 2005;20(4):312.	Abstract
154 4	Kaushik P, Mittal A, Kumar S, et al. Study the Effect of Liquid Solid Compact Technology on Drug's Pharmacokinetic and Pharmacodynamic Behaviour.	Title
154 5	Nct. Study to Improve Partner Services for STD Prevention. <a href="https://clinicaltrials.gov/show/NCT00207467">https://clinicaltrials.gov/show/NCT00207467</a> . 2005.	Title
154 6	Subject index. Journal of Chromatography B: Biomedical Sciences and Applications. 1987 1987/01/01;422:365-369.	Title
154 7	Subject index. Current Therapeutic Research. 1993 1993/12/01;54(6):856-859.	Title
154 8	Subject index. Seminars in Pediatric Infectious Diseases. 1999 1999/10/01;10(4):269-275.	Title
154 9	Subject Index. Clinical Microbiology and Infection. 2003 2003/01/01;9:440-451.	Title
155 0	Subject Index. In: Caballero B, editor. Encyclopedia of Food Sciences and Nutrition (Second Edition). Oxford: Academic Press; 2003. p. 6347-6601.	Title
155 1	Subject Index. Clinical Microbiology and Infection. 2004 2004/01/01;10:704-715.	Title
155 2	Subject Index. In: Westerink BHC, Cremers TIFH, editors. Handbook of Behavioral Neuroscience. Vol. 16: Elsevier; 2006. p. 687-697.	Title
155 3	Subject Index. In: Schaefer C, Peters P, Miller RK, editors. Drugs During Pregnancy and Lactation (Second Edition). Oxford: Academic Press; 2007. p. 853-875.	Title

155 4	Subject index to volume 13. Diagnostic Microbiology and Infectious Disease. 1990 1990/11/01/;13(6):529-541.	Title
155 5	Subject Index to volume 14. Diagnostic Microbiology and Infectious Disease. 1991 1991/11/01/;14(6):529-536.	Title
155 6	Subject index to volume 15. Diagnostic Microbiology and Infectious Disease. 1992 1992/11/01/;15(8):710-722.	Title
155 7	Subject Index Volume 74 July–December, 2006. Contraception. 2006 2006/12/01/;74(6):503-510.	Title
155 8	Subject index volumes 351–400. Journal of Chromatography A. 1987 1987/01/01/;401:137-379.	Title
155 9	Subject index volumes 401–450. Journal of Chromatography A. 1988 1988/01/01/;451:155-424.	Title
156 0	Niwa T, Imagawa Y. Substrate specificity of human cytochrome P450 (CYP) 2C subfamily and effect ofazole antifungal agents on CYP2C8. Journal of Pharmacy & Pharmaceutical Sciences. 2016;19(4):423-429.	Title
156 1	Kramer W, Stengelin S, Baringhaus K-H, et al. Substrate specificity of the ileal and the hepatic Na <sup>+</sup> /bile acid cotransporters of the rabbit. I. Transport studies with membrane vesicles and cell lines expressing the cloned transporters. Journal of Lipid Research. 1999 1999/09/01/;40(9):1604-1617.	Animal
156 2	Richer M, Allard S, Manseau L, et al. Suction-induced blister fluid penetration of cefdinir in healthy volunteers following ascending oral doses. Antimicrobial agents and chemotherapy. 1995;39(5):1082-1086.	Title
156 3	Alonso R, Rodríguez-Achaerandio A, Aguirre-Quiñonero A, et al. Supplementary Materials: Molecular Epidemiology, Antimicro-bial Surveillance, and PK/PD Analysis to Guide the Treatment of Neisseria gonorrhoeae Infections.	Title

156 4	Masoudyfar Z, Elhami S. Surface plasmon resonance of gold nanoparticles as a colorimetric sensor for indirect detection of Cefixime. <i>Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy</i> . 2019;211:234-238.	Abstract
156 5	Felmingham D, Feldman C, Hryniewicz W, et al. Surveillance of resistance in bacteria causing community-acquired respiratory tract infections. <i>Clinical Microbiology and Infection</i> . 2002 2002/01/01/;8:12-42.	Title
156 6	Nepal A, Hendrie D, Robinson S, et al. Survey of the pattern of antibiotic dispensing in private pharmacies in Nepal [Journal: Article]. <i>BMJ open</i> . 2019;9(10).	Title
156 7	Credito KL, Lin G, Pankuch GA, et al. Susceptibilities of <i>Haemophilus influenzae</i> and <i>Moraxella catarrhalis</i> to ABT-773 compared to their susceptibilities to 11 other agents. <i>Antimicrobial agents and chemotherapy</i> . 2001;45(1):67-72.	Title
156 8	Harrison CJ, Woods C, Stout G, et al. Susceptibilities of <i>Haemophilus influenzae</i> , <i>Streptococcus pneumoniae</i> , including serotype 19A, and <i>Moraxella catarrhalis</i> paediatric isolates from 2005 to 2007 to commonly used antibiotics. <i>Journal of Antimicrobial Chemotherapy</i> . 2009;63(3):511-519.	Title
156 9	Jacobs MR, Bajaksouzian S, Zilles A, et al. Susceptibilities of <i>Streptococcus pneumoniae</i> and <i>Haemophilus influenzae</i> to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 US surveillance study. <i>Antimicrobial agents and chemotherapy</i> . 1999;43(8):1901-1908.	Title
157 0	Spangler S, Jacobs M, Pankuch G, et al. Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829. <i>Journal of Antimicrobial Chemotherapy</i> . 1993;31(2):273-280.	Abstract
157 1	Abo Safe F, Salah N, Rashed M, et al. Susceptibility of Aminoglycoside Resistant <i>Acinetobacter baumannii</i> to Antibiotic Combinations. <i>Egyptian Journal of Microbiology</i> . 2019;54(1):137-147.	Title

157 2	Yeo S, Chiew Y, Fung C. Susceptibility of Haemophilus influenzae isolates with known resistance mechanisms to five cephalosporins. <i>Chemotherapy</i> . 1996;42(2):85-89.	Abstract
157 3	Jacobs MR, Bajaksouzian S, Windau A, et al. Susceptibility of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 17 oral antimicrobial agents based on pharmacodynamic parameters: 1998–2001 U.S. Surveillance Study. <i>Clinics in Laboratory Medicine</i> . 2004 2004/06/01/;24(2):503-530.	Title
157 4	Kessler RE, Fung-Tomc JC. Susceptibility of united states clinical trial isolates to cefprozil and cefaclor. <i>Diagnostic Microbiology and Infectious Disease</i> . 1994 1994/02/01/;18(2):129-132.	Title
157 5	Lee SY, Lee JH, Kim JH, et al. Susceptibility tests of oral antibiotics including cefixime against Escherichia coli, isolated from pediatric patients with community acquired urinary tract infections. <i>Clinical and Experimental Pediatrics</i> . 2006;49(7):777-783.	Abstract
157 6	Nathwani D, Boyter A, Fegan PG, et al. Switch therapy in community-acquired pneumonia. <i>Archives of Internal Medicine</i> . 1996;156(11):1235-1235.	Title
157 7	Symposia and Oral Presentations. <i>Clinical Microbiology and Infection</i> . 2012 2012/01/01/;18:1-113.	Title
157 8	Asgar MA, Yousuf RI, Shoaib MH, et al. Synergistic Nanocomposites of Different Antibiotics Coupled with Green Synthesized Chitosan-Based Silver Nanoparticles: Characterization, Antibacterial, in vivo Toxicological and Biodistribution Studies. <i>Int J Nanomedicine</i> . 2020;15:7841-7859.	Title
157 9	Kim W-J, KO K-Y, Jung MH, et al. SYNTHESIS AND BIOLOGICAL ACTIVITY OF NOVEL 3-(2-PROPENYL)-CEPHALOSPORINS II. PREPARATION OF PRODRUGS. <i>The Journal of Antibiotics</i> . 1991;44(10):1083-1087.	Title
158 0	Kim W-J, KO K-Y, KIM H, et al. Synthesis and biological activity of novel 3-(2-propenyl)-cephalosporins. I. <i>The Journal of Antibiotics</i> . 1991;44(10):1073-1082.	Title

158 1	Mehmood Y, Ghafoor S, Riaz H, et al. Synthesis, analysis and biological studies of transition metal complexes of cefixime.	Abstract
158 2	Hamashima Y. Synthesis, Biological Properties, and Pharmacokinetics of 7432-S, a New Oral Cephem. Special Publication. 1980 (70):77.	Title
158 3	Farooq S, Haq I-U, Ullah N. Synthesis, characterization and biological evaluation of N-Mannich base derivatives of 2-phenyl-2-imidazoline as potential antioxidants, enzyme inhibitors, antimicrobials, cytotoxic and anti-inflammatory agents. Arabian Journal of Chemistry. 2021 2021/04/01/;14(4):103050.	Title
158 4	Sakagami K, Sakai M, Kashi T, et al. [Synthetic cephalosporins. IV. Synthesis and antibacterial activity of 7 beta-[(Z)-2-(2-aminothiazol-4-yl)-2-(O-substituted oxyimino)acetamido]-3-(1,2,3-triazol-1-yl)methyl-3-cephem-4-carboxylic acid and related compounds]. Yakugaku Zasshi. 1989 Dec;109(12):957-61.	Not Accessible
158 5	Sakagami K, Watanabe T, Fukatsu S, et al. [Synthetic cephalosporins. V. Synthesis and antibacterial activity of 3-alkylthio-7 beta-[(Z)-2-(2-aminothiazol-4-yl)-2-(O-substituted oxyimino)acetamido]cephalosporins and related compounds]. Yakugaku Zasshi. 1989 Dec;109(12):913-25.	Not Accessible
158 6	Limarkar N, Chavda D, Thakkar V, et al. Systematic Formulation Approach for Development and Evaluation of Cefixime Granules for Pediatric Application. Journal of Pharmaceutical Research. 2022;21(1):14.	Abstract
158 7	Li J, Lu Z. Systematic identification of pharmacogenomics information from clinical trials. Journal of Biomedical Informatics. 2012 2012/10/01/;45(5):870-878.	Title
158 8	Tanvir SB, Qasim SSB, Shariq A, et al. Systematic review and meta-analysis on efficacy of cefixime for treating gonococcal infections. International Journal of Health Sciences. 2018;12(5):90.	Title
158 9	Sadick NS. SYSTEMIC ANTIBIOTIC AGENTS. Dermatologic Clinics. 2001 2001/01/01/;19(1):1-21.	Title

159 0	Table of contents. The American Journal of Medicine. 1988 1988/12/01/;85(6):921-928.	Title
159 1	Sonam, Chaudhary H, Kumar V. Taguchi design for optimization and development of antibacterial drug-loaded PLGA nanoparticles. International Journal of Biological Macromolecules. 2014 2014/03/01/;64:99-105.	Title
159 2	TELEKES A, HEGEDŰS M, KISS I. Therapeutic drug monitoring and measurement of drug concentrations using mass spectrometry. Medical Applications of Mass Spectrometry: Elsevier; 2008. p. 263-289.	Title
159 3	Isogai E, Isogai H, Hirose K, et al. Therapeutic effect of anti-TNF- $\alpha$ antibody and levofloxacin (LVFX) in a mouse model of enterohemorrhagic Escherichia coli O157 infection. Comparative Immunology, Microbiology and Infectious Diseases. 2001 2001/10/01/;24(4):217-231.	Title
159 4	Miyazaki H, Tateda K, Matsumoto T, et al. Therapeutic Efficacies of Penicillin G, Cefotaxime, and Imipenem/Cilastatin against Penicillin-Resistant Pneumococcal Pneumonia in CBA/J Mice. Journal of Infection and Chemotherapy. 1996 1996/01/01/;2(1):34-39.	Animal
159 5	Del Rosso J. Therapeutic experience with cefdinir in the treatment of uSSSIs. International journal of clinical practice. 2006;60(10):1313-1316.	Title
159 6	KM M, Palaniswamy DS, NP D, et al. Therapeutic Importance of Curcumin with a Special Emphasis on Mdr Cancer Cells and the Factors Influencing Pharmacodynamics. Indonesian Journal of Pharmacy. 2021:429-441.	Title
159 7	Raddatz JK, Ostergaard BE, Rotschafer JC. Therapeutic options for cefotaxime in the management of bacterial infections. Diagnostic Microbiology and Infectious Disease. 1995 1995/05/01/;22(1):77-83.	Title
159 8	Paudel KR, Pokhrel P, Shrestha A, et al. Therapeutic practice preference in dentistry: antibiotics, analgesics and antiseptics. Asian Journal of Medical Sciences. 2013;4(4):17-23.	Title



159 9	Helwig H. Therapy of pediatric infections with cefixime. <i>Infection</i> . 1990;18:S147-9.	Abstract
160 0	Singh A, Malhotra D, Singh K, et al. Thiazole derivatives in medicinal chemistry: Recent advancements in synthetic strategies, structure activity relationship and pharmacological outcomes. <i>Journal of Molecular Structure</i> . 2022 2022/10/15/;1266:133479.	Title
160 1	Donowitz GR. Third Generation Cephalosporins. <i>Infectious Disease Clinics of North America</i> . 1989 1989/09/01/;3(3):595-612.	Abstract
160 2	Speciale A, Blandino G, Nicoletti G. Third generation oral cephalosporins: comparative in vitro kinetics. <i>J Chemother</i> . 1995 May;7 Suppl 1:9-12.	Abstract
160 3	Rosenfeld RM, Doyle WJ, Swarts JD, et al. Third-generation cephalosporins in the treatment of acute pneumococcal otitis media: an animal study. <i>Archives of Otolaryngology–Head &amp; Neck Surgery</i> . 1992;118(1):49-52.	Animal
160 4	Foerster S, Unemo M, Hathaway LJ, et al. Time-kill curve analysis and pharmacodynamic functions for in vitro evaluation of antimicrobials against <i>Neisseria gonorrhoeae</i> . <i>bioRxiv</i> . 2015:028506.	Title
160 5	Foerster S, Unemo M, Hathaway LJ, et al. Time-kill curve analysis and pharmacodynamic modelling for in vitro evaluation of antimicrobials against <i>Neisseria gonorrhoeae</i> . <i>BMC microbiology</i> . 2016;16(1):1-11.	Title
160 6	Spangler S, Jacobs M, Appelbaum P. Time-kill studies on susceptibility of nine penicillin-susceptible and-resistant pneumococci to cefditoren compared with nine other beta-lactams. <i>The Journal of antimicrobial chemotherapy</i> . 1997;39(2):141-148.	Title
160 7	Tsuji A. Tissue selective drug delivery utilizing carrier-mediated transport systems. <i>Journal of Controlled Release</i> . 1999 1999/11/01/;62(1):239-244.	Title

1608	Begue P, Garabedian N, Quinet B, et al. Tonsil diffusion of cefixime in children. <i>Pathologie-biologie</i> . 1989;37(5):433-436.	Not Accessible
1609	DUREJA H, GUPTA S, MADAN AK. Topological models for prediction of pharmacokinetic parameters of cephalosporins using random forest, decision tree and moving average analysis. <i>Scientia Pharmaceutica</i> . 2008;76(3):377-394.	Abstract
1610	Pérez MAC, Sanz MB, Torres LR, et al. A topological sub-structural approach for predicting human intestinal absorption of drugs. <i>European Journal of Medicinal Chemistry</i> . 2004 2004/11/01/;39(11):905-916.	Title
1611	Fallah Z, Zare EN, Ghomi M, et al. Toxicity and remediation of pharmaceuticals and pesticides using metal oxides and carbon nanomaterials. <i>Chemosphere</i> . 2021 2021/07/01/;275:130055.	Title
1612	Gehanno P, Boucot I, Chiche D, et al. Traitement ambulatoire des sinusites aiguës: évaluation comparative du cefuroxime axetil et du cefixime. <i>Médecine et Maladies Infectieuses</i> . 1991;21:61-65.	Title
1613	Peyramond D, Raffi F, Lucht F, et al. Traitements antibiotiques des angines. Indications, modalités, durées. <i>Médecine et Maladies Infectieuses</i> . 1997 1997/04/01/;27(4):434-449.	Title
1614	Matsumoto S, Saito H, Inui K. Transcellular transport of oral cephalosporins in human intestinal epithelial cells, Caco-2: interaction with dipeptide transport systems in apical and basolateral membranes. <i>J Pharmacol Exp Ther</i> . 1994 Aug;270(2):498-504.	Abstract
1615	Inui K, Yamamoto M, Saito H. Transepithelial transport of oral cephalosporins by monolayers of intestinal epithelial cell line Caco-2: specific transport systems in apical and basolateral membranes. <i>J Pharmacol Exp Ther</i> . 1992 Apr;261(1):195-201.	Abstract
1616	Faure S, Perrin-Guyomard A, Delmas J-M, et al. Transfer of plasmid-mediated CTX-M-9 from <i>Salmonella enterica</i> serotype Virchow to Enterobacteriaceae in human flora-associated rats treated with cefixime. <i>Antimicrobial agents and chemotherapy</i> . 2010;54(1):164-169.	Animal

161 7	Wong H, Bohnert T, Damian-Iordache V, et al. Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspective. <i>Drug Discovery Today</i> . 2017;22(10):1447-1459.	Title
161 8	Sugawara M, Iseki K, Miyazaki K, et al. Transport characteristics of ceftibuten, cefixime and cephalixin across human jejunal brush-border membrane. <i>J Pharm Pharmacol</i> . 1991 Dec;43(12):882-4.	Abstract
161 9	Wenzel U, Gebert I, Weintraut H, et al. Transport characteristics of differently charged cephalosporin antibiotics in oocytes expressing the cloned intestinal peptide transporter PepT1 and in human intestinal Caco-2 cells. <i>J Pharmacol Exp Ther</i> . 1996 May;277(2):831-9.	Abstract
162 0	Tomita Y, Katsura T, Okano T, et al. Transport mechanisms of bestatin in rabbit intestinal brush-border membranes: role of H <sup>+</sup> /dipeptide cotransport system. <i>J Pharmacol Exp Ther</i> . 1990 Feb;252(2):859-62.	Animal
162 1	Dantzig AH, Duckworth DC, Tabas LB. Transport mechanisms responsible for the absorption of loracarbef, cefixime, and cefuroxime axetil into human intestinal Caco-2 cells. <i>Biochim Biophys Acta</i> . 1994 Apr 20;1191(1):7-13.	Abstract
162 2	Benkhelifa S, Decroix M-O, Arnaud P, et al. Transport of cephalosporins across artificial membranes and rabbit ileum. <i>International Journal of Pharmaceutics</i> . 1996 1996/12/06/;145(1):115-127.	Animal
162 3	Sai Y, Tsuji A. Transporter-mediated drug delivery: recent progress and experimental approaches. <i>Drug Discovery Today</i> . 2004 2004/08/01/;9(16):712-720.	Title
162 4	Pablo Horcajada J, García-Palomo D, Carmen Fariñas M. Tratamiento de las infecciones no complicadas del tracto urinario inferior. <i>Enfermedades Infecciosas y Microbiología Clínica</i> . 2005 2005/12/01/;23:22-27.	Title
162 5	Guggenbichler JP, Titz B, Lysy G. Treatment of acute otitis media: comparison between cefixime and cefaclor [Journal: Conference Paper]. <i>Journal of drug development, supplement</i> . 1993;6(1):23-25.	Abstract

162 6	Stein G, Christensen S, Mummaw N. Treatment of acute uncomplicated urinary tract infection with ceftibuten. <i>Infection</i> . 1991;19(2):124-126.	Title
162 7	Wagenlehner FME, Naber KG. Treatment of Bacterial Urinary Tract Infections: Presence and Future. <i>European Urology</i> . 2006 2006/02/01/;49(2):235-244.	Title
162 8	Preston SL, Drusano GL. Treatment of Community-Acquired Respiratory Tract Infections with Penicillins and Cephalosporins. <i>Community-Acquired Respiratory Infections: CRC Press; 2003</i> . p. 137-160.	Abstract
162 9	Weston JS. Treatment of Gram-Positive Infections: Past, Present, and Future. <i>Critical Care Nursing Clinics of North America</i> . 2002 2002/03/01/;14(1):17-29.	Title
163 0	Vogel F. Treatment of lower respiratory tract infections including pneumonia. Comparative study with i. vl cefotaxime/oral cefixime versus parenteral cefotaxime. <i>Fortschritte der Medizin</i> . 1994;112(28):395-398.	Abstract
163 1	Parry CM. The treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever in Viet Nam. <i>Trans R Soc Trop Med Hyg</i> . 2004 Jul;98(7):413-22.	Title
163 2	Hollier LM, Workowski K. Treatment of Sexually Transmitted Infections in Pregnancy. <i>Clinics in Perinatology</i> . 2005 2005/09/01/;32(3):629-656.	Title
163 3	Martin JM, Pitetti R, Maffei F, et al. Treatment of shigellosis with cefixime: two days vs. five days [Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial]. <i>Pediatric infectious disease journal</i> . 2000;19(6):522-526.	Abstract
163 4	Salam MA, Seas C, Khan WA, et al. Treatment of shigellosis: IV. Cefixime is ineffective in shigellosis in adults. <i>Annals of internal medicine</i> . 1995;123(7):505-508.	Abstract
163 5	VERDON MS, DOUGLAS JR JM, WIGGINS SD, et al. Treatment of uncomplicated gonorrhea with single doses of 200 mg cefixime. <i>Sexually transmitted diseases</i> . 1993:290-293.	Abstract

163 6	Thompson CN, Karkey A, Dongol S, et al. Treatment Response in Enteric Fever in an Era of Increasing Antimicrobial Resistance: An Individual Patient Data Analysis of 2092 Participants Enrolled into 4 Randomized, Controlled Trials in Nepal. <i>Clin Infect Dis.</i> 2017 Jun 1;64(11):1522-1531.	Title
163 7	Leonhardt L. Treatment results using cefixime for bacterial respiratory tract infections. <i>Infection.</i> 1990;18:S115-8.	Abstract
163 8	Guchev I, Safonova E, Tsoy A. Tsefiksim. Klinicheskaya effektivnost'pri obostrenii netyazhelyoy khronicheskoy obstruktivnoy bolezni legkikh i vliyanie na razvitie retsidivov zabolevaniya. Nablyudatel'naya programma. <i>Consilium Medicum.</i> 2013;15(3):72-78.	Title
163 9	Irani-Nezhad MH, Jalili R, Kohan E, et al. Tungsten disulfide (WS <sub>2</sub> )/fluorescein ratiometric fluorescent probe for detection of cefixime residues in milk. <i>Environmental Research.</i> 2022;205:112512.	Abstract
164 0	Nct. Typhoid Fever: Combined vs. Single Antibiotic Therapy. <a href="https://clinicaltrials.gov/show/NCT02224040">https://clinicaltrials.gov/show/NCT02224040</a> . 2014.	Title
164 1	Furman WL, Navid F, Daw NC, et al. Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors. <i>Journal of clinical oncology.</i> 2009;27(27):4599.	Title
164 2	Bignell C, FitzGerald M. UK national guideline for the management of gonorrhoea in adults, 2011. <i>International journal of STD &amp; AIDS.</i> 2011;22(10):541-547.	Title
164 3	EJIKE US, TAREKA-AKPO E. Ultraviolet spectrophotometric determination of cefixime content in some pharmaceutical brands available in the Nigerian market. <i>An International Journal of Advances in Pharmaceutical sciences.</i> 2013;6:2757-59.	Abstract
164 4	Mahdi I, Bakrim WB, Bitchagno GTM, et al. Unraveling the Phytochemistry, Traditional Uses, and Biological and Pharmacological Activities of <i>Thymus algeriensis</i> Boiss. & Reut. <i>Oxidative Medicine and Cellular Longevity.</i> 2022;2022.	Title

164 5	Walsh ML, Johnson CC. Update on Antimicrobial Agents. Nursing Clinics of North America. 1991 1991/06/01/;26(2):341-360.	Title
164 6	Dutka-Malen S, Courvalin P. Update on glycopeptide resistance in enterococci. Antimicrobial Newsletter. 1990 1990/11/01/;7(11):81-86.	Title
164 7	Barriere SL. Update on new oral cephalosporins. Antimicrobial newsletter. 1992;8(3):21-24.	Abstract
164 8	Cyr SS, Barbee L, Workowski KA, et al. Update to CDC's treatment guidelines for gonococcal infection, 2020. Morbidity and Mortality Weekly Report. 2020;69(50):1911.	Title
164 9	Lai S, Kitamura K. Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020. Annals of Emergency Medicine. 2021;78(1):49-52.	Title
165 0	Brink A. Updated guideline for the management of upper respiratory tract infections in South Africa: 2008. Southern African Journal of Epidemiology and Infection. 2008;23(4):27-40.	Title
165 1	Brink AJ, Cotton MF, Feldman C, et al. Updated recommendations for the management of upper respiratory tract infections in South Africa. SAMJ: South African Medical Journal. 2015;105(5):345-352.	Title
165 2	Fanos V, Mussap M, Osio D, et al. Urinary Excretion of N-Acetyl- $\beta$ -D-Glucosaminidase and Epidermal Growth Factor in Paediatric Patients Receiving Cefixime Prophylaxis for Recurrent Urinary Tract Infections. Clinical Drug Investigation. 2001;21(7):511-518.	Abstract
165 3	Sumirtapura YC, Pamudji JS, Ingriyani N, et al. Urinary excretion profiles of four oral cephalosporins in Indonesian healthy subjects. Acta Pharm Indonesia. 2004;29:50-58.	Abstract
165 4	Schaeffer AJ. Urinary Tract Infection. The Journal of Urology. 1992 1992/07/01/;148(1):241-245.	Title

165 5	Drekonja DM, Johnson JR. Urinary Tract Infections. Primary Care: Clinics in Office Practice. 2008 2008/06/01;/35(2):345-367.	Title
165 6	Reed MD, Blumer JL. Urologic Pharmacology in the Office Setting. Urologic Clinics of North America. 1988 1988/11/01;/15(4):737-751.	Title
165 7	Vajdle O, Šekuljica S, Guzsvány V, et al. Use of carbon paste electrode and modified by gold nanoparticles for selected macrolide antibiotics determination as standard and in pharmaceutical preparations. Journal of Electroanalytical Chemistry. 2020 2020/09/15;/873:114324.	Title
165 8	Elbe D, Frighetto L, Nickoloff D, et al. Use of cefixime in an IV to oral stepdown program to reduce antimicrobial costs. Formulary. 1998;33(1):54.	Abstract
165 9	Bailey CA, Bryla P, Malick AW. The use of the intestinal epithelial cell culture model, Caco-2, in pharmaceutical development. Advanced Drug Delivery Reviews. 1996 1996/11/15;/22(1):85-103.	Title
166 0	Reisner DP. Uses of macrolide antibiotics in obstetrics and gynecology. Primary Care Update for OB/GYNS. 1996 1996/07/01;/3(4):122-127.	Title
166 1	Harrison CJ. Using antibiotic concentrations in middle ear fluid to predict potential clinical efficacy. The Pediatric infectious disease journal. 1997;16(2):S12-S16.	Title
166 2	Al-Tamimi SA, Al-Motlaq NSA, Aly FA. Utility of Spectroscopic Studies for Quantification of Cefditoren Pivoxil in Commercial Samples. Journal of the Chemical Society of Pakistan. 2021;43(4).	Title
166 3	Dhoka MV, Harale RB, Bankhele SC, et al. Validated HPTLC method for determination of cefixime trihydrate and dicloxacillin sodium in bulk and combined pharmaceutical dosage form. Research Journal of Pharmacy and Technology. 2012;6(5):842-845.	Abstract

166 4	Dhoka MV, Gawande VT, Joshi PP. Validated HPTLC Method for Determination of Cefixime Trihydrate and Erdosteine in Bulk and combined Pharmaceutical Dosage Form. Eurasian J Anal Chem. 2013;8(3):99-106.	Abstract
166 5	Dhara P, Dhananjay M, Vandana P, et al. Validated stability indicating RP-HPLC method development and validation for simultaneous estimation of Cefixime trihydrate and levofloxacin hemihydrate in pharmaceutical dosage form. Int J Anal Tech. 2017;3(1):1-12.	Abstract
166 6	Jain N, Jain H, Jain P. Validated Stability Indicating RP-HPLC Method for Simultaneous Estimation of Ofloxacin and Cefixime in their Combined Dosage Form. Science, Technology and Arts Research Journal. 2015;3(4):93-98.	Abstract
166 7	Gawande V, Bothara K, Satija C. Validated stability-indicating HPTLC method for cefixime and azithromycin with preparative isolation, identification, and characterization of degradation products. Acta Chromatographica. 2018;30(4):212-218.	Abstract
166 8	Hassouna M, Abdelrahman M, Mohamed M. Validation of a novel and sensitive RP-HPLC method for simultaneous determination of cefixime trihydrate and sodium benzoate in powder for oral suspension dosage form. Journal of Forensic Sciences & Criminal Investigation. 2017;2(5).	Abstract
166 9	Gehring R. Veterinary-specific applications of pharmacokinetic modelling and theory: Opportunities and challenges: [SI: sn]; 2020.	Title
167 0	Ghamat SN, Talebpour Z. A vinylpyrrolidone-based thin film microextraction in combination with direct solid-state spectrofluorimetry for determination of sartans in human plasma. Analytica Chimica Acta. 2020 2020/08/08/;1124:146-155.	Title



167 1	Reddy TM, Sreedhar M, Reddy SJ. Voltammetric behavior of Cefixime and Cefpodoxime Proxetil and determination in pharmaceutical formulations and urine. Journal of pharmaceutical and biomedical analysis. 2003;31(4):811-818.	Abstract
167 2	Jain R, Gupta VK, Jadon N, et al. Voltammetric determination of cefixime in pharmaceuticals and biological fluids. Analytical biochemistry. 2010;407(1):79-88.	Abstract
167 3	Gupta VK, Jain R, Radhapyari K, et al. Voltammetric techniques for the assay of pharmaceuticals—A review. Analytical Biochemistry. 2011 2011/01/15/;408(2):179-196.	Title
167 4	Volume 14 (1991) contents. Diagnostic Microbiology and Infectious Disease. 1991 1991/11/01/;14(6):i-ix.	Title
167 5	Schentag JJ, Gilliland KK, Paladino JA. What have we learned from pharmacokinetic and pharmacodynamic theories? Clinical Infectious Diseases. 2001;32(Supplement_1):S39-S46.	Title
167 6	Abbey TC, Deak E. What's New from the CLSI Subcommittee on Antimicrobial Susceptibility Testing M100, 29th Edition. Clinical Microbiology Newsletter. 2019 2019/12/01/;41(23):203-209.	Title
167 7	Ison C, Mouton J, Jones K, et al. Which cephalosporin for gonorrhoea? Sexually transmitted infections. 2004;80(5):386-388.	Abstract
167 8	Unemo M, Lahra MM, Escher M, et al. WHO global antimicrobial resistance surveillance for Neisseria gonorrhoeae 2017–18: a retrospective observational study. The Lancet Microbe. 2021;2(11):e627-e636.	Title
167 9	Drond SB, Justribó MV. Will We Still Have Antibiotics Tomorrow? Archivos de Bronconeumología ((English Edition)). 2007 2007/01/01/;43(8):450-459.	Title
168 0	Unemo M, Lahra MM, Cole M, et al. World Health Organization Global Gonococcal Antimicrobial Surveillance Program (WHO GASP): review of new data and evidence to inform international collaborative actions and research efforts. Sexual health. 2019;16(5):412-425.	Title

168 1	Bradford PA, Miller AA, O'Donnell J, et al. Zoliflodacin: an oral spiropyrimidinetrione antibiotic for the treatment of Neisseria gonorrhoeae, including multi-drug-resistant isolates. ACS Infectious Diseases. 2020;6(6):1332-1345.	Title
168 2	Neuhauser MM, Danziger LH. $\beta$ -lactam antibiotics. Drug interactions in infectious diseases: Springer; 2005. p. 255-287.	Title
168 3	Ganapathy ME, Huang W, Rajan DP, et al. $\beta$ -Lactam Antibiotics as Substrates for OCTN2, an Organic Cation/Carnitine Transporter*. Journal of Biological Chemistry. 2000 2000/01/21/;275(3):1699-1707.	Title
168 4	Lima LM, Silva BNMD, Barbosa G, et al. $\beta$ -lactam antibiotics: An overview from a medicinal chemistry perspective. European Journal of Medicinal Chemistry. 2020 2020/12/15/;208:112829.	Title
168 5	Miller LA, Ratnam K, Payne DJ. $\beta$ -Lactamase-inhibitor combinations in the 21st century: current agents and new developments. Current Opinion in Pharmacology. 2001 2001/10/01/;1(5):451-458.	Title
168 6	Прохоров Е, Мочалова А, Ершова И, et al. Актуальные вопросы алгоритма диагностики и терапии инфекционных диарей. Актуальная инфектология. 2013 (1 (1)):81-84.	Title
168 7	Синякова ЛА, Косова ИВ. Антимикробная терапия неосложненных инфекций мочевых путей. Consilium medicum. 2014;16(7):29-33.	Title
168 8	Капашева Ш. Гестационный пиелонефрит: опыт применения цефиксима. Наука и здравоохранение. 2013 (6):72-75.	Title
168 9	Капашева Ш. ГЕСТАЦИОННОЕ ПИЕЛОНЕФРИТ: ЦЕФИКСИМ ҚОЛДАНУ ТӘЖІРИБЕСІ. Pediatric Infectious Disease. 1987;6:963-970.	Title
169 0	Жакиянова Ж, Болсынбекова С, Калибекова А, et al. Имупрет в комплексном лечении гнойного воспаления околоносовых пазух. Наука и здравоохранение. 2013 (6):75-78.	Title

169 1	Белых С. Клинический опыт применения цефалоспоринов 3-го поколения в лечении инфекции мочевыводящих путей. Наука и здравоохранение. 2013 (3):55-56.	Title
169 2	Гучев ИА, Рафальский В, Мелехина Е. Роль цефиксима в терапии обострения хронической обструктивной болезни легких. Клин микробиол и антимикробная химиотерапия. 2008;10(3):270-282.	Title
169 3	Пушкарь Д, Зайцев А. Современные пероральные цефалоспорины в лечении инфекций мочевыводящих путей. Вестник практического врача. 2012 (1):3-8.	Title
169 4	Говоров АВ, Васильев АО, Пушкарь ДЮ. Тадалафил в лечении симптомов со стороны нижних мочевых путей: обзор литературы и существующей клинической практики в России. Consilium medicum. 2014;16(7):33-41.	Title
169 5	Фриго Н, Гучев И, Сидоренко С, et al. Цефалоспорины третьего поколения в лечении гонореи. Вестник дерматологии и венерологии. 2011 (3):34-44.	Title
169 6	Гучев И, Сафонова Е, Цой А. Цефиксим. Клиническая эффективность при обострении нетяжелой хронической обструктивной болезни легких и влияние на развитие рецидивов заболевания. Наблюдательная программа. ведения пациента Терапевтические особенности и возможности • Внебольничная пневмония Критерии тяжести Оценка прогноза Схемы антимикробной терапии. 2013;15(3):72.	Title
169 7	Гучев ИА, Сафонова ЕВ. Цефиксим. Роль перорального цефалоспоринона III поколения при обострении хронической обструктивной болезни легких. Фарматека. 2011 (4):64-69.	Title
169 8	تأثير تجویز سوسپانسیون سفیکسیم در درمان سرپایی پیلونیفریت حاد کودکان. et al. شمس, سیدزاده, Journal of Advances in Medical and Biomedical Research. 2004;12(48):15-21.	Title

169 9	이수영, 이정현, 김종현, et al. 소아 원외 요로감염 환자에서 분리된 E. coli 에 대한 cefixime 을 포함한 경구 항생제의 감수성 연구. Korean Journal of Pediatrics. 2006;49(7).	Title
170 0	강원구, 권광일, 우종수. 지원자의 Cefixime 캡셀제 생체이용율에 대한 생물학적동등성 연구. 한국임상약학회지. 1998;8(1):19-22.	Title
170 1	노현구, 박기배, 이광표. 흰쥐의 비강과 공장에서의 Cefixime 의 흡수기전. 정기총회 및 학술대회. 1993;42:225-225.	Title
170 2	闫晓霞, 李源远, 李建伟. 不同处方头孢克肟胶囊在比格犬体内的药动学. 中国抗生素杂志. 2020;45(05):513-518.	Title
170 3	中村竜也, 高橋伯夫. 各種臨床分離株の経口セフェム系薬に対する薬剤感受性と Pharmacokinetics/Pharmacodynamics (PK/PD) 理論を用いたその有効性について. The Japanese Journal of Antibiotics. 2004;57(6):465-474.	Title
170 4	周颖, 孙培红, 赵侠, et al. 头孢克肟在中国健康男性志愿者的群体药代动力学研究. 临床药物治疗杂志. 2005;3(4):49-54.	Title
170 5	中村はるひ, 岩井直一. 小児期における経口抗生物質についての薬動学的検討 (第 1 報) 小児期における Cefixime の薬動学的検討. The Japanese Journal of Antibiotics. 1991;44(9):964-978.	Title
170 6	宮崎正章, 貴田嘉一, 松田博, et al. 小児科領域における Cefixime の基礎的, 臨床的検討. The Japanese Journal of Antibiotics. 1986;39(4):1166-1175.	Title

170 7	岩井直一, 柴田元博, 溝口文子, et al. 小児科領域における Cefixime の基礎的, 臨床的検討. The Japanese Journal of Antibiotics. 1986;39(4):1087-1105.	Title
170 8	西村忠史, 高島俊夫, 田吹和雄, et al. 小児科領域における Cefixime の基礎的, 臨床的検討. The Japanese Journal of Antibiotics. 1986;39(4):1115-1127.	Title
170 9	倉繁隆信, 森田英雄, 荒木久美子, et al. 小児科領域における Cefixime の臨床的検討. The Japanese Journal of Antibiotics. 1986;39(4):1157-1165.	Title
171 0	目黒英典, 有益修, 宗田英幸, et al. 小児科領域における Cefixime の臨床的検討. The Japanese Journal of Antibiotics. 1986;39(4):1007-1019.	Title
171 1	中澤進, 佐藤肇, 成田章, et al. 小児科領域における Cefixime 細粒に関する検討. The Japanese Journal of Antibiotics. 1986;39(4):1020-1034.	Title
171 2	三河春樹, 真弓光文, 秋山義之, et al. 小児科領域感染症における Cefixime の臨床的検討. The Japanese Journal of Antibiotics. 1989;42(12):2527-2539.	Title
171 3	島田馨. 総説 [最新の抗菌薬 XXIII] Cefixime. The Japanese Journal of Antibiotics. 1987;40(9):1537-1548.	Title
171 4	前田浩志, 佐古政典, 藤井明, et al. 腎機能障害例における Cefixime の体内動態. The Japanese Journal of Antibiotics. 1986;39(10):2716-2720.	Title
171 5	中野博, 世古昭三, 仁平寛巳, et al. 腎機能障害者における cefixime (CFIX) の体内動態. CHEMOTHERAPY. 1988;36(5):428-436.	Title
171 6	張蓉琴, 李銅鈴, 鄢琳, et al. 頭孢克肟咀嚼片與膠囊的相對生物利用度比較. 中國新藥與臨床雜誌. 2004;23(12):856-858.	Title

171 7	DÜRckheimer W, Adam F, Fischer G, et al. Recent Developments in the Field of Cephem Antibiotics. In: Testa B, editor. Advances in Drug Research. Vol. 17: Academic Press; 1988. p. 61-234.	Title
171 8	MacGowan AP, Wise R. Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests. Journal of Antimicrobial Chemotherapy. 2001;48(suppl_1):17-28.	Title
171 9	Faulkner RD, Fernandez P, Lawrence G, et al. Absolute bioavailability of cefixime in man. J Clin Pharmacol. 1988 Aug;28(8):700-6.	Extensive reading
172 0	Faulkner R, Yocobi L, Barone J, et al. al. e: Pharmacokinetic profile of cefixime in man. Pediatric Infectious Disease 1987b; 6: 963-970. 1987.	Extensive reading
172 1	Kamran M, Khan MA, ur Rehman M, et al. Binary Solid Lipid Nanosuspension Containing Cefixime: Preparation, Characterization and Comparative In-vivo Evaluation. Beilstein Archives. 2019;2019(1):109.	Animal
172 2	Turner JV, Maddalena DJ, Cutler DJ, et al. Multiple pharmacokinetic parameter prediction for a series of cephalosporins. Journal of pharmaceutical sciences. 2003;92(3):552-559.	Extensive reading
172 3	García-Rodríguez J, Bellido JM, Sánchez JG. Oral cephalosporins: current perspectives. International journal of antimicrobial agents. 1995;5(4):231-243.	Title
172 4	Dandekar PK, Nicolau DP. Pharmacodynamic considerations for the selection of oral cephalosporins in the treatment of rhinosinusitis. Otolaryngology - Head and Neck Surgery. 2002 2002/12/01/;127(6, Supplement):S10-S16.	Title
172 5	Liu P, Müller M, Derendorf H. Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations. International journal of antimicrobial agents. 2002;19(4):285-290.	Title
172 6	MacGowan AP, Bowker KE. Sequential antimicrobial therapy: pharmacokinetic and pharmacodynamic considerations in sequential therapy. Journal of Infection. 1998 1998/07/01/;37:30-36.	Extensive reading

172 7	Rimmer D. Third generation cephalosporins in the parenteral to oral switch. <i>Pharmacoeconomics</i> . 1994;5(2):27-33.	Title
----------	----------------------------------------------------------------------------------------------------------------------------	-------

**Supplementary Table 3: JADAD Scoring**

<b>JADAD Questions</b>						
Reference	Was the study described as randomized	Was the method used to generate the sequence of randomization described and appropriate	Was the study described as double blind	Was the method of double blinding described and appropriate	Was there a description of withdrawals and dropouts	Total score
David C. Brittain et.al(1985)	1	1	1	1	0	4
Mitsuyoshi NAKASHIMA et.al(1986)	1	1	0	0	0	2



D. R. P. GUAY et.al(1986)	0	0	0	0	0	0
ROBERT,D FAULKNER et.al(1987)	0	0	0	0	0	0
Mitsuyoshi Nakashima et.al(1987)	0	0	0	0	0	0
R. D. Faulkner et.al(1988)	1	1	0	0	0	2
R. D. Faulkneret.al(1988)	0	0	0	0	0	0
CARL ERIK NORD et.al(1988)	0	0	0	0	0	0
Robert D. Faulkner et.al(1988)	1	1	0	0	0	2
DANIEL P. HEALY et,al(1989)	1	1	0	0	0	2
J. W. Stone et.al(1989)	0	0	0	0	0	0
ROBERT D. FAULKNER et.al(1989)	1	1	0	0	0	2
D. Trenk et.al(1990)	1	0	0	0	0	1
G. Montay et.al(1991)	1	1	0	0	0	2
M. Dhib et.al(1991)	0	0	0	0	0	0

CHANTAL DUVERNE et.al(1992)	1	1	0	0	0	2
J. F. WESTPHAL et.al(1993)	0	0	0	0	0	0
Milap C.Nahata et.al(1993)	0	0	0	0	0	0
Katerina Mamzoridi et.al(1996)	0	0	0	0	0	0
X.D. LIU et.al(1997)	0	0	0	0	0	0
David E. Nix et.al(1997)	1	1	0	0	1	3
YOSHIKIYO TOYONAGA(1997)	0	0	0	0	0	0
H. CARSENTI-ETESSE et.al(1998)	1	1	1	1	0	4
E. Evene et,al(2001)	1	1	0	0	0	2
Takashi Deguchi et.al(2003)	0	0	0	0	0	0
Y.A.Asiriet.al(2005)	0	0	0	0	0	0
Ping Liu et.al(2005)	1	1	0	0	0	2
Dong Hyun Choi et.al(2007)	1	1	0	0	1	3

Parvin Zakeri-Milani et.al(2008)	1	1	0	0	1	3
Tawfeeg A. Najjaet.al(2009)	0	0	0	0	0	0
Abbas Khan et.al(2011)	0	0	0	0	0	0
Saiprasad Patil et.al(2014)	1	1	0	0	0	2
Hossein Danafar et.al(2016)	1	1	0	0	1	3
Lindley A. Barbee et.al(2018)	1	0	0	0	1	2
Muhammad Waqas Khadam et.al(2019)	0	0	0	0	0	0
Sara Aset.al(2020)	1	1	0	0	1	3
Esraa Ghazy Jabbar et.al(2021)	1	1	0	0	1	3
Yuli Subiakt et.al(2022)	1	1	1	1	0	4

**Supplementary Table 4: Critical Appraisal Skill Program**

CASP Questions											
Reference	Was there a clear statement of the aims of the research?	Is a qualitative methodology appropriate?	Was the research design appropriate to address the aims of the research?	Are the study's theoretical underpinnings clear, consistent and conceptually coherent?	Was the recruitment strategy appropriate to the aims of the search?	Was the data collected in a way that addressed the research issue?	Has the relationship between researcher and participants been adequately considered?	Have ethical issues been taken into consideration?	Was the data analysis sufficiently rigorous?	Is there a clear statement of findings?	CASP Score
David C. Brittain et.al(1985)	Y	Y	Y	Y	Y	Y	CT	N	Y	Y	8
Mitsuyoshi NAKASHIMA et.al(1986)	Y	Y	Y	Y	Y	Y	N	Y	Y	Y	9

D. R. P. GUAY et.al(1986)	Y	Y	Y	Y	Y	Y	CT	N	Y	Y	8
ROBERT,D FAULKNER et.al(1987)	Y	Y	Y	Y	Y	Y	CT	Y	Y	Y	9
Mitsuyoshi Nakashima et.al(1987)	Y	Y	Y	Y	Y	Y	N	Y	Y	Y	9
R. D. Faulkner et.al(1988)	Y	Y	Y	Y	Y	Y	Y	N	Y	Y	9
R. D. Faulkneret.al(1 988)	Y	Y	Y	Y	Y	Y	CT	N	Y	Y	8
CARL ERIK NORD et.al(1988)	Y	Y	Y	Y	Y	Y	N	Y	Y	Y	9
Robert D. Faulkner et.al(1988)	Y	Y	Y	Y	Y	Y	CT	Y	Y	Y	9

DANIEL P. HEALY et.al(1989)	Y	Y	Y	Y	Y	Y	CT	N	Y	Y	8
J. W. Stone et.al(1989)	Y	Y	CT	Y	Y	Y	CT	Y	Y	Y	8
ROBERT D. FAULKNER et.al(1989)	Y	Y	Y	Y	Y	Y	N	Y	Y	Y	9
D. Trenk et.al(1990)	Y	Y	Y	Y	Y	Y	N	Y	Y	Y	9
G. Montay et.al(1991)	Y	Y	Y	Y	Y	Y	N	N	Y	Y	8
M. Dhib et.al(1991)	Y	Y	Y	Y	Y	Y	CT	Y	Y	Y	9
CHANTAL DUVERNE et.al(1992)	Y	Y	Y	Y	Y	Y	N	Y	Y	Y	9
J. F. WESTPHAL et.al(1993)	Y	Y	CT	Y	Y	Y	CT	Y	Y	Y	8

Milap C.Nahata et.al(1993)	Y	Y	Y	Y	Y	Y	CT	N	Y	Y	8
Katerina Mamzoridi et.al(1996)	Y	Y	Y	Y	CT	Y	N	N	Y	Y	7
X.D. LIU et.al(1997)	Y	Y	Y	Y	Y	Y	N	N	Y	Y	8
David E. Nix et.al(1997)	Y	Y	Y	Y	Y	Y	Y	N	Y	Y	9
YOSHIKIYO TOYONAGA( 1997)	Y	CT	CT	Y	Y	Y	Y	N	Y	Y	7
H. CARSENTI- ETESSE et.al(1998)	Y	Y	Y	CT	Y	Y	N	N	Y	Y	7
E. Evene et,al(2001)	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	10
Takashi Deguchi et.al(2003)	Y	Y	Y	Y	Y	Y	CT	N	Y	Y	8

Y.A.Asiriet.al(2005)	Y	Y	Y	Y	Y	Y	N	N	Y	Y	8
Ping Liu et.al(2005)	Y	Y	Y	Y	Y	Y	N	N	Y	Y	8
Dong Hyun Choi et.al(2007)	Y	Y	Y	Y	Y	Y	N	Y	Y	Y	9
Parvin Zakeri-Milani et.al(2008)	Y	Y	Y	Y	Y	Y	N	Y	Y	Y	9
Tawfeeg A. Najjaet.al(2009)	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	10
Abbas Khan et.al(2011)	Y	Y	CT	Y	Y	Y	N	Y	Y	Y	8
Saiprasad Patil et.al(2014)	Y	Y	Y	CT	Y	Y	N	Y	Y	Y	8
Hossein Danafar et.al(2016)	Y	Y	Y	Y	Y	Y	N	N	Y	Y	8



Lindley A. Barbee et.al(2018)	Y	Y	Y	Y	Y	Y	Y	N	Y	Y	9
Muhammad Waqas Khadam et.al(2019)	Y	Y	Y	Y	Y	Y	N	N	Y	Y	8
Sara Aset.al(2020)	Y	Y	Y	CT	Y	Y	Y	N	Y	Y	8
Esraa Ghazy Jabbar et.al(2021)	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	10
Yuli Subiakt et.al(2022)	Y	Y	Y	Y	Y	Y	N	Y	Y	Y	9

Y: yes, N: no, CT: cannot tell.

**Supplementary Table 5: Critical Appraisal Clinical Pharmacokinetic Tool**

Reference studies																																									
Q ue sti on s	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38			
Q 1	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y		
Q 2	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	
Q 3	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	N	N	Y	Y	N	Y	Y	N	Y	Y	N	Y	Y	N	Y	Y	N	Y	Y	Y	Y	N	Y	Y

Q 4	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	N	Y	Y	N	N	Y	Y	Y	N	Y	N	N	Y	Y	Y	Y			
Q 5	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y			
Q 6	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	Y	N	N	N	N	N	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	Y	Y	Y	
Q 7	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	N	Y	Y	Y	Y	N	Y	Y	Y	N	Y	N	Y	Y	Y	N	Y			
Q 8	Y	Y	Y	Y	N	N	Y	N	N	N	N	Y	N	N	Y	Y	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N		
Q 9	Y	Y	N	Y	Y	Y	Y	N	Y	Y	N	Y	Y	Y	Y	N	Y	N	Y	Y	Y	N	Y	Y	Y	Y	Y	Y	Y	Y	Y	N	Y	N	Y	Y	Y	N	
Q 10	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	N	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	N	Y	Y	Y	Y	Y
Q 11	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	y	Y	Y	N	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	N	Y	Y	Y	Y	Y



Q 20	I D K	I D K	I D K	I D K	I D K	I D K	I D K	I D K	I D K	I D K	I D K	I D K	I D K	I D K	I D K	I D K	I D K	I D K	I D K	I D K	I D K	I D K	I D K	I D K	I D K	I D K	I D K	I D K	I D K	I D K	I D K	I D K	I D K	I D K	I D K		
Q 21	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	I D K	Y	Y	Y	Y	Y	Y	I D K	I D K	I D K	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	
T ot al sc or e	1 6	1 5	1 5	1 5	1 4	1 5	1 6	1 3	1 4	1 5	1 1	1 6	1 3	1 4	1 6	1 3	1 4	9 2	1 2	1 2	1 6	8 3	1 6	1 1	1 1	1 4	1 3	1 4	1 5	1 3	1 0	1 1	1 2	1 0	1 3	1 3	1 3

Q1: Was a clear description of the objectives of the study provided? Q2: Was a valid and comprehensive rationale provided to support the purpose of the study? Q3: Was the chosen study design appropriately selected and justified? Q4: Was the dosing (dose, route of administration, dosing interval) of the drug in the study justified for the intended study? Q5: Were the endpoints of the study appropriate to answer the objectives of the study? Q6: Were the exclusion criteria of participants included AND appropriate for the intended outcomes of the study? Q7: Q8: Where applicable, were the relevant baseline characteristics of the participants adequately described? Q9: Were plausible interacting covariates described a priori or in post hoc evaluation? Q10: Was the description of the used sample analysis methods or citations of prior validation studies provided in the publication or affiliated appendix? Q11: Was the method of data sampling appropriate for the study? Q12: Was a clear description of the sampling site and the sampling interval (the exact times at which samples are obtained) provided and justified? Q13: Was the number of half-lives elapsed within the sampling

period appropriate for the analyzed drug? Q14: Were sample storage conditions appropriate and described in a manner that could be accurately replicated? Q15: If applicable, was there a clear description of the pharmacokinetic model, its development, validation and justification for use? Q16: Was the described population pharmacokinetic approach validation method appropriate for the analysis? Q17: Were the essential pharmacokinetic parameters required to make the results applicable in clinical settings addressed? Q18: Were the pharmacokinetic equations used to calculate patient pharmacokinetic parameters disclosed or cited within the article? Q19: Were the chosen statistical tests and software to perform the statistical analysis appropriate to achieve the study objectives? Q20: Were all patients enrolled in the study accounted for? Q21: In the event of missing data or outliers, was the process for analysis justified and appropriate? Q22: Were appropriate summary statistics to describe centrality and variance used to document the pharmacokinetic results?

1:David C. Brittain et.al(1985), 2:Mitsuyoshi NAKASHIMA et.al(1986), 3:D. R. P. GUAY et.al(1986), 4:ROBERT,D FAULKNER et.al(1987), 5:Mitsuyoshi Nakashima et.al(1987), 6:R. D. Faulkner et.al(1988), 7:R. D. Faulkneret.al(1988), 8:CARL ERIK NORD et.al(1988), 9:Robert D.Faulkner et.al(1988), 10:DANIEL P. HEALY et.al(1989), 11:J. W. Stone et.al(1989), 12:ROBERT D. FAULKNER et.al(1989), 13:D. Trenk et.al(1990), 14:G. Montay et.al(1991), 15:M. Dhib et.al(1991), 16:CHANTAL DUVERNE et.al(1992), 17:J. F. WESTPHAL et.al(1993), 18:Milap C.Nahata et.al(1993), 19: Katerina Mamzoridi et.al(1996), 20: X.D. LIU et.al(1997), 21: David E. Nix et.al(1997), 22:YOSHIKIYO TOYONAGA(1997), 23:H. CARSENTIETESSE et.al(1998), 24:E. Evene et.al(2001), 25:Takashi Deguchi et.al(2003), 26:Y.A.Asiriet.al(2005), 27: Ping Liu et.al(2005), 28:, Dong Hyun Choi et.al(2007), 29:Parvin Zakeri-Milani et.al(2008), 30:Tawfeeg A. Najjaet.al(2009), 31:Abbas Khan et.al(2011), 32:Saiprasad Patil et.al(2014), 33:Hossein Danafar et.al(2016),34:Lindley A. Barbee et.al(2018), 35: Muhammad Waqas Khadam et.al(2019). 36:Sara Aset.al(2020), 37: Esraa Ghazy Jabbar et.al(2021), 38:Yuli Subiakt et.al(2022)

Y: yes, N: no, IDK: I do not know.

**Supplementary Table 6 : Cochrane Collaboration Tool**

<b>Cochrane Collaboration Questions</b>								
<b>Reference</b>	<b>Random sequence (selection bias)</b>	<b>Allocaton concealment (selection bias)</b>	<b>Binding of participant and researchers (performed bias)</b>	<b>Binding of outcome assessment (detection bias)</b>	<b>Incomplete outcome data (attrition bias)</b>	<b>Selective reporting (reporting bias)</b>	<b>Other bias</b>	<b>Total score</b>
David C. Brittain et.al(1985)	LR	UR	LR	UR	HR	LR	LR	4
Mitsuyoshi NAKASHIMA et.al(1986)	LR	UR	UR	HR	UR	LR	LR	3
D. R. P. GUAY et.al(1986)	UR	UR	UR	HR	UR	LR	LR	2
ROBERT,D FAULKNER et.al(1987)	UR	UR	UR	HR	UR	LR	LR	2

Mitsuyoshi Nakashima et.al(1987)	UR	UR	UR	UR	UR	LR	LR	2
R. D. Faulkner et.al(1988)	LR	UR	UR	UR	UR	LR	UR	2
R. D. Faulkneret.al(1988)	UR	UR	UR	UR	UR	LR	LR	2
CARL ERIK NORD et.al(1988)	UR	UR	UR	UR	UR	LR	LR	2
Robert D. Faulkner et.al(1988)	LR	LR	UR	UR	UR	LR	LR	4
DANIEL P. HEALY et,al(1989)	LR	UR	UR	UR	UR	LR	LR	3
J. W. Stone et.al(1989)	UR	UR	UR	HR	UR	LR	LR	2
ROBERT D. FAULKNER et.al(1989)	LR	LR	UR	UR	UR	LR	LR	4
D. Trenk et.al(1990)	UR	UR	UR	HR	UR	LR	LR	2
G. Montay et.al(1991)	LR	UR	UR	HR	UR	LR	LR	3
M. Dhib et.al(1991)	UR	UR	UR	HR	UR	LR	LR	2



CHANTAL DUVERNE et.al(1992)	LR	UR	UR	UR	UR	LR	LR	3
J. F. WESTPHAL et.al(1993)	UR	UR	UR	HR	UR	LR	LR	2
Milap C.Nahata et.al(1993)	UR	UR	UR	HR	UR	LR	LR	2
Katerina Mamzoridi et.al(1996)	UR	UR	UR	HR	UR	LR	LR	2
X.D. LIU et.al(1997)	UR	UR	UR	HR	UR	LR	LR	2
David E. Nix et.al(1997)	LR	UR	HR	HR	LR	LR	LR	4
YOSHIKIYO TOYONAGA(1997)	UR	UR	UR	HR	UR	LR	LR	2
H. CARSENTI- ETESSE et.al(1998)	LR	UR	LR	UR	LR	LR	UR	4
E. Evene et.al(2001)	LR	LR	HR	HR	UR	LR	LR	4
Takashi Deguchi et.al(2003)	UR	UR	UR	HR	UR	LR	LR	2
Y.A.Asiriet.al(2005)	UR	UR	UR	HR	UR	LR	LR	2
Ping Liu et.al(2005)	LR	UR	HR	HR	UR	LR	LR	3

Dong Hyun Choi et.al(2007)	LR	UR	UR	HR	UR	LR	LR	3
Parvin Zakeri- Milani et.al(2008)	LR	UR	HR	HR	UR	LR	LR	3
Tawfeeg A. Najjaet.al(2009)	UR	UR	UR	HR	UR	LR	LR	2
Abbas Khan et.al(2011)	UR	UR	UR	HR	UR	LR	LR	2
Saiprasad Patil et.al(2014)	LR	LR	HR	HR	LR	LR	LR	5
Hossein Danafar et.al(2016)	LR	LR	UR	HR	LR	LR	LR	5
Lindley A. Barbee et.al(2018)	UR	UR	HR	HR	LR	LR	LR	3
Muhammad Waqas Khadam et.al(2019)	UR	UR	UR	UR	UR	LR	LR	2
Sara Aset.al(2020)	LR	UR	UR	UR	LR	LR	LR	4
Esraa Ghazy Jabbar et.al(2021)	LR	LR	HR	HR	LR	LR	UR	4
Yuli Subiakt et.al(2022)	LR	LR	LR	UR	LR	LR	UR	5

HR: high risk, LR: low risk, UR: unclear risk.

#### References:

- Abdullah A, Mutmainnah M, Wikantyasning ER. 2022. Cocrystals of Cefixime with Nicotinamide: Improved Solubility, Dissolution, and Permeability. *Indonesian Journal of Pharmacy*.
- Bayram E, Bayram MT, Hiz S, Turkmen M. 2012. Cefixime-induced oculogyric crisis. *Pediatric emergency care*. 28(1):55-56.
- Brogden RN, Campoli-Richards DM. 1989. Cefixime. *Drugs*. 38(4):524-550.
- Genvresse I, Carbon C. 1993. Cefixime. *International Journal of Antimicrobial Agents*. 3(1):1-16.
- Jabbar EG, Al-Tamimi D, Al-Mahroos M, Al-Tamimi Z, Ibraheem JJ. 2021. Pharmacokinetics and bioequivalence study of two formulations of Cefixime Suspension. *J Adv Pharm Edu Res*. 11(1):170-177.
- Leggett NJ, Caravaggio C, Rybak MJ. 1990. Cefixime. *Dicp*. 24(5):489-495.
- Naqvi I, Saleemi A, Naveed S. 2011. Cefixime: a drug as efficient corrosion inhibitor for mild steel in acidic media. *Electrochemical and thermodynamic studies*. *Int J Electrochem Sci*. 6(1):146-161.
- Özyüncü Ö, Beksac MS, Nemutlu E, Katlan D, Kir S. 2010. Maternal blood and amniotic fluid levels of moxifloxacin, levofloxacin and cefixime. *Journal of Obstetrics and Gynaecology Research*. 36(3):484-487.

